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ABSTRACT 
 
Antibiotics are the mainstay in treatment of bacterial infections. However, resistance 
to antibacterial treatments has been rising since the 1970s, causing serious problems 
in the treatment and control of infectious diseases. Antibiotic resistance is now 
considered as one of the major global health threats of the 21st century in that the 
worldwide use of antibiotics is predicted to increase by more than 65% in the coming 
decades due to the increasing demand for meat and shift in agriculture practices in 
developing countries. New antibacterial drugs are urgently needed, but only three 
antibacterial drugs have been brought to the market since 1999 and very few new 
antibiotics are currently in development. This has prompted the search for 
alternatives to conventional antibiotics. Multiple alternative anti-infective strategies 
are being investigated, including vaccines, probiotics and phage therapy. Other 
promising alternatives to antibiotics are host defense peptides (HDPs), an important 
component of the first line of defense against infection, found in all multicellular 
organisms. HDPs are seen as true multifunctional peptides with activities as diverse 
as chemotaxis, inhibition of LPS-induced inflammation, modulation of leukocyte 
differentiation and promotion of wound healing. Interestingly, novel functions of these 
peptides are still being described to date. Many human proteins with functions not 
necessarily related to host defense behave as sources of HDPs. Some examples are 
lactoferrin, lysozyme and thrombin. Since these peptides are hidden in large proteins, 
they can be defined as “cryptic”. In order to identify by a rational approach further 
human proteins carrying cryptic HDPs, we recently developed an in-silico screening 
method to localize antimicrobial regions hidden inside the primary structure of 
precursor proteins. A wide list of potential new antimicrobial peptides was obtained 
by applying this method to about 4,000 human extracellular proteins. 
The main aim of this PhD project was the identification of interesting potential HDPs, 
to develop novel bioactive peptides. Firstly, we developed a novel and cost-effective 
method to produce recombinant HDPs, based on the use a cheap and efficient 
medium to be employed in an auto-inducing fermentation process. Furthermore, to 
avoid HDPs toxicity towards bacterial host, a novel fusion system based on a carrier 
protein (derived from a Rana pipiens ribonuclease) was used. Once optimized the 
production system, a broad characterization of two novel recombinant peptides, 
previously identified in human Apolipoprotein B (ApoB), was performed. We 
demonstrated that both peptides are endowed with a significant antimicrobial activity 
towards Gram-negative and Gram-positive strains, and are able to prevent biofilm 
formation in several strains at concentrations lower than those required to directly kill 
planktonic bacterial cells. Moreover, ApoB-derived peptides were found to be 
endowed with anti-inflammatory properties as well as the ability to promote wound 
healing in keratinocytes. In addition, two further cryptic HDPs have been structurally 
and functionally characterized. One of these HDPs has been identified in human 11-
hydroxysteroid dehydrogenase-1 β-like, the other represents the first HDP from an 
archaeal protein, the transcription factor Stf76 encoded by the hybrid plasmid-virus 
pSSVx from Sulfolobus islandicus. By means of a multidisciplinary approach 
including biochemical, cellular biology and spectroscopic techniques, the action 
mechanism of both peptides has been elucidated, and intriguing results have been 
obtained by testing their immunomodulatory and anti-cancer activities. Hence, the in 
silico-derived panel of potential HDPs is a rich source of peptides with 
pharmacologically relevant properties. 
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RIASSUNTO 
 
Negli ultimi decenni lo smisurato ed incauto uso di antibiotici per fini terapeutici, agro-
alimentari e veterinari ha determinato la progressiva diffusione di ceppi batterici 
resistenti agli antibiotici convenzionali. Si è stimato che più del 70% delle infezioni 
batteriche che colpiscono gli esseri umani sono caratterizzate da fenomeni di 
resistenza ai farmaci, ciò che le rende un grave problema per la salute umana, come 
evidenziato nel rapporto dell’Agenzia Mondiale della Sanità (2015). Negli ultimi 
decenni a suscitare maggiore preoccupazione sono stati i ceppi resistenti alla 
meticillina o alla vancomicina appartenenti al genere Staphylococcus oltre che batteri 
Gram-negativi appartenenti ai generi Escherichia, Pseudomonas e Acinetobacter. 
Tale fenomeno ha stimolato un’intensa ricerca di nuove classi di antibiotici che 
garantisca un’efficacia duratura nel tempo. Di recente, l’interesse scientifico si è 
focalizzato sui cosiddetti cAMPs (cationic Anti Microbial Peptides), peptidi dotati di 
un’attività antimicrobica ad ampio spettro, dal momento che sono attivi contro batteri 
Gram-positivi e Gram-negativi, ma anche contro funghi, virus e protozoi. Tali peptidi 
sono prodotti da un’ampia gamma di organismi tra cui batteri, piante, insetti, anfibi e 
mammiferi. L’ampia distribuzione dei cAMPs sia nel regno animale che vegetale ha 
fatto ipotizzare un loro ruolo fondamentale nel successo evolutivo degli organismi 
multicellulari; essi, infatti, sono considerati una delle più antiche “armi” della risposta 
immunitaria innata. Inizialmente identificati sulla base della loro attività antimicrobica 
ad ampio spettro, essi hanno suscitato sempre più attenzione anche per gli 
interessanti ruoli fisiologici che rivestono nella modulazione della risposta 
immunitaria. Per tale motivo sono oggi definiti, in senso più ampio, peptidi della 
difesa dell’ospite (Host Defense Peptides, HDPs). Tutti i peptidi antimicrobici naturali 
hanno origine da precursori proteici in seguito a modifiche post-traduzionali 
comprendenti quasi sempre un evento proteolitico e, in alcuni casi, glicosilazione e 
amidazione carbossi-terminale.  
La maggior parte dei peptidi antimicrobici appartiene ad una delle seguenti classi 
strutturali: (i) peptidi con struttura ad alfa-elica, privi di residui di cisteina; (ii) peptidi 
globulari con struttura beta stabilizzata da ponti disolfurici intramolecolari; (iii) peptidi 
caratterizzati da un’insolita abbondanza di specifici amminoacidi, quali istidina, 
glicina, prolina o triptofano. Nonostante la struttura primaria e secondaria e la 
lunghezza (12-50 amminoacidi) dei peptidi antimicrobici naturali possano essere 
molto diverse, essi condividono proprietà chimico-fisiche, quali la carica netta 
positiva (compresa tra +2 e +7 a pH 7) conferita dalla presenza di un elevato numero 
di residui basici e l’esposizione di regioni idrofobiche. Tali proprietà sono alla base 
del loro peculiare meccanismo d’azione. Infatti, la principale differenza tra gli HDPs e 
la maggior parte degli antibiotici convenzionali risiede nel “bersaglio molecolare” 
della loro azione. Gli antibiotici convenzionali agiscono su specifiche macromolecole 
(ribosomi, enzimi, DNA), mentre i peptidi antimicrobici agiscono a livello delle 
membrane batteriche (interna e/o esterna). Le basi molecolari del meccanismo di 
azione degli HDPs non sono del tutto chiare, sebbene si ritenga che le due 
caratteristiche molecolari comuni a tutti gli HDPs, cationicità ed anfipaticità, siano alla 
base della loro attività biologica. In particolare, evidenze sperimentali indicano che 
l’interazione primaria tra i peptidi e le cellule bersaglio è mediata dalla carica netta 
dei peptidi e che la loro selettività di azione sia da attribuire alla differente 
composizione delle membrane cellulari procariotiche ed eucariotiche. 
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La membrana batterica presenta, infatti, un’elevata percentuale di fosfolipidi acidi su 
entrambi i lati, quali cardiolipina e fosfatidilglicerolo, che conferiscono una carica 
negativa a queste superfici. Anche nel caso dei batteri Gram-negativi, la membrana 
più esterna è carica negativamente, dal momento che contiene lipopolissaccaridi 
anionici (LPS). Nel caso della membrana plasmatica delle cellule eucariotiche, 
invece, i fosfolipidi carichi negativamente sono quasi sempre localizzati sulla 
superficie interna, mentre sulla superficie esterna sono presenti fosfolipidi 
zwitterionici, quali fosfatidilcolina e fosfatidiletanolammina. Inoltre, la membrana delle 
cellule eucariotiche è ricca di colesterolo che, conferendole rigidità, la rende non 
suscettibile all’attacco dei peptidi.  
Diversi modelli sono stati proposti per spiegare l’attività biologica dei peptidi 
antimicrobici, i quali sono in grado di instaurare una interazione elettrostatica con i 
fosfolipidi anionici della membrana batterica e di adottare poi una conformazione 
anfipatica che consente loro di inserirsi nella membrana. Si innescano così una serie 
di eventi che compromettono le funzioni fisiologiche della membrana (alterazioni di 
fluidità, di spessore, di permeabilità selettiva, ecc.). Alcuni peptidi, tuttavia, sono in 
grado di esplicare un meccanismo di azione differente e, una volta attraversata la 
membrana, attaccano bersagli intracellulari. È questo il caso della buforina II, in 
grado di legare il DNA. 
Tra i modelli proposti per spiegare il meccanismo di azione dei cAMPs, il modello 
“barrel-stave” prevede che le regioni idrofobiche del peptide interagiscano con le 
catene idrocarburiche dei fosfolipidi di membrana formando un poro, la cui superficie 
interna è costituita dalle regioni idrofiliche del peptide. Tale modello si applica solo ad 
un numero di casi molto ristretto. Vi è poi il modello “toroidal” o “worm-hole” che 
sembra rappresentare il meccanismo di azione della maggior parte dei peptidi. Tale 
modello prevede l’associazione dei peptidi con i gruppi esposti dei fosfolipidi di 
membrana, ciò che provoca una curvatura del doppio strato lipidico a livello del poro. 
In questo caso, quindi, la superficie interna del canale sarà costituita sia dai peptidi 
sia dai gruppi esposti dei fosfolipidi di membrana. Un altro modello, noto come 
“carpet”, prevede che i peptidi si dispongano parallelamente alla superficie della 
membrana rivestendola come un “tappeto”. Una volta che la concentrazione dei 
peptidi ha superato un valore soglia, essi determinano poi la distruzione della 
membrana grazie alla formazione di micelle o piccoli aggregati peptidolipidici. Le 
modalità con cui i peptidi antimicrobici attraversano la capsula polisaccaridica della 
membrana esterna dei batteri Gram-negativi o la parete di peptidoglicano dei Gram-
positivi restano, invece, ancora ignote. 
Grazie al peculiare meccanismo di azione dei cAMPs, è improbabile che i batteri 
possano sviluppare una completa resistenza ai peptidi; ciò, infatti, richiederebbe un 
sostanziale cambiamento nella composizione di membrana ed implicherebbe “costi” 
metabolici troppo elevati per i batteri. Basti pensare che le membrane batteriche 
sono coinvolte in ruoli metabolici fondamentali, quali le catene di trasporto degli 
elettroni e la produzione di ATP. 
Oltre all’ attività antimicrobica diretta, gli HDPs fungono anche da molecole ponte tra 
i meccanismi dell’immunità innata e quella acquisita. Alcuni noti peptidi antimicrobici 
umani, come α- e β-defensine ed LL-37, l’unica catelicidina umana, oltre ad essere 
efficaci come antimicrobici, sono anche dotati di diverse proprietà immunomodulanti.  
Ad esempio, essi sono in grado di reclutare le cellule effettrici dell’immunità innata 
nei siti di infezione (chemiotassi dei macrofagi) ed attivare le cellule specializzate 
coinvolte nei meccanismi dell’immunità adattativa (cellule dendritiche immature, 
cellule T immature). Inoltre, alcuni peptidi cationici sono stati proposti come agenti 
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antitumorali, in virtù del loro ridotto peso molecolare, della struttura relativamente 
semplice, del basso rischio di indurre resistenza e della specificità di azione verso le 
cellule tumorali stesse. Il carattere cationico e anfipatico dei peptidi gli consente, 
infatti, di legare ed invadere le cellule tumorali, portando alla rapida distruzione delle 
membrane e alla fuoriuscita del contenuto intracellulare, con conseguente attivazione 
dei meccanismi che mediano la morte cellulare. Essi possono anche funzionare in 
sinergia con i farmaci anti-cancro convenzionali e/o con altre potenziali molecole 
antitumorali, contribuendo a migliorare l’esito della terapia. 
Ogni specie possiede una specifica ed ampia collezione di peptidi antimicrobici, il cui 
ruolo è quello di difendere l’organismo dai microbi con cui potrebbe entrare in 
contatto. Questi peptidi sono localizzati principalmente nei tessuti bersaglio 
dell’attacco dei microbi, quali gli epiteli.  Le piante producono varie classi di peptidi 
antimicrobici, inclusi i membri della famiglia delle defensine e le tionine. Anche nelle 
piante, gli HDPs sono costitutivamente presenti in organi sensibili ad infezioni 
(principalmente fiore e seme), ma la loro espressione può anche essere indotta in 
seguito all’attacco di un patogeno, in un primo momento nel sito di infezione e 
successivamente in maniera sistemica. Gli organismi invertebrati, quali insetti e 
molluschi, sono privi di immunità adattativa e devono quindi disporre di un’efficiente 
immunità innata. Negli insetti, l’espressione di peptidi antimicrobici è inducibile nel 
corpo grasso (l’equivalente funzionale del fegato), il quale secerne HDPs 
nell’emolinfa circolante. L’espressione dei peptidi antimicrobici è, invece, costitutiva 
nelle cellule epiteliali. Nei molluschi, gli HDPs sono prodotti nelle cellule del sangue e 
sono presenti ad elevate concentrazioni nell’organismo anche in assenza di uno 
stimolo esterno. I mammiferi dispongono di un vasto repertorio di peptidi 
antimicrobici, caratterizzato da uno specifico pattern di espressione. La loro 
espressione può essere, infatti, costitutiva o, più frequentemente, indotta da 
infiammazioni, danni o lesioni. I peptidi sono, in genere, prodotti come cocktails ed 
ogni tessuto possiede il proprio archivio di differenti peptidi che si delinea sulla base 
delle specifiche condizioni fisiologiche. 
I prototipi umani di HDPs sono le defensine e le catelicidine, principalmente prodotte 
dai leucociti e dalle cellule epiteliali. Le defensine sono caratterizzate da una struttura 
prevalentemente β, dalla presenza di 6 ponti disolfurici e da una carica netta positiva. 
Esse si suddividono in 2 principali sub-famiglie: α- e β-defensine. Entrambe sono 
dotate di un’attività antibatterica ad ampio spettro e di attività antifungina ed 
antivirale, associate ad un’efficiente attività immunomodulatoria. Un’altra nota classe 
di HDPs umani è rappresentata dalle catelicidine, ampiamente diffuse nei mammiferi. 
Nell’uomo è presente una sola catelicidina a struttura α-elicoidale (LL-37), derivata 
dal processamento proteolitico della proteasi 3 dei neutrofili. LL-37 svolge numerose 
funzioni immunomodulatorie e gioca, infatti, un ruolo chiave nella salute umana.  
Diversi HDPs umani, inoltre, giocano un ruolo di difesa chiave a livello della pelle. 
Tra questi, si annoverano la dermicidina e la psoriasina. La prima è costitutivamente 
secreta dalle ghiandole sudoripare e conserva la sua attività antimicrobica anche ad 
elevate concentrazioni saline o a bassi valori di pH. La psoriasina è stata isolata per 
la prima volta dai cheratinociti dell’epidermide psoriasica. In tale condizione 
patologica, la psoriasina ed altri peptidi antimicrobici sono prodotti ad alti livelli. Ciò 
spiega la bassa predisposizione dei pazienti affetti da psoriasi alle infezioni della 
pelle. Negli individui sani, la psoriasina è prodotta principalmente in aree della pelle 
ad alta densità batterica, quali le parti superiori dei follicoli del capello, il naso e il 
palmo della mano. Tale peptide presenta siti di legame per gli ioni zinco e calcio e 
attacca specificamente E. coli flagellato mediante un meccanismo non 
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membranolitico. Questa specificità di azione esemplifica l’abilità del sistema 
immunitario innato di discriminare tra microrganismi potenzialmente dannosi e 
commensali. In alternativa, la psoriasina è anche in grado di formare pori nella 
membrana di batteri Gram-positivi. Tale attività è risultata fortemente dipendente dal 
valore di pH, essendo ottimale ad un valore di pH al di sotto di 6, caratteristico della 
pelle umana. 
Negli ultimi anni in letteratura sono state descritte numerose proteine eucariotiche 
con funzioni non strettamente legate alla difesa dell’ospite, ma che agiscono da 
“contenitori” o “vettori” di peptidi antimicrobici. Secondo un modello molto suggestivo, 
quando tali proteine vengono a contatto con i batteri, l’azione delle proteasi 
batteriche, eventualmente combinata a quella di proteasi dell’ospite, consentirebbe il 
rilascio di regioni che, una volta libere dai vincoli conformazionali della proteina 
nativa, diventerebbero dei veri e propri HDPs.  
Uno degli esempi meglio descritti in letteratura è rappresentato dalla lattoferrina, una 
glicoproteina dei mammiferi presente soprattutto nel latte materno, ma anche in altre 
secrezioni, quali lacrime e saliva. La lattoferrina appartiene alla famiglia della 
transferrina ed esplica la sua attività antimicrobica agendo come potente chelante del 
ferro, un nutriente essenziale per i microrganismi. La lattoferrina possiede anche 
un’attività antimicrobica non correlata alla chelazione del ferro, destinata 
principalmente a proteggere i neonati dalle infezioni del sistema digerente. Nello 
stomaco del neonato, infatti, tale proteina viene idrolizzata dalla pepsina, ciò che 
determina il rilascio di un peptide di 25 residui amminoacidici denominato 
“lactoferricina”, il quale rappresenta un potente peptide antimicrobico. La 
lactoferricina è un antimicrobico più attivo di quanto non lo sia la lattoferrina stessa e 
i peptidi da essa derivati esplicano anche un’azione antivirale nelle fasi precoci 
dell’infezione. È stato, inoltre, dimostrato che tali peptidi svolgono un’azione 
antitumorale, dal momento che promuovono l’apoptosi nelle cellule cancerose.  
Un altro esempio ben noto in letteratura è rappresentato dal lisozima di pollo (Gallus 
gallus), una proteina dotata di una potente attività antimicrobica, dal momento che è 
in grado di idrolizzare il peptidoglicano e quindi di danneggiare la parete dei batteri, 
principalmente di quelli Gram-positivi. Diversi studi hanno dimostrato che la 
denaturazione termica della proteina ne abolisce l’attività enzimatica, ma non quella 
antimicrobica. Studi successivi hanno dimostrato, inoltre, che vari peptidi rilasciati 
dall’azione della pepsina sul lisozima si comportano come HDPs.   
Anche numerosi membri della superfamiglia delle ribonucleasi (RNasi) da vertebrati 
sono risultati dotati di attività battericida non dipendente dalla loro attività catalitica o 
dalla loro struttura tridimensionale. Gli esempi meglio noti sono la ribonucleasi ECP 
(Eosinophil Cationic Protein), la RNasi A-2 da linfociti di pollo e le RNasi Zf-1, -2 e -3 
da Zebrafish (Danio rerio). Sia nel caso dell’ECP che della RNasi A-2, è stato 
dimostrato che corti frammenti (10-30 amminoacidi) possiedono un’attività 
antimicrobica simile a quella della proteina nativa. Nel caso della RNasi Zf-3, l’attività 
antimicrobica è risultata associata alla regione C-terminale della proteina, la quale 
viene rilasciata in seguito ad un evento proteolitico operato dalla proteasi della 
membrana esterna degli enterobatteri (OmpT).  
Preliminarmente alle attività descritte nel presente progetto di dottorato, è stato 
sviluppato dal Dott. Notomista un metodo bioinformatico che consente di localizzare 
regioni antimicrobiche in precursori proteici e di fornire una predizione quantitativa 
dell’attività antibatterica ad esse associata. Ciò ha consentito di identificare con un 
approccio razionale peptidi “criptici” presenti nel secretoma umano. Sono state così 
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analizzate circa 4,000 proteine extracellulari umane ed è stata creata una lista di 
potenziali HDPs. 
Il presente progetto di dottorato si colloca in una vasta linea di ricerca il cui obiettivo 
principale è la produzione e la caratterizzazione dei più interessanti HDPs identificati 
mediante metodo bioinformatico. I primi HDPs ad essere prodotti commercialmente 
come agenti anti-infettivi, sono state le gramicidine prodotte da Bacillus brevis che 
sono state utilizzate come antibiotici per applicazioni topiche. Altri esempi sono 
rappresentati da peptidi approvati nell'industria alimentare come conservanti naturali 
o integratori alimentari, come la nisina, approvato dal 1969 e la lattoferrina aggiunto 
alla formula del latte per neonati. Il fine ultimo di questo progetto è, quindi, quello di 
selezionare candidati ideali per lo sviluppo di nuovi agenti antimicrobici ed anti-
infiammatori per uso topico, impiegabili nel trattamento di ferite chirurgiche, ulcere 
cutanee e delle mucose o nell’industria alimentare come conservanti alimentari. In 
tale contesto, l’Apolipoproteina B (ApoB) è stata identificata come un nuovo 
precursore proteico di HDPs umani. In particolare, sono state identificate due brevi 
sequenze amminoacidiche dalla putativa azione antimicrobica (regione 887-922), 
denominate ApoBL ed ApoBS per indicare, rispettivamente, una porzione lunga (long) 
di 37 amminoacidi ed una corta (short) di 25 amminoacidi. Nel corso del presente 
progetto di ricerca, questi due nuovi HDPs sono stati caratterizzati per la loro attività 
antimicrobica, anti-biofilm, anti-infiammatoria, la loro capacità di agire in sinergia con 
gli antibiotici convenzionali e l’EDTA e la loro attività di wound healing. Inoltre, è stata 
condotta una caratterizzazione strutturale e funzionale del primo HDP identificato in 
una proteina archeobatterica (una DNA-binding protein da Sulfolobus islandicus) e di 
un peptide identificato nella 11 beta-idrossisteroide deidrogenasi umana. Per 
entrambi i peptidi, è stata effettuata un’approfondita caratterizzazione chimico-fisica 
ed è stata dimostrata un’attività antibatterica ad ampio spettro. Sono state, inoltre, 
messe in evidenza interessanti capacità immunomodulanti e antitumorali. 
Gli obiettivi del presente progetto di dottorato possono essere riassunti in due punti 
fondamentali: 
1) ottimizzazione di un sistema di espressione ricombinante di peptidi antimicrobici, 
ciò che ha previsto la messa a punto di una strategia fermentativa su larga scala da 
impiegare a livello industriale per la produzione di peptidi antimicrobici di interesse 
biotecnologico; 
2) la caratterizzazione funzionale completa di peptidi HDPs identificati mediante 
metodo bioinformatico, quali due HDPs identificati nell’Apolipoproteina B umana e 
due nuovi HDPs identificati, rispettivamente, nel fattore di trascrizione Stf76 di 
Sulfolobus islandicus e nella 11 beta-idrossisteroide deidrogenasi umana. 
Lo sviluppo di un sistema di espressione di peptidi tossici in E. coli può 
rappresentare una valida ed economica alternativa alle strategie di sintesi chimica 
attualmente disponibili. Per tale motivo, in prima battuta, si è proceduto ad 
ottimizzare le condizioni colturali di E. coli puntando sullo sviluppo di un mezzo di 
coltura costituito da componenti economici e facilmente reperibili. Dal momento che 
la procedura sperimentale prevede l’accumulo della proteina di interesse nei corpi di 
inclusione, è stato messo a punto un mezzo di coltura ricco e quindi in grado di 
sostenere la formazione di grandi quantità di biomassa. È stata, inoltre, privilegiata 
una fonte di carbonio economica, quale il triptone. L’impiego di glucosio ha anche 
consentito di minimizzare l’espressione basale nella fase di crescita delle cellule 
batteriche. E’ stata anche messa a punto una procedura di auto-induzione, basata 
sull’impego di lattosio quale valida ed economica alternativa all’IPTG, come riportato 
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in letteratura per l’espressione eterologa di geni clonati in vettori pET per 
fermentazioni fed-batch in sistemi “high-cell density”.  
Nell’ottica di rendere il processo economico ed applicabile su larga scala, va anche 
segnalata l’economicità della strategia di purificazione del costrutto chimerico di 
interesse. Infatti, la presenza di un sito amminoacidico acido labile Asp-Pro, 
interposto tra la proteina carrier (onconasi) ed il peptide di interesse, consente di 
ottenere un’efficiente separazione mediante idrolisi acida selettiva, evitando così 
l’impiego di costose proteasi, ciò che è classicamente previsto in tali strategie 
sperimentali.  
La caratterizzazione funzionale completa dei peptidi oggetto del presente progetto di 
dottorato, ha riguardato l’analisi delle loro proprietà antimicrobiche, anti-biofilm ed 
immunomodulanti ed è stata in parte svolta durante il periodo di ricerca (6 mesi) nel 
gruppo diretto dal Prof. Henk P. Haagsman, presso la Faculty of Veterinary Medicine, 
Utrecht University, The Netherlands. L’esperienza di tale gruppo nel campo della 
caratterizzazione dei peptidi bioattivi è ben nota. I risultati ottenuti hanno mostrato 
che i peptidi in esame sono dotati di attività antimicrobica ad ampio spettro. È 
risultato, inoltre, molto interessante che i peptidi siano risultati in grado di esplicare 
attività anti-biofilm a concentrazioni significativamente più basse di quelle necessarie 
per ottenere effetti su cellule batteriche allo stato planctonico. Ciò riveste particolare 
importanza se si considera che l’80% delle malattie infettive croniche umane sono 
causate da batteri patogeni capaci di formare biofilm. Solo agenti battericidi in grado 
di agire in maniera specifica su cellule in stato stazionario o in lenta divisione, quali 
gli HDPs, possono risultare in grado di eradicare completamente il biofilm. In tale 
contesto appaiono fortemente promettenti “terapie combinate” basate sulla 
somministrazione di formulazioni di peptidi e antibiotici convenzionali. Allo scopo di 
valutare l’efficacia di tale approccio combinatorio, sono stati condotti studi di sinergia 
utilizzando combinazioni dei peptidi in esame con i più noti antibiotici convenzionali. 
Sono stati così dimostrati effetti sinergici sulla maggioranza dei ceppi saggiati, inclusi 
ceppi caratterizzati da un fenotipo di resistenza agli antibiotici classici. 
Nel complesso, i dati sperimentali ottenuti danno rilevanza all’effettivo impiego di 
questi peptidi per svariate applicazioni in ambito biotecnologico. Gli HDPs, infatti, 
trovano già impiego nell’industria alimentare come conservanti alimentari o come 
arma per abbattere l’impiego di antibiotici in allevamenti a scopo alimentare. Basti 
pensare alla nisina o alla lattoferrina presente nel latte in polvere. Inoltre, in ambito 
cosmetico, numerosi studi riportano dati sul loro potenziale quali componenti di 
formulazioni ad uso topico. Per quanto riguarda l’ambito clinico, ad oggi, numerosi 
HDPs sono in fase di studio pre-clinico e clinico, quale valida alternativa agli 
antibiotici convenzionali. 
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Antibiotic Resistance 
The discovery of penicillin opened a new era in the treatment of infectious diseases, 
which was described as the “golden age” of antibiotic research (1940–1962) [1]. This 
was rapidly followed by the discovery of other antimicrobials, including widely used 
antibiotics, such as streptomycin, chloramphenicol, and tetracycline. For the first 
time, many common bacterial diseases could be cured. The first antibiotics played a 
crucial role in the treatment and prevention of infections during World War II [2]. 
Antibiotics were so successful that they were considered the ultimate cure, the 
“miracle drugs” that the medical world was craving. As a result of the initial success 
of antibiotics, bacterial diseases were naively considered to be permanently 
defeated. However, the excessive and unneeded use of antibiotics led to the 
development of more and more pathogenic bacteria resistant to their inhibitory 
effects [3]. Hence, despite their initial effectiveness, most antibiotics have a limited 
life, and their efficacy is compromised by the selection of pathogens endowed with 
intrinsic or acquired resistance mechanisms [4]. Currently, antimicrobial resistance 
threatens the effective prevention and treatment of an ever-expanding range of 
infections. It is an increasingly serious threat to global public health that requires 
immediate action, since it affects all parts of the world as new resistance 
mechanisms emerge and rapidly spread around the globe [5]. 
To clarify the molecular bases of the development of antibiotic resistance phenotype, 
in recent years, scientists focused their attention on the comprehension of the intra- 
and inter-cellular processes that govern bacterial ecology. Far from being isolated 
cells, bacteria might be more appropriately viewed as disseminated multicellular 
organisms, whose interactions are mediated by complex cell-cell signaling [6, 7]. 
Cell-cell interactions can lead to the formation of spatially complex matrices 
composed by polysaccharide and extracellular DNA, and embedding bacterial cells 
that consequently form a biofilm community [8]. In this scenario, to combat bacterial 
infections, a deeper understanding of bacteria intracellular genetics and biochemistry 
is needed, as well as the comprehension of biofilm effects on antibiotic uptake and 
resistance (Figure 1).  
 
 
 
Figure 1: Schematic rapresentation of antiobiotic resistance development in the case 
of bacteria embedded in a biofilm structure (a), and in the case of planktonic cells (b). 
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Resistance phenotype in planktonic bacterial cells 
Historically, research activities aimed at the comprehension of the molecular bases of 
antibiotic resistance development have been carried out at the level of single 
planktonic cells, and have led to the identification of the following mechanisms: 
inactivation of drugs via hydrolysis (e.g., via β-lactamase) or modification (e.g., 
aminoglycoside resistance); alteration of cellular targets that become unrecognizable 
to the drug (e.g., by DNA gyrase mutation in fluoroquinolone resistance); by the 
development of permeation barriers, preventing drug access to the target (e.g., the 
Gram-negative outer membrane); and by the active efflux of drugs out of the cell via 
membrane-bound efflux transporters [9, 10] (Figure 1). The development of cellular 
resistance is generally the result of endogenous genes mutations, or is due to the 
transfer of resistance determinants from other microorganisms. Recent advances in 
genomics and metagenomics have revealed that many natural ecosystems contain a 
large number of genes whose functions can be co-opted to confer resistance to 
antimicrobials [11-14]. These genes are collectively known as the resistome [15, 16]. 
The resistome concept is anthropocentric, since the original functions of resistome 
genes were probably not related to the development of antibiotic resistance 
phenotypes. However, the resistome concept is certainly useful, since it underscores 
the role of environmental bacteria in supplying resistance genes to pathogens [17]. 
Moreover, the finding that genes able to confer resistance phenotypes may be 
recovered from extreme environments that have not been in contact with humans, 
such as the deep subsurface [18], ice [19], and permafrost [20], further suggests that 
these genes have natural roles not related to antibiotic resistance phenotype. This is 
indeed the case of multi-drug transporters, which might have evolved as transporters 
for naturally occurring substrates, serving as mechanisms to pump toxins out from 
cells, and their consequent ability to transport also antibiotics might have been 
fortuitous [21]. “Resistance” genes during the pre-antibiotic era were probably 
chromosomal, and encoded physiologically relevant functions. In the post-antibiotic 
era, resistome genes might have been laterally transferred to a new host where their 
original biochemical and genetic functions were adopted to develop antibiotic 
resistance [22]. Over the last fifty years, research has mainly focused on clinical 
aspects of antibiotic resistance, while the possible original functions of resistance 
genes have been largely overlooked. The deep comprehension of the original roles 
of these resistome elements may aid the development of successful strategies to 
fight infections caused by antibiotic resistant pathogens. 
 
Resistance phenotype in bacterial communities 
Bacterial communities can exhibit tolerance to environmental stress that single cells 
cannot, and this tolerance might be crucial for the development of resistance 
phenotype. It has been reported that microbes in a biofilm community gain additional 
antibiotic resistance that can be up to 1,000 times higher than that gained by the 
corresponding planktonic cells [23]. Community level resistance adds to the cellular 
level resistance, thus greatly enhancing the overall antibiotic resistance of the 
microbial community. [24, 25]. Bacteria aggregates in biofilm are exposed to nutrient 
and oxygen gradients that may lead to heterogeneity. In fact, cells in the deeper 
layers of biofilms may have a slower metabolism, being locally adapted to the low 
levels of nutrients and oxygen, with respect to the more metabolically active surface 
cells. This, in turn, can lead to significant differences in resistance phenotypes 
exhibited by these subpopulations in response to antimicrobial treatment [26]. A large 
percentage (80%) of bacterial infections is complicated by biofilms involvement [27]. 
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As a consequence, guidelines for antibiotic use based on studies on planktonic cells 
might not be appropriate. Biofilm-specific resistance mechanisms, which are distinct 
from the well characterized resistance mechanisms developed at the level of single 
cells, may act in an orchestrated manner to confer high levels of antibiotic resistance 
in biofilm communities. Components of the biofilm matrix form a mechanical shield 
that acts to inhibit the effect of antibiotics. The Pel (extracellular polysaccharide) and 
Psl (membrane polysaccharide) components, produced in Pseudomonas aeruginosa 
biofilms, contribute to antibiotic resistance. In fact, Pel deficient mutants were found 
to be more susceptible to aminoglycoside antibiotics tobramycin and gentamicin, with 
respect to the wild type strain [28, 29]. Extracellular DNA (eDNA) forms part of biofilm 
matrices, and may play a key role in biofilm antibiotic resistance. Since eDNA is 
negatively charged, it might act as a chelator of cationic antimicrobials [30] it can also 
act as a shield against aminoglycosides [31]. Bacteria can also become highly 
resistant to antibiotics when they experience nutrient limitation in growth media [32]. 
In fact, the starvation-induced stringent (SOS) response has been found to be 
implicated in enhanced biofilm-specific resistance towards various classes of 
antibiotics in the case of P. aeruginosa and E. coli strains [33]. A further phenomenon 
that greatly contributes to antibiotic resistance in biofilms is the emergence of 
persister cells [34], which adopt a slow or non-growing phenotype, and become 
highly resistant to environmental stresses, including antibiotic challenge. 
Furthermore, persister cells may survive even when the rest of the community has 
perished, thus creating reservoirs of surviving cells that are able to regrow and cause 
relapsing infections [35]. Metabolic quiescence is indeed a strategy to tolerate 
antibiotic exposure [36]. 
 
Synergism between resistance mechanisms 
It has also to be highlighted that, despite the inherent differences regarding the 
nature and mechanisms of cellular and community resistance, they are indeed 
synergistic. The biofilm mode of life, besides providing resistance at a community 
level, can also promote resistance at the level of single cells. Biofilm communities 
have a greatly enhanced mutation rate (up to 100 times higher with respect to 
planktonic cells) [37], which inevitably leads to faster development of antibiotic 
resistant mutants. Moreover, in biofilm communities, different microbial organisms 
are in close proximity, and there is an abundance of eDNA, what likely facilitates 
horizontal gene transfer, and acquisition and spread of resistance determinants. 
Indeed, it has been shown that biofilms may constitute specific foci of genetic 
adaptation and evolution, leading to the selection of subpopulations with a greater 
ability to acquire antibiotic resistance [38, 39]. Furthermore, traditional mechanisms 
of resistance development at a single cell level may also act in a biofilm-specific 
manner. For example, an up-regulation of certain pumps specialized in drug efflux is 
observed in P. aeruginosa and E. coli [40, 41] biofilms even without an antibiotic 
challenge, suggesting a physiological role of these pumps in the biofilm mode of life. 
As a consequence of this complex picture, the increased use of antibiotics in clinical 
practice was soon followed by the emergence of antibiotic resistance phenotypes 
(Figure 2). Indeed, resistance development was observed in target organisms within 
a few years from the introduction of antibiotics into medical practice [42]. Within 
seven years from penicillin first use, 50% of hospital Staphylococcus aureus isolates 
were resistant [43], and they represent hidden backbone of advanced medical care, 
such as surgical procedures, transplant and geriatric medicine, critical care and 
cancer chemotherapy [44]. 
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Figure 2: Monitoring the emergence of antibiotic resistance in the last decade.  
 
Unfortunately, despite the desperate need for new antibiotics, there has been little 
investment into novel antibiotics discovery by the pharmaceutical industry, largely 
because financial returns are likely to be limited. Development of antibiotics faces 
stringent government regulations that can delay new drugs entering the market [45]. 
The time between the initial discovery of a compound and its market entry takes 
about 10 years on average. This means that antibiotics launched today are the 
products of drug discovery projects initiated a decade ago [46]. In 1980, there were 
more than 25 pharmaceutical companies in the USA with active antibacterial drug 
discovery programmes [47]; today only a few of the largest companies remain active 
in the field. As a consequence, during the last two decades, a substantial gap in the 
discovery of antibacterial drugs has been created, which is responsible for the 
current lack of newly approved systemic antibacterial agents (Figure 3).  
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Figure 3: Schematic representation of the ‘discovery void’. 
 
This makes the search for novel antimicrobial therapies and approaches imperative. 
In this scenario, the exploitation of the broad antimicrobial and immunomodulatory 
properties of naturally occurring Host Defence Peptides (HDPs), first called Anti-
Microbial Peptides (AMPs), has attracted considerable attention. 
 
Host Defence Peptides 
Host defense peptides are evolutionarily conserved molecules of the innate immune 
system. They are produced by all complex animals, insects and plants, and generally 
have modest direct activity against a broad range of microorganisms including 
bacteria, viruses, fungi, and protozoa [48, 49]. Remarkably, there are more than 
2,600 known natural peptides with very diverse sequences and structures [50]. 
Naturally occurring HDPs can vary in size, ranging from 12 to 50 (or more) amino 
acids, are generally cationic owing to the presence of high levels of lysine and 
arginine residues, and contain about 50% hydrophobic amino acids [51]. These 
properties allow them to interact with membranes, and, in some cases, to penetrate 
cell membranes. HDPs are classified into four major classes based on their 
structures: β-sheet (for example, human α and β defensins), α-helical (for example, 
LL-37, magainins and mellitin), loop peptides with one disulfide bridge (for example, 
bactenecin), and peptides enriched in specific amino acids as proline, tryptophan, 
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histidine or glycine without a well-defined structure (for example, indolicidin) [52]. 
They associate preferentially with membranes of bacteria-like composition (i.e., 
negatively charged) in model systems, and many peptides are able to translocate 
into host cells. 
Several models have been proposed to explain HDPs mechanism of action, such as 
carpet model, barrel-stave model, the toroidal-pore model, and the detergent-type 
mechanism. In the case of carpet model, peptides assemble on the surface of target 
membranes, and disrupt them [53]. In the barrel-stave model, peptides are believed 
to insert into target membranes and to aggregate, thus forming a traditional ion-
channel pore. In the case of toroidal-pore model, instead, peptides are believed to 
locate close to membrane phospholipids head groups, with an initial orientation 
parallel to that of lipid bilayer surface. In this orientation, helices hydrophilic sides are 
exposed to the hydrophilic membrane head groups, whereas helices hydrophobic 
faces are buried into membrane hydrophobic core. When peptide concentration 
reaches a critical value, peptides aggregation occurs, thus determining membrane 
curvature and toroidal-pores formation [54]. Finally, in the detergent-type mechanism, 
peptides are believed to first assemble on the surface of target membranes, as in the 
carpet and toroidal-pore models, then they aggregate, thus reaching a high local 
concentration. HDPs amphipathic nature allows them to behave as detergents and to 
disrupt lipid membrane into small fragments, such as bicelles or micelles [55] (Figure 
4).  
 
 
 
Figure 4: Schematic representation of models proposed to explain HDPs mechanism 
of action. 
 
It has been suggested that peptides tend to translocate intracellularly in bacteria 
owing to the presence of a large electrical potential gradient of about 120 mV [56]. 
Their direct antimicrobial mechanism of action against bacteria often involves 
multiple different targets including bacterial membrane, essential processes that 
utilize membrane-associated intermediates, such as cell wall peptidoglycan 
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biosynthesis and possibly cell division, or essential biomolecules, such as cytosolic 
RNA, DNA, proteins, and/or enzymes/chaperones. Given to this broad range of 
targets, HDPs induction of resistance mechanisms in bacteria is improbable [57]. 
Recent studies have demonstrated that antimicrobial peptides are endowed with a 
wide range of activities in modulating the functions of host cells and tissues as part of 
natural host defences, which has led to the depiction of these peptides as Host 
Defence Peptides rather than antimicrobial peptides to better define their 
multifaceted roles as immunomodulatory mediators and, under some circumstances, 
antimicrobial agents. This concept mainly derived from the observation that many 
HDPs lose their antimicrobial potency under physiological conditions, whereas their 
immunomodulatory activities can be detected both in tissue cultures and in vivo [58]. 
Moreover, it was demonstrated that a synthetic HDP modelled on bovine bactenecin, 
although completely lacking direct antibacterial activity in vitro, protected mice from 
infection in vivo [59]. This clearly indicated that its anti-infective properties are mainly 
associated to its ability to modulate the immune response. Nowadays, the ability of 
HDPs to act as modulators of the immune response and immune cell signalling has 
been extensively studied, and their role in innate and adaptive immunity is becoming 
increasingly appreciated [60]. 
 
HDPs immunomodulatory activity 
HDPs are much more than simple immunomodulators acting through a single 
receptor or a linear signalling pathway of the immune system. This complexity has 
become clearly evident by the analysis of the protein–protein interaction network of 
the human cathelicidin LL-37 [61].  
Natural and powerful immune functions of HDPs have been also transferred to 
synthetic peptide analogues, such as the innate defense regulators (IDRs), which are 
conceptually based on natural peptides. IDRs protective effects have been 
demonstrated in mouse models upon infection with Staphylococcus aureus including 
MRSA, vancomycin-resistant enterococci (VRE), Plasmodium berghei, multi-drug-
resistant Mycobacterium tuberculosis, and herpes simplex virus [62-67]. 
HDPs and IDRs immunomodulatory activities include the ability to modulate pro- and 
anti-inflammatory responses through signaling pathways alteration, the ability to 
directly and indirectly recruite effector cells (phagocytes), the enhancement of 
extracellular and intracellular bacterial killing, the promotion of polarized dendritic cell 
maturation and macrophage differentiation, and the modulation of wound repair, 
apoptosis, and pyroptosis (Figure 5) [68-76].  
 
 
 15 
 
 
 
Figure 5: HDPs and IDRs immune functions. HDPs, once released at high 
concentrations by epithelial cells and immune cells, might exert direct antimicrobial or 
anti-biofilm activity against invading bacteria (1). At lower concentrations, HDPs 
might indirectly or directly promote the recruitment of immune cells, such as 
neutrophils and monocytes (2), suppress the induced production of proinflammatory 
cytokines, such as tumor necrosis factor (TNF)-α, interleukin-6 (IL-6), and IL-8, and 
enhance the production of anti-inflammatory mediators including IL-10 and 
chemokines (monocyte chemotactic protein 1, MCP-1) (3), induce macrophage and 
dendritic cells differentiation and activation (4), leading to the modulation of adaptive 
immunity and inducing the recruitment of T cells, and (5) regulate specific cell 
activities including autophagy and the formation of neutrophil extracellular traps 
(NETs) (6). 
 
In humans, HDPs are produced by a variety of immune cells of hematopoietic and 
epithelial origin (Table 1) [77]. Among human HDPs, six are classified as α-
defensins; four out of them are produced and stored in the secretory granules of 
neutrophils (human neutrophil peptides, HNPs), whereas two are expressed as pro-
peptides in granules of Paneth cells. When stimulated by pro-inflammatory 
molecules, both neutrophils and Paneth cells degranulate, releasing α-defensins into 
the local environment.  
Human β-defensins (HBDs), instead, play a major role in preventing the colonization 
of microbes, such as bacteria, viruses, parasites, and fungi, on epithelial surfaces. 
Some β-defensins are constitutively produced. This is the case of human β-defensin 
1 (HβD-1), which is predominantly released by keratinocytes, since it represents a 
constitutive defense. Other β-defensins, such as HBD2-4, are produced by the 
mucosal, gastrointestinal, and urogenital epithelia, and their production is induced by 
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pro-inflammatory stimuli, such as lipopolysaccharide (LPS) and tumor necrosis factor 
α (TNF-α) [78]. 
A very well studied human HDP is a cathelicidin precursor, hCAP-18, which is 
processed by serine protease 3 to generate α-helical LL-37, a 37-amino acid linear 
peptide [79]. LL-37 has been identified in many cells, tissues, and organs, as well as 
on the mucosa, and in secretions. Moreover, during infections and inflammatory 
processes, neutrophils degranulation determines the release of relatively high levels 
of LL-37 into the local environment. LL-37 has been found to be endowed with a 
broad range of immunomodulatory functions in vivo, including the direct and indirect 
recruitment of neutrophils, monocytes, and T cells, as well as a very strong anti-
endotoxin activity [80, 81]. Individuals with Kostmann disease are LL-37 deficient, 
and present a significantly reduced production of human neutrophil peptide (HNP). It 
has been found that they exhibit an increased susceptibility to severe periodontal 
diseases, what demonstrates the key role played by these peptides in host defense 
[82]. 
 
 
 
Table 1. Human HDPs: sites of production and specific targets.  
 
Anti-biofilm peptides: their potential as broad-spectrum agents 
In recent years, various approaches to treat bacterial biofilm infections (e.g., quorum 
sensing antagonists, antibodies, anti-adhesion strategies, bacteriophages, etc.) have 
been developed [83]. A promising and efficient alternative strategy might be 
represented, indeed, by cationic and amphipathic HDPs endowed with anti-biofilm 
activity [84]. One of the first successes in the field was obtained by demonstrating 
that human cathelicidin LL-37 is able to inhibit Pseudomonas aeruginosa biofilm 
formation at concentrations significantly lower than those required to kill planktonic 
organisms [85, 86]. Starting from this observation, it was demonstrated that anti-
biofilm peptides represent a distinct subset of peptides with an amino acidic 
composition similar to those of conventional HDPs, but with a structure-function 
relationship different from that of classical antimicrobial peptides [87]. Indeed, 
structure-function relationship studies have excluded significant overlaps between 
anti-biofilm and antimicrobial (vs. planktonic bacteria) activities, and it was 
demonstrated that organisms completely resistant to antibiotic peptides may be 
efficiently treated with anti-biofilm peptides [88]. Therefore, it is possible to generate 
novel anti-biofilm peptides able to: (i) kill multiple species of bacteria growing in 
biofilms, including major clinically-relevant antibiotic resistant Gram-negative and 
Gram-positive bacteria, (ii) synergistically act in combination with conventional 
antibiotics on multiple species, and (iii) affect biofilm infections in animal models.  
In this scenario, combination therapy approaches based on the concomitant 
administration of anti-biofilm peptides and conventional antibiotics offer a very 
promising and powerful weapon to treat both biofilms and dispersed infections, 
thereby forming the basis for novel and efficacy adjuvant therapies [89]. 
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HDPs applications  
HDPs applications span from pharmaceutical industry to food industry. HDPs are 
gaining attention mainly as antimicrobial alternative weapons, food preservatives and 
as immune defense regulators. Some HDPs are already in phase II or III of clinical 
trial as antimicrobials, mainly for topical applications [90-95]. The first HDPs to be 
commercially manufactured as anti-infective agents were gramicidins produced by 
Bacillus brevis [96], which were used as antibiotics for topical applications. Among 
HDP-based compounds in advanced stages of development as anti-infective drugs, it 
is worth mentioning Locilex for the treatment of diabetic foot ulcers, and OP-145 
against chronic bacterial middle-ear infections [97]. Other examples are represented 
by peptides approved in food industry as natural preservatives or dietary 
supplements, such as nisin, approved since 1969 [98], and lactoferrin added to infant 
milk formula [99].  
Currently, antimicrobial peptides application in the medical field is still one of the 
most interesting perspectives. The ability of HDPs to modulate the innate immune 
system has also made them promising candidates as vaccine adjuvants [100]. In 
fact, it was demonstrated that human neutrophil defensins can enhance both humoral 
and cell-mediated antigen specific immune response in murine models [101]. 
Moreover, since HDPs dysregulation is often associated to disease states, these 
molecules have been proposed as biomarkers for specific disorders. This was found 
to be particularly useful to identify patients with underlying bacterial infections, whose 
diagnosis would have otherwise taken a longer time. For example, urinary levels of 
specific HDPs have been found to be substantially increased in patients presenting 
infections of the urinary tract [102]. HDPs have also been identified as biomarkers in 
cancer. In fact, serum levels of specific HDPs were found to be elevated in patients 
with colon cancer, a phenomenon that was proposed as a specific marker for cancer 
diagnosis [103]. 
In the literature, new HDPs activities are continuously identified, a clear indication 
that the interest in these molecules continues to grow. A recent example is 
represented by the discovery of a new HDP from earthworms, that exerted 
neurotropic activity in mouse neural stem cells and a protective effect in a mouse 
model of Parkinson disease [104]. Another recent study describes a novel bone-
forming cell phenotype that was generated by differentiating blood-derived mono-
cytes in the presence of the HDP LL-37. The authors suggest that these cells, which 
were named monoosteophils, might potentially be used to enhance the repair of 
broken bones or even to treat osteoporosis [105, 106]. 
On the basis of these observations, it is probable that, in the next future, further 
interesting applications might be envisaged for this promising class of biomolecules. 
 
“Cryptic” HDPs 
It has been reported that many proteins whose functions are not necessarily related 
to host defense can act as sources of HDPs. Some examples are haemoglobin, 
thrombin, lactoferrin, lysozyme, histone-like proteins and vertebrate secretory 
ribonucleases [107-108]. This is also the case of apolipoproteins, proteins commonly 
known for their role in lipid transport into blood. In fact, it has been reported that 
Apoliporotein B [109] and Apolipoprotein E [110] contain hidden HDPs. Since these 
peptides are hidden within the sequences of precursor proteins, they have been 
defined “cryptic” peptides. Based on this observation, human proteome could be 
fascinatingly seen as a yet unexplored source of bioactive peptides with potential 
pharmacological applications. This has also led to the formulation of a very 
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interesting hypothesis asserting that multicellular eukaryotes, have developed a 
panel of “AMP-Releasing Proteins” (AMPRPs), which release active peptides only 
after a partial proteolytic processing operated by bacterial and/or host proteases 
[111]. As a consequence of this, bacterial strains that secrete proteases as a weapon 
against antimicrobial peptides would kill themselves by releasing “cryptic” HDPs from 
their precursor proteins. 
The identification and localization of a cryptic peptide inside its precursor protein is 
often carried out either through the analysis of peptide fragments generated by 
proteases, or by synthesizing a set of overlapping peptides, which cover the entire 
sequence of the protein of interest. Such experimental procedures are expensive and 
time-consuming. Hence, the development of faster bioinformatics approaches, 
capable of highlighting the presence of a putative antimicrobial region in a precursor 
protein, would prove extremely useful. 
 
Aims of the Thesis 
The overall aim of the present research project is the identification and 
characterization of cryptic HDPs hidden in protein precursors by using a novel 
bioinformatics method, which was recently developed by Dr. Notomista [112]. This 
method, based on a set of scoring functions, allows a semi-quantitative prediction of 
the antibacterial activity of specific amino acidic sequences contained in a precursor 
protein. Once set up, the method was validated by analyzing the sequences of 
known HDP-Releasing proteins (HDP-RPs), and it was found to a powerful tool to 
identify novel HDP-RPs. An important advantage of the recently developed method is 
that it includes some strain-specific parameters, thus offering the possibility to predict 
HDP efficacy on any desired bacterial strain. 
Once identified, human HDPs described in the present Thesis were recombinantly 
produced in Escherichia coli host. This allowed the setting up of a cost-effective 
production procedure, whose development represents the first aim accomplished in 
the present research work, which is described in Chapter 2. This aspect is 
particularly interesting since, although chemical synthesis is very efficient and 
represents the most popular strategy to produce peptides, it is a complex and costly 
process. Hence, it is well suited to obtain small amounts of peptides, but it could be 
rather expensive when peptides longer than 30 amino acids or high quantities of 
peptides are required [113]. 
The second aim of the present Thesis is reported in Chapter 3, where the production 
and the characterization of two novel bioactive HDPs identified in human 
Apolipoprotein B is reported.  
Chapter 4 mainly focuses on the structural and functional characterization of two 
novel cryptic host defense peptides. The first one was identified in human 11-
hydroxysteroid dehydrogenase-1 β-like, whereas the second one was identified in the 
transcription factor, Stf76, encoded by pSSVx, a hybrid plasmid-virus from the 
archaeon Sulfolobus islandicus. 
A general discussion on the main findings and conclusions derived from the present 
research work is reported in Chapter 5. 
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1. Introduction 
Both basic research and clinical applications require high quality peptides to be 
readily available in a cost-effective manner. This is the case of antimicrobial peptides 
(AMPs), also referred to as host defense peptides (HDPs), in order to account for 
their immunomodulatory properties. HDPs are short cationic molecules produced by 
virtually all living organisms. So far, more than 2,500 HDPs have been identified, 
which exhibit a wide range of biological activities from direct killing of invading 
pathogens to modulation of immunity and other biological responses of the host [1]. 
Due to their functional properties, HDPs potential applications range from biomedical 
therapies to food industry and agriculture field. In general, HDPs isolation from 
natural sources is a labor intensive and time-consuming process, not suitable to 
obtain peptides in large amounts. On the other hand, chemical synthesis, although 
very efficient, is a complex and costly process [2]. For this reason, it is well suited to 
obtain small amounts of peptides, but it could be rather expensive when peptides 
longer than 30 amino acids or high quantities of peptide are required. Therefore, it is 
not an ideal platform for large-scale peptide production. In this scenario, recombinant 
DNA technology provides an economical means for peptide manufacture. Indeed, 
many AMPs have been successfully obtained through recombinant production in 
various heterologous hosts [3]. Among these, Escherichia coli has been the most 
widely used host to produce recombinant peptides [4]. However, it has to be 
considered that recombinant production of peptides entails several difficulties [3, 5-7]. 
Firstly, the peptides’ antibacterial nature makes them potentially fatal to the 
producing host. Secondly, the peptides’ small size and cationic property make them 
highly susceptible to proteolytic degradation, with consequent low yields. A strategy 
that effectively overcomes both obstacles is peptide fusion to a carrier protein. By 
using this strategy, the peptide of interest can be released from the carrier by 
enzymatic or chemical cleavage at a specific site around the carrier-peptide junction. 
In general, enzymatic cleavage has been found to be less efficient than chemical 
proteolysis to obtain pure peptides [6]. The fusion design mimics the peptide 
precursor structure, since the carrier protein plays a similar role as the peptide 
natural pro-segment, thus protecting the host from the toxic peptide and the peptide 
from bacterial proteases [8]. Recently, we described the rational development of a 
new carrier protein for high yield production of recombinant peptides in E. coli [9-11]. 
The denatured form of Onconase (ONC), a RNase from Rana pipiens [12], is a very 
well suited partner, since it can be expressed at very high levels in inclusion bodies 
(about 200–250 mg/L in Terrific Broth), it is a very small protein (104 aa) thus 
allowing high yields of the peptides upon chemical cleavage, and its solubility is pH 
dependent (the denatured protein is soluble only at pH<4.0) thus allowing the 
purification of peptides soluble at pH 7.0 by selective precipitation of the carrier. 
Moreover, the chimeric construct has been designed to contain a His tag sequence, 
positioned between the ONC and the peptide moieties, suitable for an easy 
purification of the chimeric construct, a flexible linker (Gly-Thr-Gly), and a dipeptide 
(Asp-Pro), which is cleaved in mild acidic conditions thus allowing the release of the 
peptide from the carrier [9-11]. Carrier mutations were designed to minimize 
undesired cleavage events by removing all the potential unwanted cleavage sites, 
and to reduce the possibility of intra-chain disulfides formation without affecting 
expression levels of the fusion protein, its propensity to form inclusion bodies in E. 
coli and to aggregate at pH 7.0, since this feature is crucial to remove the carrier after 
the chemical cleavage by means of a simple centrifugation step [9]. The optimized 
procedure allows the purification of about 10 mg of pure peptide from 1 L of bacterial 
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culture [11].  Here, we describe the development of a novel growth medium and a 
scaling up of the present strategy, in order to set up a cost-effective and competitive 
procedure to produce large amounts of peptides needed for both basic research and 
industrial applications. To perform this optimization, a good starting point was 
represented by the simplicity and limited costs of the previously set up production 
protocol. The necessity to design a novel growth medium derives from the 
observation that LB growth medium, which is the most commonly used medium for 
culturing E. coli, although easy to make, rich in nutrients and with an optimal 
osmolarity for E. coli growth at early log phase, is generally responsible for a stop of 
bacterial cell growth at relatively low densities. This is mainly due to the presence of 
scarce amounts of carbohydrates (and other utilizable carbon sources) and divalent 
cations [13]. Not surprisingly, when the amount of peptone or yeast extract is 
increased, higher cell densities are reached [14]. By the same way, divalent cation 
supplementation (MgSO4 in the millimolar range) results in higher cell growth. 
Glucose supplementation is, instead, of limited help because acid generation by 
glucose metabolism overwhelms the limited buffer capacity of LB, at least in shake 
flasks where pH control can be laborious [15,16]. If culture acidification poses a 
problem, the media can be buffered with phosphate salts at 50 mM. Indeed, this is 
the case of 2x YT, TB (Terrific Broth) and SB (Super Broth) media, which have been 
shown to be superior to LB for reaching higher cell densities [17]. The novel culture 
medium, here developed, is composed by cheap components, readily available and 
containing defined amounts of each compound. We also set up an auto-induction 
procedure with the ultimate goal of scaling up an efficient and commercially 
competitive production strategy. The proposed experimental strategy has been 
successfully applied to GKY20 peptide, a short cationic antimicrobial peptide derived 
from the C-terminus of human thrombin [9] and to two novel HDPs identified in an 
isoform of human Apolipoprotein B (residues 887-922), and recently characterized for 
their biological activities [11]. Since the peptides GKY20, ApoB887-923, and 
ApoB887-911, upon cleavage of the chimeric construct in mild acidic conditions, are 
released with an additional proline residue at the N-terminus, they were here named 
r(P)GKY20, r(P)ApoBL, and r(P)ApoBS, respectively. 
 
2. Materials and Methods 
2.1 Bacterial strains, plasmids and bacterial culture media 
E. coli BL21(DE3) and E. coli BL21(DE3) pLysS strains, purchased from AMS 
Biotechnology, were used as host organisms for the expression of recombinant 
constructs ONC-r(P)GKY20, ONC-r(P)ApoBL, ONC-r(P)ApoBS and His6-
Apolipoprotein AI (ApoAI). To produce recombinant constructs ONC-r(P)GKY20, 
ONC-r(P)ApoBL and ONC-r(P)ApoBS in bacterial cells, the cDNAs encoding the 
antimicrobial peptides were cloned in pET-22b(+) expression vector purchased from 
Novagen. In the case of His6-ApoAI, pET-20b(+) expression vector purchased from 
Novagen has been used. Bacterial cultures were carried out accordingly to 
Sambrook [18]. All the reagents were purchased from Sigma-Aldrich, unless 
differently specified. 
 
2.2 Shake flask expression  
Competent bacterial cells were transformed with ~80 ng of recombinant plasmid, and 
incubated for 30 min on ice. Following the addition of 1 mL of LB medium, cells were 
incubated for 60 min at 37°C and then centrifuged at 12,000 rpm for 20 min at 4°C. 
Medium (1 mL) was then removed, and the cell pellet was dissolved in the remaining 
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solution (about 100 µL) and added to medium containing the appropriate antibiotic. 
Bacterial cells were then incubated over-night at 37°C on a shaker. E. coli 
BL21(DE3) cells, individually transformed with recombinant pET-22b(+) expression 
vectors containing the sequence encoding ONC-r(P)ApoBL, ONC-r(P)ApoBS or ONC-
r(P)GKY20, were incubated over-night at 37°C in 50 mL of medium supplemented 
with ampicillin (0.1 mg/mL). Following over-night incubation, cell cultures were diluted 
1:20 in 1 L of complete medium. Cultures were incubated at 37°C up to OD600nm of 3–
4. Expression of recombinant constructs was then induced by addition of IPTG 
(isopropyl-β-D-thiogalactopyranoside) at a final concentration of 0.7 mM. To verify 
recombinant constructs expression, aliquots of bacterial cells (corresponding to 0.125 
OD600nm) were taken before induction and at the end of the expression procedure, 
solubilized in lysis buffer (0.125 M Tris-HCl pH 6.8, 2% SDS, 10% glycerol) and 
analyzed by 15% SDS-PAGE. 
 
2.3 Bioreactor cultivation 
Bioreactor cultivation was performed in a BioFlo 3000 system from New Brunswick. 
This instrumentation is endowed with a 5 L vessel, temperature control by a heating 
sleeve and an integrated cooling system, monitoring of airflow rate, monitoring of pH 
values and dissolved O2 levels through specific probes (Mettler Toledo). The medium 
in bioreactor (3 L) was inoculated with E. coli BL21(DE3) or E. coli BL21(DE3)pLysS 
cells, previously transformed with recombinant vectors, and incubated over-night at 
37°C in 150 mL of antibiotic-supplemented medium (OD600 nm = 2-4). In order to 
ensure aerobic growth conditions along the entire fermentation process, dissolved 
oxygen levels were automatically adjusted through control of both airflow and stirring 
speed. Sterile antifoam A emulsion (Sigma-Aldrich) was manually added (0.01% v/v 
final concentration) under aseptic conditions prior to over-night incubation. To avoid 
undesired growth of contaminant bacterial cells upon ampicillin degradation, 
antibiotic was regularly added to bacterial cells at a rate of 100 mg/h by using a 
fermenter peristaltic pump. Along the whole fermentation process, the stirring speed 
was kept constant at 300 rpm, with an air flow rate of 10 cm3/sec. The temperature 
was kept constant at 37 °C. When bacterial culture in bioreactor reached OD600 nm of 
about 3-5, protein expression was induced by 0.7 mM IPTG added by using a 
fermenter peristaltic pump. The time of 30 min after IPTG addition was defined as the 
starting time (t = 0 h). In the case of auto-inducing expression procedure, instead, the 
time of 30 min after bacteria inoculation into the bioreactor was defined as the 
starting time (t = 0 h). Bioreactor cultivation was carried out for a total time of 24 h. 
 
2.4 Biomass determination 
In the case of both shake flask and bioreactor cultivations, samples OD 
measurements at 600 nm were performed on triplicates by using a Shimadzu 
Photometer UV-2600. For OD measurements, samples were diluted in complete 
medium. For cell dry weight determination, samples (25 mL) were harvested, 
centrifuged for 20 min at 6,000 rpm, and washed with 0.9% NaCl for three times. 
Afterwards, samples were dried over-night at 80 °C, and lyophilized before weighing. 
 
2.5 Analyses of recombinant constructs expression levels 
In the case of both shake flask and bioreactor cultivations, at established time 
intervals, bacterial aliquots (corresponding to 0.125 OD600nm) were withdrawn and 
solubilized in lysis buffer (0.125 M Tris-HCl pH 6.8 containing 2% SDS and 10% 
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glycerol), in order to determine recombinant constructs expression levels by 15% 
SDS-PAGE.  
Protein bands intensity was detected by densitometric analyses performed by using a 
ChemiDoc Imaging System (Bio-Rad). In order to estimate recombinant constructs 
expression levels, the intensity of protein bands with the expected electrophoretic 
mobility was evaluated by densitometric analyses and referred to a calibration curve 
obtained by analyzing increasing defined amounts of bovine serum albumin (BSA). 
 
2.6 Techno-economic analysis 
The determination of production strategy costs was performed by implementing the 
process sections in Superpro Designer 9.0 (Intelligen Inc.). We performed mass and 
energy balances, in order to evaluate chemicals demand, electricity consumption and 
utilities duties for each unit operation. Figure 1 reports the flow chart of the process, 
consisting of three sections: fermentation, recombinant constructs extraction and 
purification. Step 1 (fermentation) consists of pre-culture carried out in shake flasks, 
bioreactor cultivation and bacterial culture harvesting carried out by centrifugation. 
Step 2 (extraction) consists of four washing-centrifugation steps according to Katia P. 
et al [9] Step 3 (purification) is performed by expanded bed chromatography followed 
by dialysis, chimercic construct controlled hydrolysis, onconase precipitation, peptide 
lyophilization and further solubilization in an appropriate buffer. 
The chosen scenario describes, as first, the costs to produce 100 mg peptide per 
batch, then ten times scaling up simulating the case of a small-medium enterprise. 
Italy was chosen as location to fix the costs for labor, electricity and other utilities, as 
reported in Table 1. 
Capital (CAPEX) and Operating Expenditures (OPEX) were calculated according to 
the procedure reported in Table 2. The overall Lang factor for the process is about 8, 
which is in line with indications for high value products derived from production in 
bacteria [19]. Chemicals costs were obtained by bulk quotations gently provided by 
Sigma-Aldrich, Panreac Applichem and GE Healthcare Biosciences (Table 3). A 
detailed batch schedule has been implemented with operations associated to each 
unit, accordingly to the procedure reported in Figure 2. Major equipment 
depreciament has been evaluated by assuming 10 years lifetime of the process with 
an interest rate of 8%. We considered 330 days production per year to evaluate 
maintenance. 
Production process was initially fixed at a lab scale, i.e. at a working fermenter 
volume of 5 L, and then scaled up to 50 L for future scenarios. Fermenter costs were 
scaled up accordingly to power law exponents suggested by Kalk and Langlykke 
(1986) [20]. Costs of other equipments were scaled up accordingly to the model 
provided by SuperPro Designer, whereas wastewater treatment was fixed to 0.4 € m-
3 [19]. Since all the process is carried out under batchwise conditions, the labor 
demand was always fixed to 1 direct labor hour per hour for all the procedures 
described in each step. 
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Figure 1. Flow chart illustrating the production process. 
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Table 1. Unit costs of electricity, labor and utilities referred to the Italian scenario of 
industrial production. 
*source: Bureau of Labor Statistic - www.bls.gov 
**source: Eurostat - http://ec.europa.eu/eurostat/statistics-explained/index.php/Energy_price_statistics 
***source: Data are taken from SuperPro databank and linearly scaled by ratio of electricity cost in US and in Italy 
 
 
Table 2. CAPEX and OPEX evaluation. 
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Table 3. Chemical costs; source: Sigma-Aldrich, Panreac Applichem and GE 
Healthcare Biosciences. 
 
 
 
Figure 2. Detailed schedule of the operations within the whole production process. 
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3. Results 
3.1 Bacterial growth medium design 
We developed a novel semi-defined rich medium, named NoB medium, with the aim 
to obtain high cell densities and significantly higher expression levels of recombinant 
peptides and proteins. NoB medium composition is reported in Table 4. As it can be 
noticed, this medium is composed by cheap components, readily available and 
containing defined amounts of each compound. In particular, yeast extract, which is 
commonly employed as a source of exogenous factors essential for microorganism 
growth, has been replaced by known growth factors, in order to obtain a chemically 
defined medium rather than a complex crude extract whose composition varies not 
only depending on the manufacturer but also from batch to batch of the same 
manufacturer [21]. In NoB medium, yeast extract has been prevalently substituted 
with tryptone, which has a defined amino acidic composition, since it derives from 
bovine casein hydrolysis. As different batches of tryptone can contain different 
amounts of lactose, we added 4 g/L glucose to NoB medium (Table 4), in order to 
avoid undesired basal induction of recombinant protein expression. Glucose, in fact, 
acts as a repressor of lac promoter and prevents expression induction in the absence 
of IPTG. NoB medium also contains a mixture of salts providing optimal amounts of 
required metals (e.g. Mg, Ca, Zn, Fe, Mn, Cu, etc.), usually acting as cofactors for 
essential enzymatic reactions. Glycerol (1.2%) was added as main carbon source. 
Ammonium citrate was added to NoB medium both as a source of inorganic nitrogen 
and as an additional buffer system. Furthermore, since citrate acts as a chelating 
agent, its presence is fundamental to avoid transition metal cations precipitation. 
Finally, since E. coli is able to synthesize betaine from choline, a component likely 
present in yeast extract but not in tryptone, betaine was added to NoB medium, as 
this compound is one of the best osmolytes for E. coli [22].  
 
 
 
Table 4. NoB medium composition. 
 
To verify NoB medium efficiency for E. coli culturing and recombinant proteins 
production, we first performed a comparison between TB and NoB media in shake 
flasks cultures. To this purpose, we used E. coli BL21(DE3) strain as a host to 
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produce recombinant bioactive peptides r(P)GKY20, r(P)ApoBL, and r(P)ApoBS. 
Since peptides are expressed in bacterial cells as fusion proteins with onconase 
(ONC), the chimeric constructs have been here named ONC-r(P)GKY20, ONC-
r(P)ApoBL, and ONC-r(P)ApoBL, respectively. To perform a comparison between TB 
and NoB media, bacterial cells, transformed with pET recombinant plasmids, were 
grown in 50 mL of medium containing 100 μg/mL ampicillin, at 37°C over-night. 
Bacterial cultures were then used to inoculate 1 L of ampicillin containing medium. 
Glucose at a final concentration of 4 g/L was added to bacterial culture to limit 
undesired basal protein expression before induction with IPTG. Culture was then 
incubated at 37°C up to OD600nm of 1-3.5. Expression of recombinant constructs was 
induced by addition of IPTG (isopropyl-β-D-thiogalactopyranoside) at a final 
concentration of 0.7 mM. Cells were harvested after over-night induction by 
centrifugation and lysed in order to analyze recombinant constructs expression by 
15% SDS-PAGE (Figure 3-5, a and b). We found that, in the case of NoB medium, 
significantly higher expression levels were reached in the case of ONC-r(P)ApoBL 
and ONC-r(P)ApoBS recombinant constructs (Figure 3 and 4, d and e, and Table 4). 
In particular, expression levels were found to be 1.5 times and 1.6 times higher in 
NoB medium than in TB medium in the case of ONC-r(P)ApoBL and ONC-r(P)ApoBS 
recombinant constructs, respectively (Table 4). In the case of ONC-r(P)GKY20 
construct, instead, effects of NoB medium on the expression levels were found to be 
slight. Furthermore, in all the cases, we observed a strong decrease of undesired 
basal expression in NoB medium with respect to TB medium (Figure 3-5). It has also 
to be noticed that we observed faster growth kinetics in NoB medium with respect to 
TB medium. In fact, by monitoring biomass increase on the bases of OD600 nm values, 
we observed that at early stationary phase, the moment selected for IPTG addition, 
higher cell densities were achieved in NoB medium with respect to TB medium. In 
Table 4, results of typical experiments are reported. 
 
3.2 Setting up of an auto-induction protocol  
To further improve and to significantly lower the costs of the production procedure, 
we decided to set up an auto-induction protocol. To do this, we first developed an 
auto-inducing medium characterized by a well-balanced combination of different 
carbon sources and other essential nutrients, allowing cultures to grow to high cell 
densities, thus supporting the expression at high levels of the target chimeric 
proteins. Indeed, NoB medium was conceived to already possess the mineral salt 
formulation required for a successful auto-induction procedure [23]. Hence, to set up 
an efficient auto-induction protocol, NoB medium was supplemented with 0.4 % (54 
mM) glycerol and 1.92 g/L (5.6 mM) lactose [14]. Glucose was kept constant at a 
concentration of 0.5 g/L (2.8 mM) along the whole auto-induction expression 
procedure [14], in order to promote fast cellular growth in the early stages of the 
culture, while also preventing uptake and metabolism of inducing sugar (lactose). By 
this way, lactose is consumed after glucose exhaustion, with a consequent automatic 
induction of recombinant protein expression under the control of T7 promoter. In fact, 
E. coli has specific preferences with respect to alternative carbon sources, and can 
switch between them in a certain order (diauxic shift) [23].  Glucose is used as E. coli 
primary carbon source, since it efficiently inhibits the intake and metabolism of 
alternative sugars, such as lactose. Once glucose is fully metabolized, E. coli 
switches relatively fast to the use of lactose. By this way, unlike experimental 
procedures based on the use of IPTG, induction of protein expression is automatic 
and, consequently, bacterial cell growth does not need to be monitored. Furthermore, 
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to achieve sustained bacterial growth during the induction phase, glycerol is provided 
in auto-inducing media together with lactose [14, 24, 25]. NoB medium, containing 
the above reported doses of glucose, glycerol and lactose, has been here named 
auto-inducing NoB medium. As first, we set up the auto-induction procedure. To do 
this, bacterial cells were transformed with pET recombinant plasmids, and grown in 
50 mL of classical NoB medium containing 100 μg/mL ampicillin, at 37°C over-night. 
Bacterial cultures were then used to inoculate 1 L of ampicillin containing auto-
inducing NoB medium. Culture was then incubated at 37°C for 24 h, in order to allow 
automatic induction of chimeric proteins expression. Following incubation, cells were 
harvested by centrifugation and lysed in order to analyze recombinant constructs 
expression by 15% SDS-PAGE (Figure 3-5 c). We observed significantly higher 
expression levels of all the constructs under test (Figure 3-5 c, and Table 4), which 
were found to be about 1.5 times higher than those observed in NoB medium under 
IPTG induction (Table 4). However, it has to be noticed that saturation densities 
(OD600 nm values at the end of the experiment) were found to be significantly lower 
than those observed in the classical induction protocol (NoB with the addition of 
IPTG).  This is in agreement with previous findings indicating that, in shake flask 
cultivations, lactose auto-induction generally occurs in the active growth phase, with 
a possible consequent inactivation of bacterial cell growth [23]. 
 
 
 
Table 4. Expression levels of recombinant ONC-r(P)ApoBL, ONC-r(P)ApoBS and 
ONC-r(P)GKY20 in TB medium, NoB medium and auto-inducing NoB medium. 
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Figure 3. Analysis by SDS-PAGE of total proteins extracted from not induced and 
induced bacterial cells transformed with pET recombinant plasmid encoding ONC-
r(P)ApoBL construct (a, b, c). Densitometric analyses of protein bands with a 
molecular weight corresponding to that of ONC-r(P)ApoBL construct (17.4 kDa) are 
reported as histograms (d, e, f). Analysis of protein expression was per formed in TB 
medium upon IPTG induction (a, d), in NoB medium upon IPTG induction (b, e), and 
in auto-inducing NoB medium (c, f). 
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Figure 4. Analysis by SDS-PAGE of total proteins extracted from not induced and 
induced bacterial cells transformed with pET recombinant plasmid encoding ONC-
r(P)ApoBS construct (a, b, c). Densitometric analyses of protein bands with a 
molecular weight corresponding to that of ONC-r(P)ApoBS construct (16.1 kDa) are 
reported as histograms (d, e, f). Analysis of protein expression was per formed in TB 
medium upon IPTG induction (a, d), in NoB medium upon IPTG induction (b, e), and 
in auto-inducing NoB medium (c, f). 
 
 
 
Figure 5. Analysis by SDS-PAGE of total proteins extracted from not induced and 
induced bacterial cells transformed with pET recombinant plasmid encoding ONC-
r(P)GKY20 construct (a, b, c). Densitometric analyses of protein bands with a 
molecular weight corresponding to that of ONC-r(P)GKY20 construct (14.4 kDa) are 
reported as histograms (d, e, f). Analysis of protein expression was per formed in TB 
medium upon IPTG induction (a, d), in NoB medium upon IPTG induction (b, e), and 
in auto-inducing NoB medium (c, f). 
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3.3 Scaling up of the production procedure 
To scale up the production procedure and to evaluate its efficacy on a larger scale, 
we set up a fermentation process by using a 5 L fermenter. As first, we optimized the 
production procedure by using classical NoB medium and IPTG induction, and then 
we compared recombinant constructs expression yields to those obtained in auto-
inducing NoB medium to set up a competitive and cost-effective process. To this 
purpose, transformed bacterial cells were inoculated into 150 mL of classical NoB 
medium containing 100 μg/mL of ampicillin and 4 g/L glucose, and incubated at 37°C 
over-night. Bacterial cultures were then diluted into 3 L (dilution 1:20 v/v) of NoB 
medium in a 5 L batch reactor. Since in stirred bioreactors generally a higher gas–
liquid oxygen transfer is achieved than in shake flasks [23], oxygen was not expected 
to be a limiting factor. The oxygen saturation was maintained above 60% throughout 
the cultivation. Along the fermentation process, the stirring speed was kept constant 
at 300 rpm, with an air flow rate of 10 cm3/sec. To overcome advantages associated 
to ampicillin degradation, the antibiotic was added to bacterial cells at a rate of 100 
mg/h by using a fermenter peristaltic pump. In fact, a fundamental problem 
associated with the use of ampicillin resistance as a selection mechanism is the rapid 
degradation of the antibiotic by the extracellular enzyme β-lactamase [26, 27]. For 
the BL21(DE3) host strain containing the pET-type vectors, the half-life of 100 µg/mL 
ampicillin is reported to be 30 min for mid-log phase cells grown in a fermenter [28]. 
By regularly adding ampicillin, we were able to prevent undesired plasmid loss, with a 
consequent improvement of expression yields. Fermentation process was carried out 
at 37°C up to OD600nm of about 4. At this stage, expression of recombinant constructs 
was induced by addition of 0.7 mM IPTG. Fermentation was carried out for 24 h. At 
the end of the fermentation process, cells were collected by using a peristaltic pump, 
harvested by centrifugation, and lysed in order to analyze recombinant constructs 
expression by 15% SDS-PAGE (Figure 6-8). In all the cases, recombinant 
expression of chimeric constructs began at about 2-4 h after IPTG addition, reaching 
a maximum at 8 h (Figure 6-8 a, c, e). Moreover, in all the cases, protein expression 
yields were found to be significantly higher than those observed in shake flask 
cultures carried out in classical NoB medium upon IPTG induction (Figure 6-8 e, and 
Tables II and III). Saturation densities (OD600 nm values at the end of fermentation 
process) were found, instead, to be similar to those obtained in shake flasks cultures. 
Biomass was monitored on the basis of cell dry weight and represented as a curve 
(Figure 6-8 e), which was found to have a shape similar to that of the curve 
representing recombinant chimeric constructs production yields (Figure 6-8 e).  
Once verified the validity of the experimental strategy on a larger scale, we applied it 
to the auto-induction procedure, in order to develop a cost-effective production 
process to be used on an industrial scale. To this purpose, we performed the same 
experimental procedure described above with the only exception that E. coli 
BL21(DE3) cells, once transformed with recombinant pET-22b(+) expression vectors, 
were incubated over-night at 37°C in 150 mL of NoB medium supplemented with 
ampicillin (0.1 mg/mL), but lacking glucose, glycerol and lactose. Following over-night 
incubation, cell cultures were diluted 1:20 (v/v) in 3 L of auto-inducing NoB medium in 
a 5 L batch reactor.  
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Table 5. Expression levels of recombinant ONC-r(P)ApoBL, ONC-r(P)ApoBS and 
ONC-r(P)GKY20 in NoB medium and auto-inducing NoB medium. 
 
At this point, experimental conditions identical to those described above were 
applied, with the only exception of IPTG addition, since recombinant expression of 
chimeric constructs was automatically induced by lactose present in the medium. At 
defined time intervals, bacterial aliquots (corresponding to 0.125 OD600nm) were 
withdrawn and lysed to determine recombinant constructs expression levels by 15% 
SDS-PAGE (Fig. 4-6 b, d, f). Recombinant expression of chimeric constructs was 
found to begin at 4h, indicating that, at this time, glucose probably decreases, and 
lactose begins to be metabolized, with a consequent inducing effect. In our 
experimental conditions, expression levels were found to reach a maximum level at 
24 h. In all the cases, we observed recombinant constructs expression levels 
significantly higher than those obtained either in the same experimental conditions by 
using classical NoB medium (Fig. 4-6) or in shake flasks cultures by using auto-
inducing NoB medium (Table 5). Similar results were also obtained by analyzing 
saturation densities (OD600 nm values at the end of fermentation process), which were 
found to be higher than those obtained in the same experimental conditions by using 
classical NoB medium under IPTG induction for all the constructs, with the exception 
of ONC-r(P)GKY20. In the last case, in fact, biomass growth was found to be similar 
in both condition in batch reactor. 
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Figure 6. Analysis by SDS-PAGE of total proteins extracted from bacterial cells 
transformed with pET recombinant plasmid encoding ONC-r(P)ApoBL construct (a, 
b). Samples were collected at different time intervals along the fermentation process 
in batch reactor. In a, not induced cells (lane 1), cells upon 2h induction (lane 3), cells 
upon 4 h induction (lane 4), cells upon 8 h induction (lane 5), cells upon 24 h 
induction (lane 6). In b, cells at time 0 (lane 1), cells upon 2h growth (lane 3), cells 
upon 4 h growth (lane 4), cells upon 8 h growth (lane 5), cells upon 24 h growth (lane 
6).  Densitometric analyses of protein bands with a molecular weight corresponding 
to that of ONC-r(P)ApoBL construct (17.4 kDa) are reported as histograms (c, d). 
Chimeric construct expression levels (g/L) and biomass (cell dry weight, g/L) are 
reported in e and f. Analyses are representative of fermentation processes carried 
out either in classical NoB medium (a, c, e) or in auto-inducing NoB medium (b, d, f). 
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Figure 7. Analysis by SDS-PAGE of total proteins extracted from bacterial cells 
transformed with pET recombinant plasmid encoding ONC-r(P)ApoBS construct (a, 
b). Samples were collected at different time intervals along the fermentation process 
in batch reactor. In a, not induced cells (lane 1), cells upon 2h induction (lane 3), cells 
upon 4 h induction (lane 4), cells upon 8 h induction (lane 5), cells upon 9 h induction 
(lane 6), cells upon 24 h induction (lane 7). In b, cells at time 0 (lane 1), cells upon 2h 
growth (lane 3), cells upon 4 h growth (lane 4), cells upon 8 h growth (lane 5), cells 
upon 9 h growth (lane 6), cells upon 24 h growth (lane 7). Densitometric analyses of 
protein bands with a molecular weight corresponding to that of ONC-r(P)ApoBS 
construct (16.1 kDa) are reported as histograms (c, d). Chimeric construct expression 
levels (g/L) and biomass (cell dry weight, g/L) are reported in e and f. Analyses are 
representative of fermentative processes carried out either in classical NoB medium 
(a, c, e) or in auto-inducing NoB medium (b, d, f). 
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Figure 8. Analysis by SDS-PAGE of total proteins extracted from bacterial cells 
transformed with pET recombinant plasmid encoding ONC-r(P)GKY20 construct (a, 
b). Samples were collected at different time intervals along the fermentation process 
in batch reactor. In a, not induced cells (lane 1), cells upon 2h induction (lane 3), cells 
upon 4 h induction (lane 4), cells upon 8 h induction (lane 5), cells upon 24 h 
induction (lane 6). In b, cells at time 0 (lane 1), cells upon 2h growth (lane 3), cells 
upon 4 h growth (lane 4), cells upon 8 h growth (lane 5), cells upon 24 h growth (lane 
6).  Densitometric analyses of protein bands with a molecular weight corresponding 
to that of ONC-r(P)GKY20 construct (14.4 kDa) are reported as histograms (c, d). 
Chimeric construct expression levels (g/L) and biomass (cell dry weight, g/L) are 
reported in e and f. Analyses are representative of fermentation processes carried 
out either in classical NoB medium (a, c, e) or in auto-inducing NoB medium (b, d, f). 
 
3.4 Cost estimation of HDPs production from lab to larger scales 
The procedure to isolate pure recombinant HDPs has been previously described [9]. 
Briefly, upon recovery from inclusion bodies, the chimeric protein is purified by nickel 
affinity chromatography. The peptide is then released from the carrier onconase by a 
cleavage in mild acidic conditions. Since the carrier is insoluble at neutral or alkaline 
pH, the peptide is isolated from insoluble components by repeated cycles of 
centrifugation, and finally lyophilized (Figure 9). By using this experimental 
procedure, we obtained peptides 99% pure with a yield of 20-25 mg/L of bacterial 
culture. To determine yield, the purified peptide was weighed on a fine scale after 
lyophilization. However, analyses revealed that residual salts bound to the peptide 
significantly affect weight determination [29]. Indeed, when salts were removed by 
size-exclusion chromatography, peptides yield was found to be lowered to about 10-
12 mg /L of bacterial culture.  
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Figure 9. Block flow diagram describing the production and purification process of 
recombinant HDPs. 
 
Figure 10 reports the breakdown of peptide unit costs (€/mg) as a function of the 
production scale expressed as mg/batch. It has to be emphasized that, at a lab scale 
(5 L fermenter), the cost is of about 250 €/mg and it is mainly affected by the labor 
costs and by the capital investment, such as main equipment costs and additional 
fixed costs required to maintain equipment. When production scale increases to 200, 
500 or 1,000 mg/batch, the unit cost strongly decreases to 136, 65 and 42 €/mg, 
respectively. It has to be noticed that, in the last case, labor and chemical costs are 
the only relevant factors, which is typical of a production scale [19]. 
 
 
 
Figure 10. Breakdown of peptide unit production costs as a function of the production 
scale. 
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In order to identify process possible bottlenecks, costs have also been analysed by 
considering the contribution from each step of the process (fermentation, extraction 
and purification) (Figure 11). It has to be noticed that more than the half of the costs 
derives from the final purification step and that this contribution increases by 
increasing the production scale. Moreover, labor costs, instead, decrease by 
increasing the production scale, which further indicates that chemicals cost has a 
predominant effect. Indeed, the demand for chemicals, mainly guanidine, required to 
denature inclusion bodies and to perform expanded bed chromatography strongly 
affects the overall process costs. 
 
 
 
Figure 11. Impact of production process steps (fermentation, extraction and 
purification) on peptide unit production costs. 
 
4. Discussion 
Due to the current trend of reduction in the potency of commonly used antibiotics, 
there is an urgent demand for novel antimicrobials. Among these, HDPs are gaining 
great interest [30], since they generally do not lead to selection of resistant strains.  
In general, HDPs isolation from natural sources is a labor intensive and time-
consuming process, not suitable to obtain peptides in large amounts. On the other 
hand, chemical synthesis, although very efficient, is a complex and costly process 
[31]. In this scenario, to explore the pharmaceutical and therapeutic potential of 
antimicrobial peptides, a cost-effective and scalable method to produce active and 
effective HDPs is required. Procedures to express HDPs as recombinant peptides 
have encountered difficulties associated to their cytotoxicity to the bacterial host. As 
a consequence, difficulties to scale up the production process and peptide low yields 
upon purification represent main limitations [32-34]. Successful strategies are 
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generally based on the fusion of HDPs to carrier proteins. However, even when 
successful peptide expression was realized, further processing of fusion proteins, 
often requiring chemicals or costly enzymes, and multiple purification steps are 
responsible for low purification yields, with a consequent significant increase of 
production costs.  
Here, we describe a cost-effective procedure to produce high amounts of three 
different HDPs [9-11]. The strategy is mainly based on the fusion of the HDP of 
interest to a convenient carrier, i.e. onconase from Rana pipiens, which has been 
previously optimized to ensure high expression levels of chimeric constructs [9]. To 
improve the production procedure, here, we also designed a novel cheap medium, 
named NoB medium, consisting of cheap components, readily available and 
containing precise amounts of each compound. The newly set up production 
procedure was also efficiently scaled up and the costs were significantly lowered by 
developing a successful auto-inducing procedure.  
LB growth medium is the most commonly used medium for culturing E. coli, since it is 
easy to make, it is rich in nutrients, and its osmolarity is optimal for growth at early 
log phase. All these features make it adequate for protein production and 
compensate for the fact that it is not the best option to achieve high cell density 
cultures. In fact, although LB is a rich medium, bacterial cell growth usually stops at a 
relatively low density. This happens because LB contains scarce amounts of 
carbohydrates (and other utilizable carbon sources) and divalent cations [13]. Not 
surprisingly, when the amount of peptone or yeast extract is increased, higher cell 
densities are reached [14]. By the same way, divalent cation supplementation 
(MgSO4 in the millimolar range) results in higher cell growth. Glucose 
supplementation is, instead, of limited help because acid generation by glucose 
metabolism overwhelms the limited buffer capacity of LB, at least in shake flasks 
where pH control can be laborious [15, 16]. Based on these observations, we 
developed a novel medium, which was found to support significantly higher cell 
densities and recombinant expression levels with respect to conventional culture 
media. 
Furthermore, we also set up an auto-inducing expression protocol based on the 
concomitant presence of glucose, glycerol and lactose as carbon sources in the 
culture medium. By this way, recombinant constructs expression was found to be 
mediated by a common and cheap sugar, such as lactose, instead of IPTG, which 
might result too expensive for industrial purposes, even if generally required at sub 
millimolar concentrations [35-37]. Indeed, IPTG substitution was found to have 
several advantages, since this compound is not innocuous for bacterial cells and was 
found to have negative effects on bacterial cell growth [38-41]. It has also to be 
highlighted that auto-inducing procedure was found to support significantly higher 
yields of target constructs and cell biomass, with respect to conventional procedures 
based on IPTG mediated induction. The auto-induction procedure was also scaled up 
by using a 5 L fermenter system in which aerobic growth conditions were preserved 
by maintaining O2 at 60% of saturation during the entire fermentation process. 
Moreover, to overcome disadvantages associated to ampicillin degradation, the 
antibiotic was regularly added to bacterial cells at a rate of 100 mg/h by using a 
fermenter peristaltic pump. Under these experimental conditions, expression levels of 
recombinant constructs were found to be significantly higher than those obtained in 
shake flask cultures, thus suggesting that the herein developed procedure might be 
successfully applied at an industrial scale. A further main advantage of the set-up 
procedure is the possibility to separate the peptide of interest from its carrier protein 
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by mild acidic conditions because of the presence of a dipeptide Asp-Pro between 
the peptide and the onconase moieties. By this way, it has been possible to avoid the 
use specific enzymes [42], which would have made the process too expensive and 
not suitable for industrial purposes. 
Finally, to demonstrate the general validity of the set-up production strategy and its 
applicability to recombinant soluble proteins expressed in E. coli, we applied the 
auto-inducing protocol in NoB medium to the production of recombinant 
Apolipoprotein AI (ApoAI). The sequence encoding this protein was contained in the 
plasmid pET20b(+), and the protein was routinely expressed as soluble in E. coli 
BL21(DE3)pLysS cells [42]. When ApoAI expression and production were carried out 
by using the herein developed procedure, we found that the soluble protein 
expression levels were significantly higher in auto-inducing NOB medium (Figure 12) 
with respect to classical NOB medium under IPTG induction (data not shown). It has 
to be underlined that, in the case of soluble ApoAI recombinant expression, highest 
expression levels were observed after 8 h from the beginning of the fermentation 
process, with a slight decrease after 24 h, in agreement with data attesting ApoAI 
instability in bacterial expression systems [42]. However, the higher expression levels 
observed by applying this procedure with respect to conventional methods represent 
a fundamental feature attesting the general validity of the herein proposed procedure. 
   
 
 
Figure 12. Analysis by SDS-PAGE of total proteins extracted from bacterial cells 
transformed with pET recombinant plasmid encoding ApoAI (a). Samples were 
collected at different time intervals along the fermentation process in batch reactor. In 
a, not induced cells (lane 1), cells upon 2h induction (lane 3), cells upon 4 h induction 
(lane 4), cells upon 8 h induction (lane 5), cells upon 24 h induction (lane 6). 
Densitometric analyses of protein bands with a molecular weight corresponding to 
ApoAI construct (28 kDa) are reported as histograms (b). Chimeric construct 
expression levels (g/L) and biomass (cell dry weight, g/L) are reported in c. Analyses 
 44 
 
are representative of fermentation processes carried out in auto-inducing NoB 
medium. 
 
In conclusion, along this Thesis project, we set up a cost-effective large-scale 
production system, which was found to be also successfully applicable to soluble 
proteins, and to provide expression levels significantly higher than those obtained 
with conventional protocols. Since the protocol to purify HDPs was previously 
optimized and found to provide high yields of pure peptides through a rapid one-step 
purification procedure, it is tempting to speculate that this optimized procedure might 
be successfully scaled up at an industrial scale in that increasing the production 
scale at 200, 500 and 1,000 mg/batch, unit costs strongly decreased. Hence, it 
represents a cost-effective and competitive strategy to produce the high amounts of 
peptides required for basic and clinical research.  
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1. Introduction 
Apolipoproteins, the main protein components of plasma lipoproteins, are a source of 
bioactive peptides. Reports have shown that peptides derived from the cationic 
receptor binding region of Apolipoprotein E (ApoE141-149) are endowed with broad 
anti-infective activity [1]. Apolipoprotein B (ApoB) also contains two LDL (low-density 
lipoprotein) receptor binding domains, namely region A (ApoB3147-3157) and region 
B (ApoB3359-3367). Region B, more uniformly conserved across species and 
primarily involved in receptor binding, has been found to be endowed with a 
significant antiviral activity [1]. Moreover, peptides derived from ApoB have been 
already used in vaccine preparations to treat atherosclerosis [2]. When ApoE 
deficient mice have been immunized with ApoB661–680 and ApoB3136–3155 
peptides, a significant increase of the levels of peptide-specific immunoglobulins was 
detected accompanied by a concomitant increase of secreted interleukin-10 (IL-10) 
levels, with no effect on IFN-γ expression levels, thus indicating that ApoB derived 
peptides are able to modulate the immune response [2]. 
Recently, our group developed an in silico method [3] to identify HDPs in protein 
precursors and to predict quantitatively their antibacterial activity. This method 
assigns to any given peptide an antimicrobial score, called “absolute score” (AS), on 
the basis of net charge, hydrophobicity and length of the peptide and of two bacterial 
strain-dependent weight factors defining the contribution of charge and 
hydrophobicity to the antimicrobial activity. We demonstrated that AS is directly 
proportional to the antimicrobial activity of HDPs expressed as Log(1,000/MIC), 
where MIC is the minimal inhibitory concentration of the peptide. Score values lower 
than 6.5 are considered not significant as they correspond to predicted MIC values 
higher than 200 μM, while for score values higher than about 10 the linear 
relationship is no longer valid, and an increase in the score does not necessarily 
correspond to a concomitant increase in the antimicrobial activity. To analyse a 
protein potentially bearing hidden antimicrobial regions, the AS values of all the 
peptides of the desired length contained in a precursor protein can be plotted as a 
function of peptide sequence and length, thus obtaining an accurate map of the 
antimicrobial activity determinants. This method allows the identification of novel 
HDPs within the sequence of known proteins (“cryptic” HDPs), as demonstrated by 
the identification of a novel cationic HDP endowed with antibacterial and 
immunomodulatory activities in human ApoE [3], and in the transcription factor Stf76 
from the archaeon Sulfolobus islandicus. In the last case, peptide VLL-28 represents 
the first antimicrobial peptide derived from an archaeal protein [4]. 
We applied our in silico analysis method to a human Apolipoprotein B (ApoB) isoform 
[5, 6]. In Figure 1, the isometric plot of region 882-929 of this ApoB variant is shown. 
An absolute maximum, corresponding to region 887-922 (AS = 12.0), and a relative 
maximum, corresponding to residues 887-909 (AS = 10.6), are shown (Figure 1). 
Even if several ApoB functional regions have already been analysed, and in some 
cases biologically active peptides were obtained [1, 2], to the best of our knowledge, 
this is the first report identifying ApoB region 887-922 as a source of HDPs. Here, we 
report the recombinant production and characterization of two variants of the putative 
HDP identified by our bioinformatics method in human ApoB, i.e. peptides ApoB887-
923 and ApoB887-911. Both peptides include at the C-terminal side one (as in the 
case of ApoB887-923), or two (as in the case of ApoB887-911) small uncharged 
residues (serine, glycine or threonine), which are not present in the regions 
highlighted in the AS plot (Figure 1). These residues have been arbitrarily included to 
avoid that the negatively charged C-terminus of the peptide is adjacent to the 
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antimicrobial region. The sequence of peptide r(P)ApoBL is 
PHVALKPGKLKFIIPSPKRPVKLLSGGNTLHLVSTTKT, while that of peptide 
r(P)ApoBS is PHVALKPGKLKFIIPSPKRPVKLLSG.  
To evaluate the therapeutic potential of these peptides, we analysed their structure, 
antimicrobial and anti-biofilm activities, the ability to act in synergy with conventional 
antibiotics, their anti-inflammatory and wound healing properties, and their possible 
toxic effects on eukaryotic cells. 
 
 
 
Figure 1. Isometric plot showing the absolute score values (AS) of peptides with a 
length ranging from 12 to 40 residues (W12-W40) in the region 882-929 of ApoB. 
Colors were used to highlight AS values higher than 6.5, and corresponding to 
predicted MIC values on S. aureus lower than 200 µM. 
 
2. Materials and methods 
2.1. Bacterial strains and growth conditions 
Eight bacterial strains were used in the present study, i.e. E. coli ATCC 25922, 
methicillin-resistant Staphylococcus aureus (MRSA WKZ-2), Salmonella enteriditis 
706 RIVM, Bacillus globigii TNO BM013, Bacillus licheniformis ATTC 21424, 
Staphylococcus aureus ATTC 29213, Pseudomonas aeruginosa ATCC 27853, and 
Pseudomonas aeruginosa PAO1. All bacterial strains were grown in Muller Hinton 
Broth (MHB, Becton Dickinson Difco, Franklin Lakes, NJ) and on Tryptic Soy Agar 
(TSA; Oxoid Ltd., Hampshire, UK). In all the experiments, bacteria were inoculated 
and grown over-night in MHB at 37 °C. The next day, bacteria were transferred to a 
fresh MHB tube and grown to mid-logarithmic phase. 
 
2.2. Cell culture 
Murine RAW 264.7 cells, malignant SVT2 murine fibroblasts (BALBc 3T3 cells 
transformed by SV40 virus), parental murine BALBc 3T3 cells, and human HeLa and 
HaCaT cells were from ATCC, Manassas, VA. Cells were cultured in Dulbecco’s 
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modified Eagle’s medium (Sigma Aldrich, Milan, Italy), supplemented with 10% foetal 
bovine serum (HyClone, GE Healthcare Lifescience, Chicago, IL) and antibiotics, in a 
5% CO2 humidified atmosphere at 37 °C. 
 
2.3. Synthetic peptides 
CATH-2 peptide was obtained from CPC Scientific Inc. (Sunnyvale, USA), and LL-37 
peptide was from Sigma Aldrich, Milan, Italy. 
 
2.4. Expression ad isolation of recombinant ApoB derived peptides 
Expression and isolation of recombinant peptides was carried out as previously 
described by Pane K. et al [7] and in the Chapter 2. 
 
2.5. Mass spectrometry analyses 
Matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS) was 
carried out on a 4,800 Plus MALDI TOF/TOF mass spectrometer (Applied 
Biosystems, Framingham, MA) equipped with a nitrogen laser (337 nm). The peptide 
samples (1 mL) were mixed (1:1, v/v) with a 10 mg/mL solution of a-cyano-4-
hydroxycinnamic acid in acetonitrile/50mM citrate buffer (70:30 v/v). Mass calibration 
was performed using external peptide standards purchased from Applied 
Biosystems. Spectra were acquired using 5,000 shots/spectrum in a mass (m/z) 
range of 1,000–5,000 amu and raw data were analysed using Data Explorer 
Software provided by the manufacturer. 
 
2.6. Circular dichroism spectroscopy 
CD experiments were performed on a Jasco J-815 circular dichroism 
spectropolarimeter, calibrated for intensity with ammonium [D10] camphorsulfonate 
([ϴ290.5] = 7,910 deg cm2 dmol-1). The cell path length was 0.01 cm. CD spectra were 
collected at 25 °C in the 190-260 nm (far-UV) at 0.2 nm intervals, with a 20 nm/min 
scan rate, 2.5 nm bandwidth and a 16 sec response. Spectra are reported in terms of 
mean residue ellipticity, calculated by dividing the total molar ellipticity by the number 
of amino acids in the molecule. Each spectrum was corrected by subtracting the 
background, and reported without further signal processing. Lyophilized peptides 
were dissolved in ultra-pure water (Romil, Waterbeach, Cambridge, GB) at a 
concentration of 100 μM, determined on the basis of peptide dry weight and BCA 
assay (ThermoFisher Scientific, Waltham, MA). CD spectra of the peptides were 
collected in the absence or in the presence of increasing concentrations of 
trifluoroethanol (TFE, Sigma Aldrich, Milan, Italy), SDS (Sigma Aldrich, Milan, Italy) or 
lipopolysaccharide (LPS) from E. coli 0111:B4 strain (Sigma Aldrich, Milan, Italy). CD 
spectra were corrected by subtracting every time the contribution of the compound 
under test at any given concentration. CD spectra deconvolution was performed by 
using the program PEPFIT, that is based on peptide-derived reference spectra [8], in 
order to estimate secondary structure contents. A Microsoft Excel-ported version of 
PEPFIT was used for convenience [9]. 
 
2.7. Measurement of IL-6 release 
IL-6 levels were determined by ELISA assay (DuoSet ELISA kits, R&D Systems, 
Minneapolis, MN) following the manufacturer’s instructions. Briefly, RAW 264.7 cells 
(5×104) were seeded into 96-well microtiter plates, and grown to semi-confluency. 
After 24 h, the culture medium was replaced with fresh medium containing the 
peptides under test (5 or 20 μM) in the presence or in the absence of LPS from 
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Salmonella Minnesota (50 ng/mL, Sigma Aldrich, Milan, Italy) for 24 h at 37 °C. When 
the protective effect of peptides was evaluated, cells were pre-incubated with the 
peptides under test (5 or 20 μM) for 2 h at 37 °C. Following treatment, cells were 
washed three times with PBS prior to incubation with LPS (50 ng/mL) for further 24 h 
at 37 °C. In each case, at the end of incubation, the culture supernatants were 
collected, and centrifuged at 5,000 rpm for 3 min at room temperature, in order to 
remove cell debris. Samples were then analysed by reading absorbance values at 
450 nm using 550 nm as a reference wavelength at an automatic plate reader 
(FLUOstar Omega, BMG LABTECH, Ortenberg, Germany). 
 
2.8. Determination of NO production 
To determine the levels of NO released by RAW 264.7 cells, a colorimetric assay 
based on the use of Griess reagent (Sigma Aldrich, Milan, Italy) was performed. The 
levels of nitrite (NO2−) in cell supernatants were determined on the basis of a 
reference curve obtained by testing increasing concentrations (from 1 to 50 μM) of 
sodium nitrite dissolved in water. Briefly, cell culture supernatants were mixed with 
equal volumes of 1% sulphanilamide dissolved in 2.5% phosphoric acid, and 
incubated for 5 min at room temperature. Samples were then diluted 1:1 (v/v) with 
0.1% N-(1-naphthyl) ethylenediamine dihydrochloride, and incubated for further 5 min 
at room temperature. Absorbance values were then determined at 520 nm using an 
automatic plate reader (FLUOstar Omega, BMG LABTECH, Ortenberg, Germany). 
 
2.9. Antimicrobial activity assay 
The antimicrobial activity of ApoB derived peptides was tested towards eight bacterial 
strains, i.e. E. coli ATCC 25922, methicillin-resistant Staphylococcus aureus (MRSA 
WKZ-2), Salmonella enteriditis 706 RIVM, Bacillus globigii TNO BM013, Bacillus 
licheniformis ATCC 21424, Staphylococcus aureus ATCC 29213, Pseudomonas 
aeruginosa ATCC 27853, and Pseudomonas aeruginosa PAO1. In each case, 
bacteria were grown to mid-logarithmic phase in MHB at 37 °C. Cells were then 
diluted to 2x106 CFU/mL in Nutrient Broth (Difco, Becton Dickinson, FranklinLakes, 
NJ) containing increasing amounts of either r(P)ApoBL or r(P)ApoBS peptide (0.625 – 
40 μM). In each case, starting from a peptide stock solution, two-fold serial dilutions 
were sequentially carried out, accordingly to broth microdilution method [10]. 
Following over-night incubation, MIC100 values were determined as the lowest 
peptide concentration responsible for no visible bacterial growth. 
 
2.10. Killing kinetics studies 
To kinetically analyse bacterial killing by ApoB derived peptides, experiments were 
performed on E. coli ATTC 25922 and Bacillus licheniformis ATTC 21424 strains. To 
this purpose, bacteria were grown over-night in MHB medium, then diluted in fresh 
MHB, and incubated at 37 °C until logarithmic phase of growth was reached. Bacteria 
were then diluted to 4×106 CFU/mL in a final volume of 150 μL of Nutrient Broth 0.5X 
(Difco, Becton Dickinson, Franklin Lakes, NJ), and mixed with the peptide under test 
(1:1 v/v). For each strain, increasing concentrations of peptide were analysed 
(ranging from 0 to 20 μM or from 0 to 10 μM in the case of E. coli ATTC 25922 and 
Bacillus licheniformis ATTC 21424 strains, respectively. At defined time intervals, 
samples (20 μL) were serially diluted (from 10- to 10,000-fold), and 100 μL of each 
dilution were plated on TSA. Following an incubation of 16 h at 37 °C, bacterial 
colonies were counted. 
2.11. Synergy evaluation 
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Synergism between ApoB derived peptides and antimicrobial agents was assessed 
by the so called “checkerboard” assay against S. aureus MRSA WKZ-2, E. coli ATCC 
25922, P. aeruginosa ATCC 27853, P. aeruginosa PAO1, and S. aureus ATCC 
29213. To this purpose, ApoB derived peptides were tested in combination with 
EDTA or antibiotics, such as ciprofloxacin, colistin, erythromycin, kanamycin sulfate, 
and vancomycin. All these antimicrobial agents were from Sigma Aldrich, Milan, Italy. 
Two-fold serial dilutions of each ApoB derived peptide and each antimicrobial agent 
were tested in combination on each strain tested. To do this, we tested peptide 
concentrations ranging from 0 to 20 μM. Compound concentrations tested on each 
strain are reported in Table 1. The fractional inhibitory concentration (FIC) index was 
calculated as follows: FICA + FICB, where FICA = MIC of drug A in combination/MIC 
of drug A alone, and FICB = MIC of drug B in combination/MIC of drug B alone. FIC 
indexes ≤ 0.5 were classified as synergism, whereas FIC indexes between 0.5 and 4 
were associated to additive or “no interaction” effects [11]. Antagonism is usually 
associated to a FIC index > 4. 
 Table 1. Range of antimicrobial agent concentrations tested on each strain for combination therapy analyses  
 S. aureus  
ATCC 29213 
S. aureus  
MRSA WKZ-2 
P. aeruginosa 
ATCC 27853 
P. aeruginosa  
PAO1 
E. coli  
ATCC 25922 
Ciprofloxacin 0-0,5 μg/mL 0-1 μg/mL 0-2 μg/mL 0-1 μg/mL 0-0,03 μg/mL 
Colistin 0-8 μg/mL 0-8 μg/mL 0-4 μg/mL 0-4 μg/mL 0-8 μg/mL 
Erythromycin 0-4 μg/mL 0-4 μg/mL 0-16 μg/mL 0-128 μg/mL 0-128 μg/mL 
Vancomycin 0-0,25 μg/mL 0-0,5 μg/mL 0-32 μg/mL 0-4 μg/mL 0-0,25 μg/mL 
Kanamycin 0-0,5 μg/mL 0-0,125 μg/mL 0-64 μg/mL 0-8 μg/mL 0-0,125 μg/mL 
EDTA 0-24,53 μg/mL 0-49,07 μg/mL 0-392,5 μg/mL 0-196,2 μg/mL 0-98,14 μg/mL 
 
 
Table 1. Range of antimicrobial agent concentrations tested for combination therapy 
analyses. Based on bacterial strain susceptibility, different concentrations of each 
compound were used in combination with ApoB derived peptides (0- 20 μM) to 
evaluate synergistic effects. 
 
2.12. Anti-biofilm activity  
Anti-biofilm activity of ApoB derived peptides was tested on S. aureus MRSA WKZ-2, 
E. coli ATCC 25922, P. aeruginosa ATCC 27853, and P. aeruginosa PAO1 strains. 
Bacteria were grown over-night in MHB (Becton Dickinson Difco, Franklin Lakes, NJ), 
and then diluted to 1×108 CFU/mL in BM2 medium [12] containing increasing peptide 
concentrations (0 - 1 µM). Incubations with the peptides were carried out either for 4 
h, in order to test peptide effects on biofilm attachment, or for 24 h, in order to test 
peptide effects on biofilm formation. When peptide effects on pre-formed biofilm were 
evaluated, bacterial biofilms were formed for 24 h at 37 ˚C, and then treated with 
increasing concentrations (0 - 1 µM) of the peptides. In all the cases, at the end of 
the incubation, the crystal violet assay was performed. To do this, the planktonic 
culture was removed from the wells, which were washed three times with sterile PBS 
prior to staining with 0.04% crystal violet (Sigma Aldrich, Milan, Italy) for 20 min. The 
colorant excess was eliminated by three successive washes with sterile PBS. Finally, 
the crystal violet was solubilised with 33% acetic acid and samples optical 
absorbance values were determined at 630 nm by using a microtiter plate reader 
(FLUOstar Omega, BMG LABTECH, Germany). To determine the percentage of 
viable bacterial cells inside the biofilm structure, upon biofilm disruption with 0,1% 
Triton X-100 (Sigma Aldrich, Milan, Italy), bacterial cells were ten-fold diluted on solid 
TSA and incubated for 16 h at 37 °C. Once evaluated the number of colony forming 
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units, bacterial cell survival was calculated as follows: (CFUin treated sample/CFUin untreated 
sample) ×100. 
Biofilm cultivation in flow chambers was performed in minimal medium (BM2) for 48 h 
at 37°C. Once biofilm was grown, samples were treated with 1 µM of each peptide for 
24 h at 37 °C. Biofilms were then stained by using SYTO-9 dye to stain live biofilm 
cells (green signal) and propidium iodide, a normally cell-impermeable dye, to stain 
dead cells (red signal). Samples were examined by wide-field fluorescence 
microscopy. Prior to the analysis, silicone tubing was autoclaved, and the system 
was assembled and sterilized by pumping 0.5% hypochlorite at 6 rpm for 1 h by 
using a Watson Marlow 205S peristaltic pump. The system was then rinsed at 6 rpm 
with sterile water for 30 min, and then with medium for further 30 min. Flow chambers 
were then inoculated by injecting with a syringe mid-log culture diluted to an OD600 of 
0.02 (400 μL). Chambers were then left in the absence of flow for 2 h. Afterwards, the 
medium was pumped through the system at a constant rate of 0.75 rpm (3.6 mL/h). 
Analyses were performed by using a Leica DMI 4000 B wide-field fluorescence 
microscope equipped with the following filter sets: Ex 490/20-Em 525/36 for the 
acquisition of green signal and Ex 555/25-Em 605/52 for the acquisition of red signal. 
Quorum Angstrom Optigrid (MetaMorph) acquisition software was used. Images 
were obtained with a 63× objective. Deconvolution was performed by using Huygens 
Essential (Scientific Volume Imaging B.V.), and three-dimensional (3D) 
reconstructions were generated using the Imaris software package (Bitplane AG). 
 
2.13. Cytotoxicity assays 
Cytotoxic effects of ApoB derived peptides on RAW 264.7 cells were determined by 
using the cell proliferator reagent WST-1(Roche Applied Science, Mannheim, 
Germany). To this purpose, RAW 264.7 cells were plated into 96-well plates at a 
density of 5×104 cells in 100 µL medium per well, and incubated over-night at 37 °C. 
Afterwards, cells were treated with increasing concentrations (0 - 20 μM) of the 
peptides for 24 h at 37 °C. Following incubation, peptide-containing medium was 
removed, and 100 μL of fresh medium containing 10% WST-1 reagent was added to 
each well. Following an incubation of 30 min at 37 °C in the dark, sample absorbance 
values were measured at 450 nm using 650 nm as a reference wavelength at a 
microtiter plate reader (FLUOstar Omega, BMG LABTECH, Germany).  
Cytotoxic effects of peptides on the viability of malignant SVT2 murine fibroblasts, 
parental murine BALBc 3T3 fibroblasts, human HeLa cells, and human HaCaT 
keratinocytes were determined by using the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay (Sigma Aldrich, Milan, Italy), as previously 
described [13]. Briefly, cells were seeded into 96-well plates at a density of 5 × 
103/well in 100 µL medium per well, and incubated over-night at 37 °C. Afterwards, 
cells were treated with increasing concentrations (0 - 20 μM) of the peptides under 
test for 24 h at 37 °C. Following incubation, the peptide-containing medium was 
removed, and 100 μL of MTT reagent, dissolved in DMEM without phenol red (Sigma 
Aldrich, Milan, Italy), were added to the cells (100 μL/well) at a final concentration of 
0.5 mg/mL. After 4 h at 37 °C, the culture medium was removed and the resulting 
formazan salts were dissolved by the addition of isopropanol containing 0.1 N HCl 
(100 μL/well). Absorbance values of blue formazan were determined at 570 nm using 
an automatic plate reader (Microbeta Wallac 1420, Perkin Elmer).  
In all the cases, cell survival was expressed as the percentage of viable cells in the 
presence of the peptide under test, with respect to control cells grown in the absence 
of the peptide. 
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2.14. Haemolytic activity 
The release of haemoglobin from mouse erythrocytes was used as a measure for the 
haemolytic activity of ApoB derived peptides. To do this, EDTA anti-coagulated 
mouse blood was centrifuged for 10 min at 800 x g at 20 °C, in order to obtain red 
blood cells (RBCs), which were washed three times, and 200-fold diluted in PBS. 
Subsequently, 75 µL aliquots of RBCs were added to 75 µL peptide solutions (final 
concentration ranging from 0 to 20 µM) in 96-well microtiter plates, and the mixture 
was incubated for 1 h at 37 °C. Following the incubation, the plate was centrifuged 
for 10 min at 1,300 × g at 20 °C, and 100 µL supernatant of each well were 
transferred to a new 96-well plate. Absorbance values were determined at 405 nm by 
using an automatic plate reader (FLUOstar Omega, BMG LABTECH, Germany), and 
the percentage of haemolysis was calculated by comparison with the control samples 
containing no peptide (negative control) or 0.2% (v/v) Triton X-100 (positive control, 
complete lysis). Haemolysis (%) = [(Abs405 nm peptide − Abs405 nm negative 
control)/Abs405 nm 0.2% Triton − Abs405 nm negative control)] × 100. 
 
2.15. Wound healing assay 
Wound heling activity of r(P)ApoBL peptide was evaluated in vitro as previously 
described [14]. Human HaCaT keratinocytes were seeded into 12-well plates at a 
density of 6.3 x 105 cells/well in 1 mL medium per well. Following an incubation of 24 
h at 37 °C, cells were pre-treated with 3 µM mitomycin C for 30 min, in order to inhibit 
cell proliferation [15]. Cell monolayers were then wounded with a pipette tip to 
remove cells from a specific region of the monolayer. The culture medium was then 
removed and the cells were washed twice with PBS. Cells were then incubated with 
fresh culture medium containing increasing concentrations of r(P)ApoBL peptide (0 – 
0.5 – 10 – 20 µM). Wound closure was then followed by multiple field time-lapse 
microscopy (TLM) experiments, using an inverted microscope (Zeiss Axiovert 200, 
Carl Zeiss, Germany) equipped with an incubator to control temperature, humidity 
and CO2 percentage [16, 17]. Images were iteratively acquired in phase contrast with 
a CCD video camera (Hamamatsu Orca AG, Japan) by using a 10x objective. The 
microscope was also equipped with a motorized stage and focus control 
(Marzhauser, Germany) enabling automated positioning of the acquired samples. 
The workstation was controlled through a homemade software in Labview. Each cell 
sample was analysed in duplicate, and in any case at least two fields of view were 
selected. Since three independents experiments were carried out, from 4 to 12 
independent fields of view were analysed for each sample. The delay between 
consecutive imaging of the same field of view was set to 15 min. The wound closure 
dynamics were quantified by using a homemade automated image analysis software, 
that allowed to measure the size of the wound area for each time point (A). For each 
field of view, determined values were normalized with respect to the value of the 
wound area at time 0 (A0), and plotted as function of time. After an initial lag phase, 
the wound area was found to decrease with a constant velocity [18, 19]. By reporting 
A/A0 values as a function of time, a linear decrease was observed for A/A0 values 
lower than 0.8 (Figure 7b). For each sample, the lag time tL was calculated as the 
time required to obtain an initial wound closure corresponding to A/A0=0.8. Being R2 
typically higher than 0.98, the linear range of the curve was fitted, and the slope (-α) 
was considered a measure of the wound closure velocity. The values of wound 
closure velocity obtained for each field of view from three independent experiments 
were averaged (α), and normalized with respect to the value of the corresponding 
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control sample (αcontr). For each peptide concentration tested, α/αcontr values obtained 
from three independent experiments were averaged and the standard error of the 
mean was calculated to account for reproducibility [20].  
 
2.16. Statistical analyses  
Statistical analysis was performed by the Student’s t-Test. Significant differences 
were indicated as *(p < 0.05), **(p < 0.01) or ***(p < 0.001). 
 
3. Results 
3.1. Recombinant production of ApoB derived peptides 
Expression of HDPs in bacterial cells can be deleterious to the host due to their 
toxicity. For this reason, we used a procedure to produce HDPs as fusion proteins 
with onconase (ONC), a frog ribonuclease that mediates the delivery to inclusion 
bodies very efficiently, as previously described [3, 6], thus avoiding toxicity problems. 
DNA sequences encoding peptide ApoB887-923 or peptide ApoB887-911, 
synthesized by MWG Biotech in conformity with the E. coli codon usage, were cloned 
into the expression vector pET22b(+), downstream to a sequence encoding a 
mutated form of ONC. As described in Chapter 2, the resulting fusion proteins 
contain a His tag sequence, positioned between the ONC and the peptide moieties, 
suitable for easily purify the fusion protein, a flexible linker (Gly-Thr-Gly), and a 
dipeptide (Asp-Pro), which is cleaved in mild acidic conditions thus allowing the 
release of the peptide from the carrier. Since the carrier is insoluble at neutral or 
alkaline pH, ApoB derived peptides were isolated from insoluble components by 
repeated cycles of centrifugation, and finally lyophilized. Peptides purity was checked 
by SDS/PAGE and matrix assisted laser desorption ionisation (MALDI) mass 
spectrometry analyses. Recombinant peptides were found to be 99% pure. Molecular 
mass values of ApoB887-923 and ApoB887-911 were found to be 4,072.3 Da 
(Theoretical MH+ 4,072.7) and 2,820.9 Da (Theoretical MH+ 2,820.2), respectively, 
values which are in agreement with the expected molecular weight of the peptides 
including a Pro residue due to the cleavage of the Asp-Pro bond. The final yield of 
peptides ApoB887-923 and ApoB887-911, here named r(P)ApoBL and r(P)ApoBS, 
was about 7 and 4 mg/L of bacterial culture, respectively. 
 
3.2. Conformational analyses of r(P)ApoBL and r(P)ApoBS peptides by Far-UV 
circular dichroism 
To analyse the secondary structure of recombinant ApoB derived peptides, we 
performed Far-UV CD spectra, and found that both peptides are largely unstructured 
in pure water (Figure 2a and b). We also evaluated the effects of membrane-
mimicking agents, such as TFE and SDS at micellar concentrations, on peptide 
conformation. We found that r(P)ApoBL secondary structure shifts mainly towards an 
α-helical conformation in the presence of a membrane-mimicking agent, and only a 
partial (<10%) increase in β-strand content is observed (Table 2). This is clearly 
evidenced by the presence of two broad minima at around 208 and 222 nm, and a 
maximum at <200 nm (Figure 2a). A similar behavior has been described for different 
HDPs [24, 42, 43], and suggests that r(P)ApoBL peptide is prone to assume a 
specific ordered conformation when interacting with membrane-mimicking agents. 
Similar effects, even if significantly less pronounced, were observed in the case of 
r(P)ApoBS peptide (Figure 2b and Table 2). No appreciable β-strand formation was 
observed for this peptide, probably indicating that, in the r(P)ApoBL peptide, β-strand 
propensity is mainly localized in the C-terminus region. 
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We also analysed by CD spectroscopy the effects of the endotoxin LPS 
(lipopolysaccharide), the predominant glycolipid in the outer membrane of Gram-
negative bacteria [44], on peptide conformation (Figure 2c and d and Table 2). When 
r(P)ApoBL secondary structure was analysed in the presence of increasing 
concentrations (from 0.1 to 0.8 mg/mL) of E. coli LPS, the progressive appearance of 
a maximum at approximately 200 nm and of a minimum at approximately 218 nm 
suggested that the peptide tends to assume prevalently a β-strand conformation, 
probably induced by its interaction with LPS (Figure 2c and Table 2). As expected on 
the basis of previous analyses, indicating no β-strand structure in r(P)ApoBS , no 
significant effects were observed in the case of r(P)ApoBS (Figure 2d and Table 2) 
under the experimental conditions tested. 
 
                     
 
Figure 2. Far-UV CD spectra of recombinant peptides r(P)ApoBL (a, b) and 
r(P)ApoBS (c, d) at a concentration of 10 µM in the presence of the membrane-
mimicking agents TFE or SDS at micellar concentrations (a, b), or in the presence of 
increasing concentrations of LPS (c, d). 
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Table 2. Secondary structure content of ApoB derived peptides in water and in the 
presence of trifluoroethanol (TFE), sodium dodecyl sulfate (SDS), or 
lipopolysaccharide (LPS), calculated by means of PEPFIT program. 
 
 3.3. Analysis of the immunomodulatory activity of r(P)ApoBL and r(P)ApoBS 
peptides 
Based on CD analyses, we hypothesized that an interaction between r(P)ApoBL 
peptide and LPS occurs. Since it is widely reported that HDPs are able to mitigate 
the pro-inflammatory effects induced by endotoxins [24], we tested the anti-
inflammatory properties of ApoB derived peptides by monitoring their effects on LPS 
induced interleukin-6 (IL-6) release, as well as on nitric oxide (NO) release in murine 
macrophages (RAW 264.7 cell line). In fact, it is known that, upon activation by 
internal and external stimuli, macrophages produce and secrete various endogenous 
inflammatory mediators, such as nitric oxide (NO) and pro-inflammatory cytokines, 
including interleukin-6 [25, 26].  
To test the effects of ApoB derived peptides on the release of IL-6, ELISA assays 
were performed on LPS stimulated RAW 264.7 cells. As shown in Figure 3a and b, a 
significant release of IL-6 was observed in control cells incubated with LPS from 
Salmonella Minnesota (50 ng/mL). When murine macrophages were incubated with 
LPS (50 ng/mL) in the presence of either r(P)ApoBL (Figure 3a) or r(P)ApoBS (Figure 
3b) peptide, a strong decrease of IL-6 release was observed with respect to LPS 
induced control cells. Moreover, we found that both peptides have a significant 
protective effect on LPS stimulated RAW 264.7 cells. In fact, when macrophages 
were pre-treated for 2 h with either r(P)ApoBL or r(P)ApoBS peptide and then 
incubated for further 24 h with LPS, a significant decrease of IL-6 release was 
observed (Figure 3a and b).  
Similar results were observed when the effects of ApoB derived peptides were tested 
on NO release (Figure 3c and d). Also in this case, following co-incubation of cells 
with LPS from Salmonella Minnesota and either r(P)ApoBL or r(P)ApoBS peptide, a 
significant attenuation of NO release with respect to control cells was detected 
(Figure 3c and d). However, in this case, it has to be noticed that a significant effect 
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of peptides on NO release was observed only at the highest peptide concentration 
tested (20 µM), while at 5 µM concentration both peptides were found to be almost 
ineffective (Figure 3c and d). However, when RAW 264.7 cells were pre-treated for 2 
h with 5 or 20 µM of either r(P)ApoBL or r(P)ApoBS peptide and subsequently 
stimulated for 24 h with LPS (50 ng/mL), the reduction of NO release was observed 
even at 5 µM peptide concentration (Figure 3c and d), thus confirming the protective 
effect of both peptides on LPS stimulated RAW 264.7 cells. 
 
 
 
Figure 3. Effects of ApoB derived peptides on the release of IL-6 (a, b) and NO (c, d) 
in mouse macrophages RAW 264.7 stimulated with LPS (50 ng/mL) from Salmonella 
Minnesota. The effects of r(P)ApoBL (a, c) and r(P)ApoBS (b, d) peptides were 
evaluated either by co-incubating cells with peptides (5 or 20 µM) and LPS (oblique 
grey lanes) or by treating cells with the peptides (5 or 20 µM) for 2 h at 37 °C prior to 
incubation with LPS (chessboard bars). The results were compared to those obtained 
in the case of control untreated cells (white bars), cells stimulated with the LPS alone 
(black bars), or cells incubated with tdifferent concentrations (5 or 20 µM) of peptide 
(grey bars). Data represent the mean (± standard deviation, SD) of at least three 
independent experiments, each one carried out with triplicate determinations.   
 
3.4. Antimicrobial activity of r(P)ApoBL and r(P)ApoBS peptides   
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The antibacterial activity of recombinant ApoB derived peptides was determined by 
measuring their MIC100 values on a panel of Gram-negative and Gram-positive 
bacterial strains (Table 3). A significant antimicrobial activity of r(P)ApoBL and 
r(P)ApoBS peptides was detected towards four out of eight strains tested, i.e. E. coli 
ATCC 25922, P. aeruginosa PAO1, B. globigii TNO BM013, and B. licheniformis 
21424, for which almost identical MIC100 values were calculated for both ApoB 
derived peptides. Notably, MIC100 values were found to be comparable, or even 
significantly lower than those determined when control cathelidin-2 (CATH-2), a 
known HDP from chicken [48], was tested (Table 3). These data indicate that 
r(P)ApoBL and r(P)ApoBS peptides are endowed with a broad-range antimicrobial 
activity, being effective on both Gram-negative and Gram-positive bacterial strains. 
On the other hand, ApoB derived peptides were found to be ineffective towards P. 
aeruginosa ATCC 27853, methicillin-resistant S. aureus (MRSA WKZ-2), and S. 
aureus ATTC 29213 (Table 3), while, in the case of S. enteriditis 706 RIVM, a 
significant antibacterial effect was elicited only by r(P)ApoBL peptide. 
To analyse the kinetic of peptides bactericidal activity, kinetic killing curves were 
obtained by treating E. coli ATTC 25922 and B. licheniformis ATTC 21424 strains, 
highly susceptible to both peptides (Table 3), with increasing concentrations of either 
r(P)ApoBL or r(P)ApoBS for different times (0-180 min). We found that, at the highest 
peptide concentrations tested (5-10 µM), B. licheniformis cells were killed within 10 
min, while at the lowest peptide concentrations (1.25-2.5 µM) the same effect was 
obtained within 30 min (Figure 4a and c). When peptides were tested on E. coli 
ATTC 25922 at high concentrations (5-10-20 µM), bacterial cells were killed within 
120 min, while at the lowest peptide concentration (2.5 µM) the same effect was 
obtained within 180 min (Figure 4c and d). 
 
 
 
Table 3. Minimum Inhibitory Concentration (MIC, µM) values determined for 
r(P)ApoBL and r(P)ApoBS peptides tested on a panel of Gram-positive and Gram-
negative bacterial strains. Chicken CATH-2 peptide was used as a positive control. 
Values were obtained from a minimum of three independent experiments. 
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Figure 4. Time killing curves obtained by incubating Bacillus licheniformis ATTC 
21424 (a, b) and E. coli ATTC 25922 (c, d) strains with increasing concentrations of 
r(P)ApoBL (a, c) or r(P)ApoBS (b, d) peptides for different lengths of time. Data 
represent the mean (± standard deviation, SD) of at least three independent 
experiments, each one carried out with triplicate determinations.  
 
3.5. Combination therapy analyses  
To potentiate the antimicrobial efficacy of recombinant ApoB derived peptides for 
therapeutic purposes, especially against P. aeruginosa and S. aureus strains, we 
carried out combination therapy analyses by concomitantly administrating peptides 
and antibiotics in various combinations to bacteria. One of the best-known test to 
evaluate synergism between two compounds is the so called “chequerboard” 
experiment, in which a two-dimensional array of serial concentrations of test 
compounds is used as the basis for calculation of a fractional inhibitory concentration 
(FIC) index to demonstrate that paired combinations of agents can exert inhibitory 
effects that are more than the sum of their effects alone [11]. It is generally accepted 
that FIC indexes ≤ 0.5 are indicative of “synergy”; FIC indexes comprised between > 
0.5 and 4.0 are, instead, associated to “additive” or “no interaction” effects, whereas 
FIC indexes > 4.0 are indicative of “antagonism” [11]. 
As reported in Table 4, all the combinations tested were found to be effective, either 
with additive or synergistic effects between peptides and antibiotics. Notably, no FIC 
indexes higher than 2 were measured.   
The most potent combinations were obtained in the presence of EDTA, which was 
selected for its ability to affect bacterial outer membrane permeability, thus 
sensitizing bacteria to a number of antibiotics [18-30]. Very pronounced synergistic 
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effects were observed for both ApoB derived peptides in combination with EDTA on 
S. aureus MRSA WKZ-2 and both P. aeuroginosa strains.  
Both peptides were found to act synergistically with (i) ciprofloxacin on all the strains 
tested (Table 4); (ii) colistin on all the strains tested, except for S. aureus ATTC 
29213 (Table 4); (iii) vancomycin on S. aureus MRSA WKZ-2, P. aeruginosa strains 
and E. coli ATTC 25922 (Table 4); (iv) erythromycin on P. aeruginosa ATCC 27853 
(Table 4). In the latter case, a FIC index of 0.38 and 0.17 for r(P)ApoBL and 
r(P)ApoBS peptides, respectively, was obtained. In the case of kanamycin, the 
response varied depending on the peptide and the specific bacterial strain. In fact, 
r(P)ApoBL was found to act synergistically with this antibiotic prevalently on Gram-
negative bacteria, particularly on the P. aeruginosa strains, whereas r(P)ApoBS 
peptide was found to be very active in the presence of kanamycin against both S. 
aureus strains as well as against P. aeruginosa PAO1 strain (FIC indexes < 0.4).  
It should be emphasized that combinations of ApoB derived peptides with antibiotics 
or EDTA were found to have a strong antimicrobial activity even towards strains on 
which the peptides alone were found to be ineffective, such as both S. aureus strains 
and P. aeruginosa ATCC 27853 (Table 3). Notably, we did not observe any 
antagonistic interactions between the peptides and the antimicrobials. 
 
                 
Table 4. Fractional inhibitory concentration (FIC) indexes determined for r(P)ApoBL 
and r(P)ApoBS peptides tested in combination with antibiotics or EDTA on Gram-
positive and Gram-negative bacterial strains. Indexes were obtained from a minimum 
of three independent experiments, each one carried out with triplicate determinations. 
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3.6. Anti-biofilm activity of r(P)ApoBL and r(P)ApoBS peptides   
Anti-biofilm peptides represent a very promising approach to treat biofilm-related 
infections and have an extraordinary ability to interfere with various stages of the 
biofilm growth mode [31]. To test whether recombinant ApoB derived peptides are 
endowed with anti-biofilm activity, we performed experiments on different bacterial 
strains, such as E. coli ATCC 25922, Pseudomonas aeruginosa PAO1, 
Pseudomonas aeruginosa ATCC 27853, and methicillin resistant Staphylococcus 
aureus MRSA WKZ-2 in BM2 medium. The same experiments were also performed 
using LL-37 control peptide, that is a human antimicrobial peptide known to have a 
significant anti-biofilm activity against multidrug-resistant bacterial strains [32]. We 
also tested for the first-time CATH-2 anti-biofilm activity. Three different approaches 
were followed. At first, we tested the peptide effects on biofilm attachment. To do 
this, the bacterial culture, following over-night growth, was diluted in BM2 medium 
containing increasing concentrations of the peptide under test (0-1 µM), and 
incubated for 4 h at 37 °C. Following incubation, biofilm analysis by crystal violet 
staining revealed a significant dose-dependent inhibition of biofilm attachment in the 
case of E. coli ATCC 25922 (Figure 5a) and S. aureus MRSA WKZ-2 (Figure 5d) 
strains treated with r(P)ApoBL (continuous line in Figure 5a, d) or r (P)ApoBS 
(smaller dashed line in Figure 5a, d) peptides. Similar results were obtained on these 
two strains in the case of peptides CATH-2 (larger dashed line in Figure 5a, d) and 
LL-37 (dotted line in Figure 5a, d). Strong effects were also displayed by ApoB 
derived peptides on biofilm attachment in the case of P. aeruginosa PAO1 strain 
(Figure 6d). A less pronounced effect of ApoB derived peptides (about 20% inhibition 
of biofilm formation) was observed, instead, on P. aeruginosa ATCC 27853 biofilm 
attachment (Figure 6a). Second, we tested the effect of ApoB derived peptides on 
biofilm formation. To investigate this phenomenon, we followed the experimental 
procedure described above with the only exception that bacterial cells were 
incubated with increasing concentrations of peptides for 24 h at 37 °C. Also in this 
case, we observed a significant dose-dependent inhibition of biofilm formation in the 
case of E. coli ATCC 25922 (Figure 5b) and S. aureus MRSA WKZ-2 (Figure 5e) 
strains treated with r(P)ApoBL (Figure 5b, e) or r(P)ApoBS (Figure 5b, e) peptides. 
Similar effects were elicited by peptides CATH-2 (Figure 5b, e) and LL-37 (Figure 5b, 
e). ApoB derived peptides strongly affected also P. aeruginosa PAO1 biofilm 
formation (Figure 6e). In the case of P. aeruginosa ATCC 27853, instead, a less 
pronounced effect (about 20% biofilm formation inhibition) was observed for all the 
peptides under test (Figure 6b). Third, we tested the effect of ApoB derived peptides 
on pre-formed biofilms. By incubating pre-formed biofilms of E. coli ATCC 25922 
(Figure 5c) and S. aureus MRSA WKZ-2 (Figure 5f) strains with increasing 
concentrations of r(P)ApoBL (Figure 5c, f) or r(P)ApoBS (Figure 5c, f), we found a 
significant reduction (about 50%), an effect even stronger than that observed in the 
case of CATH-2 peptide (Figure 5c, f). Similar results were observed in the case of P. 
aeruginosa PAO1 strain (Figure 6f). On the other hand, when the peptides were 
tested on P. aeruginosa ATCC 27853 pre-formed biofilm, a slight effect (about 20% 
reduction) was observed for all the peptides except for CATH-2, which was found to 
have a strong effect (about 50% reduction, Figure 6c).  
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Figure 5. Anti-biofilm activity of r(P)ApoBL (–), r(P)ApoBS (- - -), CATH-2 (–––), and 
LL-37 (•••) peptides on E. coli ATCC 25922 (a, b, c) and S. aureus MRSA WKZ-2 (d, 
e, f) strains in BM2 medium. The effects of increasing concentrations of peptides 
were evaluated either on biofilm attachment (a, d), biofilm formation (b, e), or on pre-
formed (c, f) biofilm. Biofilm was stained with crystal violet and measured at 630 nm. 
Data represent the mean (±standard deviation, SD) of at least three independent 
experiments, each one carried out with triplicate determinations. For all the 
experimental points, *P < 0.05, **P < 0.01, or ***P < 0.001 were obtained for control 
versus treated samples. 
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Figure 6. Anti-biofilm activity of r(P)ApoBL (–), r(P)ApoBS (- - -), CATH-2 (–––), and 
LL-37 (•••) peptides on P. aeruginosa ATCC 27853 (a, b, c) and P. aeruginosa PAO1 
(d, e, f) strains in BM2 medium. The effects of increasing concentrations of peptides 
were evaluated either on biofilm attachment (a, d), biofilm formation (b, e), or on pre-
formed (c, f) biofilm. Biofilm was stained with crystal violet and measured at 630 nm. 
Data represent the mean (± standard deviation, SD) of at least three independent 
experiments, each one carried out with triplicate determinations. For all the 
experimental points, *P < 0.05, or **P < 0.01 were obtained for control versus treated 
samples. 
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We also evaluated the percentage of viable bacterial cells inside the biofilm structure 
by colony counting assay. We found that, even at the highest ApoB derived peptides 
concentrations tested, a significant percentage of bacterial cells appeared to be still 
alive (Table 5). Similar results were also obtained in the case of LL-37 and CATH-2 
control peptides on both P. aeruginosa strains (Table 5), even if it has to be noticed 
that, in the case of biofilm formation, both control peptides affected the viability of P. 
aeruginosa PAO1 cells more than ApoB derived peptides (Table 5). CATH-2 and LL- 
37 control peptides were also found to strongly impair the viability of E. coli ATCC 
25922 and S. aureus MRSA WKZ-2 cells in the case of biofilm eradication (Table 5). 
 
 
Table 5. Effect of r(P)ApoBL, r(P)ApoBS, CATH-2, and LL-37 peptides (1 µM) on 
biofilm attachment, formation, and eradication. To determine the percentage of viable 
bacterial cells inside the biofilm structure, biofilm was lysed with Triton X-100 (0,1%), 
bacterial cells were ten-fold diluted, and colonies were counted after an incubation of 
16 h at 37 °C. Data are expressed as percentage with respect to control untreated 
samples, and represent the mean (± standard deviation, SD) of at least three 
independent experiments, each one carried out with triplicate determinations.          
   
To deepen on ApoB derived peptides anti-biofilm activity, we also performed studies 
in continuous-flow chambers. To this purpose, we tested P. aeruginosa PAO1 pre-
formed biofilm in the absence or in the presence of r(P)ApoBL (Figure 7 b) or 
r(P)ApoBS (Figure 7 c) peptide tested at 1 µM concentration. To do this, biofilm 
growth was carried out for 48 h at 37 °C. Afterwards, pre-formed biofilm was treated 
with the peptide under test for 24 h. Analyses revealed that both peptides are able to 
strongly eradicate pre-formed biofilm, with the strongest effects observed in the 
presence of r(P)ApoBL peptide.  
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Figure 7. Flow cell analysis of P. aeruginosa PAO1 pre-formed biofilm in the absence 
(a) or in the presence of 1 µM r(P)ApoBL peptide (b) or of 1 µM r(P)ApoBS peptide 
(c). Biofilms have been stained and visualized using SYTO-9 to stain live biofilm cells 
(green) and propidium iodide, a normally cell-impermeable dye, to stain dead cells 
(red). Images were acquired by wide-field fluorescence microscopy.  
(a) PAO1 biofilm untreated. (b) PAO1 biofilm treated with 1 µM r(P)ApoBL. (c) PAO1 
biofilm treated 1 µM with r(P)ApoBS. On the left, images of PAO1 biofilm stained with 
SYTO-9; in the middle, images of PAO1 biofilm stained with propidium iodide; on the 
right, merged images are reported. Each panel shows xy, yz, and xz dimensions. 
Scale bar = 20 µm. 
 
3.7. Biocompatibility of r(P)ApoBL and r(P)ApoBS peptides  
The development of HDPs as therapeutic agents is strictly related to their selective 
toxicity towards bacterial cells [33]. The presence of zwitterionic phospholipids and 
cholesterol on the outer leaflet of eukaryotic cell membranes largely accounts for the 
preference of HDPs for bacterial membranes over eukaryotic membranes [34, 35]. 
To deepen on the therapeutic potential of ApoB derived peptides, we analysed their 
cytotoxic effects towards a panel of mouse and human eukaryotic cells. The addition 
of increasing concentrations (from 0.625 to 20 μM) of ApoB derived peptides to 
mouse macrophages Raw 264.7 cells for 24 h did not result in any significant 
reduction in cell viability (Figure 8a and c). A slight toxicity was detected only at the 
highest peptide concentrations tested (10 and 20 μM in Figure 8a and c). We also 
tested ApoB derived peptides on murine embryo fibroblasts BALBc 3T3 and their 
tumor counterpart, i.e. SVT2 simian virus 40-transformed cell line (Figure 8b and d). 
A slight toxicity (10-20%) was detected only in the case of SVT2 cells at the highest 
concentration tested (20 μM in Figure 8b and d).  Moreover, no significant toxic 
effects were detected when ApoB derived peptides were assayed on human cervical 
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cancer HeLa cells (Figure 8b and d), while a slight toxicity (~20%) was observed in 
the case of human keratinocytes (HaCaT cells) at the highest concentration (20 μM 
in Figure 8b and d). ApoB derived peptides were also tested on murine red blood 
cells (RBCs) to exclude hemolytic effects. As shown in Figure 9, both peptides did 
not exert any lytic effect on mouse RBCs, even at the highest concentration tested 
(20 μM). 
 
           
 
Figure 8. Effects of r(P)ApoBL (a, b) and r(P)ApoBS (c, d) peptides on the viability of 
RAW 264.7 (a, c), BALBc 3T3 (black bars in b, d), SVT2 (dark grey bars in b, d), 
Hela (white bars in b, d), and HaCaT (light grey bars in b, d) cells. Cell viability was 
assessed by WST-1 (a, c) or MTT (b, d) assay, and expressed as the percentage of 
viable cells with respect to controls (untreated cells). Error bars indicate standard 
deviations obtained from at least three independent experiments, each one carried 
out with triplicate determinations. 
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Figure 9. Hemolytic activity of r(P)ApoBL (a) and r(P)ApoBS (b) peptides towards 
murine red blood cells (RBCs) after 1 h incubation at 37 °C. Data represent the mean 
(± standard deviation, SD) of at least three independent experiments, each one 
carried out with triplicate determinations. 
 
3.8. Wound healing activity of r(P)ApoBL peptide 
Numerous studies support the hypothesis that human HDPs promote wound healing 
in skin, by modulating cytokine production, cell migration, proliferation and, in some 
cases, angiogenesis [36]. Based on this, we performed experiments to test whether 
r(P)ApoBL peptide is able to stimulate wound re-epithelialization by human 
keratinocytes (HaCaT cell line). To this purpose, we performed a classical in vitro 
wound healing assay to evaluate peptide effects on cell migration. HaCaT cell 
monolayers were pre-treated with 3 µM mitomycin C for 30 min, and then wounded 
with a pipette tip to remove cells from a specific region of the monolayers. 
Cells were then washed with PBS and incubated with r(P)ApoBL (0, 0.5, 10, and 20 
µM). As it is well known that the spreading of cells in the wound area is due to two 
mechanisms, i.e. cell motility and cell proliferation [16,19,37], a pre-treatment with 
mitomycin C allowed us to exclude any influence of cell proliferation on the wound 
healing process. In Figure 10a, we reported the images acquired during a time-lapse 
wound healing experiment on control cells, and on cells treated with 20 µM 
r(P)ApoBL peptide at three time points, i.e. at time 0 and at 3 and 5 h after the lag 
time (tL), defined as a transient time period (tL) before the linear decrease of the 
wound area (see below). By the comparison of the images of treated and untreated 
cells at each time point, it emerged that the cells treated with 20 µM peptide were 
able to close the wound faster than the control cells. In order to quantify the wound 
closure, we used an automated image analysis software, that allowed us to measure 
the size of the cell-free area (A) for each time point. The obtained values were 
normalized with respect to the value measured at time 0 (A0) for each field of view, 
and plotted as a function of time (Figure 10b). In Figure 10a, at t = 5 h after tL, A/A0 
values were found to be 0.20, and 0.07 for the control sample, and for the cells 
treated with 20 µM peptide, respectively. This evidence suggests that r(P)ApoBL 
peptide might be able to stimulate wound re-epithelialization by human keratinocytes. 
As shown in Figure 10b, where A/A0 values of control cells are reported as a function 
of time, after an initial lag phase (tL), the wound area decreases with a constant 
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velocity. The initial lag phase, corresponding to a transient time period (tL) before the 
linear decrease of the wound area, has been observed for all the analysed samples, 
and has been found to range between 3 and 5 h independently from peptide 
concentrations under test (Figure 10c). As the slope (a) of the line represents the 
measure of the wound closure velocity, each a value calculated in the presence of 
the peptide was normalized with respect to the value calculated for untreated cells 
(acontr), and plotted as a function of peptide concentration (Figure 10d). It appeared 
that the cells treated with the peptide show an increased wound closure velocity with 
respect to the control cells (a/acontr > 1). In particular, in the case of the cells treated 
with 10 µM peptide, an increment of about 20% in the normalized wound closure 
velocity (a/acontr = 1.21, data statistically significant) was observed. When cells were 
treated with 20 µM peptide, a slightly higher value of the normalized wound closure 
velocity was measured (a/acontr = 1.23). However, in the latter case, a higher data 
variability was observed (larger error bar), leading to a limited statistical significance 
of the result. Overall, our results indicate that r(P)ApoBL peptide is able to promote 
the migration and the consequent wound healing in HaCaT keratinocyte monolayers 
when tested at concentration values ranging between 0.5 and 20 µM. 
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Figure 10. Wound healing activity of r(P)ApoBL peptide on HaCaT cells monolayer. 
Cells were pre-treated for 30 min with 3 µM mitomycin C, and then wounded prior to 
incubation with r(P)ApoBL peptide (0.5–10–20 µM) for 12 h at 37 °C. Images were 
acquired for untreated HaCaT cells and for cells treated with 20 µM peptide (a). The 
lag phase time (tL) corresponds to the time interval before the linear decrease of the 
wound area. Images were acquired at time t = 0 (a, on the left), 3 h after tL (a, in the 
middle) and 5 h after tL (a, on the right). For each sample, A/A0 values are reported, 
where A is the wound area after a specific incubation time and A0 is the wound area 
at time 0. Scale bar = 150 µm. In (b), evolution in time of the wound area (A), 
normalized with respect to A0, is reported for a control sample. A homemade 
automated image analysis software was used to measure the size of the cell-free 
area (A) for each time point. For A/A0 values < 0.8, a linear correlation with the 
incubation time was found. The slope -α of the linear fit, reported as a continuous 
line, represents a measure of the wound closure velocity. In (c), determined tL values 
are reported as a function of peptide concentration (0– 0.5–10–20 µM). In (d), wound 
closure velocity (a), normalized with respect to control sample (acontr), is reported as a 
function of peptide concentration (0.5–10–20 µM). The dashed line corresponds to 
a/acontr = 1. In (c) and (d), each data point represents the mean (±standard error) of 
three independent experiments. **P < 0.01 was obtained for control versus treated 
samples. 
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4. Discussion 
Recently, an abundance of multidrug-resistant bacteria has emerged, whereas very 
few classes of new antibiotics have been discovered. The knowledge that HDPs may 
prevent infections in many organisms opened interesting perspectives to the 
applications of these peptides as a new class of antimicrobials. In fact, they initially 
attracted attention solely for their direct antimicrobial activity, and were studied as 
promising alternative antibiotic candidates due to their prospective potency, rapid 
action, and broad spectrum of activity against Gram-negative and Gram-positive 
bacteria, viruses, fungi and parasites [38, 39]. To date, more than 1,000 natural 
cationic HDPs with antimicrobial properties have been identified [40]. These peptides 
constitute a major component of the ancient, nonspecific innate defence system in 
most multicellular organisms [38, 39]. However, it has to be emphasized that most 
natural HDPs have, indeed, modest direct antimicrobial activities, and exhibit multiple 
mechanisms of action, with a consequent low potential to induce de novo resistance 
[38]. This class of peptides includes the bioactive peptides displaying direct 
antimicrobial activity and those that stimulate the immune system to clear or prevent 
an infection [38, 40]. In mammals, the expression of mature and biologically active 
HDPs requires a proteolytic cleavage event determining the release of the “cryptic” 
bioactive peptide from its precursor protein [41]. In fact, it should be emphasized that 
a wide variety of human proteins, whose primary functions are not necessarily related 
to host defense, contain HDPs hidden inside their sequences [42, 43]. Fascinatingly, 
human proteome could be seen as a yet unexplored source of bioactive peptides 
with potential pharmacological applications. In this context, apolipoproteins have 
been identified as a source of bioactive peptides displaying broad anti-infective and 
antiviral activities [22]. Indeed, the presence of antiviral peptides hidden within 
apolipoprotein sequences may be related to the fact that lipoproteins and viruses 
share a similar cell biological niche, having a comparable size and displaying similar 
interactions with mammalian cells and receptors [1]. ApoB is one of the several 
apolipoproteins that play key roles in lipoprotein metabolism [44], and represents the 
ligand for receptor-mediated removal of low density lipoprotein particles from 
circulation [44]. ApoB contains two LDL (low-density lipoprotein) receptor binding 
domains, namely region A (ApoB3147-3157) and region B (ApoB3359-3367), which 
is more uniformly conserved across species and that has been found to be endowed 
with a significant antiviral activity [1]. Moreover, ApoB derived peptides have been 
already used in vaccine preparations to treat atherosclerosis [2]. Here, we applied 
recently developed in silico analysis method to a human ApoB isoform [5, 6] and 
identified a novel “cryptic” HDP (region 887-922). To the best of our knowledge, this 
ApoB region has never been analysed before, since the biologically active ApoB 
peptides previously identified are located far from the high scoring region identified in 
the present work [1, 2]. By in silico analysis, we identified an absolute maximum, 
corresponding to region 887-922 (Figure 1), and a relative maximum, corresponding 
to residues 887-909 (Figure 1). Here, we focused our attention on these two ApoB 
sequences by producing in bacterial cells two recombinant HDPs, here named 
r(P)ApoBL and (P)ApoBS, 38- and 26-residue long, respectively. Both recombinant 
peptides were found to exhibit antibacterial activities against both Gram-positive and 
Gram-negative strains, including the pathogenic strains P. aeruginosa PAO1 and B. 
globigii TNO BM013, while having negligible cytotoxic effects on a panel of human 
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and murine cell lines. Time killing curves also indicated that peptides exert a strong 
bactericidal activity against susceptible strains. However, it has to be underlined that 
ApoB derived peptides were found to be ineffective towards P. aeruginosa ATCC 
27853, methicillin-resistant S. aureus (MRSA WKZ-2), and S. aureus ATTC 29213 
strains, while, in the case of S. enteriditis 706 RIVM strain, a significant antibacterial 
effect was displayed only by r(P)ApoBL peptide. This observation is in agreement with 
previous findings indicating that most natural cationic antimicrobial peptides do not 
appear to be highly optimized for direct antimicrobial activity, since it is likely that 
multiple modestly active peptides with concomitant immunomodulatory activities work 
effectively in combination and/or when induced or delivered to sites of infection [45]. 
Indeed, considering this, we performed combination therapy analyses and found that 
both ApoB derived peptides are able to act synergistically with commonly used 
antibiotics or with EDTA, the latter selected for its ability to affect the permeability of 
bacterial outer membrane, thus sensitizing bacteria to a number of antibiotics [28-30]. 
Interestingly, synergistic effects were observed towards most of the strains under 
test, including methicillin-resistant S. aureus MRSA WKZ-2, on which the peptides 
alone were found to be ineffective even at high concentrations (40 µM). Although the 
use of a single agent to treat pathogens is the most common practice in clinics, 
combination therapy approaches have several advantages, such as low potential to 
induce resistant phenotype, efficacy at lower drug doses, with a consequent 
mitigation of toxic effects, and possibility to target a broad spectrum of pathogens 
[46]. Interestingly, both r(P)ApoBL and r(P)ApoBS peptides showed synergism with 
systemic antibiotic ciprofloxacin against all the strains under test (FIC indexes 
ranging from 0.3 to 0.44). This would allow to significantly lower the doses of the 
antibiotic in the combination therapy approaches, with a consequent decrease of the 
appearance of resistant clinical isolates, an undesired phenomenon strongly affecting 
ciprofloxacin efficacy [47]. ApoB derived peptides also showed synergistic effects 
with colistin and vancomycin against most of the strains under test (FIC indexes 
ranging from 0.14 to 0.5). Since both colistin and vancomycin are responsible for 
toxic effects at high concentrations [46,48], a combination therapeutic approach 
based on a reduced frequency of antibiotic administration and/or exposure to 
antibiotic may offer several advantages over conventional dosing schemes. However, 
the most potent synergism was observed for both ApoB derived peptides in 
combination with EDTA, with FIC indexes ranging from 0.089 to 0.4. In the case of P. 
aeruginosa strains, synergism might be associated to EDTA ability to combine with 
magnesium ions playing a key role in the self-interaction of LPS molecules, with a 
consequent LPS release determining an increased permeability of bacterial 
membrane [29]. This might ultimately facilitate peptide internalization into bacterial 
cells, thus potentiating the peptide antimicrobial activity. EDTA is also known to 
determine the release of endogenous phospholipases, with a consequent alteration 
of Gram-negative bacteria outer membrane [49]. In the case of S. aureus strains, the 
increase of bacterial membrane permeability might be due to the ability of EDTA to 
solubilize extracellular polymeric substances [50], mainly composed by 
exopolysaccharides and playing a key role in biofilm establishment.  
It should be highlighted that, although in some cases FIC indexes very close to 0.5 
make it difficult to discriminate between synergistic and additive effects, no 
antagonistic interactions were observed between peptides and antimicrobials under 
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test. Furthermore, combinations of ApoB derived peptides with antibiotics or EDTA 
were found to have a strong antimicrobial activity also towards strains on which the 
peptides alone were found to be ineffective, such as both S. aureus strains and P. 
aeruginosa ATCC 27853, indicating that in drug combinations a reciprocal facilitation 
and potentiation of different mechanisms of action is realized. 
Interestingly, ApoB derived peptides are also endowed with anti-biofilm activity. 
Microorganisms growing in a biofilm state are very resilient to the treatment by many 
antimicrobial agents. Indeed, biofilm infections are a significant problem in chronic 
and long-term infections, including those colonizing medical devices and implants 
[31]. Specific cationic HDPs have recently been described to have multispecies anti-
biofilm activity, which is independent of their activity against planktonic bacteria. We 
found that ApoB derived peptides are effective on biofilm formation and biofilm 
attachment, and, even more interestingly, they strongly affect pre-formed biofilms. 
Furthermore, ApoB derived peptides display anti-biofilm activity even on bacterial 
strains not sensitive to the peptide antimicrobial activity, such as S. aureus MRSA 
WKZ-2, and, in the case of sensitive strains, even at peptide concentrations (0.625 – 
1 µM) significantly lower than those required to directly kill planktonic cells. This is in 
agreement with previous reports indicating that LL-37 peptide potently inhibits the 
formation of bacterial biofilms in vitro at the very low and physiologically meaningful 
concentration of 0.5 µg/mL, significantly lower than that required to kill or inhibit 
bacterial growth (64 µg/mL) [51]. As a consequence of this, it should be emphasized 
that even at the highest ApoB derived peptides concentrations tested, a significant 
percentage of bacterial cells inside the biofilm structure appeared to be still alive. 
This was observed for both ApoB derived peptides and LL-37 control peptide, while it 
was less pronounced in the case of CATH-2 peptide. Based on this, it is tempting to 
speculate that successful therapeutic approaches could be designed by combining 
anti-biofilm peptides and conventional antibiotics ineffective on biofilm, but effective 
on bacterial cells entrapped into the biofilm structure.  
From a structural point of view, by Far UV-CD analyses, we found that ApoB derived 
peptides are unstructured in aqueous buffer, and tend to assume a conformation in 
the presence of membrane mimicking agents. In the presence of increasing 
concentrations of LPS, r(P)ApoBL peptide was found to gradually assume a defined 
structure, what suggests a direct binding of this peptide to LPS. This was not 
observed, instead, in the case of r(P)ApoBS peptide. It has also to be highlighted that 
both r(P)ApoBL and r(P)ApoBS peptides are endowed with immunomodulatory 
activities by significantly decreasing the release of pro-inflammatory IL-6 and NO in 
LPS induced murine RAW 264.7 macrophages. Both ApoB derived peptides were 
found to efficiently act either when the cells were co-incubated with the peptide under 
test in the presence of LPS, or when the cells were pre-treated with the peptide for 2 
h and then incubated with LPS for further 24 h, thus indicating that both peptides are 
able to display a significant protective action. However, it has to be noticed that, 
differently from r(P)ApoBL peptide, r(P)ApoBS was found to play anti-inflammatory 
activities when co-incubated with LPS, only at the highest peptide concentration 
tested (20 µM), whereas both r(P)ApoBS concentrations (5 and 20 µM) were found to 
efficiently exert a protective effect. This might be due to the fact that ApoB derived 
peptides probably act through different mechanisms, with r(P)ApoBL peptide mainly 
acting by binding to LPS and consequently by interfering with its activity on target 
cells, and r(P)ApoBS peptide mainly acting on cell membrane and competing with 
LPS for the binding to specific cell sites. Therefore, a complex picture emerges, in 
agreement with the observation that HDPs immunomodulatory activities are 
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extremely diverse. Further experiments will allow us to elucidate the molecular 
mechanisms at the basis of ApoB derived peptides anti-inflammatory effects, which 
might include multiple aspects, such as stimulation of chemotaxis, suppression of 
bacterial induced pro-inflammatory cytokine production, regulation of neutrophil and 
epithelial cell apoptosis, modulation of cellular differentiation pathways, and 
promotion of angiogenesis and wound healing. As for the last aspect, in agreement 
with previous findings on LL-37 human peptide [53, 54], we found that r(P)ApoBL 
peptide is able to stimulate human keratinocytes wound re-epithelialization, an 
evidence that opens new and interesting perspectives on future topical application of 
this human HDP.  
It has to be underlined that, although there are very few HDPs currently in use in the 
market, many are progressing through clinical trials that have focused on topic rather 
than systemic treatment because of peptides potential toxicity. However, it is 
conceivable that judicious formulations of HDPs for a clinical use, e.g. peptide 
inclusion in liposomal nanoparticles, will avoid undesired toxicity and degradation, 
thus allowing a sustainable HDPs delivery. Here, we show that both ApoB derived 
peptides are not toxic for eukaryotic cells and do not determine any hemolytic effect 
when tested on murine red blood cells. These observations, associated to their 
multifunctional properties and to their ability to act synergistically in combination with 
conventional antibiotic drugs, open interesting perspectives to their therapeutic 
applications.  
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1. Introduction 
The development of bioinformatics approaches has greatly improved the 
identification of putative antimicrobial regions in protein precursors [1]. Along the 
present Thesis project, by using a recently developed bioinformatics strategy well 
described in the Chapter 3, we identified a novel HDP at the C-terminus of four 
isoforms of human 11-hydroxysteroid dehydrogenase-1 β-like and, to the best of our 
knowledge, the first HDP from an archaeal protein, the transcription factor Stf76 
encoded by the hybrid plasmid-virus pSSVx from Sulfolobus islandicus.  
Human 11β-hydroxysteroid dehydrogenase type 1 (HSD 1) is a known NADP(H)-
dependent enzyme that catalyses the conversion of inactive glucocorticoids into 
active forms. The dysregulation of this enzyme is mainly implicated in the 
development of metabolic syndromes [2]. On the contrary, human 11-hydroxysteroid 
dehydrogenase-1 β-like, also known as 11-beta-hydroxysteroid dehydrogenase type 
3 (HSD 3), has never been isolated as a protein and its membership to the 
hydroxysteroid dehydrogenase family has been assigned on the basis of the 
presence in the gene sequence of a putative dehydrogenase/reductase region 
partially similar to that extensively studied in HSD 1 [3]. The only type of evidence 
that supports the existence of HSD 3 as a protein is represented by expression data 
[4] that indicate the existence of a transcript (Gene ID: 374875) apparently 
overexpressed in the brain and in lung cancer cells. In the last protein, a high scoring 
region has been identified by our bioinformatics approach. The selected region 
includes 26 amino acid residues, and has been obtained as a synthetic peptide, here 
named GVF27. The HDP was found to exert bactericidal activities against planktonic 
and sessile bacteria, as well as anti-inflammatory properties on murine cells.  
Furthermore, we also demonstrated that DNA binding proteins can be a convenient 
source of new HDP-like peptides by identifying the first antimicrobial peptide from an 
archaeal protein, the transcription factor Stf76 encoded by the hybrid plasmid-virus 
pSSVx from Sulfolobus islandicus. This archaeal HDP, named VLL-28, was already 
shown to possess a broad-spectrum antibacterial activity and to exhibit selective 
leakage and fusogenic capability on vesicles with a lipid composition similar to that of 
bacterial membranes [5]. 
Along this Thesis project, it was characterized for the first time the antitumor activity 
of VLL-28 peptide. It has been widely reported that several antimicrobial peptides are 
also able to exert anti-cancer activity [6]. For this reason, they have been named 
“anti-cancer peptides” (ACPs). Due to the severe side effects of conventional 
chemotherapeutic agents and to the ability of metastatic tumour cells to develop a 
“multidrug resistance” phenotype, ACPs have attracted considerable attention; in 
fact, these peptides could represent a new generation of anti-cancer drugs with a 
mechanism of action well distinguished from those of conventional chemotherapeutic 
agents. Most of the ACPs described so far are HDPs able to exert on cancer cells 
toxic effects higher than those observed on normal cells. [7, 8]. This differential 
toxicity has been attributed to the fact that cancer cells often show alterations of 
membrane composition, such as loss of the asymmetric distribution of phospholipids, 
with the consequent exposure of phosphatidylserine on the outer leaflet, increased 
production of anionic lipids (e.g. sulfated lipids), sialic acid containing glycolipids, 
glycoproteins and, sometimes, a decreased production of cholesterol. This is 
responsible for an increased negative charge at the surface of tumor cells, which 
would favor the binding of ACPs, thus making these cells more susceptible to 
peptides toxic action. However, in the case of cancer cells, differently from bacterial 
killing mechanisms, toxicity is not necessarily due to accumulation of the peptide into 
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the membrane followed by cell lysis. In several cases, it has been demonstrated that 
ACPs are internalized and that the killing is mainly due to peptide interaction with one 
or more intracellular targets, such as mitochondria, DNA, cytoplasmic and nuclear 
proteins (e.g. Hsp70 [9] and DNA polymerase β [10], respectively).  
By means of a multidisciplinary approach including biochemical, cellular biology and 
spectroscopic techniques, the mechanisms of action of synthetic VLL-28 and GVF27 
peptides have been here analysed and partly elucidated. 
 
2. Materials and Methods 
2.1 Peptide Synthesis Reagents 
Polypropylene reaction vessels and sintered polyethylene frits were supplied by 
Alltech Italia. NovaSyn TGR resin, 2-(1H-benzotriazole-1-yl)-1,1,3,3-
tetramethyluronium hexafluorophosphate (HBTU), cyano-hydroxyimino-acetic acid 
ethyl ester (Oxyma) and all amino acids were from Novabiochem-Merck. N,N′-
diisopropylethylamine (DIPEA), piperidine, Kaiser test, trifluoroacetic acid (TFA), 
scavengers, fluorescein isothiocyanate (FITC) and N-methylmorpholine (NMM) were 
purchased from Sigma-Aldrich. N,N-Dimethylformamide (DMF) was purchased from 
CARLO ERBA Reagents. Acetonitrile (ACN), dichloromethane (DCM) and diethyl 
ether were purchased from VWR International. All aqueous solutions were prepared 
by using water obtained from a Milli-Q gradient A-10 system (Millipore, 18.2 MΩ·cm, 
organic carbon content ≥ 4 µg/L). 
 
2.2 Peptide Synthesis 
The sequence of GVF27 peptide is GVFYPWRFRLLCLLRRWLPRPRAWFI, whereas 
the sequence of VLL-28 peptide is VLLVTLTRLHQRGVIYRKWRHFSGRKYR. 
They were manually synthesized using the fluorenylmethyloxycarbonyl (Fmoc) solid-
phase strategy (0.2 mmol). The syntheses were performed on NovaSyn TGR resin 
(loading 0.24 mmol/g), using all standard amino acids. The Fmoc protecting group 
was removed by treatment with 30% piperidine in DMF (3 × 10 min). The amino acids 
in 10-fold excess were pre-activated with HBTU (9.8 equiv)/Oxyma (9.8 
equiv)/DIPEA (10 equiv) in DMF for 5 min and then added to the resin suspended in 
DMF. The reaction was carried out for 1 h and coupling efficiency was assessed by 
the Kaiser test. The peptides were cleaved off the resin by treatment with a mixture 
of trifluoroacetic acid (TFA)/water/triisopropylsilane (95:2.5:2.5 v/v/v) for 3 h at room 
temperature. The resins were filtered, the crude peptides were precipitated with 
diethyl ether, dissolved in H2O/ACN solution, and lyophilized. The products were 
purified by preparative RP-HPLC on a Shimadzu system equipped with a UV−visible 
detector SPD10A using a Phenomenex Jupiter Proteo column (21.2 × 250 mm; 4 μm; 
90 Å) and a linear gradient of H2O (0.1% TFA)/ACN (0.1% TFA) from 10%–55% of 
ACN (0.1%TFA) in 15 min at a flow rate of 20 mL/min. The collected fractions 
containing the peptides were lyophilized giving a final yield of about 35% of each 
pure product. The identity and purity of the compounds were assessed by the 
AGILENT Q-TOF LC/MS instrument equipped with a diode array detector combined 
with a dual ESI source on an Agilent C18 column (2.1 × 50 mm; 1.8 μm; 300 Å) at a 
flow rate of 200 μL/min and a linear gradient of H2O (0.01% TFA)/ACN (0.01% TFA) 
from 5%–70% of ACN (0.01% TFA) in 15 min. Upon mass spectrometry analysis, the 
purity of the synthesized peptides was found to be ≥ 95%. 
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2.3 Cell culture  
Murine RAW 264.7 cells, malignant SVT2 murine fibroblasts (BALBc 3T3 cells 
transformed by SV40 virus), parental BALBc 3T3 murine cells, and HEK-293 human 
embryonic kidney cells were cultured in Dulbecco’s Modified Eagle’s Medium 
(Sigma-Aldrich), supplemented with 10% fetal bovine serum (HyClone), 2 mM L-
glutamine and antibiotics, in a 5% CO2 humidified atmosphere at 37 ºC. HRCE 
(Human Renal Cortical Epithelial) cells (Innoprot) were cultured in basal medium, 
supplemented with 2% fetal bovine serum, epithelial cell growth supplement and 
antibiotics, all from Innoprot, in a 5% CO2 humidified atmosphere at 37 °C. 
 
2.4 Cytotoxicity assays  
Cells were seeded in 96-well plates (100 µL per well) at a density of 5x103 per well 
(SVT2, HEK-293, and HRCE cells) or 2.5x103 per well (BALBc 3T3 cells). VLL-28 
peptide was added to the cells 24 h after seeding for time- and dose-dependent 
cytotoxic assays. At the end of incubation, cell viability was assessed by the MTT 
assay, as previously described [11]. MTT reagent, dissolved in DMEM without phenol 
red (Sigma-Aldrich), was added to the cells (100 µL per well) to a final concentration 
of 0.5 mg/mL. After 4 h incubation at 37 °C, the culture medium was removed and 
the resulting formazan salts were dissolved by adding isopropanol containing 0.1 N 
HCl (100 µL per well). Absorbance values of blue formazan were determined at 570 
nm using an automatic plate reader (Microbeta Wallac 1420, Perkin Elmer). Cell 
survival was expressed as percentage of viable cells in the presence of the peptide 
under test, with respect to control cells grown in the absence of the peptide. In all the 
experiments described in this paper, controls were performed by supplementing the 
cell cultures with identical volumes of peptide buffer for the same lengths of time. 
 
2.5 Analysis of cell death 
Malignant SVT2 murine fibroblasts and parental BALBc 3T3 murine cells were plated 
at a density of 2×104 cells/cm2 in complete medium for 24 h and then exposed to 20 
µM VLL-28 peptide for 6, 12 or 24 h. To prepare cell lysates, both untreated and 
treated cells were scraped off in PBS, centrifuged at 1,000 g for 10 min and 
solubilised in lysis buffer (1% NP-40 in PBS, pH 7.4) containing protease inhibitors. 
After 30 min incubation on ice, lysates were centrifuged at 14,000 g for 30 min at 
4°C. Upon determination of total protein concentration in the supernatant by the 
Bradford assay, samples were analyzed by SDS-PAGE followed by Western blotting 
using specific antibodies directed towards procaspase-3 (Cell Signaling Technology) 
or p62 (Novus Biologicals) proteins. For normalization to internal standard signals, 
antibody against β-actin (Sigma-Aldrich) was used. In parallel experiments, cells 
were treated with puromycin (10 µg/mL) for 12 h or with rapamycin (20 µM) for 24 h, 
which were used as positive controls for apoptosis and autophagy induction, 
respectively.  
For morphological analyses, cells were seeded on glass coverslips in 24-well plates 
and grown to semi-confluency. Cells were then incubated for 72 h with 20 µM VLL-28 
peptide in complete medium, after which cells were washed with PBS, fixed for 10 
min at room temperature (RT) with 4% paraformaldehyde in PBS and mounted in 
50% glycerol in PBS. Samples were then examined using a confocal laser-scanner 
microscope Zeiss LSM 700. All images were taken under identical conditions. 
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2.6 Membrane preparation 
Membranes used to perform NMR experiments were isolated from BALBc 3T3 cells 
or SVT2 cells and obtained as previously described [12]. In details, cells were 
detached by using trypsin and washed twice with PBS. Afterwards, the cells were 
solubilised in PBS and homogenized by means of a pellet pestle (Sigma-Aldrich). 
Particulate matter was removed by centrifuging at 3,500 rpm for 15 min. The 
supernatant was then centrifuged at 28,000 rpm for 1 h at 4 °C. The sediment was 
washed and centrifuged at 28,000 rpm for 30 min at 4 °C. Afterwards, 180 μL of PBS 
mixed with 20 μL of D2O were added to the sediment, and the membrane was 
solubilised by passage through a 25-gauge needle (approximately 20 times).  
 
2.7 Spectroscopic studies 
CD spectra of GVF27 and VLL-28 peptides were recorded with a J-810 
spectropolarimeter equipped with a Peltier temperature control system (Model PTC- 
423-S, Jasco Europe). Far-UV measurements (190–260 nm) were carried out at 20 
°C by using a 0.1 cm optical path length cell and a peptide concentration of 25 µM in 
the case of GVF27 and 20 μM in the case of VLL-28. CD spectra were recorded as 
previously described [13]. Baseline was corrected by subtracting the complete buffer 
spectrum. 
In the case of GVF27 CD spectra, LPS from Pseudomonas aeruginosa strain 10 
(Sigma-Aldrich) and from Pseudomonas aeruginosa clinical strain KK27 [14] were 
used. Further analyses were carried out in the presence of lipoteichoic acid from 
Staphylococcus aureus (LTA, Sigma-Aldrich). All the measurements were recorded 
by using different concentrations of each compound (from 0.05 to 1.0 mg/mL). 
Baseline was corrected by subtracting the spectrum of both LPS and LTA at the 
same concentrations used for CD spectra in the presence of GVF27 peptide. 
Additional CD spectra were obtained by using different concentrations of TFE (0-
40%). Deconvolutions of CD spectra were obtained by using the web-based program 
CdPro (http://lamar.colostate.edu/~sreeram/CDPro/). Fluorescence experiments 
were carried out under the same experimental conditions used for CD analyses. 
Fluorescence spectra were collected at 20 °C by using a Varian Cary Eclipse 
spectrophotometer at λexcitation of 295 and 280 nm, by using a a 1.0 cm path length 
cell at 5 Ɛem and 5 Ɛex. Emission spectra (300-400 nm) were collected in the 
presence of 40% TFE, 5 mg/mL LPS or 10 mg/mL LTA. 
In the case of VLL-28 peptide, CD spectra were recorded in the presence of intact 
cells (800,000 cells) at different incubation times (0-10-30-60 min and 24 h) in PBS 
buffer. The baseline was corrected by subtracting the spectrum of the cells in the 
absence of the peptide at the same incubation times. 
 
2.8 Dynamic light scattering (DLS) analysis of LPS micelles  
To estimate the size of LPS particles, DLS analyses were performed. By this way, 
the Hydrodynamic Radii (RH) was measured. DLS analyses were performed by 
using a Zetasizer Nano ZS (Malvern Instruments) equipped with a 173° backscatter 
detector, at 25 °C, in disposable sizing cuvettes. DLS measurements were carried 
out in triplicate on aqueous LPS and LTA samples (0.5 mg/mL). Data were analyzed 
by using the Software of OMNISIZE (Viscotek). LPS and LTA size measurements 
were performed before and after peptide addition (0.5 mg/mL). 
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2.9 LPS binding assay 
The ability of GVF27 to neutralize LPS was evaluated by using the commercially 
available Limulus amebocyte lysate (LAL) assay (Pierce® LAL Chromogenic 
Endotoxin Quantitation Kit, Thermo Scientific) [15]. Briefly, an aliquot (25 μL) of 
serially diluted peptide (6.25-12.5-25 μM) was added to 25 μL of 0.5 U/mL LPS from 
E. coli O11:B4 for 30 min at 37 °C. The mixture was then incubated with 50 μL of 
Limulus amebocyte lysate reagent for 10 min. Absorbance at 405 nm was measured 
10 min after the addition of the chromogenic substrate Ac-Ile-Glu-Ala-Arg-p-
nitroanilide (100 μL). The amount of unbound LPS was extrapolated from a standard 
curve, and the percentage of inhibition was calculated as follows: [(amount of free 
LPS in control sample) − (amount of free LPS in test sample)] ×100/amount of free 
LPS in control sample. 
 
2.10 Measurement of nitric oxide production 
To determine the levels of NO released by RAW 264.7 cells, a colorimetric assay 
based on the use of Griess reagent (Sigma Aldrich) was performed. The levels of 
nitrite (NO2−) in cell supernatants were determined on the basis of a reference curve 
obtained by testing increasing concentrations (from 1 to 50 μM) of sodium nitrite 
dissolved in water. Briefly, cell culture supernatants were mixed with equal volumes 
of 1% sulphanilamide dissolved in 2.5% phosphoric acid, and incubated for 5 min at 
room temperature. Samples were then diluted 1:1 (v/v) with 0.1% N-(1-naphthyl) 
ethylenediamine dihydrochloride, and incubated for further 5 min at room 
temperature. Absorbance values were then determined at 520 nm using an 
automatic plate reader (FLUOstar Omega, BMG LABTECH). 
 
2.11 Measurement of interleukin-6 production 
IL-6 levels were determined by ELISA assay (DuoSet ELISA kits, R&D Systems) 
following the manufacturer’s instructions. Briefly, RAW 264.7 cells (5×104) were 
seeded into 96-well microtiter plates, and grown to semi-confluency. After 24 h, the 
culture medium was replaced with fresh medium containing the peptides under test 
(5 or 20 µM) in the presence or in the absence of LPS from Salmonella Minnesota 
(50 ng/mL, Sigma Aldrich) for 24 h at 37 °C. When the protective effect of the peptide 
was evaluated, cells were pre-incubated with the peptide (5 or 20 µM) for 2 h at 37 
°C. Following treatment, cells were washed three times with PBS prior to incubation 
with LPS (50 ng/mL) for further 24 h at 37 °C. In each case, at the end of incubation, 
the culture supernatants were collected, and centrifuged at 5,000 rpm for 3 min at 
room temperature, in order to remove cell debris. Samples were then analysed by 
reading absorbance values at 450 nm using 550 nm as a reference wavelength at an 
automatic plate reader (FLUOstar Omega, BMG LABTECH). 
 
2.12 Nuclear magnetic resonance spectroscopy 
All NMR experiments were carried out at 298K using an Inova 600 MHz spectrometer 
(Varian Inova), equipped with a cryogenic probe optimized for 1H detection. For 
chemical shift assignment and conformational analysis, 1 mg of VLL-28 peptide was 
dissolved either in 500 µL of 20 mM sodium phosphate pH 7 containing 10% v/v D2O 
or in 500 µL of the same buffer containing 25% (v/v) TFE (2,2,2-trifluoroethanol-D3 
99.5% isotopic purity, Sigma-Aldrich). One-dimensional (1D) 1H spectra were 
acquired with a spectral width of 7,191.66 Hz, relaxation delay of 1.03 s, 7k data 
points for acquisition and 16k for transformation. Bi-dimensional (2D) [1H, 1H] total 
correlation spectroscopy (TOCSY) [16, 17], double quantum filtered correlated 
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spectroscopy (COSY) [18] and nuclear Overhauser effect spectroscopy (NOESY) 
[19] were performed by acquiring 32 or 64 scans per t1 increment with a spectral 
width of 7,191.66 Hz along both t1 and t2, 2,048 × 256 data points in t2 and t1, 
respectively, and recycle delay of 1.0 s. Water suppression was achieved by means 
of Double Pulsed Field Gradient Spin Echo (DPFGSE) sequence [20, 21]. TOCSY 
experiments were recorded by using a DIPSI-2 mixing scheme of 70 ms with 7.7 kHz 
spin-lock field strength. NOESY spectra were carried out with a mixing time of 250 
ms. Data were typically apodized with a square cosine window function and zero 
filled to a matrix of size 4,096 × 1,024 before Fourier transformation and baseline 
correction.  
To analyse VLL-28 interaction with intact cells and isolated cell membranes, 
sediments corresponding to 18 x 106 cells and membranes isolated from 18 x 106 
cells, obtained as reported above, were solubilized in 150 µL of PBS buffer (pH 7.4) 
and 10% H2O, to obtain reference spectra, or in the presence of VLL-28 peptide (430 
µM) in PBS buffer. STD spectra were acquired with 10,000 scans with on-resonance 
irradiation at 5.2 ppm for saturation of membrane lipids resonances and off-
resonance irradiation at 30 ppm. A train of 40 Gaussian shaped pulses of 50 ms with 
1 ms delay between pulses was used, for a total saturation time of 2 s. STD spectra 
were obtained by internal subtraction of saturated spectrum from off-resonance 
spectrum by phase cycling. STD spectra of the peptide alone were also acquired and 
did not show any signal. 2D [1H, 1H] TOCSY and trNOESY spectra of VLL-28 peptide 
were acquired in the presence of isolated cell membranes. All NMR data were 
processed with the software VNMRJ 1.1.D (Varian Inova). 1D spectra were analyzed 
by using ACD/NMR Processor 12.0 (www.acdlabs.com). 2D TOCSY, COSY and 
NOESY spectra for proton chemical shift assignment were analyzed by using 
Homoscope, a tool available in CARA (Computer Aided Resonance Assignment) 
software [22]. 
 
2.13 Statistical analyses 
Results are presented as the mean ± standard error of the mean values (SEM) of at 
least three independent experiments. All samples were compared to negative 
controls in the absence of the peptide under test. *p < 0.05; **p < 0.01; ***p < 0.001. 
 
3. Results 
3.1 STRUCTURAL AND FUNCTIONAL CHARACTERIZATION OF SYNTHETIC 
GVF27 PEPTIDE 
 
3.1.1 Circular Dichroism and Fluorescence Spectroscopy analyses  
Structural analyses by CD spectroscopy provide a qualitative picture of the main 
structural elements of a given peptide. To elucidate this point, we performed Far-UV 
CD spectra of synthetic GVF27 peptide both in water and in 10 mM Hepes pH 7.4, 
and found that the peptide is largely unstructured. On the contrary, it was found to be 
structured in 40% TFE (Figure 1). This behaviour has been described for several 
HDPs [23, 24], which have been found prone to assume a specific conformation 
when interacting with membrane-mimicking agents, such as TFE. Deconvolution data 
(see Methods), reported in Table 1, indicate that structured GVF27 adopts a 
predominant α-helical structure, which was found to be ≈ 50%.  
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Figure 1. Far-UV CD spectra of GVF27 peptide in the presence of increasing 
concentrations of TFE. 
 
 α-helix (%) β-strand (%) coil (%) 
GVF27 18.2 24.0 57.8 
GVF27 - 40% TFE 52.6  7.2  40.2  
GVF27 - 0,4 mg/mL LPS from  
Pseudomonas aeruginosa strain 10 
30.8  18.6  50.6  
GVF27 - 0,4 mg/mL LPS from 
Pseudomonas aeruginosa strain KK27 
32.1  12.3  55.5  
GVF27 - LTA 0,4 mg/mL 33.0  19.5  47.5  
 
Table 1. Secondary structure content of GVF27 peptide, calculated by means of 
CDPRO program. 
 
To further characterize structural properties of GVF27, we also analysed its 
interaction with LPS and LTA, the main constituents of the cell wall of Gram-negative 
and -positive bacteria, respectively. CD spectra in the presence of LPS isolated from 
two different P. aeruginosa strains (strain 10 and clinical isolate KK27 strain) are 
shown in Figure 2 (panels a and b). 
GVF27 CD spectrum in water has a minimum at around 205 nm, indicative of a 
disordered conformation. In the presence of LPS (Figure 2 a-b), instead, peptide 
spectra present two minima centred at around 210 and 225 nm, suggesting the ability 
of the peptide to assume an α-helical conformation upon interaction with LPS. The 
deconvolution data (Table 1) indicate that the increase in α-helical structure (about 
31-32%) is similar in the presence of both types of LPS, whereas amounts of beta 
and coil structure appear slightly different. When CD spectra were acquired in the 
presence of LTA (Figure 2c), a relatively flat shape minimum centred at 215 nm was 
observed. This is indicative of the presence of significant amounts of both α-helical 
and beta structures, as indicated by deconvolution data (Table 1). 
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Figure 2. Far-UV CD spectra of GVF27 peptide in the presence of increasing 
concentrations of LPS from P. aeruginosa 10 (a), from P. aeruginosa KK27 (b) and of 
LTA from Staphylococcus aureus (c).  
 
a 
b 
c 
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Spectrofluorometric data were also collected to analyse the effects of GVF27 
interaction with LPS and LTA on peptide tertiary structure (Figure 3). This was 
performed by taking advantage of the presence of three Trp residues in GVF27 
peptide. Fluorescence spectra were recorded upon excitation at 280 nm and 295 nm. 
Upon peptide interaction with LPS, LTA and TFE, a blue shift of the maximum 
emission wavelength was observed, indicating that GVF27 becomes structured, in 
agreement with CD data. In the presence of TFE, instead, a less marked effect was 
observed (Figure 3). 
 
 
 
Figure 3. Intrinsic fluorescence spectra of GVF27 peptide in H2O and in the presence 
of TFE (40%), LPS (0,5 mg/mL) and LTA (1 mg/mL). 
 
3.1.2 GVF27 peptide assembles LPS aggregates 
Dynamic Light Scattering (DLS) is a well-known technique used to measure 
Brownian motion (diffusion) and size distribution of particles in solution. For this 
reason, DLS experiments were performed to evaluate whether GVF27 peptide is able 
to alter the size of LPS and LTA micelles (above their critical micelle concentration). 
In both cases, GVF27 was found to promote the formation of larger aggregates 
(Figure 4). In particular, the data indicate that LPS from Pseudomonas is poly-
dispersed in solution, with major size-populations having a hydrodynamic radius 
centred at about 40 nm (Figure 4). Incubation of LPS with GVF27 is responsible for a 
shift of LPS micelles average size to higher values centred at about 260 nm. On the 
other hand, when the peptide was incubated with LTA, the diameter of the 
aggregates was found to be about 100 nm (average value), indicating a weaker 
efficay of GVF27 in determining LTA aggregates association. It can be hypothesized 
that this aggregation promoting action, already observed for different antimicrobial 
peptides [25], represents a key element of peptide anti-inflammatory mechanism of 
action, based on LPS neutralization. In fact, by this way, the peptide might inhibit the 
interaction of LPS with its cell receptors, with a consequent blocking of cytokine 
production and release [26]. 
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Figure 4. Effect of GVF27 on the structural organization of LPS or LTA micelles. 
Dynamic light scattering of LPS from P. aeruginosa 10 (top) or LTA (bottom) before 
and after incubation with the peptide. 
 
3.1.3 Anti-inflammatory properties of GVF27 peptide 
Data reported above indicate that GVF27 is able to assume specific conformations in 
the presence of membrane mimicking agents, LPS and LTA, as well as to induce 
aggregation of LPS, and, to a lesser extent, of LTA. As it has been already reported 
that several HDPs are able to mitigate up-regulation of LPS-induced pro-
inflammatory mediators and cytokines [27], it seemed interesting to verify if GVF27 
possesses anti-inflammatory properties. To collect data on potential anti-
inflammatory properties of GVF27 peptide, nitric oxide (NO) production and 
interleukin IL-6 release were analyzed in murine macrophages RAW 264.7 treated 
with GVF27 and LPS. 
NO plays diverse roles in biological systems, since it is a mediator of vasodilatation, 
platelet aggregation and neurotransmission, and regulates function, death and 
survival of various cell types including many of those involved in immunity and 
inflammation [28, 29]. To study the effect of GVF27 on NO production in LPS induced 
RAW 264.7 cells, we performed three type of treatments: (i) cells were concomitantly 
treated with peptide (5 or 20 µM) and LPS (50 ng/mL) for 24 h; (ii) cells were treated 
with the peptide alone (5 or 20 µM) for 2 h and then incubated with LPS from 
Salmonella Minnesota (50 ng/mL) for further 24 h; (iii) cells were first treated for 2 h 
with LPS (50 ng/mL) and then incubated with the peptide (5 or 20 µM) for further 24 
h. As shown in Figure 5A, the co-incubation of cells with GVF27 and LPS determines 
a strong attenuation of NO production, which was found to be more pronounced in 
the presence of higher concentrations of the peptide. Conversely, when RAW 264.7 
cells were pre-incubated with the peptide and subsequently stimulated with LPS, the 
effect of GVF27 on NO production was found to be not significant (Figure 5A). 
Similarly, when RAW 264.7 cells were pre-incubated with LPS and subsequently 
treated with GVF27 (5 or 20 µM), we revealed a slight dose-dependent reduction of 
NO production (Figure 5A). 
Cytokines are key mediators of inflammatory response. They are small proteins 
(about 25 kDa) released by many cell types, usually after an activation signal, to 
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induce a response upon binding to specific receptors. IL-6 is a monomer produced by 
T cells, macrophages and endothelial cells. It stimulates growth and differentiation of 
B and T cells, and the production of acute phase proteins, such as C-reactive protein 
[30]. By ELISA assays we analyzed the effects of GVF27 on IL-6 release in RAW 
264.7 cells by following the same experimental scheme described for NO production. 
The peptide showed a strong inhibitory effect on IL-6 secretion when macrophages 
were co-incubated with GVF27 (5 or 20 µM) and LPS (50 ng/mL) for 24 h (see Figure 
5B). Moreover, we found that GVF27 was able to exert a significant dose-dependent 
protective effect on RAW 264.7 cells. Indeed, as shown in Figure 5B (on the centre), 
when RAW 264.7 cells were pre-treated with GVF27 (5 or 20 µM) for 2 h and then 
incubated with 50 ng/mL LPS for further 24 h, a limited secretion of IL-6 was 
observed. When cells, instead, were pre-incubated with LPS and then subjected to 
the action of the peptide (Figure 5B, on the right), a slight secretion of IL-6 was 
revealed. This suggests that, although cells are incubated with the endotoxin for a 
very short time, the peptide is indeed still able to attenuate the secretion of the 
interleukin under test. Collectively, these data clearly indicate that GVF27 peptide is 
able to exert an intriguing anti-inflammatory action on mouse macrophages under 
LPS stimulation. 
 
 
 
Figure 5.  (a) Effect of GVF27 on NO production in LPS induced mouse 
macrophages RAW 264.7. (b) Effect of GVF27 on IL-6 release in LPS induced 
mouse macrophages RAW 264.7. All the experiments were carried out for total 24 h. 
Data represent the mean (± standard deviation, SD) of at least 3 independent 
experiments, each one carried out with triplicate determinations. *p<0.05, **p<0.01, 
or ***p<0.001 were obtained for control versus treated samples. 
 
Finally, the ability of GVF27 peptide to bind to LPS (Figure 6) was evaluated and 
further confirmed by using the chromogenic LAL (Limulus amaebocyte lysate) assay 
[31]. To this purpose, the peptide at three different concentrations (6.25 - 12.5 - 25 
μM) was incubated with LPS from Escherichia coli 011:B4 for 30 minutes at 37 °C, 
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following the manufacturer instructions. As shown in Figure 6, GVF27 at a 
concentration of 12.5 μM was found to neutralize about 40% of LPS, whereas GVF27 
25 μM completely neutralized LPS, thus supporting the hypothesis that GVF27 might 
act in a dose-dependent manner as a scavenger of Gram-negative bacteria LPS 
(Figure 6).  
 
                            
 
Figure 6. LPS neutralization in the presence of GVF27. Peptide at different 
concentrations (6.25 – 12.5 – 25 µM) was incubated with the endotoxin (0.25 
units/mL) for 30 min at 37 °C and the amount of free endotoxin was quantified by LAL 
assay. Data represent the mean (± standard deviation, SD) of at least 3 independent 
experiments, each one carried out with triplicate determinations. *p<0.05, **p<0.01, 
or ***p< 0.001 were obtained for control versus treated samples. 
 
3.2 STRUCTURAL AND FUNCTIONAL CHARACTERIZATION OF VLL-28 
PEPTIDE ANTITUMOR ACTION  
 
3.2.1 The selective antitumor action of VLL-28 peptide 
The cytotoxicity of VLL-28 peptide was tested on malignant SVT2 murine fibroblasts 
(BALBc 3T3 cells transformed by SV40 virus). The peptide was found to be a strong 
inhibitor of malignant fibroblast growth, since a dose- and time-dependent inhibition 
of cell viability was observed (Figure 7a). Moreover, the peptide was found to be 
inactive toward the parental non-malignant line of 3T3 fibroblasts tested under the 
same experimental conditions (Figure 7b), thus indicating that VLL-28 peptide is 
highly selective for malignant cells. This evidence was also confirmed by 
morphological analyses through light microscopy of SVT2 (Figure 8a and b) and 
BALBc 3T3 cells (Figure 8 c and d) untreated (7a, c) or treated (7b, d) with 20 µM 
VLL-28 peptide.  Accordingly, only in the case of SVT2 cancer cells, a severe 
alteration of cell morphology, together with the massive presence of cell debris, was 
observed. Remarkably, this peptide was also found to be effective and selective 
against human tumour cells, as demonstrated by MTT assays performed on 
transformed HEK-293 cells (Figure 7c). No toxic effects were detected, instead, on 
primary human renal (HRCE) cells (Figure 7d). 
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Figure 7. Effects of VLL-28 peptide on the viability of SVT2 (a), BALBc 3T3 (b), HEK-
293 (c), or HRCE (d) cells. MTT assays were performed on cells treated with 
increasing amounts of the peptide (5, 10 and 20 µM) for different lengths of time (24, 
48 and 72 h). The viability of cell samples was expressed as the percentage of MTT 
reduction with respect to control cells, tested under the same conditions but in the 
absence of the peptide. Data represent the mean (± standard deviation, SD) of at 
least 4 independent experiments, each one carried out with triplicate determinations. 
*p<0.05, **p<0.01, or ***p<0.001 were obtained for control versus treated samples in 
the case of SVT2 cells treated with VLL-28 peptide for 48 and 72 h. 
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Figure 8. Morphological analyses of SVT2 (a, b) and Balbc 3T3 (c, d) cells untreated 
(a, c) or treated (b, d) with 20 µM VLL-28 peptide for 72 h. All images were acquired 
at the same magnification. 
 
3.2.2 Cell death pathway activated by cell treatment with VLL-28 peptide 
To elucidate cell death pathways selectively activated by cell treatment with VLL-28 
peptide, we performed western blot analyses by using antibodies specifically 
recognizing pro-caspase 3 and p62 proteins. The activation of procaspase-3 to 
caspase-3 is a key event in the apoptotic execution phase, since caspase-3 is 
considered the most important of the executioner caspases and is activated by any of 
the initiator caspases (caspase-8, caspase-9, or caspase-10) [32]. p62, instead, is 
generally used as a marker to study autophagic flux, since it accumulates when 
autophagy is inhibited, whereas p62 decreased levels can be observed when 
autophagy is induced [33].  
To get insight into cell death pathways activated by cell treatment with VLL-28, 
western blot analyses were performed (Figure 9 a and b). In the case of SVT2 cells, 
it was observed a significant increase of p62 levels upon 6 h treatment with 20 µM 
VLL-28 (Figure 9a), indicative of a stress leading to cell death with a consequent 
block of autophagy flux [34]. Accordingly, procaspase-3 levels were found to be lower 
than in control cells upon 6 and 12 h treatment with 20 µM VLL-28 (Figure 9a), 
indicating a significant (about 30%) activation of procaspase-3 to caspase-3 
associated to apoptosis induction. This activation appears even stronger (about 50%) 
upon 24 h treatment (Figure 9a), and is associated to a significant decrease of p62 
levels (Figure 9a), in agreement with a time-dependent activation of apoptotic cell 
pathway. 
In the case of non-malignant BALBc 3T3 cells, instead, no significant effects on 
procaspase-3 and p62 levels were observed upon cell treatment with 20 µM VLL-28 
peptide for different time intervals (6, 12 and 24 h) (Figure 9b). In agreement with the 
results reported above, this indicates that these cells are not susceptible to VLL-28 
peptide toxic effects. In conclusion, experimental data indicate that VLL-28 exerts its 
selective antitumor action through a time-dependent activation of apoptotic cell 
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pathway, as demonstrated by the progressive maturation of procaspase-3 to the 
active caspase-3. 
 
 
 
Figure 9. Analysis of cell death pathways activated by the treatment of SVT2 and 
BALBc 3T3 cells with 20 µM VLL-28 peptide. In a and c, lane 1, total proteins 
extracted from untreated cells; lane 2, total proteins extracted from cells treated with 
rapamycin; lane 3, total proteins extracted from cells treated with puromycin; lane 4, 
total proteins extracted from cells treated with the peptide for 6 h; lane 5, total 
proteins extracted from cells treated with the peptide for 12 h; lane 6, total proteins 
extracted from cells treated with the peptide for 24 h. Western blots were performed 
by using antibodies directed towards procaspase-3, p62, and endogenous β-actin 
used as an internal standard. The densitometric analyses of protein bands, 
specifically recognized by anti-procaspase-3 and anti-p62 antibodies, are reported in 
b and d, respectively, where data represent the mean (± standard deviation, SD) of 3 
independent experiments. *p<0.05, **p<0.01, or ***p<0.001 were obtained for control 
versus treated samples. 
 
3.2.3 VLL-28 Far-UV CD analyses in the presence of eukaryotic cells 
VLL-28 CD spectra were registered in the presence of either BALBc 3T3 or SVT2 
cells (Figure 10). We found that, in the presence of BALBc 3T3 cells, VLL-28 peptide 
appears structured over time, and a prevalence of α-helical structure is observed 
upon 1 h incubation (Figure 10a). Indeed, the spectrum shows two minima centred at 
around 208 and 222 nm, typical of an α-helical structure. Differently, when VLL-28 
peptide was analysed in the presence of SVT2 intact cells, a decrease of CD signal 
was observed, which might be indicative of a fast internalization of VLL-28 peptide 
into SVT2 target cells, occurring already after 10 min incubation (Figure 10b). 
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Figure 10. Far UV CD spectra of VLL-28 peptide (●) recorded in the presence of 
BALBc 3T3 (a) or SVT2 cells (b) after incubation for 0 (■), 10 (▲), 30 (♦), 60 (*) min 
and 24 h (○). 
 
3.2.4 NMR conformational analysis of VLL-28 peptide 
In order to analyse VLL-28 interaction with intact cells and isolated cell membranes, 
we performed NMR studies. As first, we carried out a conformational analysis of the 
peptide in the absence and in the presence of TFE (Figure 11 and 12), and found 
that VLL-28 does not adopt a well-defined conformation in the absence of TFE, as 
indicated by sharp and low-dispersed resonances in both the amide/aromatic and the 
aliphatic regions (Figure 12a). On the other hand, in the presence of 25%TFE, 
resonances of the amide, aromatic and aliphatic protons resulted more dispersed 
(Figure 11b). In particular, the HN indolic of the tryptophan, clearly distinguishable at 
10.14 ppm in the absence of TFE, exhibited up-field shift at 9.94 ppm upon addition 
of TFE, suggesting a more buried side chain. Moreover, 2D [1H, 1H] NOESY 
spectrum of VLL-28 peptide was found to contain a significant higher number of 
cross-peaks with respect to that recorded in the absence of TFE, indicating a more 
ordered conformation (Figure 12). By using a combination of TOCSY and NOESY 
spectra, accordingly to the standard procedures, an almost complete assignment of 
proton resonances of VLL-28 peptide could be achieved in the presence of TFE. 
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Figure 11. Expansions of the HN/aromatic (left) and the aliphatic (right) regions of the 
1D 1H NMR spectrum of VLL-28 in phosphate buffer pH 7 at 298K in the absence 
(blue, a) and presence (red, b) of 25% TFE. Different vertical scales are used in the 
HN/aromatic and the aliphatic regions. 
 
 
 
Figure 12. Expansions of the HN-aliphatic and aromatic-aliphatic correlation region of 
the 2D [1H, 1H] NOESY spectra of VLL-28 peptide in PBS at 298K in the absence (a) 
and in the presence (b) of 25% TFE. 
 
To assess the secondary structure of VLL-28 peptide in 25% TFE, the Hα chemical 
shift deviations from random coil values (ΔδHα) and the NOE patterns were analysed. 
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Interestingly, two regions encompassing residues V37- R48 and V50-S59 showed the 
deviations larger than the average ΔδHα (average= -0.31 ppm), suggesting that the 
peptide assumes two consecutive helices separated from G49 (Figure 13a). 
Accordingly, HN-HN, Hαi-HNi+3 and Hαi-Hβi+3 NOEs characteristic of α-helical 
conformation, not present in the absence of TFE, were observed starting from 
residues V37 to S59 (Figure 13b and c).  
 
 
 
Figure 13. Chemical shift deviation from random coil values of Δα backbone atoms 
(ΔHα) plotted as a function of residue number (a). Two segments with α-helical 
conformation, encompassing residues V37-R58 and V50-S59, were suggested from 
the ΔHαs and are indicated above the plot. In b and c:  expansions of the HN-HN 
correlation region of the 2D [1H, 1H] NOESY spectra of VLL-28 peptide in PBS at 
298K in the absence and in the presence of 25% TFE, respectively. HNi-HNi+1 cross-
peaks, selectively observed in (c), are labeled. 
 
3.2.5 Analysis of VLL-28 binding to tumor and normal cell membranes by NMR 
studies  
In order to gain insight into the mechanism of antitumor action of VLL-28 peptide, we 
performed NMR saturation transfer difference (STD) binding analyses of the peptide 
in the presence of intact SVT2 and BALBc 3T3 cells, as well as in the presence of 
isolated cell membranes. Attempts to study the interaction of the peptide with intact 
cells failed (data not shown) because the proton resonances in the1H NMR spectra of 
VLL-28 peptide vanished in the presence of both cell lines. 
Recently, it has been proposed the use of native cell membranes to overcome 
peptide cell internalization issues in “on-cell” NMR binding experiments [12]. This 
approach provided several improvements in the quality of the 1H and STD spectra 
with respect to those acquired in the presence of intact cells. First of all, by using this 
approach, 1H NMR signals of the peptide appear sharper and better resolved. 
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Moreover, STD signals are significantly stronger and background signals appear 
much weaker in both the 1H and the STD spectra. Based on this, we carried out STD 
NMR experiments of VLL-28 peptide in the presence of isolated cell membranes. 
Interestingly, 1H NMR peptide signals resulted well visible in the presence of both 
SVT2 and BALBc 3T3 cell membranes (Figure 12), what allowed to perform STD 
NMR binding experiments. In particular, we evaluated the binding capability of VLL-
28 peptide to the two main components of cell membranes, i.e. proteins and lipids. 
To do this, we acquired STD spectra at two different saturation frequencies, one to 
selectively saturate proteins (0.2 ppm) and the other one to saturate lipids (5.2 ppm). 
Remarkably, 1H STD spectra analyses revealed that VLL-28 peptide receives a 
detectable saturation transfer in the presence of cell membranes only when lipids are 
saturated (Figure 14). This effect, found to be negligible in the absence of cell 
membranes (Figure 14b), indicates the ability of VLL-28 peptide to bind to the lipid 
component of cell membranes. This finding is in agreement with previous results 
indicating that the peptide is able to interact with lipids mimicking bacterial 
membranes [5]. It is worth noting that different patterns of STD signals were obtained 
in the presence of BALBc 3T3 and SVT2 cell membranes (Figure 14). In particular, a 
higher number of STD signals, with stronger intensities, were observed in the 
presence of BALBc 3T3 cell membranes compared to those observed in the 
presence of SVT2 cell membranes. This might be due to a different mechanism of 
peptide interaction with membranes isolated from different cell lines. Accordingly, 
Far-UV CD analyses suggest that the peptide is selectively internalized into SVT2 
tumor cells and not into BALBc 3T3 cells. 
  
 
 
Figure 14. Reference 1H (a) and STD NMR (b) spectra of VLL-28 in the absence and 
in the presence of SVT2 (c) or BALBc 3T3 (d) cell membranes. 
 
3.8 Definition of membrane interaction sites of VLL-28 peptide 
To define membrane interaction sites of VLL-28 peptide, we performed proton 
assignments in the presence of cell membranes. As a control, data obtained for the 
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peptide in TFE were used. Because of spectral overlaps, several ambiguities were 
obtained. Nonetheless, almost all the aromatic protons and some aliphatic protons 
could be assigned unambiguously. In Table 2, the possible proton assignments of the 
STD signals plotted in figure 15a are reported. Interestingly, in the HN/aromatic 
region of the STD spectrum, besides two non-assigned HN signals at 8.19 and 8.10 
ppm, several aromatic protons were found to be saturated, especially in the presence 
of BALBc 3T3 membranes, suggesting that peptide binding to membranes is 
mediated by hydrophobic interactions. In particular, Y52 and W55 residues seem to 
be involved in the interaction in the case of both cell lines, whereas F58 is saturated 
only in the presence of BALBc 3T3 membranes. Moreover, it has to be noticed that 
the aromatic side chains of HƐ1, H46 and H57 at 7.78 and 7.71 ppm are clearly not 
saturated in the case of both cell membranes, and the STD signal at 7.49 ppm is 
attributed to the overlapped HƐ22 Q47 and Hz2 W55 protons. Based on this, it is very 
likely that the STD signal at 6.85 ppm, corresponding to the overlapped Hδ2 H57 and 
HƐ21 Q47, is due to the latter proton. In the aliphatic region, several signals overlap 
allows the unambiguous identification of only four protons: Hα G49, Hβ3 Y52, Hγ12 
I51 and Hγ2 V50. Nonetheless, STD signals from 3.20 to 2.98 ppm show the 
involvement of the side-chains of Arg and Lys residues in the interaction with 
membrane. Methyl group of Leu, Val and Thr, localized in the N-terminal region, 
seem to be involved as well. Overall, these data indicate that the interaction of VLL-
28 peptide with cell membranes is mediated by its N-terminal region, as well as by its 
central region (V37-F58) (Figure 15). It has to be highlighted that both peptide 
regions assume an α-helical conformation in the presence of TFE. Moreover, as 
expected, the binding seems to be mainly mediated by aromatic and basic amino 
acid residues.  
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Figure 15. (a) Bar graphs of STD signal intensities (ISTD) for the VLL-28 HN/aromatic 
and aliphatic protons receiving saturation transfer in the presence of BALBc 3T3 (red 
bars) and SVT2 (blue bars) cells. In the x-axis label, HNbb = not assigned backbone 
amide protons, R = R44/R48/R53/R61/R64; K = K54/K64; Y = Y52/Y63; L = 
L38/L39/L45; T = T41/T43. (B) The VLL-28 sequence is reported. VLL-28 residues 
showing STD effect in the presence of both cell membranes are highlighted in 
magenta, whereas those affected only in the presence of BALBc 3T3 cells are 
reported in red. Asterisks indicate that, due to overlapped proton resonances, one or 
both the threonine residues are possibly involved in the interaction with BALBc 3T3 
and SVT2 cell membranes. Residues that are not involved in the binding or that 
could not be identified unambiguously are indicated in black. 
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Note: Rx= R44/R48/R53/R61/R64; Kx= K54/K64; Yx= Y52/Y63; Lx= L38/L39/L45; Tx= T41/T43 
 
Table 2. VLL-28 residues playing a key role in the binding to BALBc 3T3 and SVT2 
cell membranes.  
 
4. Discussion 
Host defense peptides (HDPs) are important modulators able to prevent microbial 
colonization and tissue damage in both mammalian and non-mammalian systems 
[35]. HDPs beneficial effects may encompass direct antimicrobial activity, binding to 
and inactivation of endotoxins, such as LPS or LTA, with a consequent reduction of 
detrimental pro-inflammatory response, as well as direct effects on cell behaviors, 
such as enhancement of migration and proliferation. 
In this Chapter, two novel HDPs identified by using a bioinformatics tool recently 
developed by our research group have been described. One is the first HDP 
identified in an archaeal protein, i.e. the transcription factor Stf76 encoded by the 
hybrid plasmid-virus pSSVx from Sulfolobus islandicus, here named VLL-28. The 
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second is a HDP identified in human 11-hydroxysteroid dehydrogenase-1 β-like, here 
named GVF27. 
We demonstrated that GVF27 peptide exhibits very interesting immune-modulating 
activities. As first, we verified by Far-UV CD analyses that GVF27 is unstructured in 
aqueous buffer, whereas it assumes an α-helical conformation in the presence of 
TFE. Further CD analyses together with dynamic light scattering measurements have 
also highlighted that the peptide is able to interact with both LPS and LTA, thus 
suggesting that it can bind to microbial surfaces via these wall determinants. The 
ability of GVF27 to interact with LPS has been also confirmed by different 
experimental approaches, and it has been also demonstrated that the peptide exerts 
anti-inflammatory activities. Indeed, GVF27 was found to strongly down-regulate NO 
release and IL-6 production in murine macrophages under LPS stimulation. This 
effect was obtained by co-incubating the cells with the endotoxin in the presence of 
the peptide. Moreover, it is worth noting that in murine macrophages pre-treated with 
GVF27 and then incubated with LPS, a decrease of both NO and IL-6 release was 
still detectable, thus suggesting the ability of the peptide to exert a protective effect. 
Based on these observations, at least three different mechanisms might be 
envisaged to explain GVF27 immune-modulatory properties. Firstly, GVF27 might 
modulate cell response to pro-inflammatory mediators by acting as an endotoxin 
scavenger during the initial steps of infection. In this case, the peptide might bind to 
and neutralize the endotoxin directly. Secondly, GVF27 might mitigate inflammatory 
dysfunction by interacting with membrane receptors, i.e. CD14, with a consequent 
down-regulation of several pro-inflammatory pathways. Thirdly, endogenous GVF27, 
upon internalization into paracrine cells, might contribute to the attenuation of the 
inflammatory response by interacting with intracellular targets. All these observations 
open an interesting scenario, since GVF27 is a “hidden” peptide in a protein 
precursor, that has not been yet characterized. Based on our results, it is tempting to 
speculate that the protein is constitutively present under physiological conditions and 
able to release, upon a proteolytic event activated by pathogen invasion, a fragment 
containing GVF27 peptide. 
The second part of this Chapter focuses on VLL-28 peptide, which was firstly 
identified as an antimicrobial peptide. Here, VLL-28 was found to be also endowed 
with selective antitumor activity. It is well known that the outer surface of cancer cell 
membranes is generally more negatively charged than that of normal cells, although 
not as anionic as in bacteria. DLS and NMR data clearly show that VLL-28 interacts 
with cell membranes of both malignant and not malignant eukaryotic cell lines. The 
binding has been found to be mainly mediated by aromatic and basic residues in the 
case of both types of cell membranes, although with slight differences. Nevertheless, 
CD analyses suggest that VLL-28 peptide might be selectively internalized into tumor 
cells, a key element to explain peptide selective antitumor activity. Based on this, cell 
membrane of tumor cells might not be the main target of peptide antitumor action and 
probably intracellular targets are involved in its mechanism of action. It is also 
important to highlight that Archaea have been so far considered as source of 
biotechnologically relevant enzymes, but, to the best of our knowledge, no ACPs 
have been so far isolated from organisms belonging to this kingdom. Hence, these 
data represent the first evidence that archaeal microorganisms could bear also an 
unexplored repertoire of such kind of molecules exerting a trans-kingdom action. 
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Increasing resistance of bacteria to antibiotics is one of the biggest problems facing 
healthcare in the 21st century [1, 2]. Important factors behind growing resistance are 
over-and misuse of antibiotics, including the massive use of antibiotic growth 
promoters in the livestock industry [3,4]. Therefore, multiple countries have restricted 
the use of antibiotics for food producing animals [5]. As a consequence, scientists in 
both the human and veterinary fields are busily investigating alternatives to 
conventional antibiotics [6, 7].  
Host Defense Peptides (HDPs) are believed to be promising alternatives to 
conventional antibiotics. These highly diverse, short and cationic peptides are an 
essential part of the innate immune system [8]. In vertebrates, the two main classes 
of HDPs are cathelicidins and defensins. The broad-spectrum antimicrobial activity, 
as well as the multiple immunomodulatory functions of HDPs, are important features 
in their development as anti-infectious [9,10]. 
It should be emphasized that a wide variety of human proteins, whose primary 
function is not necessarily related to host defense, contain HDPs hidden inside their 
sequences [11,12]. Extensive efforts have been paid to the purification of such 
endogenous bioactive peptides to identify new regulatory mechanisms and the flow 
of signalling mechanisms, including peptide synthesis, maturation, secretion, and 
degradation. For instance, mRNAs encoding peptidergic factors are translated into 
biologically inactive precursor proteins, which are transported into the endoplasmic 
reticulum and processed by various enzymes, including signal peptidases and 
prohormone convertases, during the transport from endoplasmic reticulum to 
secretary vesicles via trans-Golgi networks (Figure 1) [13]. 
 
 
 
Figure 1. Schematic representation of maturation processes converting inactive 
precursors of peptidergic factors into functional proteins. 
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Therefore, it is expected that a large number of unidentified functional peptides can 
be produced from precursor proteins of peptidergic factors. Furthermore, many 
fragment peptides may be produced during maturation or degradation processes of 
functional proteins (such as mitochondrial enzymes and other regulatory proteins). 
Such peptides might be endowed with several biological activities distinct from those 
of their parental proteins. These functional cryptic peptides that are hidden in protein 
precursors are often named ‘‘cryptides’’ [14,15]. Since neutrophils are leukocytes that 
play central roles in innate defense systems, due to their migration from blood stream 
to tissue injury sites upon stimulation by various chemo-attractants [16], the presence 
of unidentified factors that induce immediate migration and activation of neutrophils is 
expected. Nobuhiko Ueki et al. isolated neutrophil-activating peptidergic factors, such 
as mitocryptide-1 and -2, that indeed induce immediate migration and activation of 
neutrophils. Interestingly, during the purification of these two peptides, they isolated 
further peptide containing fractions able to activate neutrophils [17]. In addition to 
functional peptides hidden in mammalian proteins, bioactive peptides may be hidden 
in proteins of many other organisms although they may not be involved in the 
physiological regulations in mammals. Such peptides are now also actively searched 
for in proteins of plants and microorganisms to facilitate the developments of drugs 
and food supplements. These widespread screenings are encouraged by the recent 
rapid developments in experimental techniques for purification, identification, and 
synthesis (multiple, simultaneous synthesis, in particular). Smith and his coworkers 
named ‘‘cryptome’’ the comprehensive screening and identification of hidden peptide 
sequences with biological activities; they also searched for bioactive peptides 
produced by enzymatic digestion of various proteins. Yoshikawa and his coworkers 
isolated ‘‘soymetide’’, a peptide derived from soybean b-conglycinin by tryptic 
digestion promotingf phagocytosis of neutrophils. 
In addition to functional peptides hidden in mammalian proteins, bioactive peptides 
may be hidden in proteins of many other organisms. Smith and his coworkers named 
‘‘cryptome’’ the panel of bioactive peptides hidden in protein precursors and released 
by maturation processes and hydrolytic events. Recently, the number of databases 
(genome, cDNA, and protein sequences) collecting cryptic peptides is growing fast 
and many different species are widely covered. In this scenario, the improvement of 
prediction technologies is expected to greatly increase the number of identified 
functional cryptic bioactive peptides, thus greatly contributing to the development of 
novel drugs and food supplements/nutrients. By using the recently developed in silico 
method [18] to identify cryptic HDPs in protein precursors and to predict quantitatively 
their antibacterial activity, novel HDPs were identified within the sequence of known 
proteins, such as human apolipoprotein E [19], the transcription factor Stf76 from the 
archaeon Sulfolobus islandicus [20], human apolipoprotein B and human 11-
hydroxysteroid dehydrogenase-1 β-like. In the latter case, further potential peptides, 
possibly released by human neutrophil elastase, have been predicted in the C-
terminal region of the four isoforms in which GVF27 was identified. Indeed, as shown 
in Figure 2, these potentially active peptides are virtually superimposable to GVF27 
and all have high antimicrobial scores, clearly supporting our idea that it is 
conceivable to look at human proteins as active reservoirs of HDPs. 
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Figure 2. In silico prediction of potential peptides released by human neutrophil 
elastase from the C-terminal region of the four isoforms containing the GVF27 
sequence. For each putative peptide (#1, #2, #3 and #4), the antimicrobial score has 
been calculated following the bioinformatics procedure. 
 
The main aim of this PhD Thesis was the identification of novel HDPs by using this 
novel bioinformatics tool, in order to evaluate their potential as antimicrobial, anti-
biofilm, anti-inflammatory and anticancer agents.  
In general, HDPs isolation from natural sources is a laborious and time-consuming 
process, not suitable to obtain peptides in large amounts. On the other hand, 
chemical synthesis, although very efficient, is a complex and costly process [21]. 
Based on this, a cost-effective and scalable method to produce HDPs is required. 
Procedures to express HDPs as recombinant peptides have encountered difficulties 
mainly due to their cytotoxicity to the bacterial host, difficulties to scale up the 
production protocol and low purification yields [22-24]. To overcome these important 
issues, we used a novel fusion system based on onconase enzyme used as a carrier 
[25]. Furthermore, we designed a novel rich and cheap culture medium, and 
developed an auto-inducing procedure to be applied to a fermentation process. The 
analysis of the procedure costs highlighted that the unit cost strongly decreased with 
the production scale at 200, 500 and 1000 mg/batch, thus indicating that the set-up 
procedure is a cost-effective and competitive strategy to produce the high amounts of 
peptides required for basic and clinical research (Chapter 2). 
Once optimized the expression system described in the Chapter 2, a broad 
characterization of the two ApoB derived recombinant peptides was performed 
(Chapter 3). It was observed that both peptides are endowed with a significant 
antimicrobial activity towards Gram-negative and Gram-positive strains. In most 
cases, peptide antimicrobial activity was found to be comparable to that of the 
positive control CATH-2, a well-known antimicrobial peptide [26]. Interestingly, ApoB 
derived peptides are also endowed with anti-biofilm activity. Microorganisms growing 
in a biofilm state are very resilient to the treatment with many antimicrobial agents. 
Indeed, biofilm infections are a significant problem in chronic and long-term 
infections, including those colonizing medical devices and implants [27]. It was found 
that ApoB derived peptides exert a strong effect on biofilm formation and biofilm 
attachment, and, even more interestingly, they strongly affect pre-formed biofilms. 
Furthermore, ApoB derived peptides display anti-biofilm activity even on bacterial 
strains not sensitive to the peptide antimicrobial activity, such as S. aureus MRSA 
WKZ-2, and, in the case of sensitive strains, even at peptide concentrations 
significantly lower than those required to directly kill planktonic cells. This is in 
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agreement with previous reports indicating that LL-37 peptide potently inhibits the 
formation of bacterial biofilms in vitro at the very low and physiologically meaningful 
concentration of 0.5 µg/mL, significantly lower than that required to kill or inhibit 
bacterial growth (64 µg/mL) [28]. Moreover, it has been reported that other specific 
cationic HDPs, such as 1018 peptide, are endowed with multispecies anti-biofilm 
activity, which has been found to be independent from their activity against planktonic 
bacteria [29]. 
It should also be emphasized that even at the highest ApoB derived peptides 
concentrations tested, a significant percentage of bacterial cells inside the biofilm 
structure appeared to be still alive. This was observed for both ApoB derived 
peptides and LL-37 control peptide, while it was less pronounced in the case of 
CATH-2 peptide. Based on this, it is tempting to speculate that successful therapeutic 
approaches could be designed by combining anti-biofilm peptides and conventional 
antibiotics ineffective on biofilm, but effective on bacterial cells entrapped into the 
biofilm structure.  
Moreover, ApoB derived peptides were found to be endowed with anti-inflammatory 
activity as well as with wound healing promoting properties. We also demonstrated 
that these two HDPs are able to synergistically act in combination with conventional 
antibiotics, thus opening interesting perspectives to their future applications in 
combinatorial therapeutic approaches. Further experiments will allow us to elucidate 
the molecular mechanisms at the basis of ApoB derived peptides anti-inflammatory 
effects, which might include multiple aspects, such as stimulation of chemotaxis, 
suppression of bacterial induced pro-inflammatory cytokine production, regulation of 
neutrophil and epithelial cell apoptosis, modulation of cellular differentiation 
pathways, and promotion of angiogenesis and wound healing. As for the last aspect, 
in agreement with previous findings on LL-37 human peptide [30,31], we found that 
r(P)ApoBL peptide is able to stimulate human keratinocytes wound re-
epithelialization, an evidence that opens new and interesting perspectives on future 
topical application of this human HDP. 
In the Chapter 4, two further cryptic HDPs have been structurally and functionally 
characterized. The first HDP has been identified in human 11-hydroxysteroid 
dehydrogenase-1 β-like, while the second represents the first HDP from an archaeal 
protein, the transcription factor Stf76 encoded by the hybrid plasmid-virus pSSVx 
from Sulfolobus islandicus. By using a multidisciplinary approach including 
biochemical, cellular biology and spectroscopic techniques, a wide characterization 
of both peptides was performed revealing very interesting immunomodulatory and 
anticancer activities.  
From a structural point of view, in agreement with the canonical properties of most 
HDPs, it was verified by CD experiments that GVF27 peptide is unstructured in 
aqueous buffer, whereas it tends to assume a helical conformation in the presence of 
TFE. Further tests have also allowed us to highlight peptide binding to both LPS and 
LTA, albeit in a less effective manner with the latter, thus suggesting that it can bind 
to the microbial surfaces via these wall determinants. The ability of GVF27 to interact 
with LPS has been also confirmed by different approaches, thanks to which it has 
been possible to show that the peptide is able to inhibit the pro-inflammatory 
response. Indeed, GVF27 strongly down-regulates the release of NO and the 
production of IL-6 both in LPS pre-treated murine macrophages cells and upon co-
administration of the peptide and the endotoxin. Moreover, it is worth noting that in 
murine macrophages treated with GVF27 and then subjected to LPS stimulation, a 
decrease of both NO and IL-6 was still detectable, thus indicating tha the peptide is 
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also able to exert a protective effect. Finally, it seems very interesting the ability of 
GVF27 to attenuate LPS-induced pro-inflammatory response and its apparent ability 
to protect the cells by mitigating upstream the effects of infection. In both cases, it 
seems plausible to hypothesize for GVF27 different targets. In our opinion, at least 
three mechanisms could be responsible for GVF27 immune-modulatory properties. 
As first, GVF27 might modulate cellular response to pro-inflammatory mediators by 
acting as an endotoxin scavenger during initial steps of infection. In this case, the 
peptide could bind to and neutralize the endotoxin directly. Secondly, GVF27 might 
reduce inflammatory dysfunction during immune response by interacting with 
membrane receptors, i.e. CD14, that then would activate down regulation of different 
pro-inflammatory pathways. Thirdly, endogenous GVF27, or GVF27 internalized by 
paracrine cells, may contribute to the attenuation of the inflammatory response by 
interacting with intracellular targets. 
VLL-28 peptide, previously identified as an HDP [32], was found to be also endowed 
with a selective cytotoxic activity towards both murine and human cancer cells. This 
makes VLL-28 a potential member of anti-cancer peptides (ACPs). In the literature, 
several have been reported to successfully kill tumor cells both in vitro and in vivo 
and also to prevent metastases formation [33-35].  
However, a clear structure to function relationship analysis of these ACPs is still 
lacking, although it might greatly contribute to the development of novel and effective 
drugs. Table1 shows the primary sequence of several ACPs identified in the last 
years. 
 
 
 
Table 1. Peptides with anti-cancer activity [36] 
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ACPs studied can target different solid and hematologic malignancies, and the Table 
2 summarizes ACPs able to target solid tumors. 
 
 
 
Table 2. Peptides targeting solid tumors [36] 
 
Microorganisms belonging to the archaeal kingdom have been so far considered as a 
source of biotechnologically relevant enzymes and proteins [37-39]. To the best of 
our knowledge, potential ACPs have never been identified in this kingdom. Our data 
represent the first evidence that archaeal microorganisms could bear an unexplored 
repertoire of such kind of molecules exerting a trans kingdom action. The intrinsic 
stability to physical and chemical agents of Stf76, the parental source of VLL-28, let 
us to hypothesize that VLL-28 might be a promising “lead compound” to further 
develop novel drugs upon chemical modifications, such as introduction of D-amino 
acids and/or modified amide bounds, which would further increase its stability to 
proteases [40]. 
It has to be considered there are very few HDPs currently in use in the market, but 
many of them are progressing through clinical trials, focused on topic rather than 
systemic treatment because of peptides potential toxicity or immunogenicity. Here, it 
was shown that both ApoB derived peptides and GVF27 peptide are not toxic for 
eukaryotic cells, at least in the experimental conditions tested, and do not determine 
any hemolytic effect when tested on murine red blood cells. These observations, 
associated to their multifunctional properties, open interesting perspectives to their 
therapeutic applications. Moreover, it has to be highlighted that these peptides derive 
from a human protein and consequently the risk to trigger immune reactions is 
minimized. On the bases of obtained results, these peptides may be used either 
alone for topical applications or in combinations with other substances to develop 
suitable combinatorial therapeutic approaches, and/or in edible films to be used for 
food packaging and preservation. Suitable delivery systems, such as hydrogels and 
liposomes, could be also designed to develop novel cosmetic formulations. 
In conclusion, the aims of the present PhD Thesis are centred in the main issue of 
deepening the comprehension of HDPs mechanism of action and structure to 
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function relationships, a key aspect to further understand the complex role of these 
intriguing peptides in the defence against infections and to identify novel application 
fields. 
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ABBREVIATIONS 
 
MRSA: methicillin-resistant Staphylococcus aureus; VRE: vancomycin-resistant 
enterococci; HDPs: host defence peptides; AMPs: antimicrobial peptides; LPS: 
lipopolysaccharide; ApoE: Apolipoprotein E; ApoB: Apolipoprotein B; LDL: low-
density lipoprotein; IL-10: interleukin-10; MIC: minimal inhibitory concentration; TSA: 
Tryptic Soy Agar; AS: absolute score; MHB: Muller Hinton Broth; NB: Nutrient Broth; 
LB: Luria-Bertani; IPTG: isopropyl-β-D-thiogalactopyranoside; TFE: trifluoroethanol; 
TFA: trifluoroacetic acid; SDS: sodium dodecyl sulfate; FIC: fractional inhibitory 
concentration; EDTA: ethylenediaminetetraacetic acid; IL-6: interleukin-6; NO: nitric 
oxide; CATH-2: cathelicidin-2; ONC: onconase; PBS: phosphate-buffered saline; CD: 
circular dichroism; DLS: dynamic light scattering; MTT: 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide; MALDI-MS: matrix assisted laser desorption 
ionisation mass spectrometry; RBCs: red blood cells; WH: wound healing; LTA: 
lipoteichoic acid; LAL: limulus amaebocyte lysate; SD: standard deviation; CFU: 
colony forming unit; HBTU: 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium 
hexafluorophosphate; OXYMA: cyano-hydroxyimino-acetic acid ethyl ester; DIPEA: 
N,N′-diisopropylethylamine; MeIm: 4-methylimidazole; MSNT: 1-(Mesitylene-2-
sulfonyl)-3-nitro-1,2,4-triazole; DMF: N,N-Dimethylformamide; ACN: Acetonitrile; 
DCM: dichloromethane; Fmoc: fluorenylmethyloxycarbonyl; TOCSY: total correlated 
spectroscopy; NOESY: nuclear overhauser effect spectroscopy; OPEX: operating 
expenditure; CAPEX: capital expenditure. 
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Background:About twenty variants of apolipoproteinA-I (ApoA-I) are associated to hereditary systemic amyloid-
oses. Although themolecular bases of this disease are still largely unknown, it has been hypothesized that ApoA-I
proteolysis is a key event in pathogenesis, since it triggers the release of anN-terminal fragment (80–100 residue
long) thatmisfolds to formamyloid deposits in peripheral organs and tissues. It is also known that cellmembrane
lipids play a key role in the ﬁbrillogenic pathway. In the case of ApoA-I related amyloidosis caused by L174Smu-
tation, the 93-residue N-terminal fragment of ApoA-I ([1-93]ApoA-I) was found to be the major constituent of
ex vivo ﬁbrils.
Methods:With the main goal to investigate the interaction of either [1-93]ApoA-I and ApoA-I with biomimetic
membranes, we set-up an experimental system based on the Raman Tweezers methodology. We tested GUVs
composed by two types of zwitterionic lipids with a different ﬂuidity degree, i.e. dioleoylphosphatidylcholine
(DOPC) and dipalmitoylphosphatidylcholine (DPPC).
Results: We found that [1-93]ApoA-I induces conformational disorder in an ordered lipid bilayer. When
interacting with ﬂuid phases, instead, the fragment was found to be able to penetrate the membrane bilayer in-
ducing an alignment of lipid chains.
Conclusions: The interaction features of [1-93]ApoA-I with biomimetic membranes strongly depend on the lipid
phase. Full-length ApoA-I was found to have similar effects, even if signiﬁcantly less pronounced.
General signiﬁcance: Our observations shed light on still largely unknownmolecular bases of ApoA-I ﬁbrillogenic
domain interaction with membranes.
© 2016 Elsevier B.V. All rights reserved.
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1. Introduction
It is known that the interaction of proteinswith chemical groups ex-
posed on a membrane surface is able to modify their conformational
states [1–3]. On the other hand, it has also been reported that proteins
can alter membrane ﬂuidity, and/or permeate the membrane bilayer,
eventually extracting membrane lipids [4]. In the case of natively un-
folded polypeptides, it has been demonstrated that, upon interaction
with surfaces, they readily adopt helical structures that represent key
intermediates in the amyloid formation process [5]. In particular, anion-
ic surfaces and anionic phospholipid-richmembranes can play key roles
either in triggering protein–protein aggregation (ﬁbrillogenesis) by act-
ing as conformational catalysts for amyloid ﬁbril deposition [1], or as in-
hibitors of ﬁbrillogenesis [6].
Membranes also play a key role in amyloidoses associated with
speciﬁc variants of apolipoprotein A-I (ApoA-I), the major structural
component of high density lipoproteins (HDL). Speciﬁc ApoA-I mu-
tations are responsible for well-known familial systemic amyloidosis
[7], characterized by amyloid deposition in peripheral organs, such
as heart, liver or kidneys. In rarer cases, amyloid is also found in
the testes and adrenal glands [7–9]. Notably, the molecular bases of
the onset and development of this pathology are still largely
unknown.
The prevailing concept in this ﬁeld is that ApoA-I proteolysis is a key
event in the development of the disease, since it triggers the release of
the N-terminal fragment (80–100 residue long) that misfolds to form
amyloid deposits [10]. In both lipid-bound and lipid-free ApoA-I, this re-
gion 80–100 forms well-ordered helical structures [11–13] and is ex-
pected to be protected from proteolysis. Nevertheless, it is emerging
that a single point amyloidogenic mutation is able to profoundly alter
the protein 3D structure, thus presumably exposing protein regions to
proteolytic attack. In ApoA-I amyloidosis caused by the presence of
L174S mutation, the 93-residue N-terminal polypeptide of ApoA-I
(henceforth denoted as [1-93]ApoA-I) was found to be the major con-
stituent of ex vivo ﬁbrils [14]. Recently, we produced a recombinant
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version of this polypeptide, which was found to be natively unfolded in
aqueous solutions at pH 7.0 [15]. Upon acidiﬁcation to pH 4.0, we ob-
served a conformational transition towards a helical state, which we
have proposed to be a key intermediate in the ﬁbrillogenic pathway,
leading to the formation of a β-sheet-based polymeric structure that
evolves into typical amyloid ﬁbrils [15]. Moreover, we also demonstrat-
ed that a lipid environment induces and stabilizes helical intermediates
of [1-93]ApoA-I, thus affecting its aggregation pathway [16]. This is
noteworthy considering that ApoA-I functional role is strictly related
to its interactions with lipids and that the N-terminal region of ApoA-I
contributes to the binding of the native protein to lipids [17–18]. In par-
ticular, cholesterol, a natural ApoA-I ligand, is able to induce a transition
towards a helical conformation and to inhibit protein aggregation in a
concentration- and time-dependentmanner [16]. Similar to cholesterol,
zwitterionic, negatively and positively charged liposomeswere found to
be able to increase the helical content, with negatively charged lipo-
somes showing the greatest effect in inducing helical species [16].
The work presented herein is committed to shed light on the interac-
tion of the ﬁbrillogenic polypeptide [1-93]ApoA-I with cellular
membranes. It has to be noticed that interaction of unaggregated [1-
93]ApoA-I with cell membranes represents a key event in the develop-
ment of ApoA-I associated amyloidoses, but molecular details and conse-
quences of this interaction are still largely unknown.We investigated the
role of membrane ﬂuidity by taking advantage of the use of Giant
Unilamellar Vesicles (GUVs) as synthetic biomimetic systems. GUVs are
spherical phospholipid bilayers entrapping a closedwater-ﬁlled compart-
ment [19], typically used to gain insight intomembrane organization and
response to external agents. Plasmamembrane of eukaryotic cellsmay be
considered as composed of small ﬂuid domains, in which lipids are ar-
ranged in a liquid–crystalline phase nucleated within a continuous,
more ordered gel phase [20]. Hence, in order to properly simulate these
membrane phases, we used GUVs composed of two kinds of zwitterionic
lipids endowed with different ﬂuidity properties, such as dioleoylphos-
phatidylcholine (DOPC) and dipalmitoylphosphatidylcholine (DPPC).
Since DOPC andDPPCmelting temperatures are−16.5 °C and 41.3 °C, re-
spectively, they are representative of the ﬂuid-like state L α (DOPC) and of
the gel state L β (DPPC) at room temperature (T = 24 °C) [21]. Analyses
were performed by taking advantage of Raman Tweezers (RT) methodol-
ogy, i.e. the combination of a Raman spectrometer and an Optical
Tweezers (OT) [22]system [23]. This approach presents speciﬁc beneﬁts
with respect to well-consolidated techniques used to investigate mem-
brane properties, such as Differential Scanning Calorimetry (DSC) [24],
and ﬂuorescence-based techniques [25,26]. As a matter of fact, RT can
beused to trap and interrogate single objects, in order to provide informa-
tion on their chemical components, without the need of sample labeling.
Moreover, the analysis of Raman spectra is able to revealmolecular details
of protein species/lipid interaction features. In particular, on the bases of
selected Raman band changes, it is possible to identify the speciﬁc lipid
moieties involved into the interaction with proteins. Furthermore, the
use of OT allows the investigation of GUVs in the absence of any
surface-induced spurious effect. Furthermore, RT allows the acquisition
of the signal from a single GUV, thus giving the possibility to explore the
heterogeneity of the system under investigation. In the present study,
GUV manipulation by OT, combined with the non-destructive nature of
Raman spectroscopy, gave us the opportunity to follow over time the in-
teraction of single GUVs with the proteins under test. Being Raman spec-
tra sensitive to molecular conformations, we were able to observe the
reorganization of GUV phospholipid bilayer upon interaction with
ApoA-I or with [1-93]ApoA-I. Interestingly, our results, besides revealing
that [1-93]ApoA-I plays a key role in ruling ApoA-I interactionwithmem-
branes, indicate that the interaction of the ﬁbrillogenic polypeptide with
DPPC–GUVs has effects that resemble lipid phase transition induced by
melting. Instead, the interaction with DOPC-based bilayers induces an
alignment ofmembrane lipid chains, similar to that induced by cholester-
ol [27]. The same phenomena, even if signiﬁcantly less pronounced, were
observed for full-length ApoA-I.
2. Material and methods
2.1. Proteins under test
ApoA-I was purchased from Sigma-Aldrich (St Louis, MO, USA). [1-
93]ApoA-I polypeptide was expressed and puriﬁed as previously de-
scribed [16], omitting the neutralization step with ammonium hydrox-
ide. The ﬁnal yield of the procedure was estimated to be 2.5 mg/L of
bacterial culture. Pure [1-93]ApoA-I was lyophilized and stored at
−70 °C until use. For experimental purposes, the polypeptide was dis-
solved in the appropriate buffer and centrifuged before use.
2.2. Experimental set-up
The Raman analysis presented in this work was performed by using
a combined Optical Tweezers and micro-Raman system. The set-up has
been described in detail elsewhere [23,28]. Brieﬂy, it consisted essen-
tially in a home-made inverted microscope, endowed with a trapping
beam (Nd:YAG, 1064 nm, Ventus 1064) and a Raman probe at 532 nm
(Spectra Physics Millennia Xs). The microscope was equipped with a
100× objective lens (Olympus oil-immersion inﬁnity corrected objec-
tive, 1.4 N.A.), in which both lasers were injected through a dichroic
mirror, reﬂecting near-IR radiation and being transparent to visible ra-
diation. The back-scattered photons followed back along the same opti-
cal pathway, reaching ﬁnally a holographic notch ﬁlter where the
elastically scattered photons were suppressed. The resulting radiation
was focused through a 50 μm aperture pinhole for confocal detection
geometry and subsequently sent to a spectrometer (TRIAX 180, Jobin-
Yvon) for the spectral analysis. The Raman radiation was detected by
using a thermoelectrically cooled charge-coupled device (Pixis 100,
Princeton Instruments), at the spectrometer exit. Raman spectra were
acquired in the 900–1800 cm−1 spectral range. It should be noticed
that the CH 2/CH 3 stretching bands in the 2800–3000 cm−1 region
also provide information about the order of lipid architecture. However,
in our case, the analysis of Raman bands in this region is complicated by
the presence of the broad Raman bands in the 3000 cm−1 region due to
H 2O. In fact, even if H 2O is a weak scatterer, Raman spectra of GUVs in
aqueous solution present a signiﬁcant contribution from water, due to
the reduced scattering volume from the very thin (~5 nm) GUV mem-
brane. The sample under investigation was placed in a chamber
consisting of two 150 μm glass coverslips (Knittel Glasser, thickness
no.1), sealedwith paraﬁlm stripes, which also act as an ~100 μm spacer.
In order to maximize the GUV signal, the membrane was placed in the
Raman confocal scattering volume by acting on the galvo-mirrors con-
trolling the trapping laser beam position.
2.3. Data analysis
Principal Component Analysis (PCA) is a statistical tool that allows
the decomposition of a multidimensional data set, in order to reduce
its dimensionality while retaining the relevant characteristics contribut-
ing tomost of its variance [29]. Fromamathematical point of view, PCA is
an orthogonal linear transformation that converts the original data (var-
iables) into a new basis of uncorrelated coordinates (Principal Compo-
nents, PCs), which are a linear combination of the original variables.
PCs are ordered on the basis of their contribution to variation, with the
ﬁrst PC exhibiting the greatest contribution. The results of a PCA are
given in terms of component scores and loadings. Loadings are the coef-
ﬁcients of the linear combination deﬁning the PCs, in that they express
the contribution of each original variable to the global variance of data
set. Scores, instead, are the coordinates of the original data in the PC
space. When PCA is applied to Raman spectra, the loadings enable the
identiﬁcation of themore relevant variables (i.e.wavenumbers), provid-
ing information on how they are correlated. Each score represents a
whole spectrum plotted in a three dimensional space (score space),
with points corresponding to similar spectra clustered together [30].
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2.4. Preparation of DPPC– and DOPC–GUVs
GUVswere prepared following a procedure similar to that previous-
ly described [19]. Brieﬂy, 3 mg of lipids (DOPC or DPPC) by Avanti were
dissolved in 500 μL of chloroform (0.1 M). An aliquot (20 μL) of this so-
lution was added to 200 μL of methanol and 980 μL of chloroform in a
50 mL round-bottom ﬂask. Water (2.8 mL) was then slowly added
alongside the ﬂask walls. Finally, this solution was rotoevaporated for
3 min at a pressure of 10mbar and a temperature of ~40 °C. This proce-
dure provides vesicles whose diameter is in the range between 1 and
30 μm, as observed by bright ﬁeld microscopy [31]. Vesicles with a di-
ameter in the 4–8 μm range were selected for the experiments.
3. Results and discussion
As ﬁrst, we acquired the Raman spectra of [1-93]ApoA-I and full-
length ApoA-I in aqueous buffer. Fig. 1 shows the spectrum of a
0.76 μM [1-93]ApoA-I (a) and a 7.6 μM ApoA-I (b) aqueous solution in
the spectral range between 900 and 1800 cm−1.
Spectra were acquired by using a Raman probe power of 3 mW and
an integration time τ=30 s. Under these experimental conditions, both
signals exhibit only broad features due to the weak Raman bending
mode around 1640 cm−1, while no signiﬁcant contribution from pro-
teinaceous bands was detected, as a consequence of the low protein
concentration. Trace c and d in Fig. 1 show, instead, the Raman spectra
of an optically trapped DPPC– or DOPC–GUV, respectively, acquired
under the same experimental conditions of traces a and b (no proteins
added). The obtained Raman spectra present spectral features mainly
arising from vibrations of the hydrocarbon chains, withminor contribu-
tion of polar groups. The assignment of the prominent peaks, reported
in Table 1, has been performed on the basis of the criteria reported in
[32–36].
According to these papers, the low-wavelength region is dominated
by skeletal optical modes (SOM). These modes, being mainly C\\C
stretching vibrations delocalized along the entire acyl chain, provide in-
formation on the intrachain conformation. In particular, the relative in-
tensity of trans/gauche peaks can be used to monitor the transition of
a lipid to an ordered/disordered phase [37]. On the other hand, CH
modes are essentially not coupled to the chain and are sensitive to lat-
eral interactions inside the bilayer, so that the strength of these vibra-
tions provides information on the interchain order. In particular,
according to ref. [32], the decrease of the CH bending mode in CH2
with respect to that in CH3 is indicative of a reduced interchain order.
In the case of DOPC–GUV spectrum, a strong feature at 1655 cm−1
takes into account the presence of the C_C bond. Obviously, the ratio
of trans-to-gauche band intensity is larger for DPPC– than for DOPC–
GUV, indicating that there is a higher degree of conformational order
in the fully saturated lipid. After this preliminary step, we proceeded
to investigate the interaction of [1-93]ApoA-I and ApoA-I with DPPC–
and DOPC–GUVs. To this purpose, polypeptide and full-length protein
were incubated with preformed GUVs at a protein:lipid molar ratio of
~1:100, up to 2 h (τﬁn). It should be noticed that, even at a lipid-to-
protein molar ratio of 100:1, the lipid architecture can be signiﬁcantly
perturbed by proteins. As a matter of fact, due to the different sizes of
proteins and lipids, protein–lipid interaction is not a one-to-one interac-
tion. In particular, assuming for ApoA-I an effective diameter of 4.5 nm
(estimated from its molecular weight, 28 kDa) and taking into account
that head group area of one lipid molecule is ~0.71 nm2, it is possible
to estimate that ~25 lipid molecules directly interact with a single full-
length protein. Moreover, it should be also noticed that both full-
length protein and polypeptide can oligomerize in aqueous solution.
In particular, ApoA-I exhibits an apparent hydrodynamic diameter of
11 nm in aqueous solution,which is consistentwith the size of a protein
dimer [38] This means that each dimer potentially interacts with ~130
lipid molecules. For this study, we acquired the Raman spectrum of 40
single, optically trapped GUVs at the initial state (τ0) and at the end of
incubation (τﬁn). Moreover, to follow the kinetics of lipid/protein
Fig. 1. Representative Raman spectra of proteins and lipids (DPPC and DOPC) under investigation. (A) Raman spectra of a 0.76 μM [1–93]ApoA-I (a) and a 7.6 μM full-length ApoA-I
(b) aqueous solution in the spectral range between 900 and 1800 cm−1. Spectra were obtained with an integration time of 30 s and a power of ~3 mW on the sample. c, d: single
DPPC– (c) and DOPC–GUV (d) Raman spectra, acquired under the same experimental conditions in the absence of proteins. (B) Sketch of the chemical structure of DOPC and DPPC.
Table 1
Assignment of the prominent Raman features observed in DPPC– and DOPC–
GUVs [32–34,36].
Wavenumber (cm−1) Assignment
1063 SOM (trans)
1080 SOM (gauche)
1098 SOM (trans)
1128 SOM (trans)
1240 PO2- antisym stretch
1264 _C\\H bend
1296 CH2 twist
1440 CH bend in CH2
1460 CH bend in CH3
1655 C_C stretch
1735 C_O stretch
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interaction, for 5 GUVs we performed a spectral interrogation every
2 min for the ﬁrst 30 min, and then every 10min up to 2 h. As a control,
these analyses were performed on simple GUVs (no proteins added).
3.1. Interaction of [1-93]ApoA-I with DPPC–GUVs (gel phase)
Fig. 2A reports typical spectra of DPPC–GUVs analyzed upon incuba-
tion with the polypeptide (trace a) or the full-length protein (trace b),
acquired at τﬁn.
Remarkably, quite relevant changeswith respect to τ0 were observed
in both cases, even if more pronounced in the case of [1-93]ApoA-I. The
main spectral changes involve the region 1170–1270 cm -1, associated
with interactions of the PO 2- groups of the phospholipid polar headmoi-
ety, as well as regions 950–1100 cm -1 and 1400–1480 cm -1, which are
sensitive to variations in the acyl chain order. The most striking differ-
ences speciﬁcally associated with the interaction of [1-93]ApoA-I with
DPPC–GUVs lie in region 1170–1270 cm -1. Actually, two additional
bands are present around 1218 and 1240 cm -1 and appear to be notably
pronounced in the case of Raman spectra of DPPC–GUVs recorded in the
presence of the ﬁbrillogenic polypeptide. These bands aremuch less pro-
nounced in the presence of ApoA-I and appear to be hardly visible in the
absence of proteins (Fig. 1)[35]. According to literature [36], the afore-
mentioned bands are associated with the asymmetric stretching vibra-
tions of the PO 2- groups. In particular, it has been previously reported
that the antisymmetric stretching band lies around 1240 cm -1 in dry
DPPC–GUV and shifts to ~1220 cm -1 in fully hydrated DPPC [36]. From
Fig. 2, it is possible to note that lipid–protein interaction is responsible
for a strong decrease of the all-trans band at 1128 cm -1, as well as of
the band at 1063 cm -1 [37]. On the contrary, the gauchemarker around
1080 cm -1, generally associated with the presence of gauche chain
segments [37], is signiﬁcantly more pronounced upon DPPC–GUV inter-
action with the ﬁbrillogenic polypeptide. This kind of spectral changes
has been observed at a temperature almost corresponding to the lipid
phase transition [32]. Under these conditions, lipid physical state passes
from the ordered gel phase Iβ (below T c), where the hydrocarbon chains
are fully extended and closely packed, to the more disordered Iα phase
(above T c), where the hydrocarbon chains are randomly oriented and
ﬂuid. In agreement with this, the band around 1440 cm -1 appears to
beweakenedwith respect to that around 1460 cm -1, which is indicative
of a reduced lateral packing, and a consequent more disordered lipid
chain architecture [32,34]. To better assess the differences between the
three analyzed samples, we evaluated the intensity of the most promi-
nent peaks involved in spectral changes by performing a ﬁtting with a
multi peakGaussian function in all the aforementioned regions. In partic-
ular, to properly take into account the presence of all spectral features,
we used a 4 Gaussian convolution for 950–1100 cm -1 region, a 2 Gauss-
ian convolution for 1170–1270 cm -1 region and a 2 Gaussian convolu-
tion for 1400–1480 cm -1 region. In all the cases, a fourth order
polynomial curve was added in order to take into account a residual
background not completely removed by the subtraction of the back-
ground signal. In Fig. 2B, we show a typical result of the ﬁtting procedure
for one of the spectra acquired for the polypeptide in the 950–1100 cm -1
region, at τ=0and τ=τﬁn. The same procedurewas used for all the GUV
spectra acquired for the three investigated samples. Some signiﬁcant
outcomes of this procedure are reported in Fig. 2C.
Inmore detail, panel i) reports themean values of α=(I 1218+I 1240),
i.e. the integrated area under the two aforementioned PO 2- stretching
bands, along with the standard deviations over the 40 GUV spectra. As
mentioned above, this parameter fully differentiates the analyzed sam-
ples, highlighting the ability of the polypeptide to interact with the
Fig. 2. Analysis of the interaction of ApoA-I and [1-93]ApoA-I with DPPC GUVs. (A) Typical normalized Raman signals of DPPC GUVs upon incubation with [1-93]ApoA-I (trace a) or full-length
protein (trace b), acquired at τﬁn (120 min). (B) Representative ﬁtting curves for a spectrum of the polypeptide in the region 950–1100 cm−1. The dotted lines represent the separate
contributions of the four Gaussian curves used as ﬁt functions. Moreover, hatched areas correspond to the integrated area under the peaks used for evaluation of γ. (C) α (i), β (ii), γ
(iii) and δ (iv) mean values obtained by the ﬁtting procedure are exempliﬁed in panel B. The error bars correspond to the standard deviations over the 40 spectra analyzed for each sample.
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polar heads of DPPC. A similar behavior, although at amuch lesser extent,
was recorded for the full-length protein. As a matter of fact, it is reason-
able to think that the polypeptide interacts with the PO 2- bond in a man-
ner that induces some modiﬁcations of the PO 2- bond polarizability,
responsible for the enhanced Raman activity. It should be also pointed
out that, differently from the polypeptide sample, the spectra corre-
sponding to the ApoA-I–GUV complex present a consistent ﬂuctuation
of the ratio β= I 1218/I 1240, as reported in Fig. 2C, panel ii. This is clearly
suggestive of a random protein positioning in the lipid head region,
which gives rise to a different environment for the PO 2- bond. Intriguing-
ly, in this frame, the lowerβ value for ApoA-Iwith respect to [193]ApoA-I
could be ascribed to a lower exposure to solvent of the PO 2- bond in the
case of full-length proteinwith respect to its fragment. The two additional
parameters reported in Fig. 2C, namely the ratios γ=I 1128/I 1080
(panel iii) and δ= I 1440/I 1460 (panel iv), are indicative of the protein/
polypeptide interaction with the lipid acyl chains. As discussed above,
their decreasewith respect to the pure lipid case is indicative of a reduced
order for the acyl chain assembly. In particular, the similar γ and δ values
obtained in our analysis clearly prove that the polypeptide shares with
the full-length ApoA-I protein the ability to interact with the lipid mem-
brane bilayer. This, in turn, is likely due to the presence, in both protein
and fragment helices, of a non-polar side, clearly prone to be buried
into the hydrophobic region of the bilayer. Notably, our observations
are in agreement with recently published data indicating that 1-83
ApoA-I peptide, which is part of [1-93]ApoA-I analyzed herein, contains
four most probable membrane-binding regions [39]. Globally, these ob-
servations let us hypothesize that the ApoA-I N-terminal ﬁbrillogenic do-
main is responsible for protein/ﬁbril attachment to the surface of lipid
vesicles.
Interestingly, all the spectral modiﬁcations induced by both poly-
peptide and full-length protein are detected very early (within
~5 min), reaching a steady state within 20 min. Fig. 3A reports the
time evolution of γ obtained for a single optically trapped DPPC–GUV
interacting with [1-93]ApoA-I. A similar evolution has been observed
also for the other parameters evaluated herein, as well as for GUVs
upon interaction with ApoA-I. In both cases, their behavior resembles
a sigmoidal curve, with a transition in the 10–30 min region. This indi-
cates that the interaction of both the ﬁbrillogenic polypeptide and the
full-length protein with DPPC–GUVs have effects that resemble the
lipid phase transition induced by melting, which are much more pro-
nounced in the case of the ﬁbrillogenic polypeptide [32]. This observa-
tion could be also veriﬁed by using DSC on a statistically signiﬁcant
number of GUVs. However, it has to be noticed that, in the case of the
approach herein proposed, sample heterogeneity is completelymasked.
3.2. Interaction of [1-93]ApoA-I with DOPC–GUVs (liquid phase)
As mentioned above, the effect of ApoA-I ﬁbrillogenic fragment on
the ﬂuid membrane phase was explored by analyzing its interaction
with DOPC–GUVs at room temperature (~24 °C). However, different
from the DPPC–GUVs case, the spectroscopic effect of this interaction
was not immediately detectable. Although, in principle, this could be as-
cribed to a weak lipid–protein interaction, we argued that this could be
likely due to the obvious difﬁculty in identifying protein effects in a rel-
atively disordered structure. Therefore, in order to appreciate the ﬁne
tuning of DOPC–GUV spectra upon interactionwith proteins, we choose
to analyze our set of data by Principal Component Analysis (PCA). PCA
was performed by using a home-made MATLAB, MathWorks software,
based on theuse of the princomp routine. Before analysis, Raman spectra
were pre-processed by removing a fourth-order polynomial curve and
eliminating spurious signals deriving from cosmic ray contributions.
Spectra were also normalized and mean centered before the decompo-
sition in PCs.
Fig. 4 shows the three-dimensional score plot obtained by analyzing
the 120 spectra for the ﬁrst 3 PCs, which globally take into account al-
most 92% of the total spectra variability (see Fig. 4B) In the score plot,
the symbols corresponding to [1-93]ApoA-I–GUV and ApoA-I–GUV
complexes are triangles and squares, respectively, while spectra corre-
sponding to GUVs are represented by dots. Interestingly, points corre-
sponding to the spectra of each sample tend to be clustered together,
with some overlapping between the two protein-containing systems.
Most of data variability (~75%) is taken into account by PC1. Notably,
PC1 scores of the samples containing the polypeptides and the full-
length protein are quite apart from the pure GUV sample, which, in-
stead, occupy a score plot region of relatively low PC1 score values.
The reason of this differentiation can be ﬁgured out by PC1 loading in-
spection (Fig. 5A) This loading exhibits main features at around
1655 cm -1, associated with oleﬁnic vibrations of unsaturated chain
segments.
In particular, they appear as negative peaks, with some overlapping
with dispersive-like features, indicative of a shift to lowerwavenumbers
of the correspondingRamanpeaks. According to literature [40], a shift of
oleﬁnic vibration to lower wavenumbers can be indicative of an elonga-
tion of the C_C bond. Therefore, positive PC1 scores correspond to
spectra of lipid structures where C_C bond is weakened (negative
load features) and/or elongated (dispersive load features). As PC1, also
PC2 component provides differentiation between the two protein-
containing systems and the pure DOPC–GUVs, although points corre-
sponding to the ﬁrst two samples occupy the same score plot region.
As a matter of fact, the main features of PC2 loading lie in the region
around 1450 cm -1, including the two CH modes around 1440 cm -1
and 1460 cm -1. Clearly, the simultaneous presence of a positive feature
around 1440 cm -1 and a negative feature around 1460 cm -1 suggests
that higher PC2 score values correspond to more ordered lipid struc-
tures. Interestingly, the improved acyl chain order seems to be some-
what related to the shift of oleﬁnic band highlighted by PC1 loading.
In particular, a more ordered acyl chains conﬁguration could result
from a higher interchain pressure, giving rise to a repulsion between
chains lying at opposite sides of the C_C bonds and, as a consequence,
to a C_C bonding elongation. The last PC herein analyzed, PC3, takes
into account about 10% of the total data variability. As for PC2, this com-
ponent highlights differences between spectra of pure DOPC with re-
spect to the two protein-containing systems, with the latter exhibiting
PC3 scores spread out through PC3 score axis. However, the mean PC3
score is higher for [1-93]ApoA-I (triangles) than for full-length ApoA-I
(squares), therefore suggesting a more pronounced effect of [1-93]
ApoA-I with respect to the full-length protein on the lipid membrane
(Fig. 4A). PC3 loading is quite complex, presenting both positive and
Fig. 3. Kinetic analysis of protein–DPPC GUV interaction. Time evolution of observed
gamma for a single, optically trapped DPPC–GUV interacting with the polypeptide (A),
the full-length protein (B) and in the absence of proteins (C).
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negative features. The prominent positive peak is around 1440 cm -1, in
close proximity with a negative feature at 1460 cm -1, and this, as for
PC2, can be read in terms of a higher interchain order. Notably, PC3 load-
ing also exhibits relatively sharp bands at 1063 and 1128 cm -1, which
are all correlated to C\\C vibrations of trans isomers, indicating that
the increase in PC3 scores implies an increased number of trans isomers.
The corresponding decrease of gauche isomers is, instead, pointed out
by the negative load peak at ~1080 cm -1. Therefore, PC3 highlights
the presence of lipid structures characterized by a higher order in both
intermolecular and intramolecular acyl chains.
As for the DPPC case, we also analyzed the time evolution of single,
optically trapped GUVs. However, in this case, the time evolution was
followed by PC analysis of single GUVs spectrally interrogated while
interacting with polypeptides/proteins (no meaningful data can be ex-
tracted for DOPC-–GUVs in aqueous buffer) Fig. 6 reports the PC1
score evolution for the two protein-containing samples. Interestingly,
both sets of data suggest a faster interaction with respect to DPPC–
GUVs,with a steady state reached upon 10min incubation. This outcome
could be due to the higher ﬂuidity of DOPC bilayer.
4. Conclusions
Globally, our results indicate that the interaction features of [1-
93]ApoA-I with eukaryotic membranes strongly depend on the lipid
phase. In particular, ApoA-I N-terminal ﬁbrillogenic polypeptide was
found to induce a conformational disorder in ordered gel lipid bilayers.
In addition, the ﬁbrillogenic polypeptide was also found to induce
changes in vibrations close to the polar part of phospholipids, in partic-
ular in PO 2- stretching band. On the basis of this observation, we conjec-
ture that a signiﬁcant portion of [1-93]ApoA-I molecules is not deeply
buried inside the bilayer, but remains in close proximity to the mem-
brane–water interface. Similar effects, even if signiﬁcantly less pro-
nounced, were observed when DPPC–GUVs were incubated with full-
length ApoA-I.
We also provide evidence that [1-93]ApoA-I is able to interact with
liquid-like lipid bilayers, simulated by DOPC–GUVs. In this case, we an-
alyzed our data set by PCAanddemonstrated that [193]ApoA-I polypep-
tide can reside within the lipid bilayer, inducing an additional pressure
between adjacent lipid chains. This limits chain movements and favors
the more ordered CH bending mode in CH 2 with respect to that in
CH 3. We also observed a reduction of C_C band, probably ascribed to
Fig. 4. PC analysis of DOPC–GUVs upon interactionwith ApoA-Iﬁbrillogenic polypeptide or the full-length protein. (A) Score plot relative to the PC analysis of DOPC–GUV spectra acquired
at τ0. Points corresponding to [1-93]ApoA-I–GUV complexes and ApoA-I–GUV spectra are represented by triangles and squares, respectively, while spectra corresponding to GUVs in the
absence of proteins are represented by dots. (B) Cumulative variance for the ﬁrst 5 PCs.
Fig. 5. Analysis of the interaction of ApoA-I and [1-93]ApoA-I with DOPC–GUVs by PCA.
PC1-, PC2- and PC3-loading plot (curves A, B and C, respectively) resulting from the
analysis of all the 120 GUV spectra.
Fig. 6. Kinetic analysis of protein–DOPC–GUV interaction. PC1-score time evolution for a
single optically trapped GUV interacting with [1-93]ApoA-I (A) and ApoA-I (B) molecules.
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reducedmobility of C_C bonds due to the peptide residence in the kink
region of lipid chains. Interestingly, our analyses on DOPC-–GUVs sug-
gest the absence of a signiﬁcant interaction of either [1-93]ApoA-I or
ApoA-I with lipid polar heads. This could indicate that, in the ﬂuid
(L α) phase, protein species tend to penetrate themembrane bilayer, in-
stead of remaining in proximity to the lipid–water interface. This obser-
vation is also in agreement with the reported existence of plasma
membrane areas endowed with high afﬁnity for full-length ApoA-I
[41], as well as with our previous results indicating that [1-93]ApoA-I
polypeptide is efﬁciently internalized and subsequently degraded in
target cells [42]. To our knowledge, the ability of the polypeptide to pen-
etrate membrane ﬂuid phases inducing an alignment of lipid chains has
not been previously described. This indicates that the polypeptide may
alter the bilayer mechanical stability, with effects similar to those in-
duced by cholesterol [43–45], an event that might play an important
role in the development of the pathology.
Globally, our observations, revealing the speciﬁc ability of a natively
unfolded pathogenic polypeptide to insert in, and possibly to cross cell
membranes, provide a contribute to shed light on the intriguing and
still largely unknown molecular level details of its interaction with bio-
logical membranes.
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a b s t r a c t
Host defence peptides (HDPs) are short, cationic amphipathic peptides that play a key role in the
response to infection and inflammation in all complex life forms. It is increasingly emerging that HDPs
generally have a modest direct activity against a broad range of microorganisms, and that their anti-
infective properties are mainly due to their ability to modulate the immune response. Here, we report
the recombinant production and characterization of two novel HDPs identified in human
Apolipoprotein B (residues 887–922) by using a bioinformatics method recently developed by our group.
We focused our attention on two variants of the identified HDP, here named r(P)ApoBL and r(P)ApoBS,
38- and 26-residue long, respectively. Both HDPs were found to be endowed with a broad-spectrum
antimicrobial activity while they show neither toxic nor haemolytic effects towards eukaryotic cells.
Interestingly, both HDPs were found to display a significant anti-biofilm activity, and to act in synergy
with either commonly used antibiotics or EDTA. The latter was selected for its ability to affect bacterial
outer membrane permeability, and to sensitize bacteria to several antibiotics. Circular dichroism analyses
showed that SDS, TFE, and LPS significantly alter r(P)ApoBL conformation, whereas slighter or no signif-
icant effects were detected in the case of r(P)ApoBS peptide. Interestingly, both ApoB derived peptides
were found to elicit anti-inflammatory effects, being able to mitigate the production of pro-
inflammatory interleukin-6 and nitric oxide in LPS induced murine macrophages. It should also be
emphasized that r(P)ApoBL peptide was found to play a role in human keratinocytes wound closure
in vitro. Altogether, these findings open interesting perspectives on the therapeutic use of the herein iden-
tified HDPs.
 2017 Elsevier Inc. All rights reserved.
1. Introduction
The excessive and sometimes improper use of antibiotics has
been responsible for the development of resistant bacterial iso-
lates, the so-called ‘superbugs’, such as methicillin-resistant Sta-
phylococcus aureus (MRSA) [1], vancomycin-resistant enterococci
(VRE), and multidrug-resistant Pseudomonas, Klebsiella, and Acine-
tobacter [2]. This made the search for novel antimicrobial therapies
and approaches imperative. In this scenario, the broad
immunomodulatory properties of naturally occurring host defence
peptides (HDPs) have attracted considerable attention. HDPs, also
known as antimicrobial peptides (AMPs), are evolutionarily
conserved molecules of the innate immune system. They are a
http://dx.doi.org/10.1016/j.bcp.2017.01.009
0006-2952/ 2017 Elsevier Inc. All rights reserved.
Abbreviations: MRSA, methicillin-resistant Staphylococcus aureus; VRE,
vancomycin-resistant enterococci; HDPs, host defence peptides; AMPs, antimicro-
bial peptides; LPS, lipopolysaccharide; ApoE, Apolipoprotein E; ApoB, Apolipopro-
tein B; LDL, low-density lipoprotein; IL-10, interleukin-10; MIC, minimal inhibitory
concentration; TSA, Tryptic Soy Agar; AS, absolute score; MHB, Muller Hinton
Broth; NB, Nutrient Broth; IPTG, isopropyl-b-D-thiogalactopyranoside; TFE, triflu-
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red blood cells; WH, wound healing.
⇑ Corresponding author at: Department of Chemical Sciences, University of
Naples Federico II, 80126 Naples, Italy
E-mail address: anarciel@unina.it (A. Arciello).
Biochemical Pharmacology xxx (2017) xxx–xxx
Contents lists available at ScienceDirect
Biochemical Pharmacology
journal homepage: www.elsevier .com/locate /b iochempharm
Please cite this article in press as: R. Gaglione et al., Novel human bioactive peptides identified in Apolipoprotein B: Evaluation of their therapeutic poten-
tial, Biochem. Pharmacol. (2017), http://dx.doi.org/10.1016/j.bcp.2017.01.009
key element of the ancient, nonspecific innate defence system in
most multicellular organisms, representing the first line of defence
against invading microbes [3,4]. Found in all complex living organ-
isms, HDPs have first attracted considerable attention for their
modest antimicrobial activity directed towards a broad spectrum
of pathogens including bacteria, viruses, fungi, and protozoa
[3,4]. Natural HDPs have a size ranging from 12 to 50 amino acids,
are mostly cationic owing to the presence of high levels of lysine
and arginine residues, and contain over 50% hydrophobic amino
acids [3,5]. These properties are at the basis of HDPs’ ability to
interact with membranes, and, in some cases, to penetrate cell
membranes. In model systems, HDPs associate preferentially with
negatively charged membranes of bacteria-like composition, but
many peptides are also able to translocate into host cells. To date,
the molecular bases of their selectivity towards bacterial mem-
branes are still poorly understood [6]. It has been suggested that
HDPs tend to translocate into bacterial cells owing to the presence
of a large electrical potential gradient [7]. However, although
HDPs’ direct antimicrobial mechanism of action against bacteria
mainly involves interaction with the bacterial membrane, multiple
targets have been identified, such as cell wall peptidoglycans,
cytosolic RNA, proteins, or cytosolic enzymes/chaperones [6,8].
Hence, the selection of resistance mechanisms in bacteria is
improbable, since the removal of a single target, e.g. by mutation,
would still allow other targets to mediate HDPs direct killing activ-
ity [8]. However, it is becoming increasingly evident that these
peptides are endowed with a wide range of biological activities,
such as multispecies anti-biofilm properties, modulation of innate
immune response, and anticancer, analgesic, antioxidant and anti-
inflammatory activities [3,9–13]. Therefore, although these bioac-
tive peptides were often named AMPs, more recently they have
been termed as HDPs to describe more appropriately the breadth
of their activities [14]. Due to HDPs’ multifunctional properties,
as well as to the increased bacterial resistance to conventional
antibiotics, these peptides have great chance to be used as anti-
infective and immunomodulatory therapeutics. Although very
few HDPs are currently in use in the market, many of them are pro-
gressing through clinical trials for the treatment of diseases includ-
ing microbial infections, organ failure, immune disorders, wound
healing, diabetes and cancer [15,16]. Currently, most of the thera-
pies based on HDPs that have entered clinical trials were designed
for topical applications [17], presumably due to issues concerning
their stability and toxicity [18].
Natural cationic HDPs are encoded by genes from many organ-
isms. In mammals, HDPs are expressed in a variety of cell types
including monocytes/macrophages, neutrophils, epithelial cells,
keratinocytes, and mast cells [19–21]. They are usually synthesized
as pro-peptides from which mature and biologically active HDPs
are released by bacterial and/or host proteases [20]. Apolipopro-
teins are a source of bioactive peptides. Previous reports have
shown that peptides derived from the cationic receptor binding
region of Apolipoprotein E (ApoE141-149) are endowed with broad
anti-infective activity [22]. Apolipoprotein B (ApoB) also contains
two LDL (low-density lipoprotein) receptor binding domains,
namely region A (ApoB3147-3157) and region B (ApoB3359-
3367). Region B, more uniformly conserved across species and pri-
marily involved in receptor binding, has been found to be endowed
with a significant antiviral activity [22]. Moreover, peptides
derived from ApoB have been already used in vaccine preparations
to treat atherosclerosis [23]. When ApoE deficient mice have been
immunized with ApoB661–680 and ApoB3136–3155 peptides, a
significant increase of the levels of peptide-specific immunoglobu-
lins was detected accompanied by a concomitant increase of
secreted interleukin-10 (IL-10) levels, with no effect on IFN-c
expression levels, thus indicating that ApoB derived peptides are
able to modulate the immune response [23].
Recently, our group developed an in silicomethod [K. Pane et al.
submitted, 24] to identify HDPs in protein precursors and to pre-
dict quantitatively their antibacterial activity. This method assigns
to any given peptide an antimicrobial score, called ‘‘absolute score”
(AS), on the basis of net charge, hydrophobicity and length of the
peptide and of two bacterial strain-dependent weight factors
defining the contribution of charge and hydrophobicity to the
antimicrobial activity. We demonstrated that AS is directly propor-
tional to the antimicrobial activity of HDPs expressed as Log(1000/
MIC), where MIC is the minimal inhibitory concentration of the
peptide. Score values lower than 6.5 are considered not significant
as they correspond to predicted MIC values higher than 200 lM,
while for score values higher than about 10 the linear relationship
is no longer valid, and an increase in the score does not necessarily
correspond to a concomitant increase in the antimicrobial activity.
In order to analyse a protein potentially bearing hidden antimicro-
bial regions, the AS values of all the peptides of the desired length
contained in a precursor protein can be plotted as a function of
peptide sequence and length, thus obtaining an accurate map of
the antimicrobial activity determinants. This method allows the
identification of novel HDPs within the sequence of known pro-
teins (‘‘cryptic” HDPs), as demonstrated by the identification of a
novel cationic HDP endowed with antibacterial and immunomod-
ulatory activities in human ApoE [24], and in the transcription fac-
tor Stf76 from the archaeon Sulfolobus islandicus. In the last case,
peptide VVL-28 represents the first antimicrobial peptide derived
from an archaeal protein [25].
On the basis of the interesting results obtained in the case of
human ApoE, we applied our in silico analysis method to a human
Apolipoprotein B (ApoB) isoform [26,27]. In Fig. 1, the isometric
plot of region 882–929 of this ApoB variant is shown. An absolute
maximum, corresponding to region 887–922 (AS = 12.0), and a rel-
ative maximum, corresponding to residues 887–909 (AS = 10.6),
are shown (Fig. 1). Even if several ApoB functional regions have
already been analysed, and in some cases biologically active pep-
tides were obtained [22,23], to the best of our knowledge, this is
the first report identifying ApoB region 887–922 as a source of
HDPs.
Here, we report the recombinant production and characteriza-
tion of two variants of the putative HDP identified by our bioinfor-
matics method in human ApoB, i.e. peptides ApoB887-923 and
ApoB887-911. Both peptides include at the C-terminal side one
(as in the case of ApoB887-923), or two (as in the case of
ApoB887-911) small uncharged residues (serine, glycine or thre-
onine), which are not present in the regions highlighted in the AS
plot (Fig. 1). These residues have been arbitrarily included to avoid
that the negatively charged C-terminus of the peptide is adjacent
to the antimicrobial region.
To evaluate the therapeutic potential of these peptides, we
analysed their structure, antimicrobial and anti-biofilm activities,
the ability to act in synergy with conventional antibiotics, their
anti-inflammatory and wound healing properties, and their possi-
ble toxic effects on eukaryotic cells.
2. Materials and methods
2.1. Bacterial strains and growth conditions
Eight bacterial strains were used in the present study, i.e. E. coli
ATCC 25922, methicillin-resistant Staphylococcus aureus (MRSA
WKZ-2), Salmonella enteriditis 706 RIVM, Bacillus globigii TNO
BM013, Bacillus licheniformis ATTC 21424, Staphylococcus aureus
ATTC 29213, Pseudomonas aeruginosa ATCC 27853, and Pseu-
domonas aeruginosa PAO1. All bacterial strains were grown in Mul-
ler Hinton Broth (MHB, Becton Dickinson Difco, Franklin Lakes, NJ)
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and on Tryptic Soy Agar (TSA; Oxoid Ltd., Hampshire, UK). In all the
experiments, bacteria were inoculated and grown overnight in
MHB at 37 C. The next day, bacteria were transferred to a fresh
MHB tube and grown to mid-logarithmic phase.
2.2. Cell culture
Murine RAW 264.7 cells, malignant SVT2 murine fibroblasts
(BALBc 3T3 cells transformed by SV40 virus), parental murine
BALBc 3T3 cells, and human HeLa and HaCaT cells were from ATCC,
Manassas, VA. Cells were cultured in Dulbecco’s modified Eagle’s
medium (Sigma Aldrich, Milan, Italy), supplemented with 10% foe-
tal bovine serum (HyClone, GE Healthcare Lifescience, Chicago, IL)
and antibiotics, in a 5% CO2 humidified atmosphere at 37 C.
2.3. Synthetic peptides
CATH-2 peptide was obtained from CPC Scientific Inc. (Sunny-
vale, USA), and LL-37 peptide was from Sigma Aldrich, Milan, Italy.
2.4. Expression ad isolation of recombinant ApoB derived peptides
Expression and isolation of recombinant peptides was carried
out as previously described [24,28]. Briefly, E. coli BL21(DE3) cells
were transformed with pET recombinant plasmids, and grown in
10 mL of Terrific Brothmedium (TB) containing 100 lg/mL of ampi-
cillin, at 37 C up to OD600nm of 2. These cultures were used to inoc-
ulate 1 L of TB/ampicillin medium. Glucose at final concentration of
4 g/L was added to cultures to limit protein expression before
induction with IPTG. Cultures were incubated at 37 C up to
OD600nm of 3.5–4. Expression of recombinant proteins was induced
by addition of IPTG (isopropyl-b-D-thiogalactopyranoside) at final
concentration of 0.7 mM. Cells were harvested after overnight
induction by centrifugation at 8,000g for 15 min at 4 C andwashed
with 50 mM Tris–HCl buffer pH 7.4. The bacterial pellet was sus-
pended in 50 mM Tris-HCl buffer pH 7.4 containing 10 mM
ethylenediaminetetraacetic acid (EDTA), and sonicated in a cell dis-
ruptor (10 x 1 min cycle, on ice). The suspension was then cen-
trifuged at 18,000g for 60 min at 4 C. The insoluble fractions
werewashed three times in 0.1 M Tris–HCl buffer pH 7.4 containing
10 mM EDTA, 2% Triton X-100, and 2 M urea, followed by repeated
washes in 0.1 M Tris–HCl buffer pH 7.4. Following washing steps,
100 mg of fusion proteins were dissolved in 10 mL of denaturing
buffer (6 M guanidine/HCl in 50 mM Tris–HCl, pH 7.4) containing
10 mM b-mercaptoethanol. Mixtures were incubated at 37 C for
3 h under nitrogen atmosphere on a rotary shaker, and then cen-
trifuged at 18,000g for 60 min at 4 C. Soluble fractions were then
collected and purified by affinity chromatography onNi SepharoseTM
6 Fast Flow resin (GE Healthcare Lifescience, Chicago, IL). The chro-
matographic fractions were analysed by 15% SDS/PAGE, pooled, and
extensively dialyzed against 0.1 M acetic acid pH 3 at 4 C. Any
insoluble material was removed by centrifugation and filtration.
The sample containing the fusion construct was then acidified to
pH 2.0 by the addition of 0.6 M HCl to allow the cleavage of Asp-
Pro linker peptide, purged with N2, and incubated at 60 C for
24 h in a water bath. The pH was then increased to 7–7.2 by the
addition of 1 M NH3, and incubated overnight at 28 C to selectively
precipitate the carrier ONC-DCless-H6, that is insoluble at neutral
or alkaline pH values. The peptides were isolated from insoluble
components by repeated cycles of centrifugation, and finally lyo-
philized. Their purity was checked by SDS/PAGE and mass spec-
trometry analyses. Lyophilized peptides were then dissolved in
pure water, unless differently specified, and quantified by BCA
assay (ThermoFisher Scientific, Waltham, MA).
2.5. Mass spectrometry analyses
Matrix-assisted laser desorption/ionisation mass spectrometry
(MALDI-MS) was carried out on a 4800 Plus MALDI TOF/TOF mass
spectrometer (Applied Biosystems, Framingham, MA) equipped
with a nitrogen laser (337 nm). The peptide samples (1 mL) were
mixed (1:1, v/v) with a 10 mg/mL solution of a-cyano-4-
Fig. 1. Isometric plot showing the absolute score values (AS) of peptides with a length ranging from 12 to 40 residues (W12-W40) in the region 882–929 of ApoB. Colors were
used to highlight AS values higher than 6.5, and corresponding to predicted MIC values on S. aureus lower than 200 lM.
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hydroxycinnamic acid in acetonitrile/50 mM citrate buffer (70:30
v/v). Mass calibration was performed using external peptide stan-
dards purchased from Applied Biosystems, Framingham, MA. Spec-
tra were acquired using 5,000 shots/spectrum in a mass (m/z)
range of 1,000–5,000 amu and raw data were analysed using Data
Explorer Software provided by the manufacturer.
2.6. Circular dichroism spectroscopy
CD experiments were performed on a Jasco J-815 circular
dichroism spectropolarimeter, calibrated for intensity with ammo-
nium [D10] camphorsulfonate ([h290.5] = 7,910 deg cm2 dmol1).
The cell path length was 0.01 cm. CD spectra were collected at
25 C in the 190–260 nm (far-UV) at 0.2 nm intervals, with a
20 nm/min scan rate, 2.5 nm bandwidth and a 16 s response. Spec-
tra are reported in terms of mean residue ellipticity, calculated by
dividing the total molar ellipticity by the number of amino acids in
the molecule. Each spectrum was corrected by subtracting the
background, and reported without further signal processing. Lyo-
philized peptides were dissolved in ultra-pure water (Romil,
Waterbeach, Cambridge, GB) at a concentration of 100 lM, deter-
mined on the basis of peptide dry weight and BCA assay (Thermo-
Fisher Scientific, Waltham, MA). CD spectra of the peptides were
collected in the absence or in the presence of increasing concentra-
tions of trifluoroethanol (TFE, Sigma Aldrich, Milan, Italy), SDS
(Sigma Aldrich, Milan, Italy) or lipopolysaccharide (LPS) from E.coli
0111:B4 strain (Sigma Aldrich, Milan, Italy). CD spectra were cor-
rected by subtracting every time the contribution of the compound
under test at any given concentration. CD spectra deconvolution
was performed by using the program PEPFIT, that is based on
peptide-derived reference spectra [29], in order to estimate sec-
ondary structure contents. A Microsoft Excel-ported version of
PEPFIT was used for convenience [30].
2.7. Measurement of IL-6 release
IL-6 levels were determined by ELISA assay (DuoSet ELISA kits,
R&D Systems, Minneapolis, MN) following the manufacturer’s
instructions. Briefly, RAW 264.7 cells (5  104) were seeded into
96-well microtiter plates, and grown to semi-confluency. After
24 h, the culture medium was replaced with fresh medium con-
taining the peptide under test (5 or 20 lM) in the presence or in
the absence of LPS from Salmonella Minnesota (50 ng/mL, Sigma
Aldrich, Milan, Italy) for 24 h at 37 C. When the protective effect
of peptides was evaluated, cells were pre-incubated with the pep-
tide under test (5 or 20 lM) for 2 h at 37 C. Following treatment,
cells were washed three times with PBS prior to incubation with
LPS (50 ng/mL) for further 24 h at 37 C. In each case, at the end
of incubation, the culture supernatants were collected, and cen-
trifuged at 5,000 rpm for 3 min at room temperature, in order to
remove cell debris. Samples were then analysed by reading absor-
bance values at 450 nm using 550 nm as a reference wavelength at
an automatic plate reader (FLUOstar Omega, BMG LABTECH, Orten-
berg, Germany).
2.8. Determination of NO production
To determine the levels of NO released by RAW 264.7 cells, a
colorimetric assay based on the use of Griess reagent (Sigma
Aldrich, Milan, Italy) was performed. The levels of nitrite (NO2)
in cell supernatants were determined on the basis of a reference
curve obtained by testing increasing concentrations (from 1 to
50 lM) of sodium nitrite dissolved in water. Briefly, cell culture
supernatants were mixed with equal volumes of 1% sulphanil-
amide dissolved in 2.5% phosphoric acid, and incubated for 5 min
at room temperature. Samples were then diluted 1:1 (v/v) with
0.1% N-(1-naphthyl) ethylenediamine dihydrochloride, and incu-
bated for further 5 min at room temperature. Absorbance values
were then determined at 520 nm using an automatic plate reader
(FLUOstar Omega, BMG LABTECH, Ortenberg, Germany).
2.9. Antimicrobial activity assay
The antimicrobial activity of ApoB derived peptides was tested
towards eight bacterial strains, i.e. E. coli ATCC 25922, methicillin-
resistant Staphylococcus aureus (MRSA WKZ-2), Salmonella enteridi-
tis 706 RIVM, Bacillus globigii TNO BM013, Bacillus licheniformis
ATCC 21424, Staphylococcus aureus ATCC 29213, Pseudomonas
aeruginosa ATCC 27853, and Pseudomonas aeruginosa PAO1. In each
case, bacteria were grown to mid-logarithmic phase in MHB at
37 C. Cells were then diluted to 2  106 CFU/mL in Nutrient Broth
(Difco, Becton Dickinson, Franklin Lakes, NJ) containing increasing
amounts of either r(P)ApoBL or r(P)ApoBS peptide (0,625–40 lM).
In each case, starting from a peptide stock solution, twofold serial
dilutions were sequentially carried out, accordingly to broth
microdilution method [31]. Following overnight incubation,
MIC100 values were determined as the lowest peptide concentra-
tion responsible for no visible bacterial growth.
2.10. Killing kinetics studies
To kinetically analyse bacterial killing by ApoB derived pep-
tides, experiments were performed on E. coli ATTC 25922 and Bacil-
lus licheniformis ATTC 21424 strains. To this purpose, bacteria were
grown overnight in MHB medium, then diluted in fresh MHB, and
incubated at 37 C until logarithmic phase of growth was reached.
Bacteria were then diluted to 4  106 CFU/mL in a final volume of
150 lL of Nutrient Broth 0.5X (Difco, Becton Dickinson, Franklin
Lakes, NJ), and mixed with the peptide under test (1:1 v/v). For
each strain, increasing concentrations of peptide were analysed
(ranging from 0 to 20 lM or from 0 to 10 lM in the case of
E. coli ATTC 25922 and Bacillus licheniformis ATTC 21424 strains,
respectively). At defined time intervals, samples (20 lL) were seri-
ally diluted (from 10- to 10,000-fold), and 100 lL of each dilution
was plated on TSA. Following an incubation of 16 h at 37 C, bacte-
rial colonies were counted.
2.11. Synergy evaluation
Synergism between ApoB derived peptides and antimicrobial
agents was assessed by the so called ‘‘checkerboard” assay against
S. aureus MRSA WKZ-2, E. coli ATCC 25922, P. aeruginosa ATCC
27853, P. aeruginosa PAO1, and S. aureus ATCC 29213 strains. To
this purpose, ApoB derived peptides were tested in combination
with EDTA or antibiotics, such as ciprofloxacin, colistin, ery-
thromycin, kanamycin sulfate, and vancomycin. All these antimi-
crobial agents were from Sigma Aldrich, Milan, Italy. Twofold
serial dilutions of each ApoB derived peptide and each antimicro-
bial agent were tested in combination on each strain tested. To
do this, we tested peptide concentrations ranging from 0 to
20 lM. Compound concentrations tested on each strain are
reported in Table 1. The fractional inhibitory concentration (FIC)
index was calculated as follows: FICA + FICB, where FICA = MIC of
drug A in combination/MIC of drug A alone, and FICB = MIC of drug
B in combination/MIC of drug B alone. FIC indexes 6 0.5 were clas-
sified as synergism, whereas FIC indexes between 0.5 and 4 were
associated to additive or ‘‘no interaction” effects [32]. Antagonism
is usually associated to a FIC index > 4.
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2.12. Anti-biofilm activity
Anti-biofilm activity of ApoB derived peptides was tested on S.
aureus MRSA WKZ-2, E. coli ATCC 25922, P. aeruginosa ATCC
27853, and P. aeruginosa PAO1 strains. Bacteria were grown over-
night in MHB (Becton Dickinson Difco, Franklin Lakes, NJ), and then
diluted to 1  108 CFU/mL in BM2medium [33] containing increas-
ing peptide concentrations (0–1 lM). Incubations with the pep-
tides were carried out either for 4 h, in order to test peptide
effects on biofilm attachment, or for 24 h, in order to test peptide
effects on biofilm formation. When peptide effects on preformed
biofilm were evaluated, bacterial biofilms were formed for 24 h
at 37 C, and then treated with increasing concentrations
(0–1 lM) of the peptide under test. In all the cases, at the end of
the incubation, the crystal violet assay was performed. To do this,
the planktonic culture was removed from the wells, which were
washed three times with sterile PBS prior to staining with 0.04%
crystal violet (Sigma Aldrich, Milan, Italy) for 20 min. The colorant
excess was eliminated by three successive washes with sterile PBS.
Finally, the crystal violet was solubilised with 33% acetic acid and
samples optical absorbance values were determined at 630 nm by
using a microtiter plate reader (FLUOstar Omega, BMG
LABTECH, Germany). To determine the percentage of viable
bacterial cells inside the biofilm structure, upon biofilm
disruption with 0,1% Triton X-100 (Sigma Aldrich, Milan, Italy),
bacterial cells were ten-fold diluted on solid TSA and
incubated for 16 h at 37 C. Once evaluated the number of colony
forming units, bacterial cell survival was calculated as follows:
(CFUin treated sample/CFUin untreated sample)  100.
2.13. Cytotoxicity assays
Cytotoxic effects of ApoB derived peptides on RAW 264.7 cells
were determined by using the cell proliferator reagent WST-1
(Roche Applied Science, Mannheim, Germany). To this purpose,
RAW 264.7 cells were plated into 96-well plates at a density of
5  104 cells in 100 lL medium per well, and incubated overnight
at 37 C. Afterwards, cells were treated with increasing concentra-
tions (0–20 lM) of the peptide under test for 24 h at 37 C. Follow-
ing incubation, peptide-containing medium was removed, and
100 lL of fresh medium containing 10% WST-1 reagent was added
to each well. Following an incubation of 30 min at 37 C in the
dark, sample absorbance values were measured at 450 nm using
650 nm as a reference wavelength at a microtiter plate reader
(FLUOstar Omega, BMG LABTECH, Germany).
Cytotoxic effects of peptides on the viability of malignant SVT2
murine fibroblasts, parental murine BALBc 3T3 fibroblasts, human
HeLa cells, and human HaCaT keratinocytes were determined by
using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) assay (Sigma Aldrich, Milan, Italy), as previously
described [34]. Briefly, cells were seeded into 96-well plates at a
density of 5  103/well in 100 lL medium per well, and incubated
overnight at 37 C. Afterwards, cells were treated with increasing
concentrations (0–20 lM) of the peptide under test for 24 h at
37 C. Following incubation, the peptide-containing medium was
removed, and 100 lL of MTT reagent, dissolved in DMEM without
phenol red (Sigma Aldrich, Milan, Italy), were added to the cells
(100 lL/well) at a final concentration of 0.5 mg/mL. After 4 h at
37 C, the culture medium was removed and the resulting for-
mazan salts were dissolved by the addition of isopropanol contain-
ing 0.1 N HCl (100 lL/well). Absorbance values of blue formazan
were determined at 570 nm using an automatic plate reader
(Microbeta Wallac 1420, Perkin Elmer).
In all the cases, cell survival was expressed as the percentage of
viable cells in the presence of the peptide under test, with respect
to control cells grown in the absence of the peptide.
2.14. Haemolytic activity
The release of haemoglobin from mouse erythrocytes was used
as a measure for the haemolytic activity of ApoB derived peptides.
To do this, EDTA anti-coagulated mouse blood was centrifuged for
10 min at 800g at 20 C, in order to obtain red blood cells (RBCs),
which were washed three times, and 200-fold diluted in PBS. Sub-
sequently, 75 lL aliquots of RBCs were added to 75 lL peptide
solutions (final concentration ranging from 0 to 20 lM) in 96-
well microtiter plates, and the mixture was incubated for 1 h at
37 C. Following the incubation, the plate was centrifuged for
10 min at 1,300g at 20 C, and 100 lL supernatant of each well
were transferred to a new 96-well plate. Absorbance values were
determined at 405 nm by using an automatic plate reader (FLUOs-
tar Omega, BMG LABTECH, Germany), and the percentage of
haemolysis was calculated by comparison with the control
samples containing no peptide (negative control) or 0.2% (v/v) Tri-
ton X-100 (positive control, complete lysis). Haemolysis (%) =
[(Abs405 nm peptide  Abs405 nm negative control)/(Abs405 nm 0.2%
Triton  Abs405 nm negative control)]  100.
2.15. Wound healing assay
Wound healing activity of r(P)ApoBL peptide was evaluated
in vitro as previously described [35]. Human HaCaT keratinocytes
were seeded into 12-well plates at a density of 6.3  105 cells/well
in 1 mL medium per well. Following an incubation of 24 h at 37 C,
cells were pre-treated with 3 lM mitomycin C for 30 min, in order
to inhibit cell proliferation [36]. Cell monolayers were then
wounded with a pipette tip to remove cells from a specific region
of the monolayer. The culture medium was then removed and
the cells were washed twice with PBS. Cells were then incubated
with fresh culture medium containing increasing concentrations
of r(P)ApoBL peptide (0–0.5–10–20 lM). Wound closure was then
followed by multiple field time-lapse microscopy (TLM) experi-
ments, using an inverted microscope (Zeiss Axiovert 200, Carl
Zeiss, Germany) equipped with an incubator to control tempera-
ture, humidity and CO2 percentage [37,38]. Images were iteratively
acquired in phase contrast with a CCD video camera (Hamamatsu
Table 1
Range of antimicrobial agent concentrations tested on each strain for combination therapy analyses.
S. aureus ATCC 29213 S. aureus MRSA WKZ-2 P. aeruginosa ATCC 27853 P. aeruginosa PAO1 E. coli ATCC 25922
Ciprofloxacin 0–0,5 lg/mL 0–1 lg/mL 0–2 lg/mL 0–1 lg/mL 0–0,03 lg/mL
Colistin 0–8 lg/mL 0–8 lg/mL 0–4 lg/mL 0–4 lg/mL 0–8 lg/mL
Erythromycin 0–4 lg/mL 0–4 lg/mL 0–16 lg/mL 0–128 lg/mL 0–128 lg/mL
Vancomycin 0–0,25 lg/mL 0–0,5 lg/mL 0–32 lg/mL 0–4 lg/mL 0–0,25 lg/mL
Kanamycin 0–0,5 lg/mL 0–0,125 lg/mL 0–64 lg/mL 0–8 lg/mL 0–0,125 lg/mL
EDTA 0–24,53 lg/mL 0–49,07 lg/mL 0–392,5 lg/mL 0–196,2 lg/mL 0–98,14 lg/mL
Each antimicrobial agent was tested for synergistic effects with ApoB derived peptides (0–20 lM) within the concentration range listed in the table, depending from the
sensitivity of the specific bacterial strain.
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Orca AG, Japan) by using a 5 objective. The microscope was also
equipped with a motorized stage and focus control (Marzhauser,
Germany) enabling automated positioning of the acquired sam-
ples. The workstation was controlled through a homemade soft-
ware in Labview. Each cell sample was analysed in duplicate, and
in any case at least two fields of view were selected. Since three
independents experiments were carried out, from 8 to 12 indepen-
dent fields of view were analysed for each sample. The delay
between consecutive imaging of the same field of view was set
to 15 min. The wound closure dynamics were quantified by using
a homemade automated image analysis software, that allowed to
measure the size of the wound area for each time point (A). For
each field of view, determined values were normalized with
respect to the value of the wound area at time 0 (A0), and plotted
as function of time. After an initial lag phase, the wound area was
found to decrease with a constant velocity [39,40]. By reporting A/
A0 values as a function of time, a linear decrease was observed for
A/A0 values lower than 0.8 (Fig. 9b). For each sample, the lag time
tL was calculated as the time required to obtain an initial wound
closure corresponding to A/A0 = 0.8. Being R2 typically higher than
0.98, the linear range of the curve was fitted, and the slope (a)
was considered a measure of the wound closure velocity. The val-
ues of wound closure velocity obtained for each field of view from
three independent experiments were averaged (a), and normalized
with respect to the value of the corresponding control sample
(acontr). For each peptide concentration tested, a/acontr values
obtained from three independent experiments were averaged
and the standard error of the mean was calculated to account for
reproducibility [41].
2.16. Statistical analysis
Statistical analysis was performed using a Student’s t-Test. Sig-
nificant differences wereindicated as *(P < 0.05), **(P < 0.01) or
***(P < 0.001).
3. Results
3.1. Recombinant production of ApoB derived peptides
Expression of HDPs in bacterial cells can be deleterious to the
host due to their toxicity. For this reason, we used a procedure to
produce HDPs as fusion proteins with onconase (ONC), a frog
ribonuclease that mediates the delivery to inclusion bodies very
efficiently, as previously described [24,27], thus avoiding toxicity
problems. DNA sequences encoding peptide ApoB887-923 or
Fig. 2. Far-UV CD spectra of recombinant peptides r(P)ApoBL (a, c) and r(P)ApoBS (b, d) at a concentration of 10 lM in the presence of increasing concentrations of membrane-
mimicking agents TFE or SDS at micellar concentrations (a, b) or of LPS (c, d).
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peptide ApoB887-911, synthesized by MWG Biotech in conformity
with the E. coli codon usage, were cloned into the expression vector
pET22b(+), downstream to a sequence encoding a mutated form of
ONC. The resulting fusion proteins contain a His tag sequence,
positioned between the ONC and the peptide moieties, suitable
for an easy purification of the fusion protein, a flexible linker
(Gly-Thr-Gly), and a dipeptide (Asp-Pro), which is cleaved in mild
acidic conditions thus allowing the release of the peptide from the
carrier. Since the carrier is insoluble at neutral or alkaline pH, ApoB
derived peptides were isolated from insoluble components by
repeated cycles of centrifugation, and finally lyophilized. Peptides’
purity was checked by SDS/PAGE and matrix assisted laser desorp-
tion ionisation (MALDI) mass spectrometry analyses. Recombinant
peptides were found to be 99% pure. Molecular mass values of
ApoB887-923 and ApoB887-911 were found to be 4,072.3 Da (The-
oretical MH+ 4072.7) and 2,820.9 Da (Theoretical MH+ 2820.2),
respectively, values which are in agreement with the expected
molecular weights of the peptides with the addition of a Pro
Fig. 3. Effects of ApoB derived peptides on the release of IL-6 (a, b) and NO (c, d) in mouse macrophages RAW 264.7 stimulated with LPS (50 ng/mL) from Salmonella
Minnesota. The effects of r(P)ApoBL (a, c) and r(P)ApoBS (b, d) peptides were evaluated either co-incubating cells with the peptide under test (5 or 20 lM) and LPS (oblique
grey lanes) or by treating cells with the peptide under test (5 or 20 lM) for 2 h at 37 C prior to incubation with LPS (chessboard bars). Results were compared to those
obtained in the case of control untreated cells (white bars), cells stimulated with the LPS alone (black bars), or cells incubated with two different concentrations (5 or 20 lM)
of peptide (grey bars). Data represent the mean (±standard deviation, SD) of at least three independent experiments, each one carried out with triplicate determinations.
*P < 0.05, **P < 0.01, or ***P < 0.001 were obtained for control versus treated samples.
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Fig. 4. Time killing curves obtained by incubating Bacillus licheniformis ATTC 21424 (a, b) and E. coli ATTC 25922 (c, d) strains with increasing concentrations of r(P)ApoBL (a, c)
or r(P)ApoBS (b, d) peptides for different lengths of time. Data represent the mean (±standard deviation, SD) of at least three independent experiments, each one carried out
with triplicate determinations.
Fig. 5. Anti-biofilm activity of r(P)ApoBL (–), r(P)ApoBS (---), CATH-2 (–––), and LL-37 () peptides on E. coli ATCC 25922 (a, b, c) and S. aureusMRSAWKZ-2 (d, e, f) strains
in BM2 medium. The effects of increasing concentrations of peptides were evaluated either on biofilm attachment (a, d), biofilm formation (b, e), or on pre-formed (c, f)
biofilm. Biofilm was stained with crystal violet and measured at 630 nm. Data represent the mean (±standard deviation, SD) of at least three independent experiments, each
one carried out with triplicate determinations. For all the experimental points, *P < 0.05, **P < 0.01, or ***P < 0.001 were obtained for control versus treated samples.
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residue deriving from the cleavage of the Asp-Pro bond. The final
yield of peptides ApoB887-923 and ApoB887-911, here named r
(P)ApoBL and r(P)ApoBS, was about 7 and 4 mg/L of bacterial cul-
ture, respectively.
3.2. Conformational analyses of r(P)ApoBL and r(P)ApoBS peptides by
Far-UV circular dichroism
To analyse the secondary structure of recombinant ApoB
derived peptides, we performed Far-UV CD spectra, and found that
both peptides are largely unstructured in pure water
(Fig. 2a and b). We also evaluated the effects of membrane-
mimicking agents, such as TFE and SDS at micellar concentrations,
on peptide conformation. We found that r(P)ApoBL secondary
structure shifts mainly towards an a-helical conformation in pres-
ence of both membrane-mimicking agents, and only a partial
(<10%) increase in b-strand content is observed (Table 2). This is
clearly evidenced by the presence of two broad minima at around
208 and 222 nm, and a maximum at <200 nm (Fig. 2a). A similar
behavior has been described for different HDPs [24,42,43], and
suggests that r(P)ApoBL peptide is prone to assume a specific
ordered conformation when interacting with membrane-
mimicking agents. Similar effects, even if significantly less pro-
nounced, were observed in the case of r(P)ApoBS peptide (Fig. 2b
and Table 2). No appreciable b-strand formation was observed
for this peptide, probably indicating that, in the r(P)ApoBL peptide,
b-strand propensity is mainly localized in the C-terminus region.
We also analysed by CD spectroscopy the effects of the endo-
toxin LPS (lipopolysaccharide), the predominant glycolipid in the
outer membrane of Gram-negative bacteria [44], on the peptide
conformations (Fig. 2c and d and Table 2). When r(P)ApoBL sec-
ondary structure was analysed in the presence of increasing con-
centrations (from 0.1 to 0.8 mg/mL) of E. coli LPS, the progressive
appearance of a maximum at approximately 200 nm and of a min-
imum at approximately 218 nm suggested that the peptide tends
to assume a prevalently b-strand conformation, probably induced
by its interaction with LPS (Fig. 2c and Table 2). As expected on
the basis of previous analyses, in which r(P)ApoBS does not show
any b-strand content, no significant effects were observed in the
case of r(P)ApoBS (Fig. 2d and Table 2) under the experimental con-
ditions tested.
3.3. Analysis of the immunomodulatory activity of r(P)ApoBL and r(P)
ApoBS peptides
Based on CD analyses, we hypothesized that an interaction
between r(P)ApoBL peptide and LPS occurs. Since it is widely
reported that HDPs are able to mitigate the pro-inflammatory
effects induced by endotoxins [45], we tested the anti-
inflammatory properties of ApoB derived peptides by monitoring
their effects on LPS induced interleukin-6 (IL-6) release, as well
as on nitric oxide (NO) release in murine macrophages (RAW
264.7 cell line). In fact, it is known that, upon activation by internal
and external stimuli, macrophages produce and secrete various
endogenous inflammatory mediators, such as nitric oxide (NO)
and pro-inflammatory cytokines, including interleukin-6 [46,47].
To test the effects of ApoB derived peptides on the release of
IL-6, ELISA assays were performed on LPS stimulated RAW 264.7
cells. As shown in Fig. 3a and b, a significant release of IL-6 was
observed in control cells incubated with LPS from Salmonella
Fig. 6. Anti-biofilm activity of r(P)ApoBL (–), r(P)ApoBS (---), CATH-2 (–––), and LL-37 () peptides on P. aeruginosa ATCC 27853 (a, b, c) and P. aeruginosa PAO1 (d, e, f)
strains in BM2medium. The effects of increasing concentrations of peptides were evaluated either on biofilm attachment (a, d), biofilm formation (b, e), or on pre-formed (c, f)
biofilm. Biofilm was stained with crystal violet and measured at 630 nm. Data represent the mean (±standard deviation, SD) of at least three independent experiments, each
one carried out with triplicate determinations. For all the experimental points, *P < 0.05, or **P < 0.01 were obtained for control versus treated samples.
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Fig. 7. Effects of r(P)ApoBL (a, b) and r(P)ApoBS (c, d) peptides on the viability of RAW 264.7 (a, c), BALBc3T3 (black bars in b, d), SVT2 (dark grey bars in b, d), Hela (white bars
in b, d), and HaCaT (light grey bars in b, d) cells. Cell viability was assessed by WST-1 (a, c) or MTT (b, d) assay, and expressed as the percentage of viable cells with respect to
controls (untreated cells). Error bars indicate standard deviations obtained from at least three independent experiments, each one carried out with triplicate determinations.
Fig. 8. Haemolytic activity of r(P)ApoBL (a) and r(P)ApoBS (b) peptides towards murine red blood cells (RBCs) after 1 h of incubation at 37 C. Data represent the mean
(±standard deviation, SD) of at least three independent experiments, each one carried out with triplicate determinations.
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Minnesota (50 ng/mL). When murine macrophages were incubated
with LPS (50 ng/mL) in the presence of either r(P)ApoBL (Fig. 3a) or
r(P)ApoBS (Fig. 3b) peptide (two different peptide concentrations),
a strong decrease of IL-6 release was observed with respect to LPS
induced control cells. Moreover, we found that both peptides have
a significant protective effect on LPS stimulated RAW 264.7 cells. In
fact, when macrophages were pre-treated for 2 h with either r(P)
ApoBL or r(P)ApoBS peptide and then incubated for further 24 h
with LPS, a significant decrease of IL-6 release was observed
(Fig. 3a and b).
Similar results were observed when the effects of ApoB derived
peptides were tested on NO release (Fig. 3c and d). Also in this case,
following co-incubation of cells with LPS from Salmonella Min-
nesota and either r(P)ApoBL or r(P)ApoBS peptide, a significant
attenuation of NO release with respect to control cells was
detected (Fig. 3c and d). However, in this case, it has to be noticed
that a significant effect of peptides on NO release was observed
only at the highest peptide concentration tested (20 lM), while
at 5 lM concentration both peptides were found to be almost
ineffective (Fig. 3c and d). However, when RAW 264.7 cells were
Fig. 9. Wound healing activity of r(P)ApoBL peptide on HaCaT cells monolayer. Cells were pre-treated for 30 min with 3 lM mitomycin C, and then wounded prior to
incubation with r(P)ApoBL peptide (0.5–10–20 lM) for 12 h at 37 C. Images were acquired for untreated HaCaT cells and for cells treated with 20 lM peptide (a). The lag
phase time (tL) corresponds to the time interval before the linear decrease of the wound area. Images were acquired at time t = 0 (a, on the left), 3 h after tL (a, in the middle)
and 5 h after tL (a, on the right). For each sample, A/A0 values are reported, where A is the wound area after a specific incubation time and A0 is the wound area at time 0. Scale
bar = 150 lm. In (b), evolution in time of the wound area (A), normalized with respect to A0, is reported for a control sample. A homemade automated image analysis software
was used to measure the size of the cell-free area (A) for each time point. For A/A0 values < 0.8, a linear correlation with the incubation time was found. The slope a of the
linear fit, reported as a continuous line, represents a measure of the wound closure velocity. In (c), determined tL values are reported as a function of peptide concentration (0–
0.5–10–20 lM). In (d), wound closure velocity (a), normalized with respect to control sample (acontr), is reported as a function of peptide concentration (0.5–10–20 lM). The
dashed line corresponds to a/acontr = 1. In (c) and (d), each data point represents the mean (±standard error) of three independent experiments. **P < 0.01 was obtained for
control versus treated samples.
Table 2
Analysis of r(P)ApoBL and r(P)ApoBS peptides secondary structure.
H2O TFE
a-Helix (%) b-Strand (%) Random coil (%) a-Helix (%) b-Strand (%) Random coil (%)
r(P)ApoBL 5 12 83 26 18 56
r(P)ApoBS 7 3 90 26 0 74
SDS LPS
a-Helix (%) b-Strand (%) Random coil (%) a-Helix (%) b-Strand (%) Random coil (%)
r(P)ApoBL 17 21 62 11 64 25
r(P)ApoBS 29 3 68 18 2 80
Secondary structure content of ApoB derived peptides in water and in the presence of trifluoroethanol (TFE), sodium dodecyl sulfate (SDS), and lipopolysaccharide (LPS),
calculated by means of PEPFIT program.
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pre-treated for 2 h with 5 or 20 lM of either r(P)ApoBL or r(P)
ApoBS peptide and subsequently stimulated for 24 h with LPS
(50 ng/mL), a significant reduction of NO release was observed
even at 5 lMpeptide concentration (Fig. 3c and d), thus confirming
the protective effect of both peptides on LPS stimulated RAW 264.7
cells.
3.4. Antimicrobial activity of r(P)ApoBL and r(P)ApoBS peptides
The antibacterial activity of recombinant ApoB derived peptides
was determined by measuring their MIC100 values on a panel of
Gram-negative and Gram-positive bacterial strains (Table 3). A sig-
nificant antimicrobial activity of r(P)ApoBL and r(P)ApoBS peptides
was detected towards four out of eight strains tested, i.e. E. coli
ATCC 25922, P. aeruginosa PAO1, B. globigii TNO BM013, and B.
licheniformis 21424, for which almost identical MIC100 values were
calculated for both ApoB derived peptides. Notably, MIC100 values
were found to be comparable or even significantly lower than
those determined when control cathelicidin-2 (CATH-2), a known
HDP from chicken [48], was tested (Table 3). These data indicate
that r(P)ApoBL and r(P)ApoBS peptides are endowed with a
broad-range antimicrobial activity, being effective on both Gram-
negative and Gram-positive bacterial strains. On the other hand,
ApoB derived peptides were found to be ineffective towards P.
aeruginosa ATCC 27853, methicillin-resistant S. aureus (MRSA
WKZ-2), and S. aureus 29213 (Table 3), while, in the case of S.
enteriditis 706 RIVM, a significant antibacterial effect was elicited
only by r(P)ApoBL peptide.
To analyse the kinetic of peptides bactericidal activity, kinetic
killing curves were obtained by treating E. coli ATTC 25922 and
B. licheniformis ATTC 21424 strains, highly susceptible to both pep-
tides (Table 3), with increasing concentrations of either r(P)ApoBL
or r(P)ApoBS for different times (0–180 min). We found that, at
the highest peptide concentrations tested (5–10 lM), B. licheni-
formis cells were killed within 10 min, while at the lowest peptide
concentrations (1.25–2.5 lM) the same effect was obtained within
30 min (Fig. 4a and b). When peptides were tested on E. coli ATTC
25922 at high concentrations (5–10-20 lM), bacterial cells were
killed within 120 min, while at the lowest peptide concentration
(2.5 lM) the same effect was obtained within 180 min
(Fig. 4c and d).
3.5. Combination therapy analyses
To potentiate the antimicrobial efficacy of recombinant ApoB
derived peptides for therapeutic purposes, especially against
P. aeruginosa and S. aureus strains, we carried out combination
therapy analyses by concomitantly administrating peptides and
antibiotics in various combinations to bacteria. One of the best
known tests to evaluate synergism between two compounds is
the so called ‘‘chequerboard” experiment, in which a two-
dimensional array of serial concentrations of test compounds is
used as the basis for calculation of a fractional inhibitory concen-
tration (FIC) index to demonstrate that paired combinations of
agents can exert inhibitory effects that are more than the sum of
their effects alone [32]. It is generally accepted that FIC indexes
60.5 are indicative of ‘‘synergy”; FIC indexes comprised between
>0.5 and 4.0 are, instead, associated to ‘‘additive” or ‘‘no interac-
tion” effects, whereas FIC indexes >4.0 are indicative of ‘‘antago-
nism” [32].
As reported in Table 4, all the combinations tested were found
to be effective, either with additive or synergistic effects between
peptides and antibiotics. Notably, no FIC indexes higher than 2
were measured.
The most potent combinations were obtained in the presence of
EDTA, which was selected for its ability to affect bacterial outer
membrane permeability, thus sensitizing bacteria to a number of
antibiotics [49–51]. Very pronounced synergistic effects were
observed for both ApoB derived peptides in combination with
EDTA on S. aureus MRSA WKZ-2 and both P. aeuroginosa strains.
Both peptides were found to act synergistically with (i) cipro-
floxacin on all the strains tested (Table 4); (ii) colistin on all the
strains tested, except for S. aureus ATTC 29213 (Table 4); (iii) van-
comycin on S. aureus MRSA WKZ-2, P. aeruginosa strains and E. coli
ATTC 25922 (Table 4); (iv) erythromycin on P. aeruginosa ATCC
Table 3
Antibacterial activity of ApoB derived peptides.
MIC100 (lM)
r(P)ApoBL r(P)ApoBS CATH-2
Gram-negative strains
Escherichia coli ATCC 25922 10 10 10
Pseudomonas aeruginosa ATCC 27853 >40 >40 10
Pseudomonas aeruginosa PAO1 20 20 20
Salmonella enteriditis 706 RIVM 10 >40 10
Gram-positive strains
Staphilococcus aureus MRSA WKZ-2 >40 >40 10
Bacillus globigii TNO BMO13 5 2.5 5
Bacillus licheniformis ATCC 21424 1.25 1.25 20
Staphylococcus aureus ATCC 29213 >40 >40 10
Minimum Inhibitory Concentration (MIC, lM) values determined for r(P)ApoBL and
r(P)ApoBS peptides tested on a panel of Gram-positive and Gram-negative bacterial
strains. Chicken CATH-2 peptide was used as a positive control. Values were
obtained from a minimum of three independent experiments.
Table 4
Combination therapy analyses.
Bacterial strains Antibiotic RFICIa
r(P)
ApoBL
r(P)
ApoBS
Methicillin resistant S. aureus MRSA
WKZ-2
Ciprofloxacin 0,328 0,365
Colistin 0,340 0,350
Erythromycin 1,094 1,375
Vancomycin 0,425 0,316
Kanamycin 2,000 0,387
EDTA 0,278 0,360
S. aureus ATTC 29213 Ciprofloxacin 0,340 0,413
Colistin 1,049 1,024
Erythromycin 1,049 1,146
Vancomycin 1,049 1,097
Kanamycin 1,049 0,352
EDTA 1,049 0,351
P. aeruginosa ATCC 27853 Ciprofloxacin 0,347 0,328
Colistin 0,267 0,255
Erythromycin 0,389 0,170
Vancomycin 0,379 0,306
Kanamycin 0,479 1,030
EDTA 0,333 0,089
P. aeruginosa PAO1 Ciprofloxacin 0,396 0,444
Colistin 0,144 0,266
Erythromycin 0,569 0,556
Vancomycin 0,500 0,486
Kanamycin 0,507 0,389
EDTA 0,396 0,438
E. coli ATCC 25922 Ciprofloxacin 0,363 0,442
Colistin 0,438 0,292
Erythromycin 1,243 1,292
Vancomycin 0,428 0,426
Kanamycin 0,603 0,572
EDTA 0,729 0,750
Fractional inhibitory concentration (FIC) indexes determined for r(P)ApoBL and r(P)
ApoBS peptides tested in combination with antibiotics or EDTA on Gram-positive
and Gram-negative bacterial strains. Indexes were obtained from a minimum of
three independent experiments, each one carried out with triplicate
determinations.
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27853 (Table 4). In the latter case, a FIC index of 0.38 and 0.17 for r
(P)ApoBL and r(P)ApoBS peptides, respectively, was obtained. In the
case of kanamycin, the response varied depending on the peptide
and the specific bacterial strain. In fact, r(P)ApoBL was found to
act synergistically with this antibiotic prevalently on Gram-
negative bacteria, particularly on the P. aeruginosa strains, whereas
r(P)ApoBS peptide was found to be very active in the presence of
kanamycin against both S. aureus strains as well as against P. aerug-
inosa PAO1 strain (FIC indexes < 0.4).
It should be emphasized that combinations of ApoB derived
peptides with antibiotics or EDTA were found to have a strong
antimicrobial activity also towards strains on which the peptides
alone were found to be ineffective, such as both S. aureus strains
and P. aeruginosa ATCC 27853 (Table 3). Notably, we did not
observe any antagonistic interactions between the peptides and
the antimicrobials under test.
3.6. Anti-biofilm activity of r(P)ApoBL and r(P)ApoBS peptides
Anti-biofilm peptides represent a very promising approach to
treat biofilm-related infections and have an extraordinary ability
to interfere with various stages of the biofilm growth mode [52].
To test whether recombinant ApoB derived peptides are endowed
with anti-biofilm activity, we performed experiments on different
bacterial strains, such as E. coli ATCC 25922, Pseudomonas aerugi-
nosa PAO1, Pseudomonas aeruginosa ATCC 27853, and methicillin-
resistant Staphylococcus aureus MRSA WKZ-2 in BM2 medium.
The same experiments were also performed using LL-37 control
peptide, that is a human antimicrobial peptide known to have a
significant anti-biofilm activity against multidrug-resistant bacte-
rial strains [53]. We also tested for the first time CATH-2 anti-
biofilm activity. Three different approaches were followed. At first,
we tested the peptide effects on biofilm attachment. To do this, the
bacterial culture, following overnight growth, was diluted in BM2
medium containing increasing concentrations of the peptide under
test (0–1 lM), and incubated for 4 h at 37 C. Following incubation,
biofilm analysis by crystal violet staining revealed a significant
dose-dependent inhibition of biofilm attachment in the case of
E. coli ATCC 25922 (Fig. 5a) and S. aureus MRSA WKZ-2 (Fig. 5d)
strains treated with r(P)ApoBL (continuous line in Fig. 5a, d) or r
(P)ApoBS (smaller dashed line in Fig. 5a, d) peptides. Similar results
were obtained on these two strains in the case of peptides CATH-2
(larger dashed line in Fig. 5a, d) and LL-37 (dotted line in Fig. 5a, d).
Strong effects were also displayed by ApoB derived peptides on
biofilm attachment in the case of P. aeruginosa PAO1 strain
(Fig. 6d). A less pronounced effect of ApoB derived peptides (about
20% inhibition of biofilm formation) was observed, instead, on P.
aeruginosa ATCC 27853 biofilm attachment (Fig. 6a).
Second, we tested the effect of ApoB derived peptides on biofilm
formation. To investigate this phenomenon, we followed the
experimental procedure described above with the only exception
that bacterial cells were incubated with increasing concentrations
of peptides for 24 h at 37 C. Also in this case, we observed a signif-
icant dose-dependent inhibition of biofilm formation in the case of
E. coli ATCC 25922 (Fig. 5b) and S. aureus MRSA WKZ-2 (Fig. 5e)
strains treated with r(P)ApoBL (Fig. 5b, e) or r(P)ApoBS (Fig. 5b, e)
peptides. Similar effects were elicited by peptides CATH-2
(Fig. 5b, e) and LL-37 (Fig. 5b, e). ApoB derived peptides strongly
affected also P. aeruginosa PAO1biofilm formation (Fig. 6e). In the
case of P. aeruginosa ATCC 27853, instead, a less pronounced effect
(about 20% biofilm formation inhibition) was observed for all the
peptides under test (Fig. 6b).
Third, we tested the effect of ApoB derived peptides on pre-
formed biofilms. By incubating preformed biofilms of E. coli ATCC
25922 (Fig. 5c) and S. aureus MRSA WKZ-2 (Fig. 5f) strains with
increasing concentrations of r(P)ApoBL (Fig. 5c, f) or r(P)ApoBS
(Fig. 5c, f), we found a significant reduction (about 50%), an effect
even stronger than that observed in the case of CATH-2 peptide
(Fig. 5c, f). Similar results were observed in the case of P. aeruginosa
PAO1 strain (Fig. 6f). On the other hand, when the peptides were
tested on P. aeruginosa ATCC 27853 preformed biofilm, a slight
effect (about 20% reduction) was observed for all the peptides
except for CATH-2, which was found to have a strong effect (about
50% reduction, Fig. 6c).
We also evaluated the percentage of viable bacterial cells inside
the biofilm structure by colony counting assay. We found that,
even at the highest ApoB derived peptides concentrations tested,
a significant percentage of bacterial cells appeared to be still alive
(Table 5). Similar results were also obtained in the case of LL-37
and CATH-2 control peptides on both P. aeruginosa strains (Table 5),
even if it has to be noticed that, in the case of biofilm formation,
both control peptides affected the viability of P. aeruginosa PAO1
cells more than ApoB derived peptides (Table 5). CATH-2 and LL-
37 control peptides were also found to strongly impair the viability
of E. coli ATCC 25922 and S. aureusMRSAWKZ-2 cells in the case of
biofilm eradication (Table 5).
3.7. Biocompatibility of r(P)ApoBL and r(P)ApoBS peptides
The development of HDPs as therapeutic agents is strictly
related to their selective toxicity towards bacterial cells [54]. The
presence of zwitterionic phospholipids and cholesterol on the
Table 5
Effects of peptides on the viability of bacterial cells inside the biofilm structure.
In biofilm attachment (%) In biofilm formation (%) In biofilm eradication (%)
r(P)ApoBL r(P)ApoBS CATH-2 LL-37 r(P)ApoBL r(P)ApoBS CATH-2 LL-37 r(P)ApoBL r(P)ApoBS CATH-2 LL-37
E. coli 
ATCC 25922 105±7 101±9 15±5 97±8 79±7 79±9 40±3 73±12 83±14 80±5 15±2 37±6
MRSA WKZ-2
90±7 102±9 35±5 70±4 66±7 60±8 23±3 69±12 66±11 70±3 10±2 17±6
P. aeruginosa
ATCC 27853 76±11 68±10 91±5 60±13 66±13 64±14 96±16 77±15 70±15 59±9 59±12 69±5
P. aeruginosa 
PAO1 52±12 77±15 45±7 47±7 55±14 57±14 35±16 25±14 44±15 86±6 50±10 58±9
Effects of r(P)ApoBL, r(P)ApoBS, CATH-2, and LL-37 peptides (1 lM) on the viability of bacterial cells inside the biofilm structure. To determine the percentage of viable
bacterial cells, biofilm was lysed with Triton X-100 (0,1%), bacterial cells were ten-fold diluted, and colonies were counted after an incubation of 16 h at 37 C. Data are
expressed as percentage with respect to control untreated samples, and represent the mean (±standard deviation, SD) of at least three independent experiments, each one
carried out with triplicate determinations. For all the experimental points, *P < 0.05, or **P < 0.01 were obtained for control versus treated samples.
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outer leaflet of eukaryotic cell membranes largely accounts for the
preference of HDPs for bacterial membranes over eukaryotic mem-
branes [55,56]. To deepen on the therapeutic potential of ApoB
derived peptides, we analysed their cytotoxic effects towards a
panel of mouse and human eukaryotic cells. The addition of
increasing concentrations (from 0.625 to 20 lM) of ApoB derived
peptides to mouse macrophages Raw 264.7 cells for 24 h did not
result in any significant reduction in cell viability (Fig. 7a and c).
A slight toxicity was detected only at the highest peptide concen-
trations tested (10 and 20 lM in Fig. 7a and c). We also tested ApoB
derived peptides on murine embryo fibroblasts BALBc 3T3 and
their tumor counterpart, i.e. SVT2 simian virus 40-transformed cell
line (Fig. 7b and d). A slight toxicity (10–20%) was detected only in
the case of SVT2 cells at the highest concentration tested (20 lM in
Fig. 7b and d). Moreover, no significant toxic effects were detected
when ApoB derived peptides were assayed on human cervical can-
cer HeLa cells (Fig. 7b and d), while a slight toxicity (20%) was
observed in the case of human keratinocytes (HaCaT cells) at the
highest concentration (20 lM in Fig. 7b and d). ApoB derived pep-
tides were also tested on murine red blood cells (RBCs) to exclude
haemolytic effects. As shown in Fig. 8, both peptides did not exert
any lytic effect on mouse RBCs, even at the highest concentration
tested (20 lM).
3.8. Wound healing activity of r(P)ApoBL peptide
Numerous studies support the hypothesis that human HDPs
promote wound healing in skin, by modulating cytokine produc-
tion, cell migration, proliferation and, in some cases, angiogenesis
[57]. Based on this, we performed experiments to test whether r
(P)ApoBL peptide is able to stimulate wound re-epithelialization
by human keratinocytes (HaCaT cell line). To this purpose, we per-
formed a classical in vitro wound healing assay to evaluate peptide
effects on cell migration. HaCaT cell monolayers were pre-treated
with 3 lM mitomycin C for 30 min, and then wounded with a pip-
ette tip to remove cells from a specific region of the monolayers.
Cells were then washed with PBS and incubated with r(P)ApoBL
(0, 0.5, 10, and 20 lM). As it is well known that the spreading of
cells in the wound area is due to two mechanisms, i.e. cell motility
and cell proliferation [37,40,58], a pre-treatment with mitomycin C
allowed us to exclude any influence of cell proliferation on the
wound healing process.
In Fig. 9a, we reported the images acquired during a time-lapse
wound healing experiment on control cells, and on cells treated
with 20 lM r(P)ApoBL peptide at three time points, i.e. at time 0
and at 3 and 5 h after the lag time (tL), defined as a transient time
period (tL) before the linear decrease of the wound area (see
below). By the comparison of the images of treated and untreated
cells at each time point, it emerged that the cells treated with
20 lMpeptide were able to close the wound faster than the control
cells. In order to quantify the wound closure, we used an auto-
mated image analysis software, that allowed us to measure the size
of the cell-free area (A) for each time point. The obtained values
were normalized with respect to the value measured at time 0
(A0) for each field of view, and plotted as a function of time
(Fig. 9b). In Fig. 9a, at t = 5 h after tL, A/A0 values were found to
be 0.20, and 0.07 for the control sample, and for the cells treated
with 20 lM peptide, respectively. This evidence suggests that r
(P)ApoBL peptide might be able to stimulate wound re-
epithelialization by human keratinocytes. As shown in Fig. 9b,
where A/A0 values of control cells are reported as a function of
time, after an initial lag phase (tL), the wound area decreases with
a constant velocity. The initial lag phase, corresponding to a tran-
sient time period (tL) before the linear decrease of the wound area,
has been observed for all the analysed samples, and has been found
to range between 3 and 5 h independently from peptide concentra-
tions under test (Fig. 9c).
As the slope (a) of the line represents the measure of the wound
closure velocity, each a value calculated in the presence of the pep-
tide was normalized with respect to the value calculated for
untreated cells (acontr), and plotted as a function of peptide concen-
tration (Fig. 9d). It appeared that the cells treated with the peptide
show an increased wound closure velocity with respect to the con-
trol cells (a/acontr > 1). In particular, in the case of the cells treated
with 10 lM peptide, an increment of about 20% in the normalized
wound closure velocity (a/acontr = 1.21, data statistically signifi-
cant) was observed. When cells were treated with 20 lM peptide,
a slightly higher value of the normalized wound closure velocity
was measured (a/acontr = 1.23). However, in the latter case, a
higher data variability was observed (larger error bar), leading to
a limited statistical significance of the result.
Overall, our results indicate that r(P)ApoBL peptide is able to
promote the migration and the consequent wound healing in
HaCaT keratinocyte monolayers when tested at concentration val-
ues ranging between 0.5 and 20 lM.
4. Discussion
Recently, an abundance of multidrug-resistant bacteria has
emerged, whereas very few classes of new antibiotics have been
discovered. The knowledge that HDPs may prevent infections in
many organisms opened interesting perspectives to the applica-
tions of these peptides as a new class of antimicrobials. In fact, they
initially attracted attention solely for their direct antimicrobial
activity, and were studied as promising alternative antibiotic can-
didates due to their prospective potency, rapid action, and broad
spectrum of activity against Gram-negative and Gram-positive
bacteria, viruses, fungi and parasites [59,60]. To date, more than
1,000 natural cationic HDPs with antimicrobial properties have
been identified [61]. These peptides constitute a major component
of the ancient, nonspecific innate defence system in most multicel-
lular organisms [3,19,59,60]. However, it has to be emphasized
that most natural HDPs have, indeed, modest direct antimicrobial
activities, and exhibit multiple mechanisms of action, with a con-
sequent low potential to induce de novo resistance [59]. This class
of peptides includes both the bioactive peptides displaying direct
antimicrobial activity and those that stimulate the immune system
to clear or prevent an infection [59,61]. In mammals, the expres-
sion of mature and biologically active HDPs requires a proteolytic
cleavage event determining the release of the ‘‘cryptic” bioactive
peptide from its precursor protein [62]. In fact, it should be empha-
sized that a wide variety of human proteins, whose primary func-
tions are not necessarily related to host defence, contain HDPs
hidden inside their sequences [63,64]. Fascinatingly, human pro-
teome could be seen as a yet unexplored source of bioactive pep-
tides with potential pharmacological applications. In this context,
apolipoproteins have been identified as a source of bioactive pep-
tides displaying broad anti-infective and antiviral activities [22].
Indeed, the presence of antiviral peptides hidden within
apolipoprotein sequences may be related to the fact that lipopro-
teins and viruses share a similar cell biological niche, having a
comparable size and displaying similar interactions with mam-
malian cells and receptors [22]. ApoB is one of the several
apolipoproteins that play key roles in lipoprotein metabolism
[65], and represents the ligand for receptor-mediated removal of
low density lipoprotein particles from circulation [65]. ApoB con-
tains two LDL (low-density lipoprotein) receptor binding domains,
namely region A (ApoB3147-3157) and region B (ApoB3359-3367),
which is more uniformly conserved across species and that has
been found to be endowed with a significant antiviral activity
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[22]. Moreover, ApoB derived peptides have been already used in
vaccine preparations to treat atherosclerosis [23]. Here, we applied
our in silico analysis method to a human ApoB isoform [26,27] and
identified a novel ‘‘cryptic” HDP (region 887–922). To the best of
our knowledge, this ApoB region has never been analysed before,
since all the previously identified biologically active ApoB peptides
are far from the high scoring region identified in the present work
[22,23]. By applying our in silico analysis, we identified an absolute
maximum score, corresponding to region 887–922 (Fig. 1), and a
relative maximum score, corresponding to residues 887–909
(Fig. 1). Here, we focused our attention on these two ApoB
sequences by producing in bacterial cells two recombinant HDPs,
here named r(P)ApoBL and (P)ApoBS, 38- and 26-residue long,
respectively. Both recombinant peptides were found to exhibit
antibacterial activities against both Gram-positive and Gram-
negative strains, including the pathogenic strains P. aeruginosa
PAO1 and B. globigii TNO BM013, while having negligible cytotoxic
effects on a panel of human and murine cell lines. Time killing
curves also indicated that peptides exert a strong bactericidal
activity against susceptible strains. However, it has to be under-
lined that ApoB derived peptides were found to be ineffective
towards P. aeruginosa ATCC 27853, methicillin-resistant S. aureus
(MRSAWKZ-2), and S. aureus ATTC 29213 strains, while, in the case
of S. enteriditis 706 RIVM strain, a significant antibacterial effect
was displayed only by r(P)ApoBL peptide. This observation is in
agreement with previous findings indicating that most natural
cationic antimicrobial peptides do not appear to be highly opti-
mized for direct antimicrobial activity, since it is likely that multi-
ple modestly active peptides with concomitant
immunomodulatory activities work effectively in combination
and/or when induced or delivered to sites of infection [66]. Indeed,
considering this, we performed combination therapy analyses and
found that both ApoB derived peptides are able to synergistically
act with either commonly used antibiotics or EDTA, the latter
selected for its ability to affect bacterial outer membrane perme-
ability, thus sensitizing bacteria to a number of antibiotics [49–
51]. Interestingly, synergistic effects were observed towards most
of the strains under test, including methicillin-resistant S. aureus
MRSA WKZ-2, on which peptides alone were found to be ineffec-
tive even at high concentrations (40 lM). Although the use of a sin-
gle agent to treat pathogens is the most common practice in clinics,
combination therapy approaches have several advantages, such as
low potential to induce resistant phenotype, efficacy at lower drug
doses, with a consequent mitigation of toxic effects, and possibility
to target a broad spectrum of pathogens [67]. Interestingly, both r
(P)ApoBL and r(P)ApoBS peptides showed synergism with systemic
antibiotic ciprofloxacin against all the strains under test (FIC
indexes ranging from 0.3 to 0.44). This would allow to significantly
lower the doses of the antibiotic in the combination therapy
approaches, with a consequent decrease of the appearance of resis-
tant clinical isolates, an undesired phenomenon strongly affecting
ciprofloxacin efficacy [68]. ApoB derived peptides also showed syn-
ergistic effects with colistin and vancomycin against most of the
strains under test (FIC indexes ranging from 0.14 to 0.5). Since both
colistin and vancomycin are responsible for toxic effects at high
concentrations [67,69], a combination therapeutic approach based
on a reduced frequency of antibiotic administration and/or expo-
sure to antibiotic may offer several advantages over conventional
dosing schemes. However, the most potent synergism was
observed for both ApoB derived peptides in combination with
EDTA, with FIC indexes ranging from 0.089 to 0.4. In the case of
P. aeruginosa strains, synergismmight be associated to EDTA ability
to combine with magnesium ions playing a key role in the self-
interaction of LPS molecules, with a consequent LPS release deter-
mining an increased permeability of bacterial membrane [50]. This
might ultimately facilitate peptide internalization into bacterial
cells, thus potentiating the peptide antimicrobial activity. EDTA is
also known to determine the release of endogenous phospholi-
pases, with a consequent alteration of Gram-negative bacteria
outer membrane [70]. In the case of S. aureus strains, the increase
of bacterial membrane permeability might be due to the ability of
EDTA to solubilize extracellular polymeric substances [71], mainly
composed by exopolysaccharides and playing a key role in biofilm
establishment.
It should be highlighted that, although in some cases FIC
indexes very close to 0.5 make it difficult to discriminate between
synergistic and additive effects, no antagonistic interactions were
observed between peptides and antimicrobials. Furthermore, com-
binations of ApoB derived peptides with antibiotics and EDTA were
found to have a strong antimicrobial activity also towards strains
on which the peptides alone were found to be ineffective, such
as both S. aureus strains and P. aeruginosa ATCC 27853, indicating
that in drug combinations a reciprocal facilitation and potentiation
of different mechanisms of action is realized.
Interestingly, ApoB derived peptides are also endowed with
anti-biofilm activity. Microorganisms growing in a biofilm state
are very resilient to the treatment by many antimicrobial agents.
Indeed, biofilm infections are a significant problem in chronic
and long-term infections, including those colonizing medical
devices and implants [52]. Specific cationic HDPs have recently
been described to have multispecies anti-biofilm activity, which
is independent of their activity against planktonic bacteria [9].
We found that ApoB derived peptides are effective on biofilm for-
mation and biofilm attachment, and, even more interestingly, they
strongly affect pre-formed biofilms. Furthermore, ApoB derived
peptides display anti-biofilm activity even on bacterial strains
not sensitive to the peptide antimicrobial activity, such as S. aureus
MRSA WKZ-2, and, in the case of sensitive strains, even at peptide
concentrations (0.625–1 lM) significantly lower than those
required to directly kill planktonic cells. This is in agreement with
previous reports indicating that LL-37 peptide potently inhibits the
formation of bacterial biofilms in vitro at the very low and physio-
logically meaningful concentration of 0.5 lg/mL, significantly
lower than that required to kill or inhibit bacterial growth
(64 lg/mL) [72]. As a consequence of this, it should be emphasized
that even at the highest ApoB derived peptides concentrations
tested, a significant percentage of bacterial cells inside the biofilm
structure appeared to be still alive. This was observed for both
ApoB derived peptides and LL-37 control peptide, while it was less
pronounced in the case of CATH-2 peptide. Based on this, it is
tempting to speculate that successful therapeutic approaches
could be designed by combining anti-biofilm peptides and conven-
tional antibiotics ineffective on biofilm, but effective on bacterial
cells entrapped into the biofilm structure.
From a structural point of view, by Far UV-CD analyses, we
found that ApoB derived peptides are unstructured in aqueous buf-
fer, and tend to assume a conformation in the presence of mem-
brane mimicking agents. In the presence of increasing
concentrations of LPS, r(P)ApoBL peptide was found to gradually
assume a defined structure, what suggests a direct binding of this
peptide to LPS. This was not observed, instead, in the case of r(P)
ApoBS peptide. It has also to be highlighted that both r(P)ApoBL
and r(P)ApoBS peptides are endowed with immunomodulatory
activities by significantly decreasing the release of pro-
inflammatory IL-6 and NO in LPS induced murine RAW 264.7
macrophages. Both ApoB derived peptides were found to efficiently
act either when the cells were co-incubated with the peptide under
test in the presence of LPS or when the cells were pre-treated with
the peptide for 2 h and then incubated with LPS for further 24 h,
thus indicating that both peptides are able to display a significant
protective action. However, it has to be noticed that, differently
from r(P)ApoBL peptide, r(P)ApoBS was found to play anti-
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inflammatory activities, when co-incubated with LPS, only at the
highest peptide concentration tested (20 lM), whereas both r(P)
ApoBS concentrations (5 and 20 lM) were found to efficiently exert
a protective effect. This might be due to the fact that ApoB derived
peptides probably act through different mechanisms, with r(P)
ApoBL peptide mainly acting by binding to LPS and consequently
interfering with its activity on target cells, and r(P)ApoBS peptide
mainly acting on cell membrane and competing with LPS for the
binding to specific cell sites. Therefore, a complex picture emerges,
in agreement with the observation that HDPs immunomodulatory
activities are extremely diverse [14]. Further experiments will
allow us to elucidate the molecular mechanisms at the basis of
ApoB derived peptides anti-inflammatory effects, which might
include multiple aspects, such as stimulation of chemotaxis, sup-
pression of bacterial induced pro-inflammatory cytokine produc-
tion, regulation of neutrophil and epithelial cell apoptosis,
modulation of cellular differentiation pathways, and promotion
of angiogenesis and wound healing. As for the last aspect, in agree-
ment with previous findings on LL-37 human peptide [73,74], we
found that r(P)ApoBL peptide is able to stimulate human ker-
atinocytes wound re-epithelialization in vitro, an evidence that
opens new and interesting perspectives on future topical applica-
tions of this human HDP.
It has to be underlined that, although there are very few HDPs
currently in use in the market, many are progressing through clin-
ical trials that have focused on topic rather than systemic treat-
ment because of peptides potential toxicity. However, it is
conceivable that judicious formulations of HDPs for a clinical use,
e.g. peptide inclusion in liposomal nanoparticles, will avoid unde-
sired toxicity and degradation, thus allowing a sustainable HDPs
delivery [18]. Here, we show that both ApoB derived peptides are
not toxic for eukaryotic cells and do not determine any haemolytic
effect when tested on murine red blood cells. These observations
associated to their multifunctional properties and to their ability
to synergistically act in combination with conventional antibiotic
drugs open interesting perspectives to their therapeutic
applications.
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Abstract 
 
Background 
Host Defence Peptides (HDPs) are evolutionarily conserved components of innate immunity. Human HDPs, 
produced by a variety of immune cells of hematopoietic and epithelial origin, are generally grouped into two 
families: beta structured defensins and variably-structured cathelicidins. We report the characterization of a 
very promising cryptic human HDP, here called GVF27, identified in 11-hydroxysteroid dehydrogenase-1 β-
like protein. 
 
Methods 
Conformational analysis of GVF27 and its propensity to bind endotoxins were performed by NMR, Circular 
Dichroism, Fluorescence and Dynamic Light Scattering experiments. Crystal violet and WST-1 assays, ATP 
leakage measurement and colony counting procedures were used to investigate antimicrobial, anti-biofilm, 
cytotoxicity and hemolytic activities. Anti-inflammatory properties were evaluated by ELISA.  
 
Results 
GVF27 possesses significant antibacterial properties on planktonic cells and sessile bacteria forming biofilm, 
as well as promising dose dependent abilities to inhibit attachment or eradicate existing mature biofilm. It is 
unstructured in aqueous buffer, whereas it tends to assume a helical conformation in mimic membrane 
environments as well as it is able to bind lipopolysaccharide (LPS) and lipoteichoic acid (LTA). Notably it is 
2	
	
not toxic towards human and murine cell lines and triggers a significant innate immune response by 
attenuating expression levels of pro-inflammatory interleukins and release of nitric oxide in LPS induced 
macrophages  
 
Conclusion 
Human GVF27 may offer significant advantages as leads for the design of human-specific therapeutics. 
 
General significance 
Human cryptic host defence peptides are naturally no immunogenic and for this they are a real alternative for 
solving the lack of effective antibiotics to control bacterial infections. 
 
Highlights 
A new human cryptic peptide, named GVF27, has been identified in 11-hydroxysteroid dehydrogenase-1 β-like 
 
GVF27 is unstructured in aqueous buffer but assumes a well defined conformation in mimic membrane environments 
GVF27 exerts anti-biofilm actions and broad spectrum antimicrobial activities 
GVF27 binds bacterial endotoxins as LPS and LTA 
GVF27 induces mitigation of pro-inflammatory mediators production in LPS induced murine macrophages 
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1. Introduction  
 
Antimicrobial peptides are natural multifunctional molecules produced by various organisms such as 
mammals, arthropods, plants and bacteria [1,2]. The largest group of antimicrobial peptides includes cationic 
antimicrobial peptides, also called host defense peptides (HDPs), effectors of the innate immune system that 
contribute to the rapid clearance of adverse biological agents [3]. In contrast to conventional antibiotics, 
HDP-mediated killing of microorganisms occurs via multiple mechanisms attacking both the cell membrane 
and/or intracellular targets [4]. Cationic HDPs have been proved to be active against virtually all types of 
existing pathogens which have shown none or poor ability to develop resistance to their antimicrobial 
activity [4,5]. In fact, it has been proposed that the resistance mechanisms would have high impacts on 
fitness and virulence of the mutants, since the pathogens need to acquire mutations on membrane and wall 
composition [6]. For this reason, current reports point out to the great potential of this class of innate immune 
molecules to constitute a novel group of wide spectrum therapeutic effectors.  
Cationic HDPs are divided into subgroups on the basis of their amino acid composition and structure 
[7]: α-helical peptides, linear peptides enriched for specific amino acids (e.g. proline and arginine), and 
peptides containing cysteine residues and prone to form stable β-sheets. Cationic HDPs generally contain 
12–50 amino acids, with 2-9 positively charged lysine or arginine residues, and up to 50% hydrophobic 
amino acids. They are able to interact with and insert into biomembranes on the basis of their hydrophobicity 
and net positive charge, conformational flexibility and secondary structure [8]. Additionally, many cationic 
HDPs can potentially prevent septic shock via their anti-endotoxic activity through electrostatic interactions 
with lipopolysaccharides (LPS) and lipoteichoic acid  (LTA) in the bacterial membrane [9,10]. 
In addition to their antimicrobial activity, HDPs are able to modulate immune response, including 
the boosting of innate immunity and the suppression of inflammatory responses/endotoxaemia [11,12]. It has 
been noted indeed that some HDPs regulate LPS-induced gene transcription and cytokine production by 
several mechanisms as inhibition of LPS-induced translocation of the NF-kB subunits p50 and p65 [13], 
selective inhibition of gene transcription (e.g. p50, TNFAIP2) [13], reduction of the expression of others 
(TNF-α) [13], triggering of MAPK pathways that can impact on pro-inflammatory pathways [14], direct 
interaction with LPS to reduce its binding to LBP, MD2, or another component of the TLR4 receptor 
complex, thus reducing activation of the downstream pathway [15],  and protection against the development 
of endotoxin shock in vivo [16]. Cationic HDPs may act either directly or indirectly, by selectively inducing 
chemokine production in immune cells and recruitment of other immune cells to the site of infection [17,18]. 
At the same time, HDPs may enhance antigen uptake and presentation and inhibit apoptosis of neutrophils 
and macrophages [17,18]. 
Cationic HDPs are expressed in different cell types, including monocyte/macrophages, neutrophils, 
epithelial cells, keratinocytes and mast cells. Some HDPs are constitutively expressed, whereas others are 
inducible by pathogen signature molecules, inflammatory conditions or tissue injury [19]. They are generally 
expressed as pro-peptides that undergo subsequent proteolytic processing to release the biologically active, 
mature host defense peptide [20].  
It has been widely reported that in multicellular eukaryotes several proteins, with properties not 
necessarily associated to immunity, are sources of “cryptic” cationic host defense peptides [21]. These HDP 
releasing proteins release biologically active peptides only after their proteolytic processing by bacterial 
and/or host proteases. 
The use of bioinformatic approaches has increased the possibility to highlight the presence of 
putative antimicrobial regions in proteins, thus representing an extremely useful tool for the discovery of 
new cryptic host defense peptides [22]. The bioinformatic strategy we recently developed [23] for the 
identification of potential HDP releasing proteins and the accurate localization of the fragment(s) hidden in 
their amino acidic sequences, is an example of such a procedure. The procedure we have developed is based 
on the finding that the antimicrobial potency (AP) of an HDP [defined as AP = Log(1000/MIC)]	is linearly 
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correlated to an “absolute score” (AS) which depends on charge, hydrophobicity and length of the peptide, 
and on two bacterial strain specific coefficients which determine the contribution of charge and 
hydrophobicity to the antimicrobial potency. Calculation of AS by a sliding window analysis provides a 
simple and effective method to localize HDPs (“cryptic” HDPs) contained within the structure of proteins, 
but also to analyze the internal structure of long HDPs, thus providing a very valuable tool for HDP 
identification and analysis.  
Analyzing a pool of human secreted proteins using this approach, we identified a region rich in very 
high scoring peptides (see Figure S1A and B) at the C-terminus of four isoforms of human 11-
hydroxysteroid dehydrogenase-1 β-like (accession number UniProtKB: Q7Z5J1). It should be noted that 
human 11β-hydroxysteroid dehydrogenase type 1 (HSD 1) is a known NADP(H)-dependent enzyme that 
catalyzes the conversion of inactive glucocorticoids into active forms and its dysregulation is mainly 
implicated in the development of metabolic syndromes [24]. On the contrary, human 11-hydroxysteroid 
dehydrogenase-1 β-like, also known as 11-beta-hydroxysteroid dehydrogenase type 3 (HSD 3), the sequence 
in which the high scoring region has been found, has never been isolated as a protein and its membership to 
the hydroxysteroid dehydrogenase family has been assigned on the basis of the presence in the gene 
sequence of a putative dehydrogenase/reductase region partially similar to that extensively studied in HSD 1 
[25]. The only type of evidence that supports the existence of HSD 3 as a protein is represented by 
expression data [26] that indicate the existence of a transcript (Gene ID: 374875) apparently overexpressed 
in the brain and in lung cancer cells. 
The isometric plot of the C-terminal region shows an absolute maximum (AS = 18.7 using the 
parameters determined for S. aureus C623) corresponding to a 39 residue long peptide (the longer arrow in 
Figure S1A) and a local maximum (AS = 16.1) corresponding to a 26 residue long peptide (the shorter arrow 
in Figure S1A). The region selected for the characterization (Figure S1A and C), herein called GVF27, 
corresponds to this local maximum plus the glycine residue located upstream the 26 residues. The glycine 
residue was included in the peptide as, according to [27], a glycine at the N-terminus of an antimicrobial 
peptide is favorable for the activity. 
In this work, we fully characterize peptide GVF27 describing its bactericidal properties against 
planktonic and sessile bacteria, its cytotoxic and anti-inflammatory effects on murine cells and its structural 
properties in the presence of mimic membrane agents and wall bacterial determinants, such as LPS and LTA. 
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A 
SP|Q7Z5J1-2|DHI1L_HUMAN  MKVLLLTGLGALFFAYYWDDNFDPASLQGARVLLTGANAGVGEELAYHYARLGSHLVLTA 60 
SP|Q7Z5J1-5|DHI1L_HUMAN  ------------------------------------------------------------ 
SP|Q7Z5J1-6|DHI1L_HUMAN  MKVLLLTGLGALFFAYYWDDNFDP------------------------------------ 24 
SP|Q7Z5J1-7|DHI1L_HUMAN  ------------------------------------------------------------ 
 
SP|Q7Z5J1-2|DHI1L_HUMAN  HTEALLQKVVGNCRKLGAPKVFYIAADMASPEAPESVVQFALDKLGGLDYLVLNHIGGAP 120 
SP|Q7Z5J1-5|DHI1L_HUMAN ---------------------------MASPEAPESVVQFALDKLGGLDYLVLNHIGGAP 33 
SP|Q7Z5J1-6|DHI1L_HUMAN  ---------------------------------------------GGLDYLVLNHIGGAP 39 
SP|Q7Z5J1-7|DHI1L_HUMAN ------------------------------------------------------------ 
 
SP|Q7Z5J1-2|DHI1L_HUMAN AGTRARSPQATRWLMQVNFVSYVQLTSRALPSLTDSKGSLVVVSSLLGRVPTSFSTPYSA 180 
SP|Q7Z5J1-5|DHI1L_HUMAN  AGTRARSPQATRWLMQVNFVSYVQLTSRALPSLTDSKGSLVVVSSLLGRVPTSFSTPYSA 93 
SP|Q7Z5J1-6|DHI1L_HUMAN  AGTRARSPQATRWLMQVNFVSYVQLTSRALPSLTDSKGSLVVVSSLLGRVPTSFSTPYSA 99 
SP|Q7Z5J1-7|DHI1L_HUMAN --------------MQVNFVSYVQLTSRALPSLTDSKGSLVVVSSLLGRVPTSFSTPYSA 46 
 
SP|Q7Z5J1-2|DHI1L_HUMAN      AKFALDGFFGSLRRELDVQDVNVAITMCVLGLRDRASAAEAVRGVTRVKAAPGPKAALAV 240 
SP|Q7Z5J1-5|DHI1L_HUMAN      AKFALDGFFGSLRRELDVQDVNVAITMCVLGLRDRASAAEAVRGVTRVKAAPGPKAALAV 153 
SP|Q7Z5J1-6|DHI1L_HUMAN      AKFALDGFFGSLRRELDVQDVNVAITMCVLGLRDRASAAEAVRGVTRVKAAPGPKAALAV 159 
SP|Q7Z5J1-7|DHI1L_HUMAN      AKFALDGFFGSLRRELDVQDVNVAITMCVLGLRDRASAAEAVRGVTRVKAAPGPKAALAV 106 
 
SP|Q7Z5J1-2|DHI1L_HUMAN      IRGGATRAAGVFYPWRFRLLCLLRRWLPRPRAWFIRQELNVTAAAA 286 
SP|Q7Z5J1-5|DHI1L_HUMAN      IRGGATRAAGVFYPWRFRLLCLLRRWLPRPRAWFIRQELNVTAAAA 199 
SP|Q7Z5J1-6|DHI1L_HUMAN      IRGGATRAAGVFYPWRFRLLCLLRRWLPRPRAWFIRQELNVTAAAA 205 
SP|Q7Z5J1-7|DHI1L_HUMAN      IRGGATRAAGVFYPWRFRLLCLLRRWLPRPRAWFIRQELNVTAAAA 152 
 
B 
 
C 
1                                      27 
GVFYPWRFRLLCLLRRWLPRPRAWFIR 
 
Figure S1 Analysis of the hypothetical antimicrobial region at the C-terminus of isoforms 2, 5, 6 and 7 of human 
11-hydroxysteroid dehydrogenase-1 like. Panel A shows a multiple alignment of isoforms 2, 5, 6 and 7 of human 11-
hydroxysteroid dehydrogenase 1 β-like. The region highlighted in yellow has been selected for the analysis shown in 
panel B. Peptide GVF27 is shown in red. Panel B shows an isometric plot of the absolute antimicrobial scores (AS) of 
all the peptides of length between 12 and 40 residues (W12-W40 on the ordinate) in the C-terminus of human 11-
hydroxysteroid dehydrogenase 1 β-like. AS values were calculated using the parameters determined for strain S. aureus 
C623. Colors have been used to highlight scores corresponding to significant hypothetical MIC values, in particular an 
AS > 7 corresponds to a hypothetical MIC lower than 65 µM. Panel C shows the sequence of GVF27 colored 
according to the properties of amino acids (blue, positively charged; green, hydrophobic; grey, glycine and proline). 
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2. Materials and methods 
2.1 Peptide synthesis 
Peptide GVF27 was manually synthesized using the fluorenylmethyloxycarbonyl (Fmoc) solid-phase 
strategy (0.1 mmol). Synthesis was performed on NovaSyn TGA resin (loading 0.25 mmol/g), using all 
standard amino acids. The first amino acid was bound to the resin by treatment with Fmoc-Thr(tBu)-OH 
(5equiv)/MSNT (5 equiv)/MeIm (3.75 equiv) in DCM for 3 h. Fmoc protecting group was removed by 
reaction with 30% piperidine in DMF (3 × 10 min). The amino acids in 10-fold excess were pre-activated 
with HBTU (9.8 equiv)/HOBT (9.8 equiv)/DIPEA (10 equiv) in DMF for 5 min and then added to the resin 
suspended in DMF. The reaction was carried out for 1 h and coupling efficiency was assessed by the Kaiser 
test. The peptide was cleaved off the resin by treatment with a mixture of trifluoroacetic acid 
(TFA)/water/triisopropylsilane (95:2.5:2.5 v/v/v) for 3 h at room temperature. Resin was filtered, and crude 
peptide was precipitated with diethyl ether, dissolved in H2O/ACN solution, and lyophilized. The product 
was purified by preparative RP-HPLC on a Shimadzu system equipped with a UV−visible detector SPD10A 
using a Phenomenex Jupiter Proteo column (21.2 × 250 mm; 4 µm; 90 Å) and a linear gradient of H2O (0.1% 
TFA)/ACN (0.1% TFA) from 20%–80% of ACN (0.1%TFA) in 20 min at a flow rate of 20 mL/min. Identity 
and purity of the compound were assessed by LC/MS using an AGILENT Q-TOF LC/MS instrument 
equipped with a diode array detector combined with a dual ESI source and an Agilent C18 column (2.1 × 50 
mm; 1.8 µm; 300 Å) at a flow rate of 200 µL/min and a linear gradient of H2O (0.01% TFA)/ACN (0.01% 
TFA) from 5%–70% of ACN (0.01% TFA) in 15 min.  
2.2 Antimicrobial activity assays 
Antimicrobial activity of GVF27 peptide was tested against Escherichia coli ATCC 25922, MRSA 
WKZ-2 (methicillin-resistant Staphylococcus aureus), Salmonella enteriditis 706 RIVM, Bacillus globigii 
TNO BM013, Bacillus licheniformis ATCC 21424, Staphylococcus aureus ATCC 29213, Pseudomonas 
aeruginosa PAO1, and Pseudomonas aeruginosa ATCC 27853. Bacteria were grown to mid-logarithmic 
phase in Muller Hinton broth (MHB) at 37°C. Cells were then diluted to 2 x 106 CFU/mL in Difco 0.5X 
Nutrient Broth (Becton-Dickenson, Franklin Lakes, NJ) containing increasing amounts of GVF27 (0,6-40 
µM). Starting from a peptide stock solution, two-fold serial dilutions were sequentially carried out, 
accordingly to broth microdilution method [28]. Following over-night incubation, MIC100 values were 
determined as the lowest peptide concentration responsible for no visible bacterial growth. Similar 
antimicrobial assays to test salt resistant properties of GVF27 have been carried out following the same 
procedure described above and using 0.5X Nutrient Broth medium containing physiological concentrations 
of divalent cations as CaCl2 and MgSO4 (0.265 g/L and 0.097 g/L respectively). 
2.3 Killing kinetics 
To assess the time point of bacterial growth inhibition, killing kinetics with GVF27 were performed. Two 
different peptide concentrations (1 or 10 µM GVF27) were incubated with mid-logarithmic (2×106 CFU/mL) 
E. coli ATCC 25922 or MRSA WKZ-2. At 1, 5, 10, 20, 30, 60 and 120 min, 100 µL aliquots were taken and 
immediately plated on TSA. Additionally, 20 µL aliquots were diluted 10- to 1,000-fold and again 100 µL 
was plated. After 16 h incubation at 37 °C the surviving bacteria were counted. 
2.4 ATP leakage measurements  
 
MRSA WKZ-2 and Escherichia coli ATCC 25922 were grown in Muller Hinton broth (MHB) at 
37°C to mid-logarithmic phase. Bacteria were centrifuged, resuspended in 10 mM phosphate buffer pH 7.0 + 
1:100 MHB and diluted to 2×107 CFU/mL. From each diluted sample, 60 μL of bacterial suspension were 
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incubated with 60 μL peptide solution (0.5 or 2 μM) for 5 min at 37°C. Samples were then centrifuged, the 
supernatant was stored at 4°C until further use, and the bacterial pellet was suspended in lysis buffer and 
further incubated at 100°C. Cell lysates were centrifuged and supernatants were kept on ice. Subsequently, 
both intra- and extracellular ATP levels were determined using the Roche ATP bioluminescence kit HS II 
(Roche Diagnostics Nederland B.V., Almere, the Netherlands), according to the manufacturer's protocols. 
 
2.5 Serum Stability Assays 
 
The proteolytic susceptibility of GVF27 peptide was determined in 50% (v:v) human serum (Lonza, 
Basel, Switzerland). Human serum was previously activated by cooling at 4°C, centrifugation at 13,000 x g 
for 5 min and incubation at 37°C for 10 min in order to eliminate the lipid fraction. Then, 250 µL of serum 
was added to a 250 µL of an aqueous solution of GVF27 at a concentration of 1 mg/mL. The mixture was 
incubated at 37°C and, after 1, 2, 3 and 24 h, samples (25 μL) were centrifuged at 13,000 x g for 5 min and 
the supernatant was added to 75 µL of H2O containing 0.1% TFA and further centrifuged. Supernatants were 
finally analyzed by the analytical Agilent 1200 Series Liquid Chromatograph, equipped with a binary pump 
delivery system, robotic autosampler, column thermostat and multi-wavelength detector. An ET 250/8/4 
Nucleosil 5-C18 column Machery-Nagel column (300 x 4 mm, 5 µm) and a linear gradient of H2O 
(0.1%TFA)/CH3CN (0.1%TFA) from 5 to 70% of CH3CN (0.1%TFA) in 30 min at flow rate of 1 mL/min 
were employed. The experiment was run in duplicate. 
 
 
2.6 Anti-biofilm activity assays 
 
Escherichia coli strain ATCC 25922 was grown over-night in Muller Hinton broth (MHB) and then 
diluted to 1×108 CFU/mL in BM2 medium containing increasing peptide concentrations (0.125-32 µM). 
Incubation with the peptide was carried out either for 4 h, in order to test peptide effects on biofilm 
attachment, or for 24 h, in order to test peptide effects on biofilm formation. When peptide effects on 
preformed biofilm were evaluated, bacterial biofilms were formed for 24 h at 37 °C, and then treated with 
increasing concentrations of the peptide (0.125-32 µM).  In all the cases, at the end of the incubation, the 
crystal violet assay [29] was performed. To do this, the planktonic culture was removed from the wells, 
which were washed three times with sterile PBS prior to staining with 0.04% crystal violet for 20 min. The 
colorant excess was eliminated by three successive washes with sterile PBS. Finally, the crystal violet was 
solubilized with 33% acetic acid and samples optical absorbance values were determined at 630 nm by using 
a microtiter plate reader (FLUOstar Omega, BMG LABTECH, Germany). To determine the percentage of 
viable bacterial cells inside the biofilm structure, upon biofilm disruption with 0,1% Triton X-100, bacterial 
cells were ten-fold diluted on solid TSA and incubated for 16 h at 37 °C. Once evaluated the number of 
colony forming units, bacterial cell survival was calculated as follows: (CFUin treated sample/CFUin untreated sample) x 
100.  
	
 
2.7 Cytotoxicity Assay 
 
Cytotoxic effects of peptide on RAW 264.7 cells were determined using the cell proliferation reagent 
WST-1 (Roche Applied Science, Mannheim, Germany), designed to be used for the spectrophotometric 
quantification of cell proliferation. Briefly 5×104 cells were seeded into a 96-well plate and incubated at 37°C 
with 5% CO2. Medium was then replaced with 100 μL of fresh media containing peptide solution to a final 
concentration ranging from 0–40 μM/well. After 24 h of incubation at 37°C, the peptide-containing medium 
was removed, and 100 μL of fresh medium containing 10% WST-1 reagent was added to each well and 
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incubated for 30 min at 37°C in the dark. Subsequently, the absorbance was measured in a microtiter plate 
reader (FLUOstar Omega, BMG labtech) at 450 nm, using 650 nm as the reference wavelength. 
 
2.8 Hemolytic Assay 
 
EDTA anti-coagulated mouse blood was centrifuged for 10 min at 800 × g (20°C) to sediment the 
red blood cells. Pelleted RBCs were washed three times and diluted 200-fold in PBS. In 96-well 
polypropylene plates, 75 μL of serial peptide dilutions (0–80 μM) were mixed with an equal volume of RBC 
suspension and incubated for 1 h at 37 °C. PBS served as baseline and a 0.2% (v/v) Triton X-100 solution 
served as a control for complete lysis. Supernatants, collected after 10 min centrifugation at 1300 × g (20°C), 
were transferred into polystyrene 96-wells plates and absorbance was measured at 405 nm. Hemolysis (%) 
was calculated as follows: ((APeptide −ABlank)/(ATriton − ABlank)) × 100. 
 
 
2.9 Measurement of nitric oxide production  
 
Nitric oxide production was assessed as the accumulation of nitrite (NO2−) in cell supernatants as a result of 
24 h incubation period. Nitrite concentrations were determined by a colorimetric reaction using the Griess 
reagent. Briefly, cell culture supernatants were mixed with an equal volume of 1% sulfanilamide (dissolved 
in 2.5% phosphoric acid) and incubated for 5 min. The same volume of 0.1% N-(1-naphthyl) 
ethylenediamine dihydrochloride was added and incubated for 5 min. The absorbance was measured at 520 
nm using a 96-well microplate reader (FLUOstar Omega, BMG labtech). 
 
 
2.10 Inhibition of IL-6 production mediated by GVF27 
 
The ability of the peptide to modulate cytokine production in RAW 264.7 cells was measured by 
ELISA (enzyme-linked immunosorbent assay). Cells (5×104 cells/well) were seeded into 96-wells microtiter 
plates. The next day, culture medium was discarded and replaced with fresh medium either containing 1)  a 
mixture of peptide (5 or 20 µM) and 50 ng/mL LPS (co-incubation) or 2) peptide alone (5 or 20 µM) for an 
initial incubation of 2 h followed by addition of 50 ng/mL LPS from Salmonella Minnesota (pre-incubation) 
or, 3) 50 ng/mL LPS for an initial incubation of 2 h followed by addition of peptide (5 or 20 µM, post-
incubation). In all the cases, culture supernatants were collected after a total of 24 h incubation time. After 
each initial incubation with either LPS or peptide, the cells were washed three times with PBS prior to the 
subsequent addition of peptide or LPS to remove any residual traces of agents used during the pre-
incubation. Expression levels of mouse IL-6 were measured using the commercial available DuoSet ELISA 
kits (R&D Systems), following the protocols provided by the manufacturer. All samples were centrifuged 
briefly at 5,000 rpm for 3 min at room temperature to remove cell debris prior to use. Microtiter plates were 
read at 450 nm using 550 nm as a reference wavelength to correct optical imperfections of the microtiter 
plate.  
 
2.11 LPS binding assay 
The ability of GVF27 to neutralize LPS was determined using the commercially available Limulus 
amebocyte lysate (LAL) assay (Pierce® LAL Chromogenic Endotoxin Quantitation Kit, Thermo Scientific, 
USA) [30]. Briefly, 25 µL of serially diluted peptide (25,12.5, 6.25 µM) was added to 25 µL of 0.5 U/ml E. 
coli O11:B4 LPS for 30 min at 37 °C, followed by incubation with 50 µL of amoebocyte lysate reagent for 
10 min. Absorbance at 405 nm was measured 10 min after the addition of 100 µL of the chromogenic 
User  5/4/y 15:57
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substrate, Ac-Ile-Glu-Ala-Arg-p-nitroanilide. The amount of non-bound LPS was extrapolated from a 
standard curve, and percentage inhibition calculated as: [(amount of free LPS in control samples) − (amount 
of free LPS in test samples)] × 100/amount of free LPS in control samples. 
2.12 Spectroscopic studies 
CD spectra of GVF27 were recorded with a J-810 spectropolarimeter equipped with a Peltier 
temperature control system (Model PTC- 423-S, Jasco Europe, Cremella, LC, Italy). Far-UV measurements 
(190–260 nm) were carried out at 20° C using a 0.1 cm optical path length cell and a peptide concentration of 
25 µM. CD spectra were recorded as described elsewhere [31,32]. Baseline was corrected by subtracting the 
complete buffer spectrum. CD spectra were carried out in the presence of LPS from Pseudomonas 
aeruginosa strain 10 (Sigma, purified by phenol extraction) and from P.	 aeruginosa clinical strain KK27 
(kindly provided by Prof. De Castro). Further analyses were carried out in the presence of lipotechoic acid 
from Staphylococcus aureus (LTA, Product Number L 2515, Sigma). All measurements were recorded using 
different concentration of each compound (from 0.05 to 1.0 mg/mL). Baseline was corrected by subtracting 
the spectrum of both LPS and LTA alone at the same concentration. Additional CD spectra were performed 
using different concentrations of trifluoroethanol (TFE) (0-40%). Deconvolutions of CD spectra were 
obtained using the web-based program CdPro (http://lamar.colostate.edu/~sreeram/CDPro/). 
Fluorescence experiments were carried out under the same conditions used for CD analyses. 
Fluorescence spectra were collected at 20°C using a Varian Cary Eclipse spectrophotometer at λ excitation 
of 295 and 280 nm, a 1.0 cm path length cell at 5 εem and 5 εex. Emission spectra (300-400 nm) were 
collected in the presence of 40% TFE, 5 mg/mL LPS or 10 mg/mL LTA. 
 
 
2.13 LPS micelles measurements by using dynamic light scattering (DLS) 
To estimate the average size of the LPS particles, the Hydrodynamic Radii (RH) was measured by 
Dynamic Light Scattering technique (DLS). DLS measurements were carried out using a Zetasizer Nano ZS 
(Malvern Instruments, Westborough, MA) equipped with a 173° backscatter detector, at 25 °C, using a 
disposable sizing cuvette. DLS measurements in triplicate were carried out on aqueous LPS and LTA 
samples at 0.5 mg/mL. Data were analyzed using the Software of OMNISIZE (Viscotek). LPS and LTA size 
measurements were performed before and after peptide addition (0.5 mg/mL).  
 
2.14 Nuclear magnetic resonance spectroscopy 
 
NMR experiments were recorded at 25 °C on a Varian Unity INOVA 600 MHz NMR spectrometer 
equipped with a cold probe. Two-dimensional (2D) nuclear Overhauser effect spectroscopy (NOESY), total 
correlation spectroscopy (TOCSY) and 2D double-quantum-filtered correlated spectroscopy (DQFCOSY) 
experiments were recorded [33]. NOESY mixing times were 200 ms and TOCSY mixing times were 70 ms. 
These experiments were collected with 512 and 1024 complex points with acquisition times of 64 and 128 
ms in the indirectly and directly acquired 1H dimensions, respectively. The DQFCOSY experiment was 
collected with 1024 and 2048 complex points and acquisition times of 128 and 256 ms in the indirectly and 
directly acquired 1H dimensions, respectively. In all experiments water suppression was obtained using pre-
saturation in order to simultaneously suppress the hydroxyl protons from TFE that are in fast exchange with 
protons from water. Hydroxyl protons from TFE were seen to attenuate signals in both 1D and 2D datasets in 
WATERGATE based suppression. 1D spectra were analyzed using ACD/NMR Processor 12.0 (ACD/NMR 
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Processor Freeware, Version 12.01 Advanced Chemistry Development, Inc., Toronto, ON, Canada (2012), 
www.acdlabs.com). 2D TOCSY and NOESY spectra for 1H chemical shift assignment were analyzed using 
Neasy, a tool available in CARA (Computer Aided Resonance Assignment) software (Keller, R. L. J. The 
Computer Aided Resonance Assignment Tutorial.  CANTINA Verlag, 2004, downloaded from cara.nmr.ch). 
Structure calculation was performed with the program CYANA version 2.1 [34]. The NOE cross peak 
intensities were used to obtain distance constraints. The angle restraints were derived from 3JHNHα 
coupling constants. Structure calculations were initiated from 100 random conformers; the 20 structures with 
the lowest CYANA target function ns were analyzed with the programs MOLMOL [35] and PyMOL 
Molecular Graphics System, Version 1.8 Schrödinger, LLC. (http://www.pymol.org/). 
 
2.15 Statistics 
 
Results are presented as the mean ± standard error of the mean (SEM) of at least three independent 
experiments. Statistical significance was assessed using one-way ANOVA in Prism software, version 6.02 
(GraphPad Prism, La Jolla, CA, USA).  All samples were compared to the negative control. *p < 0.05; 
**p < 0.01; ***p < 0.001. 
 
3. Results  
 
3.1 Antibacterial activity  
 
The antibacterial effectiveness of synthetic GVF27 (see Methods) was determined by measuring its 
MIC values on a panel of Gram-negative and Gram-positive strains (Table 1). All GVF27 MIC values are 
comparable to those observed for control peptide CATH-2 [36,37] both on Gram-negative and Gram-
positive strains (Table 1). In order to verify salt resistant properties of GVF27, MIC values were  determined 
also in the presence of physiological amounts of divalent cations (see Methods). As shown in Table S1, MIC 
values determined in the presence of divalent cations were practically identical to those obtained in NB (see 
Table 1 and S1), thus indicating that antimicrobial properties of GVF27 are not affected by the different 
experimental conditions tested. When the killing rate of GVF27 was measured, none of the strains analyzed 
(MRSA WKZ-2 and E.coli ATCC 25922) survived after 2 h at 10 µM peptide doses (see Figure S2).  
 
 
GRAM POSITIVE                                                              
STRAINS 
 
GVF27
 
 
CATH-2 
 
GRAM NEGATIVE                                                              
STRAINS 
 
GVF27 
 
 
 
CATH-2
MIC values (µM) MIC values (µM) 
 
MRSA 
WKZ-2 
 
5 
 
10 
 
 
E. coli 
ATCC 25922 
 
10 
 
10 
 
B. globigii  
TNO BMO13 
 
5 
 
5 
 
P. aeruginosa  
ATCC 27853 
 
10 
 
10 
 
B. licheniformis 
ATCC 21424 
 
5 
 
20 
 
P. aeruginosa  
PAO1 
 
20 
 
20 
 
S. aureus  
ATCC 29213 
 
5 
 
10 
 
S. enteriditis  
706 RIVM 
 
 
10 
 
10 
  
Table 1 Minimum Inhibitory Concentration (MIC, µM) values of GVF27 peptide, compared to those obtained 
for chicken cathelicidin-2 (CATH-2), against a panel of Gram-positive and Gram-negative bacteria. Values were 
obtained from a minimum of three independent trials.  
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GRAM POSITIVE                                                              
STRAINS 
 
0.5X NB
 
 
0.5X NB +
cations 
 
GRAM NEGATIVE                                                              
STRAINS 
 
0.5X NB 
 
 
0.5X NB + 
cations 
MIC values (µM) MIC values (µM) 
 
MRSA 
WKZ-2 
 
5 
 
10 
 
 
E. coli 
ATCC 25922 
 
10 
 
10 
 
B. globigii  
TNO BMO13 
 
5 
 
5 
 
S. enteriditis 
 706 RIVM 
 
 
10 
 
40 
 
 
 
Table S1 Minimum Inhibitory Concentration (MIC, µM) values of GVF27 peptide, tested in different media, 
against a panel of two Gram-positive and two Gram-negative bacteria. Values were obtained from a minimum of 
three independent trials.  
 
 
 
Figure S2	Antibacterial activity rate of GVF27, evaluated by colony count assay, against MRSA WKZ-2 and 
Escherichia coli ATCC 25922. 	
	
One of the mechanisms through which HDPs kill bacterial cells is by forming pores into biological 
membranes, resulting in the leakage of small molecules [38, 39]. We tried to collect data on the mechanism 
of the antibacterial activity of GVF27 by measuring ATP levels in the media in which bacterial cells are 
grown in the presence of the peptide. In fact, in bacterial cells intracellular ATP concentration is maintained 
constant and the release of ATP into the environment can be detected by chemiluminescence, which 
indicates the disruption of the cell membrane. Thus, we performed an assay to detect ATP leakage using two 
bacterial strains, E. coli and MRSA, treated with two different doses of GVF27 for 20 min (see Methods). As 
shown in Figure 1 (panels A and B), the presence of ATP in the culture media is evident. Thus, we can 
confidently conclude that GVF27 has a lytic effect both on MRSA WKZ-2 and on E.coli cells, with MRSA 
WKZ-2 cells being particularly sensitive to the peptide. As it is shown in Figure 1, GVF27 induced in 
MRSA WKZ-2 cells a release of 70% ATP at a concentration of 0.5 µM. To obtain the same degree of ATP 
leakage in E. coli cells it was necessary a higher concentration of GVF27.  
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Figure 1. GVF27-induced ATP leakage in Escherichia coli ATCC 25922 (A) and MRSA WKZ-2 (B) after 
treatment with 0.5 or 2 μM GVF27. The assays were performed in three independent experiments.  
	
Bacteria mainly exist as multicellular aggregates embedded within a self-produced extracellular 
polymeric matrix. In this condition, known as biofilm, growing microbial cells are physiologically distinct 
from planktonic cells. As natural HDPs have emerged as promising anti biofilm candidates to be used as an 
alternative to conventional antibiotics, we evaluated if GVF27 is endowed with anti-biofilm activity by 
performing experiments on E. coli ATCC 25922 in BM2 medium. E. coli was grown over-night, diluted in 
BM2 medium containing increasing concentrations of the peptide (from 0,125 to 32 µM), and then incubated 
for 24 h, at 37˚C. Following incubation, the analysis of biofilm production by crystal violet staining revealed 
a dose-dependent inhibition of biofilm formation, with about 90% inhibition at the highest concentration of 
peptide tested (Figure 2A). We also collected data that would indicate that GVF27 peptide exerts a 
significant effect on biofilm attachment. To investigate this, we followed the experimental procedure 
described above with the only exception that bacterial cells were incubated with increasing concentrations of 
peptide for 4 h, at 37°C. Also in this case, we observed a dose-dependent inhibition of biofilm attachment, 
with almost total inhibition at 32 µM peptide concentration (Figure 2A). Interestingly, GVF27 was found to 
exert significant effects also on preformed biofilms. This was evaluated by incubating preformed biofilm 
(see Methods) with increasing concentrations of the peptide for 24 h, at 37°C. At the highest peptide 
concentration tested, we observed a significant (∼20%) reduction of the preformed biofilm (Figure 2A). 
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Figure 2. A. Biofilm inhibitory activity of GVF27 against E. coli strain in BM2 medium. The effects of increasing 
concentrations of GVF27 peptide were evaluated either on biofilm formation, biofilm attachment, or on pre-formed 
biofilm. Biofilm was stained with crystal violet and measured at 630 nm. Shown are mean + SD values of three 
independent experiments. B. Effects of increasing concentrations of GVF27 peptide on the viability of E. coli 
ATCC 25922 bacterial cells inside the biofilm structure. Cell viability was assessed by colony counting assay and 
expressed as the percentage of viable bacterial cells in treated samples with respect to the control untreated sample. 
Shown are mean + SD values of three independent experiments. 
 
A  
B  
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Experiments	
Biofilm	formation	 Biofilm	attachment	 Pre-formed	biofilm	
Peptide	
[µM]	
p-value	 Peptide	
[µM]	
p-value	 Peptide	
[µM]	
p-value	
0,125	 0,476	 0,125	 0,449	 0,125	 0,189	
0,25	 0,349	 0,25	 0,160	 0,25	 0,137	
0,5	 0,662	 0,5	 0,424	 0,5	 0,144	
1	 0,137	 1	 0,463	 1	 0,085	
2	 0,647	 2	 0,509	 2	 0,102	
4	 0,249	 4	 0,383	 4	 0,128	
8	 0,059	 8	 0,087	 8	 0,105	
16	 0,027	 16	 0,023	 16	 0,082	
32	 0,016	 32	 0,025	 32	 0,027		
Table S3 P-values obtained for the experiments showed in Figure 2A 
 
 
In all cases, we also evaluated the percentage of viable bacterial cells inside the biofilm by colony 
counting assay. We found (Figure 2B) an almost total reduction of bacterial viability when 32 µM GVF27 
was added prior to biofilm attachment, a significant reduction (90%) when it was added prior to biofilm 
formation and a reduction of about 50% when the peptide was tested on pre-formed biofilm.  
	
3.2 Cytotoxicity assays of GVF27 on eukaryotic cells 
 
As already reported [38, 39], the promising interest in the use of HDPs stems from their selective 
action on bacterial cells. We thus studied the cytotoxic effect of GVF27 towards mouse macrophages and 
erythrocytes. The addition of increasing concentrations (from 0.6 to 40 μM) of GVF27 to mouse 
macrophages RAW 264.7 cells  for 24 h did not result, in any significant reduction in cell viability (Figure 
S3A). The same peptide concentrations were tested also on mouse erythrocytes to detect any hemolytic 
activity of GVF27. As shown in Figure S3B , the peptide did not exert any lytic effect on mouse red blood 
cells, even at the highest concentration tested. The cytotoxicity of GVF27 was also measured against human 
keratinocytes (HaCat) and on human cervical cancer cells (HeLa). In all cases, no significant cytotoxicity 
was ever observed (data not shown). It should be underlined that GVF27 is toxic to bacterial cells (Table 1, 
figures S2, 1 and 2) at concentrations similar to that used in the cytotoxicity assays described above. 
Moreover, it should be noted that all the experiments mentioned above were carried out after an incubation 
time of 24 h, since the analysis of GVF27 stability in serum (see Methods) indicated that peptide degradation 
was almost complete after 24h (see Table S2).   
 
 
 
 
 
 
 
 
Table S2 Analysis of serum stability of GVF27 by RP-HPLC (see Methods) 
Time	(hour)	 Area	%	0	 100	1	 63	2	 41	3	 30	24	 6	
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Figure S3 Cytotoxicity of GVF27 on eukaryotic cells. A) Effect of GVF27 on the viability of mouse macrophages 
RAW 264.7. B) Hemolytic activity of GVF27 on mouse erythrocytes. In both experiments the mean values ± SD 
from three independent experiments run in triplicate are shown.  
 
3.3 Conformational studies of GVF27  
 
3.3.1 Circular Dichroism and Fluorescence  
Structural analysis by CD spectroscopy provides a qualitative picture of the structural elements that 
are present in a given peptide. Far-UV CD spectra indicate that GVF27 is largely unstructured both in water 
and in 10 mM Hepes pH 7.4. On the contrary, it is structured in 40% TFE (Figure 3). This behavior can be 
observed also for other HDPs [40, 41], all prone to assume a specific conformation when interacting with 
membrane-mimicking agents like TFE. Moreover, deconvolution data (see Methods) reported in Table 2, 
indicate that structured GVF27 adopts a predominant helical structure (approximately of ≈ 50%).  
 
 
Figure 3: Far UV CD of GVF27 in the presence of increasing concentrations of TFE 
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	 % α -helical	 %	β -strand	 %	coil	
GVF27	 18.2	 24.0	 57.8	
GVF27	-	40	%TFE	 52.6		 7.2		 40.2		
GVF27	-	0,4	mg/mL	LPS	from	
Pseudomonas	aeruginosa	
strain	10	
30.8		 18.6		 50.6		
GVF27	-	0,4	mg/mL	LPS	from	
Pseudomonas	aeruginosa	
strain	KK27	
32.1		 12.3		 55.5		
GVF27	-	LTA	0,4	mg/mL	 33.0		 19.5		 47.5		
 
Table 2: Secondary structure content of GVF27, calculated by means of CDPRO program.  
 
To further characterize structural properties of GVF27, the interaction with LPS and LTA, the main 
constituents of the cell wall of Gram negative and positive bacteria, respectively, was analyzed. CD spectra 
in the presence of LPS isolated from two different P. aeruginosa strains (strain 10 and clinical isolate KK27 
strain) are shown in Figure 4 (panels A and B).  
GVF27 spectrum in water has a minimum at around 205 nm, indicating that the peptide is in a 
disordered conformation. Instead, in the presence of LPS (Fig. 4A-B), the peptide spectra present two 
minima centered around 210 and 225 nm, suggesting that in both cases it is able to assume a helical 
conformation upon interaction. The deconvolution data (Table 2) confirm that both LPSs induce a similar 
increase in the amount of helical structure (about 31-32%) but with slightly different amounts of beta and 
coil structure. 
CD spectra, acquired in the presence of LTA, (Figure 4C), showed a relatively flat shape minimum 
centered at 215 nm, due to the presence of significant amounts both of alpha and beta structures as shown by 
deconvolution data (Table 2).    
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Figure 4 Far UV CD of GVF27 in the presence of increasing concentrations of LPS from P. aeruginosa 10 (A), 
from P. aeruginosa KK27 (B) and of LTA from Staphylococcus aureus (C) 
C 
B 
A 
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Spectrofluorimetric data were also collected to investigate if the interaction of GVF27 with LPS and 
LTA could influence the tertiary structure of the peptide based on the presence in the sequence of three Trp 
residues (see Fig. S1). Fluorescence spectra were recorded upon excitation at 280 nm and 295 nm and 
showed (see Fig. S4) that the interaction of the peptide with LPS, LTA, and TFE results in a blue shift of the 
wavelength of the maximum of emission, indicating that GVF27 folds upon interaction with LPS or LTA, in 
agreement with CD data. However, in the presence of TFE a less marked effect was observed. 
 
 
 
 
Figure S4 Tryptophan fluorescence spectra for GVF27 in H2O and in the presence of TFE (40%), LPS (0,5 
mg/mL) and LTA (1 mg/mL). 
	
3.3.2 Structural characterization by NMR  
 
A deeper investigation of the conformational preferences of peptide GVF27 was performed by NMR 
spectroscopy. In order to investigate the influence of the environment experienced by a membrane-
interacting peptide on the structure, the NMR study was carried out both in bulk water, simulating the 
transport fluid, and in 30% TFE-d3/H2O) 30:70 (v/v) mixture, which reduces solvent polarity. The 
comparison of 1D spectra under these two conditions, reported in Figure 5A (upper and lower trace for water 
and TFE/water mixture respectively) reveals that in the less polar environment the dispersion of the chemical 
shift is higher. This is confirmed by the comparison of the 2D NOESY spectra, reported in the panel B and C 
respectively, showing also a higher number of cross-peaks in the presence of TFE. Then, NMR 
characterization of GVF27 was performed in TFE-d3/H2O 30:70 (v/v) mixture at 298K. The standard 
sequential assignment approach based on homonuclear 2D 1H NMR [42] allowed the complete sequence 
specific 1H NMR assignment (Table 3). Particularly, identification of spin systems and resonance 
assignment were established by a combination of two-dimensional DQF-COSY and TOCSY spectra, 
whereas sequence-specific assignment was obtained by NOESY experiments. 
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Residue NH αH βH γH Others 
Gly1 7.97 3.70    
Val2 8.10 3.99 1.95 0.96  
Phe3 7.90 4.58 2.92  2,6H 7.32; 3,5H 7.24 
Tyr4 7.58 4.48 2.67  2,6H 6.95; 3,5H 6.73 
Pro5  4.32 2.13; 1.98 1.89 δCH2 3. 45 
Trp6 7.68 4.32   2H 7.23; 4H 7.57; 6H 7.20; 
7H 7.52; NH 10.02 
Arg7 8.03 4.09 1.74  δCH2 2.84 
Phe8 7.76 4.59 2.88  2,6H 7.22; 3,5H 7.34 
Arg9 7.86 3.85 1.60; 1.48 1.62 δCH2 2.95 
Leu10 7.74 3.96 1.74 1.50 δCH3 0.85 
Leu11 8.37 3.93 1.73 1.45 δCH3 0.91 
Cys12 7.56 4.58 3.00   
Leu13 7.85 3.88 1.65 1.48 δCH3 0.82 
Leu14 7.53 4.08 1.83 1.54 δCH3 0.93 
Arg15 7.57 3.94 1.71   
Arg16 7.55 4.00 1.89 1.71 δCH2 3.33 
Trp17 7.26 4.36 3.24; 3.00  2H 7.13; 4H 7.35; 6H 7.11; 
7H 7.22; NH 9.89 
Leu18 7.72 3.97 1.58 1.40 δCH3 0.90 
Pro19  4.21 2.40; 2.24 1.88 δCH2 3. 55 
Arg20 8.08 4.13 1.65 1.48 δCH2 3.03 
Pro21  4.23 2.40; 2.19  δCH2 3. 36 
Arg22 7.88 4.27 1.79 1.54 δCH2 3.06 
Ala23 7.25 4.16 1.27   
Trp24 7.46 4.32 3.26; 3.19  2H 7.02; 4H 7.31; 6H 7.07; 
7H 7.20; NH 9.99 
Phe25  4.41 2.78; 2.64  2,6H 7.00; 3,5H 6.80 
Ile26 7.45 4.02 1.67 1.20 γCH3 0.93; δCH3 0.78 
Arg27 7.32 4.32 1.53;1.28  δCH2 2.98 
 
 
Table 3: Proton chemical shifts (ppm) of GVF27 in TFE-d3/H2O (30:70) at 298 K 
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Figure 5. NMR conformational analysis. A) Superposition 1H-NMR spectrum of GVF27 in water (upper) and in 
water/TFE mixture (lower).  B) 2D [1H, 1H] NOESY spectrum of GVF27 in water at 298 K and pH 7.0 and C) in 
water/TFE mixture at 298 K and pH 7.0  
 
The values of the deviation of Hα chemical shifts (ΔδHα) analysis performed by using Chemical 
Shift Index (CSI) (Figure S5) [43] and the 3JHN-Hα couplings (Figure S6) indicate the presence of a 
random coil structure in aqueous solution. On the other hand, GVF27 shows a significant change in the 1H 
chemical shifts and in3JHN-Hα coupling values when TFE is added, suggesting that the entire polypeptide 
chain is involved in a conformational transition. Indeed, the ΔδHα and the 3JHN-Hα coupling values indicate 
a high helical propensity of the entire polypeptide chain. Further, the 2D [1H, 1H] NOESY analysis showed 
several HN–HN (i, i+1), Hα–HN (i, i+3), and Hα-Hβ (i, i+3) connectivities (see Figure S7), confirming the 
presence of a helical conformation, in agreement with the trend suggested by the CSI analysis based on Hα 
and with CD data. 
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Figure S5. Hα chemical shift difference (ΔδHα) plotted for 27 residues of GVF27 in water (red) and in TFE-
d3/H2O 30:70 (blue) at 298 K and pH 7.0. Negative ΔδHα (ΔδHα ≥ 0.10 ppm) are indicative of helical 
conformation.   
 
Figure S6. Observed values of the 3JHNHα couplings for the peptide GVF27 in water (red) and TFE-d3/H2O 
30:70 (blue) mixture plotted against the residue number. Typical values of 3JHNHα are 4 Hz for a α-helix, 9 Hz 
for a sheet and 7 Hz for a random coil structure. 
A set of 267 (119 intra-residual, 88 sequential and 66 medium and long-range) experimental NOE 
constraints (Table 4) was used as upper limits of inter-proton distances for structure calculations by CYANA 
program [34]. The backbone overlay of the best 20 CYANA conformers displays a good convergence 
confirmed by a backbone and all heavy atoms root-mean-square difference (rmsd) values of 0.19±0.10Å and 
1.24±0.15 Å respectively (Figure 6). Apart from some dynamic fraying at the N-terminus, the calculated 
structures comprise a regular α-helix, in agreement with the NOE data, H-bonding (Table 5) and the pattern 
of φ/ψangles (Figure S7). 
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No. of the distance restraints  
   Unambiguous NOE 267 
   Ambiguous NOE 91 
   Total NOE 358 
Divided into  
   Intra-residue NOE 119 
   Sequential NOE 88 
   Medium- and Long- range NOE 60 
Residual NOE violations  
   Number>0.1°  
   Maximum, Å 
 
±1 
0.16±0.06 
Residual angle violations  
   Number>2.0°  
   Maximum, Å 
 
0±0 
0 
R.m.s.d (Å) a  to a mean structure  
   Backbone (residues (5-20) 0.19 ±0.10 
   Heavy atoms (residues (5-20) 1.24±0.15 
Ramachandran plot residues (%)b  
   In most favored regions 62.1 
   In additional allowed regions 27.3 
   In generously allowed regions 10.6 
   In disallowed regions 0.0 
  
 
Table 4: CYANA structural statistic of GVF27 in TFE-d3/H2O (30:70) 
	
	
	
	
	
Number Residue Atom Number Residue Atom Distance (Å) 
7 Arg HN 3 Phe O 1.97 
11 Leu HN 7 Arg O 2.20 
13 Leu HN 9 Arg O 1.94 
14 Leu HN 10 Leu O 1.92 
22 Arg HN 18 Leu O 2.10 
23 Ala HN 19 Pro O 1.99 
24 Phe HN 21 Pro O 1.95 
	
	
Table 5: Observed and calculated average hydrogen bond lengths for GVF27 in TFE-d3/H2O (30:70) 
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Figure	S7:	Ramachandran	plot	for	the	GVF27	mean	structure	in TFE-d3/H2O 30:70 mixture.	
 
 
Figure 6:  NMR structures of GVF27 in TFE-d3/H2O 30:70 mixture at 298 K A) Backbone superposition of the 20 
energy-minimized structures and B) Ribbon model of a representative structure 
 
 
3.4 GVF27 assembles LPS aggregates 
 
DLS is a well-known technique used to measure Brownian motion (diffusion) and size distribution 
of particles in solution. For this reason DLS experiments were used to investigate whether peptide GVF27 
may alter the size of micelles of LPS and LTA (above their critical micelle concentration). In both cases 
GVF27 displayed an associating action, promoting the formation of larger aggregates. In particular, the data 
indicate that LPS from Pseudomonas is poly-dispersed in solution with major size-populations having a 
hydrodynamic radius centered at about 40 nm (Figure 7). Incubation of LPS with GVF27 causes a shift of 
the average size of LPS micelles to a higher value centered at about 260 nm. On the other hand, when the 
peptide was incubated with LTA, a mean diameter of 100 nm of the aggregates was observed, indicating a 
weaker potency of GVF27 in associating LTA aggregates. 
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It can be hypothesized that this aggregation action, already observed for other antimicrobial peptides 
[44], may be part of a LPS neutralization mechanism, inhibiting the interaction of LPS with its cell receptors, 
with the concomitant blocking of cytokine production and release [45].   
 
 
Figure 7: Effect of GVF27 on the structural organization of LPS or LTA micelles. Light scattering of LPS from P. 
aeruginosa 10 (top) or LTA (bottom) before and after incubation with the peptide 
 
 
3.5 Anti-inflammatory properties of GVF27  
Data above would indicate that GVF27 is able to assume specific conformations in the presence of 
mimic membrane agents, LPS and LTA, as well as to induce aggregation of LPS, and to a lesser extent of 
LTA. As it is has been already reported that several HDPs are able to mitigate up-regulation of LPS-induced 
pro-inflammatory mediators and cytokines [7, 46,47], it seemed interesting to verify if GVF27 could possess 
also putative anti-inflammatory properties. To collect data on possible anti-inflammatory properties of 
GVF27, nitric oxide production and interleukin Il-6 release by murine macrophages RAW 264.7 treated with 
GVF27 and LPS were analyzed. 
Nitric oxide (NO) plays diverse roles in biological systems: it is a mediator of vasodilatation, platelet 
aggregation and neurotransmission, and regulates function, death and survival of various cell types including 
many of those involved in immunity and inflammation [48, 49].  
To study the effect of GVF27 on NO production in LPS activated RAW 264.7 cells, we performed 
three types of treatments: 1. medium containing a mixture of peptide (5 or 20 µM) and 50 ng/mL LPS;  
medium containing peptide alone (5 or 20 µM) for an initial incubation of 2 h followed by addition of 50 
ng/mL LPS from Salmonella Minnesota; 2. medium containing 50 ng/mL LPS for an initial incubation of 2 h 
followed by addition of peptide (5 or 20 µM). In all the cases, culture supernatants were collected after 24h. 
As shown in Figure 8A, GVF27 exerts a strong dose-dependent attenuation of the production of NO when 
co-incubated with 50 ng/mL LPS. Conversely, when we performed a pre-incubation of RAW 264.7 cells 
with peptide and subsequently we induced LPS stimulation, the effect of GVF27 on NO production was not 
significant (Figure 8A). Similarly, when RAW 264.7 cells were pre-incubated with LPS and subsequently 
treated with 5 or 20 µM of GVF27, we revealed a slight dose dependent reduction of NO production (Figure 
8A).  
Cytokines are small proteins (about 25 kDa) released by many cell types, usually after an activation 
signal, and they induce a response by binding specific receptors. IL-6 is a monomer produced by T cells, 
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macrophages and endothelial cells. It is able to determine growth and differentiation of B and T cells, and the 
production of acute phase proteins, like C-reactive protein [50].  
When we analyzed the effect of GVF27 on RAW 264.7 cells by ELISA (see Methods), following the 
same scheme used in the NO production assay, we revealed a strong inhibitory effect exerted by the peptide 
on the secretion of IL-6 when the macrophages were co-incubated for 24 h with GVF27 (5 or 20 µM) and 50 
ng/ml LPS (see Figure 8B). Moreover, we found that GVF27 was also able to exert a significant dose 
dependent protective effect on cells. Indeed, as shown in Figure 8B (on the center), when RAW 264.7 cells 
were pre-treated for two hours with 5 or 20 µM GVF27 and then incubated for an additional 22h with 50 
ng/ml LPS, we observed a reduction of the IL-6 secretion, indicating a prolonged peptide effect. When cells, 
were pre-incubated with LPS and then subjected to the action of the peptide (see Figure 8B – on the right), 
still we were able to observe a reduction in IL-6 secretion, although the LPS-induced secretion itself was 
already low due to the very short LPS incubation time in this set-up Collectively, these data indicate that 
GVF27 is able to exert an intriguing anti-inflammatory effect on LPS treated cells.   
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Figure 8 (A) Effect of GVF27 on NO production in LPS induced mouse macrophages RAW 264.7.. (B) 
Effect of GVF27 on IL-6 release in LPS induced mouse macrophages RAW 264.7 LPS extracted from 
Salmonella minnesota was assayed at a final concentration of 50 ng/mL  (see methods). All experiments 
were carried out for a total incubation time of 24 h. 
 
Finally, the ability of GVF27 to bind LPS, was further confirmed by a different approach using the 
chromogenic LAL (Limulus amaebocyte lysate) assay [51] Three different concentrations of GVF27 (6.25 - User  5/4/y 16:05
Eliminato: 46
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12.5 – 25 μM) were incubated for 30 minutes at 37 °C with LPS from Escherichia coli 011:B4 following 
manufacturer instructions. As shown in Figure S8, a concentration of 12.5 μM GVF27 was enough to 
neutralize about 40% of LPS whereas the presence of 25 μM GVF27 completely neutralized LPS thus 
supporting the hypothesis that GVF27 might act in a dose-dependent manner as a scavenger of Gram 
negative’s LPS (Figure S8). 
	
	
Figure S8 Neutralization LPS in the presence of GVF27. Peptide was incubated with the endotoxin (0.25 
units/mL) for 30 min and the amount of free endotoxin quantified by LAL assay (see methods). 
 
4. Discussion  
Host defense peptides (HDPs) are important modulators in both mammalian and non-mammalian 
systems to prevent microbial colonization and tissue damage [52]. In mammals, such peptides constitute the 
major proportion (over 10% of total protein) among immune cells involved in immediate defense against 
aggressive microbes as well as in acute inflammatory reactions [53]. HDPs beneficial effects may encompass 
direct antimicrobial activity, binding to and inactivating endotoxins, such as LPS or LTA, which reduce the 
detrimental pro-inflammatory response, and one or more direct effects on cellular behaviors, such as 
enhanced migration and proliferation. The majority of HDPs share common biochemical features, including 
relatively small size, cationicity and amphipathicity in membrane-mimicking environments. These features 
allow them to selectively interact with and damage bacterial membranes.  
A number of human proteins, whose primary functions are not necessarily related to host defense, 
contain HDPs hidden inside their sequence [54-55, 40]. Our group has established a bioinformatic procedure 
(manuscript submitted) through which it is possible to identify host defense peptides in precursor protein 
sequences and predict their strain dependent antimicrobial propensities. By using this tool to analyze about 
4,000 human secreted proteins, a cryptic peptide has been identified in human 11-hydroxysteroid 
dehydrogenase-1 β-like (accession number UniProtKB: Q7Z5J1), here named GVF27, with potent 
antimicrobial activity (see Fig. S1).  
The experiments described in this paper confirm that GVF27 peptide exhibits antibacterial activities, 
with MIC values comparable to that of a well studied cathelicidin, against a broad spectrum of both Gram-
positive and -negative strains. Interestingly, its antibacterial properties are not limited to planktonic cells but 
are significant also on sessile bacteria forming biofilm. Indeed, here we provide evidences that GVF27 
inhibits biofilm formation, as well as it is able to eradicate existing mature biofilm in a dose dependent 
manner. In addition, GVF27 is also able to induce a strong reduction of viable sessile bacterial cells. This 
suggests that our peptide presents affinity for biofilm components, presumably extracellular DNA and/or 
polysaccharides, but also retains its ability to attack bacterial membranes due to its amphipatic properties. 
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This clearly confers to the peptide a relevant potential as an anti-biofilm agent alternative to conventional 
antibiotics, the latter almost totally ineffective against microbes encapsulated in biofilm.  
A crucial point regarding the development of membranolytic antimicrobial therapeutics is that they 
must not destroy the membrane of mammalian cells. We showed here that, although endowed with 
antimicrobial activity, GVF27 displays virtually no hemolytic and cytotoxic activity on an assortment of 
murine and human cell lines. This implies that GVF27, probably due its net positive charge composition, has 
evident high membrane selectivity towards bacterial cells but not mammalian cells.  
From a structural point of view, in agreement with the canonical properties of most HDPs, we 
verified by CD and NMR experiments that GVF27 is unstructured in aqueous buffer whereas it tends to 
assume a helical conformation in the presence of TFE. Moreover, NMR data clearly indicate that the spatial 
segregation of polar and apolar amino acids of GVF27 are on opposite faces oriented along the axis of a 
helical structure. This would indicate that GFV27 is able to assume an optimal conformation to effectively 
promote strong membrane association. 
Further tests by CD and light scattering have also allowed to highlight that the peptide is able to 
interact both with LPS and LTA, albeit in a less effective manner with the latter, thus suggesting that it can 
bind to the microbial surfaces via these wall determinants. The ability of GVF27 to interact with LPS has 
been also confirmed by different approaches, thanks to which it has been possible to show that the peptide is 
able to inhibit the pro-inflammatory response. Indeed, GVF27 strongly down-regulates the release of NO and 
the production of IL-6 both in LPS pre-treated murine macrophages cells and upon co-administration of the 
peptide and the endotoxin. Moreover, it is worth noting that in murine macrophages treated with GVF27 and 
then subjected to LPS, a decrease of both NO and IL-6 was still detectable, thus suggesting also a protecting 
action for the peptide. This opens an interesting scenario because GVF27 is a “hidden” peptide in a protein 
that, although not yet been characterized, could be constitutively present under physiological conditions and 
able to release, by induced proteolysis, a fragment containing GVF27 in response to pathogen invasion. Our 
hypothesis is substantiated by an in silico prediction of peptides obtainable as a result of hydrolysis, which 
was carried out on the isoforms in which we identified GVF27 by simulating hydrolysis mediated by 
neutrophil elastase. Indeed, as shown in Figure S9, possible peptides released by hydrolysis are virtually 
superimposable to GVF27 and all have high antimicrobial scores, thus clearly supporting our idea that 
human proteins may fascinatingly be seen as active reservoirs of HDPs.   
 
 
 
 
 
Figure S9 In silico prediction, on the C-terminal region of the four isoforms in which we have 
identified GVF27, of hypothetical peptides released by cleavage mediated by human neutrophil 
elastase. For each putative peptide (#1, #2, #3 and #4) has been also calculated the antimicrobial score by 
using the bioinformatics procedure described in Pane et al 2017 (reference n. 23). 
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 Finally, it seems very interesting the ability of GVF27 to attenuate LPS-induced pro-inflammatory 
response and its apparent ability to protect the cells by mitigating upstream the effects of infection. In both 
cases it seems plausible to hypothesize for GVF27 different targets.   
In our opinion at least three mechanisms could be responsible for GVF27 immune-modulatory 
properties. First, GVF27 might modulate cellular response to pro-inflammatory mediators by acting as an 
endotoxin scavenger during initial steps of infection. In this case the peptide could bind to and neutralize the 
endotoxin directly. Second, GVF27 might reduce inflammatory dysfunction during immune response by 
interacting with membrane receptors, i.e CD14, that then would activate down regulation of different pro-
inflammatory pathways. Third, endogenous GVF27, or internalized from paracrine cells, may contribute to 
attenuation of the inflammatory response by interacting with intracellular targets. Based on these hypotheses 
and on the evidences described in this work, it is indisputable that the existence of cryptic HDPs implies that 
innate immunity is more complex than usually believed and that human proteome is an unexplored and 
essential source of bioactive agents. 
In conclusion, GVF27 may offer several advantages compared to other antimicrobial agents,: (i) it is 
non-immunogenic given its human origin; (ii) specifically targets bacterial strains, (iii) is not hemolytic and 
contributes to enhance anti-inflammatory response without altering cell viability. 
Thus, we confidentially believe that structural, immunomodulatory and antimicrobial data of GVF27 
presented in this work, could serve as leads for the design of human-specific therapeutics.  
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Abstract 
VLL-28, previously identified and characterized as an antimicrobial peptide from the archaeal 
kingdom, is here demonstrated to selectively exert cytotoxic activity against murine and human 
tumor cells. Through a combined approach of NMR spectroscopy, Circular Dichroism and Dynamic 
Light Scattering, the interaction with the membranes of both parental and malignant cell lines is  
proven and the binding residues were identified. Importantly, microscopy data show that VLL-28 is 
internalized only into tumor cells, thus suggesting that the cell membrane is not the main target and 
that not yet identified intracellular components are involved. Finally, it is shown that cell death is 
mainly caused by a time-dependent activation of apoptotic pathways. 
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Antimicrobial peptides (AMPs) are short peptides endowed with direct and broad-spectrum 
antimicrobial activity and represent essential components of the innate immune system of higher 
eukaryotes, being the first line of defense against microbial invasions (1, 2). In addition to a direct 
antimicrobial action, AMPs show a wide panel of biological activities including anti-inflammatory, 
anti-viral, chemoattractive and pro-angiogenic activity (1, 3-6). AMPs are very heterogeneous in 
length, amino-acid composition, secondary structure and mechanism of action; however, the 
majority of them shows a peculiar abundance of cationic and hydrophobic residues. These AMPs, 
also called Host Defence Peptides (HDPs)(7), kill bacterial cells through a specific mechanism i.e. 
targeting bacterial membranes (2, 6, 8): the net positive charge drives the adsorption of the peptide 
onto the surface of bacterial membranes which are richer in anionic lipids than eukaryotic 
membranes, hence the hydrophobic residues mediate the insertion of the peptide into the membrane. 
The accumulation of peptide molecules in the membrane causes the alteration of its 
structure/permeability, accompanied by a severe impairment of the membrane functions that 
eventually lead to the death of bacterial cells, often by cell lysis (2, 6, 8). Since eukaryotic plasma 
membranes show an asymmetric distribution of negatively charged phospholipids, generally present 
only in the inner leaflet of the membrane, HDPs are not able to effectively adsorb to eukaryotic 
cells. The presence of cholesterol further prevents the insertion into and the perturbation of the 
eukaryotic membranes. Nonetheless, it is worth mentioning that at high concentration several HDPs 
become toxic also for eukaryotic cells. 
Intriguingly, several AMPs endowed with anti-cancer activity (9) are defined as “anti-cancer 
peptides” (ACPs), because they show a much stronger toxicity for cancer cells than that towards 
normal cells. This differential toxicity has been attributed to the fact that transformation of 
eukaryotic cells is often associated to alterations of the membrane composition (10), such as: i) loss 
of the asymmetric distribution of phospholipids with exposure of phosphatidylserine on the outer 
leaflet, ii) increased production of anionic lipids (e.g. sulfated lipids), sialic acid containing 
glycolipids and glycoproteins, and sometimes iii) decreased production of cholesterol. Altogether 
these events lead to an augmented negative charge at the external surface of tumor cells that, in 
turn, would favor the binding of ACPs. However, differently from bacterial killing mechanisms, the 
death of tumor cells is not necessarily due to accumulation of the peptide into the membrane 
followed by their lysis. Indeed, in several cases it has been demonstrated that ACPs are internalized 
and the cell death occurs upon the interaction with one or more intracellular targets, such as 
mitochondria, DNA, cytoplasmic and nuclear proteins (e.g. HSP70(11) and DNA polymerase β(12), 
respectively). Moreover, it is worth noting that these ACPs usually induce apoptosis rather than 
necrosis. (9) 
Due to the severe side effects of conventional chemotherapeutic agents and the ability of some 
tumor cells to develop the multidrug resistant phenotype, ACPs have attracted considerable 
attention. Indeed, these peptides could help to develop a new generation of anti-cancer drugs with a 
mechanism of action well distinguished from those of conventional chemotherapeutic agents. 
As not all the HDPs are ACPs and the killing mechanism seems to differ for each ACP and tumor 
cell line, the rationale development of new antitumor agents based on CAMPs/ACPs requires 
further investigations. In particular, the identification and characterization of new ACPs could help 
to better define the requirements for a strong and selective antitumor activity. 
Recently, we have developed an in silico tool allowing to identify HDP-like peptides hidden into 
the sequences of proteins not necessarily involved in host defense (13). Using this tool we have 
already identified three new human HDPs (14-16). Furthermore, we have demonstrated that DNA 
binding proteins can be a convenient source of new HDP-like peptides by identifying the first HDP 
from an archaeal protein, the transcription factor Stf76 encoded by the hybrid plasmid-virus pSSVx 
from Sulfolobus islandicus (17). This archaeal HDP, named VLL-28 from its sequence(16), has a 
broad-spectrum antibacterial activity and exhibits selective leakage and fusogenic capability on 
vesicles with a lipid composition similar to that of bacterial membranes. Moreover, we have shown 
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that VLL-28 retains the ability of the parental protein to bind nucleic acids (both single and double 
strand DNA). Using a fluorescent derivative, we have demonstrated that VLL-28 localizes not only 
on the cell membrane but also in the cytoplasm of Escherichia coli, thus suggesting that it could 
target both membranes and intracellular components of bacterial cells. 
Here we report for the first time the characterization of the antitumor activity of VLL-28. By means 
of a multidisciplinary approach including biochemical, cellular biology and spectroscopic 
techniques, the action mechanism of VLL-28 has been elucidated. Intriguingly, it has been proved 
to be an effective ACP able to selectively kill tumor cells by inducing apoptosis. 
 
Results and Discussion 
Selective antitumor action of VLL-28 peptide 
To assess whether VLL-28 was endowed with anti-cancer activity, cytotoxicity assays were 
performed on malignant SVT2 mouse fibroblasts and parental non-malignant BALBc 3T3 mouse 
fibroblasts. Interestingly, these studies have shown that the peptide VLL-28 exerts a dose- and time-
dependent inhibition of viability on malignant SVT2 murine fibroblasts (see Figure 1a). 
Conversely, the peptide was found to be inactive towards the non-malignant line of BALBc 3T3 
fibroblasts (Figure 1b). This evidence was also confirmed by morphological analyses through light 
microscopy, where a severe alteration of cell morphology with the presence of cell debris was 
observed only in the case of SVT2 cancer cells (Figure S1). Remarkably, this peptide was also 
found to be effective and selective against human tumor cell lines, as demonstrated by MTT assays 
performed on transformed HEK-293 cells and human primary renal cortical epithelial (HRCE) cells 
(Figure S2). In agreement with these results, it has been previously reported that other AMPs, which 
are toxic for bacteria but not for normal mammalian cells, are instead cytotoxic for cancer cells 
(18). 
Internalization of VLL-28 peptide 
Most AMPs and ACPs share a common membranolytic mechanism of action that results first either 
in the selective disruption or permeation of the cancer cell membrane and then in the swelling of 
mitochondria. Nonetheless, a non-membranolytic mechanism of action is increasingly recognized as 
an alternative ACPs mechanism. (19) To test whether the selective antitumor activity of VLL-28 
was associated to a membranolytic mechanism and/or to its internalization, we performed 
experiments by using the peptide labeled with fluorescein isothiocyanate (FITC). To this purpose, 
SVT2 and BALBc 3T3 cells were incubated for 12 h with 20 µM FITC-labeled VLL-28, since this 
concentration of peptide turned out to be the most effective in terms of cytotoxicity. As shown in 
Figure 2a, in the case of SVT2 cells, VLL-28 fluorescent signal appears to be mostly intracellular 
already after 12 h of incubation, thus indicating that the peptide is internalized into the target cancer 
cells. On the other hand, the peptide (green) mainly co-localizes with WGA (red) at the plasma 
membrane in BALBc 3T3 cells (as indicated by arrows in Figure 2b). The failed internalization of 
VLL-28 into these latter cells is consistent with the absence of cytotoxicity emerged from viability 
tests (Figure 1b). Fluorescent staining was found to be specific, as no fluorescent signals were 
observed in the absence of FITC-labeled peptide (data not shown). Since the internalization has 
been observed at a time point preceding the cell death (48-72h), the molecular target of VLL-28 
might be a not yet identified intracellular component.   
 
VLL-28 CD analyses in the presence of intact eukaryotic cells 
Since differences in the plasma membrane composition between normal and cancer cells are 
supposed to contribute to the selective permeability and toxicity of ACPs towards the latter, we 
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resolved to examine if the presence of the two different cell lines affect differently the secondary 
structure of VLL-28. Interestingly, VLL-28 CD spectra registered in the presence of either BALBc 
3T3 or SVT2 whole cells revealed a different behavior (Figure 3). In particular, in the presence of 
BALBc 3T3 cells, VLL-28 seems to gradually get structured over time until a prevalence of helical 
structure is observed upon 1 h incubation (Figure 3a). Indeed, the spectrum shows two minima, at 
208 and 222 nm, typical of helical structure, in agreement with CD data obtained in the presence of 
n-dodecyl-phosphatidylcholine (DPC), a well-known eukaryotic membrane mimetic agents.(16) 
Differently, in the presence of SVT2 intact cells, a drop in the CD signal is observed suggesting a 
fast internalization process of VLL-28, occurring already after 10 min (Figure 3b), as confirmed by 
confocal microscopy data (Figure 2).  
 
NMR conformational analysis of VLL-28  
In order to gain insight into the mechanism of action of VLL-28 and provide information on the 
basis of the different behaviors of VLL-28 with regard to the two studied cell lines, a NMR 
conformational analysis of the peptide in the absence and in the presence of TFE, a well-known 
structuring solvent, has been initially carried out. (Figure S3 and S4).  According with what 
previously observed by CD analysis (16), VLL-28 does not adopt a well-defined conformation in 
phosphate neutral solution, as indicated by sharp and low-dispersed resonances in both the 
amide/aromatic and the aliphatic regions (Figure S3a). Upon addition of TFE (25% v/v), amide, 
aromatic and aliphatic proton resonances resulted significantly more dispersed (Figure S3b). In 
particular, the tryptophan side chain HN, clearly distinguishable at 10.14 ppm in the absence of TFE 
(Figure S3a, left), exhibits up-field shift at 9.94 ppm upon addition of TFE (Figure S3b, left), 
possibly induced by an aromatic-aromatic long-range interaction. Moreover, 2D [1H, 1H] NOESY 
spectrum of VLL-28 peptide contains a consistent higher number of cross-peaks with respect of that 
recorded in the absence of TFE, indicating a more structured conformation (Figure S4). Almost 
complete assignment of proton resonances of VLL-28 has been achieved in 25% TFE by using a 
combination of TOCSY and NOESY spectra, according to the standard procedures (Table S1). 
To assess the secondary structure of VLL-28 in 25% TFE, analyses of the Hα chemical shift 
deviations from random coil values (∆δHα) and of the NOE patterns were performed. Interestingly, 
two regions encompassing residues V37- R48 andV50-S59 showed large negative deviations ( ∆δHα < 
-0.1 ppm), suggesting that the peptide mostly assumes a helical conformation, which is lost in the 
last C-terminal amino acids. (Figure 4a). Accordingly, HN-HN NOEs, together with Hαi-HNi+3 and 
Hαi-Hβi+3 NOEs, were observed starting from residues V
37 to S59 only in the presence of TFE 
(Figure 4b and c), further confirming the helical structure of that region in TFE.  
 
 
STD NMR interaction studies of VLL-28 with tumor and normal cell membranes and 
definition of its binding epitopes 
 
To identify binding residues of VLL-28 saturation transfer difference (STD) NMR binding 
experiments of the peptide in the presence of intact SVT2 and BALBc 3T3 cells (20), as well as of 
their isolated membranes, were performed. Unfortunately, 1H NMR VLL-28 proton resonances 
vanish when in presence of each of the two cell lines, thus hampering a detailed molecular analysis 
of the VLL-28 interaction with the cellular membranes (data not shown).  
Very recently, we described the use of native cell membranes to overcome peptide cell 
internalization issues in “on-cell” NMR binding experiments(21). This approach provides a 
significant improvement of NMR peptide spectra with respect to those acquired by using intact 
cells. Particularly, in the presence of isolated membranes, the 1H NMR signals of the peptide are 
sharper and better resolved, the STD signals appear significantly stronger, and background signals 
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of the cellular components result much weaker in both the 1H and the STD spectra.(21) On the basis 
of the biochemical evidences of peptide internalization (see above), we carried out STD NMR 
experiments of the VLL-28 peptide in the presence of isolated membranes. 
Interestingly, 1H NMR peptide signals resulted well visible in the presence of both SVT2 and 
BALBc3T3 cell membranes as in the sole buffer (Figure S5), thus allowing to perform STD NMR 
binding studies. In particular, we evaluated the binding capability of VLL-28 to the two different 
components of the cell membrane, proteins and lipids, acquiring STD spectra at two different 
saturation frequencies, i.e. one to selectively saturate proteins (0.2 ppm) and another one to saturate 
lipids (5.2 ppm) (22) Remarkably, the 1H STD spectra showed that VLL-28 receives a detectable 
saturation transfer in the presence of cell membranes only when lipids are saturated (Figure 5). This 
effect, which is negligible in the absence of cell membranes (Figure 5b), provides a direct 
observation of the binding of VLL-28 to the lipid component of the cell membranes. This finding is 
in agreement with previous results showing that the peptide is able to interact with lipids mimicking 
bacterial membranes (16). It is worth of note that differences in the STD spectra were observed for 
BALBc 3T3 and SVT2 cell membranes (Figure 5). In particular, a higher number of STD signals, 
with stronger intensities, were observed in the presence of BALBc 3T3 cell membranes compared 
with those of SVT2 (Figure 6A). In particular, all the binding residues of VLL-28 to the SVT2 cell 
membranes are in common with that of the BALBc 3T3 cell membranes. Specifically, VLL28 
residues involved in both BALBc 3T3  and SVT2 interactions are G49, Y52 and W55 (Figure 6b, 
highlighted in magenta). Moreover, one or both of the two threonine residues, T41 and T43, appear 
involved in the VLL-28 interaction with both cell lines. On the other hand, Q47, V50, I51 and F58, 
together with the acetyl N-terminal, show protons that are saturated only in the presence of BALBc 
3T3 membranes (Figure 6b, highlighted in red).  Furthermore, strong STD effects were observed for 
side-chains of arginine and lysine residues. However, due to the spectral overlap and to the presence 
of a high number of basic residues in the peptide sequence they could not identified unambiguously. 
Moreover, methyl of leucine (L) and valine (V) localized in the N-terminal region, seem to be 
involved as well.  
Overall, these data indicate that the interaction of VLL-28 with cell membranes is mediated by the 
N-terminal and the central regions (V37-F58) (Figure 6), which interestingly correspond to the 
portions of the peptide that assume helical conformation in presence of TFE. Specifically, the 
binding to both the cell membranes seems to be mainly mediated by aromatic and basic residues, as 
could be expected for peptide-lipid interactions 
Different STD intensities of the peptide induced by the interaction with BALBc 3T3 and SVT2 cell 
membranes are likely ascribed to a different interaction mechanism between the peptide and the two 
membranes. In particular, stronger STD effects observed in the presence of non-tumor BALBc 3T3 
membranes indicates that a fast-exchange equilibrium between the free form and a well-recognized 
bound conformation occurs. Since fast-exchange regime are observed with lower affinity 
interaction, this could explain the inability of VLL-28 to penetrate these cell membranes. 
Differently, the reduced STD effects, observed in the presence of SVT2 membranes, can be 
ascribed to a stronger interaction with the cell membranes possibly being the first step of an 
internalization process. 
 
 
Effect of VLL-28 on zeta-potential of cell membranes 
Zeta potential of cell membranes has been used as a possible marker for the assessment of 
membrane damage and could be suitable to study the permeabilizing property of the VLL-28 
peptide. (23) Zeta potential analyses were performed on E. coli, BALBc 3T3 and SVT2 cells. The 
measured zeta potential in our experimental conditions for the cells in the absence of any peptide is 
−43.93mV for E. coli (Figure S6), -6.91mVfor BALBc 3T3 and -12.91mV for SVT2 cells, 
respectively, indicating that their surfaces are all negatively charged and, as already known, that the 
surface of the bacterial membranes is more negatively charged than mammalian cells.(24, 25) This 
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is due to both lipid composition and negatively charged cell surface macromolecules, as described 
also for other systems(9).  Furthermore, Z-potential measurements clearly demonstrated that the 
surface of SVT2 has a more negative charge than BALBc 3T3 cells. The addition of VLL-28 
caused an increase of Z-potential values towards neutralization indicating that the peptide is 
interacting with the surface of all the cells tested (Figure 7 a and b and S6). Given the role of 
electrostatic interactions in driving the AMPs initial adsorption onto the extracellular surface, it is 
reasonable to question if VLL-28, as ACP, exerts the same kind of action. In accordance with the 
general mechanism of action of AMPs, VLL-28 fully neutralizes E. coli cell’s surface potential to 
exert its antimicrobial action (Figure S6). Differently, on eukaryotic cells, VLL-28 is able to 
increase the Z-potential but never reaching full neutralization even at concentrations ≥ 20µM thus 
indicating that total surface neutralization is not necessary to elicit its anticancer action.(26)  
 
Cell death pathway activated by cell treatment with VLL-28 
To elucidate cell death pathways selectively activated by cell treatment with VLL-28, we performed 
western blot analyses by using antibodies specifically recognizing pro-caspase 3 and p62 proteins. 
The activation of procaspase-3 to caspase-3 is a key event in the apoptotic execution phase, since 
caspase-3 is considered the most important among executioner caspases and is activated by any of 
the initiator caspases (caspase-8, caspase-9, or caspase-10).(27) p62, instead, is generally used as a 
marker to study the autophagic flux, since it accumulates when autophagy is inhibited, whereas p62 
decreased levels can be observed when autophagy is induced (28).  
To get insight into cell death pathway induced by VLL-28, western blot analyses were performed 
on SVT2 cells in comparison with BALBc 3T3 (Figure 8a-d). In SVT2 cells it was found a 
significant increase of p62 levels upon 6 h treatment with 20 µM VLL-28 (Figure 8a, d), indicative 
of a stress leading to cell death with a consequent block of autophagy flux (29). Accordingly, 
procaspase-3 levels appear lower than in control cells upon 6 and 12 h treatment (Figure 8a, b), 
indicating a significant (about 30%) activation of procaspase-3 to caspase-3 associated to apoptosis 
induction. This activation appears even stronger (about 50%) after 24 h of treatment (Figure 8a, b), 
and is associated to a significant decrease of p62 levels (Figure 8a, d), in agreement with a time-
dependent activation of apoptotic cell pathway. 
In the case of non-malignant BALBc 3T3 cells, instead, no significant effects on procaspase-3 
levels were observed upon cell treatment with 20 µM VLL-28 peptide at different time intervals (6, 
12 and 24 h) (Figure 8B, C), in agreement with the results reported above. This indicates that these 
cells are not susceptible to VLL-28 peptide toxic effects. Moreover, no significant effects were 
observed also when p62 levels were analyzed, except for 72 h treatment, where a slight increase of 
p62 levels was observed (Figure 8b, d). Since no effects on cell viability were detected by MTT 
assays, this might be indicative of a slight cell perturbation counteracted by autophagy activation.  
Hence, experimental data revealed that VLL-28 exerts its action through a time-dependent 
activation of apoptotic cell pathways as demonstrated by the maturation of procaspase-3 to the 
caspase-3 (30). This is in agreement with data reported in the literature indicating that several 
potential ACPs are able to induce apoptosis in human cancer cell lines of different origin, such as 
breast, uterine cervix, liver and prostate (9).  Apoptosis induction, with some degree of selectivity 
towards cancer cells, has been described also in the case of ACPs effective on metastatic tumor 
cells or on cancer endothelial cells (9). Since metastases are the main cause of conventional therapy 
failure, peptides able to specifically interfere with the process of metastases formation by 
stimulating apoptosis induction in neoplastic cells represent valuable resources in cancer treatment 
(9). These observations associated to the strong and selective toxic effects exerted by VLL-28 
peptide towards cancer cells open interesting perspective to future applications of this peptide.  
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Concluding remarks 
The cytotoxic activities of several AMPs turn this group of molecules into an amazing pool of new 
templates for anticancer drug development (31). Accordingly, VLL-28, previously identified as an 
AMP (16), is here found to be endowed also with selective cytotoxic activity towards both murine 
and human cancer cells, thus pointing to VLL-28 as a potential chemotherapeutic agent. 
Microorganisms belonging to the archaeal kingdom have been so far considered as source of 
biotechnologically relevant enzymes and proteins (32-40), but there are no reports regarding 
potential ACPs isolated from this kingdom. This paper represents the first evidence that archaeal 
microorganisms could bear also an unexplored repertoire of such kind of molecules exerting a trans-
kingdom action. Given the intrinsic stability to physical and chemical agents of Stf76, the parental 
source of VLL-28, it is foreseen that VLL-28 might be a promising “lead compound” for future 
development of novel drugs, upon chemical modifications, i.e. D-amino acids, an all-hydrocarbon 
bridge, and/or modified amide bounds to further increase its stability to proteases (41). 
 
Methods 
Peptide Synthesis Reagents 
Polypropylene reaction vessels and sintered polyethylene frits were supplied by Alltech Italia 
(Milan, Italy). NovaSyn TGR resin, 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium 
hexafluorophosphate (HBTU), cyano-hydroxyimino-acetic acid ethyl ester (Oxyma) and all amino 
acids were purchased from Novabiochem-Merck (Nottingham, U.K.). N,N′-diisopropylethylamine 
(DIPEA), piperidine, Kaiser test, trifluoroacetic acid (TFA), scavengers, fluorescein isothiocyanate 
(FITC) and N-methylmorpholine (NMM) were purchased from Sigma-Aldrich (Milan, Italy). N,N-
Dimethylformamide (DMF) was purchased from CARLO ERBA Reagents (Milan, Italy). 
Acetonitrile (ACN), dichloromethane (DCM) and diethyl ether were purchased from VWR 
International (Milan, Italy). All aqueous solutions were prepared by using water obtained from a 
Milli-Q gradient A-10 system (Millipore, 18.2 MΩ·cm, organic carbon content ≥ 4 µg/L). 
Peptide Synthesis 
VLL-28 and FITC-VLL-28 (VLL-28 derivative with an additional glycine residue at the C-terminus 
as spacer and a lysin residue for FITC labeling) peptides were manually synthesized using the 
fluorenylmethyloxycarbonyl (Fmoc) solid-phase strategy (0.2 mmol). The syntheses were 
performed on NovaSyn TGR resin (loading 0.24 mmol/g), using all standard amino acids. The 
Fmoc protecting group was removed by treatment with 30% piperidine in DMF (3 × 10 min). The 
amino acids in 10-fold excess were pre-activated with HBTU (9.8 equiv)/Oxyma (9.8 
equiv)/DIPEA (10 equiv) in DMF for 5 min and then added to the resin suspended in DMF. The 
reaction was performed for 1 h and the coupling efficiency was assessed by the Kaiser test. In the 
case of FITC-VLL-28 peptide, once synthesis was completed, the ivDde protecting group of 
Lys(ivDde) residue was selectively removed by treatment of the peptidyl resin with a solution of 
2% hydrazine in DMF (20 x 3 min). FITC labeling was then performed with 2 equiv of fluorescein 
isothiocyanate and 4 equiv of NMM in DMF for 5 h.  
The peptides were finally cleaved off the resins by treatment with a mixture of trifluoroacetic acid 
(TFA)/water/triisopropylsilane (95:2.5:2.5 v/v/v) for 3 h at room temperature. The resins were 
filtered, the crude peptides were precipitated with diethyl ether, dissolved in H2O/ACN solution, 
and lyophilized. The products were purified by preparative RP-HPLC on a Shimadzu system 
equipped with a UV−visible detector SPD10A using a Phenomenex Jupiter Proteo column (21.2 × 
250 mm; 4 µm; 90 Å) and a linear gradient of H2O (0.1% TFA)/ACN (0.1% TFA) from 10%–55% 
of ACN (0.1%TFA) in 15 min at a flow rate of 20 mL/min. The collected fractions containing the 
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peptides were lyophilized giving a final yield of about 35% of each pure product. The identity and 
purity of the compounds were assessed by the AGILENT Q-TOF LC/MS instrument equipped with 
a diode array detector combined with a dual ESI source on a Agilent C18 column (2.1 × 50 mm; 1.8 
µm; 300 Å) at a flow rate of 200 µL/min and a linear gradient of H2O (0.01% TFA)/ACN (0.01% 
TFA) from 5%–70% of ACN (0.01% TFA) in 15 min. 
 
Cell culture  
Malignant SVT2 murine fibroblasts (BALBc 3T3 cells transformed by SV40 virus), parental 
BALBc 3T3 murine cells, and HEK-293 human embryonic kidney cells were cultured in 
Dulbecco’s Modified Eagle’s Medium (Sigma-Aldrich), supplemented with 10% fetal bovine serum 
(HyClone), 2 mM L-glutamine and antibiotics, in a 5% CO2 humidified atmosphere at 37 ºC. HRCE 
(Human Renal Cortical Epithelial) cells (Innoprot) were cultured in basal medium, supplemented 
with 2% fetal bovine serum, epithelial cell growth supplement and antibiotics, all from Innoprot, in 
a 5% CO2 humidified atmosphere at 37 °C (42).  
Cytotoxicity assays  
Cells were seeded in 96-well plates (100 µL per well) at a density of 5x103 per well (SVT2, HEK-
293, and HRCE cells) or 2.5x103 per well (BALBc 3T3 cells). VLL-28 peptide was added to the 
cells 24 h after seeding for time- and dose-dependent cytotoxic assays. At the end of incubation, cell 
viability was assessed by the MTT assay, as previously described(43). In brief, MTT reagent, 
dissolved in DMEM in the absence of phenol red (Sigma-Aldrich), was added to the cells (100 µL 
per well) to a final concentration of 0.5 mg/mL. After a 4-h incubation at 37 °C, the culture medium 
was removed and the resulting formazan salts were dissolved by adding isopropanol containing 0.1 
N HCl (100 µL per well). Absorbance values of blue formazan were determined at 570 nm using an 
automatic plate reader (MicrobetaWallac 1420, Perkin Elmer). Cell survival was expressed as 
percentage of viable cells in the presence of the peptide, with respect to control cells grown in the 
absence of the peptide. In all of the experiments described in this paper, controls were performed by 
supplementing the cell cultures with identical volumes of peptide buffer for the same time span. 
Obtained data represent the mean (± standard deviation) of at least 4 independent experiments, each 
one carried out with triplicate determinations. Statistical analysis was performed using a Student’s t-
Test, and significant differences were indicated as *(P < 0.05), **(P < 0.01) or ***(P < 0.001).    
Analysis of cell death 
Cells were plated in 6-well plates (1mL per well) at a density of 1x106 cells per well in complete 
medium for 24 h and then exposed to 20 µM VLL-28 for 6, 12 or 24 h To prepare cell lysates, both 
untreated and treated cells were scraped off in PBS, centrifuged at 1,000 x g for 10 min and 
resuspended in lysis buffer (1% NP-40 in PBS, pH 7.4) containing protease inhibitors. After 30 min 
of incubation on ice, lysates were centrifuged at 14,000 x g for 30 min at 4 °C. Upon determination 
of total protein concentration in the supernatant by the Bradford assay, samples were analyzed by 
SDS-PAGE followed by Western blotting using specific antibodies directed towards procaspase-3 
(Cell Signaling Technology) or p62 (Novus Biologicals) proteins. For normalization to internal 
standard signals, antibodies against β-actin (Sigma-Aldrich) were used. In parallel experiments, 
cells were treated with puromycin (10 µg/mL) for 12 h or with rapamycin (20 µM) for 24 h, which 
were used as positive controls for apoptosis and autophagy induction, respectively.  
For morphological analyses, cells were seeded on glass coverslips in 24-well plates and grown to 
semi-confluency. Cells were then incubated for 72 h with 20 µM VLL-28 peptide in complete 
medium, after which cells were washed with PBS, fixed for 10 min at room temperature (RT) with 
4% paraformaldehyde in PBS and mounted in 50% glycerol in PBS. Samples were then examined 
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using a confocal laser-scanner microscope Zeiss LSM 700. All images were taken under identical 
conditions. 
Fluorescence studies 
Fluorescence analyses were performed as previously described (44). Briefly, cells were seeded on 
glass coverslips in 24-well plates, grown to semi-confluency, and then incubated for 12 h with 20 
µM FITC-labeled VLL-28. Following incubation, cells were washed with PBS and then fixed for 
10 min at RT with 4% paraformaldehyde in PBS. Cell membranes were labeled by incubating the 
cells with Wheat Germ Agglutinin (WGA, 5 µg/mL) Alexa Fluor®594 Conjugate (ThermoFisher 
Scientific) for 10 min at RT. Cells were then washed twice in PBS following the manufacturer’s 
instructions. Confocal microscopy analyses were performed with a confocal laser-scanner 
microscope Zeiss LSM 700.   
Circular dichroism analyses 
 
Far-UV CD spectra were recorded on a Jasco J-810 spectropolarimeter (JASCO Corp) equipped 
with a PTC-423S/15 peltier temperature controller in the wavelength interval of 198–260 nm. 
Experiments were performed using a 20 µM VLL-28 solution (in PBS pH7.4) in a 0.1 cm path-
length quartz cuvette as already reported in Notomista et al.(16) 
CD spectra in the presence of intact cells were registered using 8 105 BALBc 3T3 cells or SVT2 
cells at different incubation times (0, 10, 30, 60 min and 24 h) in PBS buffer. The baseline was 
corrected by subtracting the spectrum of the cells alone at the same time of incubation. (41, 45, 46)  
 
Membrane preparation 
Membranes used in NMR experiments were isolated from BALBc 3T3 or SVT2 cells and obtained 
as reported in Farina et al. (21). In details, cells were detached from the flask with trypsin and 
washed twice with PBS. Then the cells were transferred into homogenization buffer containing PBS 
and homogenized by means of a pellet pestle (Sigma). Particulate matter was removed by 
centrifuging at 3,500 rpm for 15 min. The supernatant was then centrifuged at 28000 rpm for 1 h at 
4 °C. The pellet was washed and centrifuged at 28000 rpm for 30 min at 4 °C. 180 µL of PBS plus 
20 µL D2O were added to the pellet, and the membrane was re-suspended by 20 passages through a 
25 gauge needle.  
 
NMR spectroscopy 
All NMR experiments were carried out at 298K using an Inova 600 MHz spectrometer (Varian Inc., 
Palo Alto, CA, USA), equipped with a cryogenic probe optimized for 1H detection.  
NMR samples were prepared as follows. For chemical shift assignment and conformational 
analysis, 1 mg of VLL-28 was dissolved either in 500 µL sodium phosphate 20 mM pH 7.0 with 
10% v/v D2O or in 500 µL of the same buffer containing 25% (v/v) TFE (2,2,2-trifluoroethanol-D3 
99.5% isotopic purity, Sigma-Aldrich). One-dimensional (1D) 1H spectra were acquired with a 
spectral width of 7191.66 Hz, relaxation delay 1.03 s, 7k data points for acquisition and 16k for 
transformation. Bi-dimensional (2D) [1H, 1H] total correlation spectroscopy (TOCSY),(47) double 
quantum filtered correlated spectroscopy (COSY)(48) and nuclear Overhauser effect spectroscopy 
(NOESY) (49) were acquired with 32 or 64 scans per t1 increment with a spectral width of 7191.66 
Hz along both t1 and t2, 2048 × 256 data points in t2 and t1, respectively, and recycle delay 1.0 s. 
Water suppression was achieved by means of Double Pulsed Field Gradient Spin Echo (DPFGSE) 
sequence.(50, 51) TOCSY experiments were recorded using a DIPSI-2 mixing scheme of 70 ms 
with 7.7 kHz spin-lock field strength. NOESY spectra were carried out with a mixing time of 250 
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ms. Data were typically apodized with a square cosine window function and zero filled to a matrix 
of size 4096 × 1024 before Fourier transformation and baseline correction.  
According to the procedure recently reported (21) for interaction studies of VLL-28 with intact cells 
and isolated membranes of BALBc 3T3 and SVT2 cell lines, pellet of 18 x 106 cells and membranes 
from 18 x 106 cells, obtained as reported above, were re-suspended in 150 µL of PBS buffer (pH 
7.4) and 10% 2H2O, to obtain reference spectra, or of VLL-8 (430 µM) in PBS buffer. STD spectra 
were acquired with 10000 scans with on-resonance irradiation at 0.2 ppm or 5.2 ppm for saturation 
of membrane proteins or lipids resonances, respectively, and off-resonance irradiation at 30 ppm. A 
train of 40 Gaussian shaped pulses of 50 ms with 1 ms delay between pulses were used, for a total 
saturation time of 2 s. STD spectra were obtained by internal subtraction of saturated spectrum from 
off-resonance spectrum by phase cycling. STD spectrum of the only peptide was also acquired and 
did not show any signal. 2D [1H, 1H] TOCSY and NOESY spectra of VLL-28 in presence of 
isolated membranes were also acquired, similarly to those of the peptide alone.  
All NMR data were processed with the software VNMRJ 1.1.D (Varian Inc.). 1D spectra were 
analyzed using ACD/NMR Processor 12.0 [www.acdlabs.com]. 2D TOCSY, COSY and NOESY 
spectra for proton chemical shift assignment were analyzed using Homoscope, a tool available in 
CARA (Computer Aided Resonance Assignment) software. Chemical shift assignments of VLL-28 
in the absence of TFE are referred to residual water proton signals, (4.75 ppm), whereas in 25% 
TFE to residual TFE proton signals (3.88 ppm). Chemical shift deviations from random coil values 
for Hα were calculated using the ChemShiftDeviationsFile script available in CARA. 
 
Zeta-Potential measurements of bacterial and eukaryotic cells in the presence of VLL-28 
BL21 DE3 E. coli cells were plated on Luria-Bertani agar overnight at 37 °C. An isolated bacterial 
colony was used to inoculate Mueller Hinton Broth (MHB; OXOID, Hampshire, UK), and the 
bacterial culture was allowed to grow overnight at 37 °C. 100 µL of culture was used to freshly 
inoculate 5 ml of MHB. The suspension was incubated at 37 °C for ~ 2 h, until a final bacterial 
concentration of ~ 3 × 108 colony forming units per ml (CFU/mL) was reached (OD600nm ~ 0.1). 
Bacterial suspensions were diluted using fresh MHB to 3 × 107 CFU/mL for zeta-potential studies. 
Afterwards, cells were centrifuged at 12,000 × g for 5 min, and washed three times using 20 mM 
sodium phosphates buffer, pH 7.4. The zeta-potential of bacterial cells was determined at 25 °C 
from the mean of 3 measurements (50 runs each), in the absence and presence of different VLL-28 
concentrations (0-10 µM). Zeta-potential values were obtained by phase analysis light scattering 
(PALS) in a Zetasizer Nano ZS (Malvern Instruments, Malvern, UK), using disposable zeta cells 
with gold electrodes. Values of viscosity and refractive index were set to 0.8872 cP and 1.330, 
respectively.  
Confluent BALBc 3T3 and SVT2 cells were washed with PBS buffer followed by trypsinization. 
Zeta potential measurements of eukaryotic cells were performed using the Diffusion Barrier 
Technique (Malvern, Application Note). 4x105 cells were dispensed into the disposable zeta cells 
with gold electrodes in PBS with and without the peptide (from 0 to 50 µM) and allowed to 
equilibrate for 30 min at 37°C. One measurement (~70 runs each) was performed with a constant 
voltage of 40 V. The complete experiment was carried out at least two times using independent 
cellular suspensions. 
 
Figure legends 
Figure 1. Effects of the peptide VLL-28 on the SVT2 (a) and BALBc 3T3 (b) cell viability. MTT 
assays were performed on cells treated with increasing amounts of the peptide (5, 10 and 20 µM) 
for different time spans (24, 48 and 72 h). The viability of cell samples was expressed as the 
percentage of MTT reduction with respect to control cells, tested under the same conditions but in 
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the absence of the peptide. Data represent the mean (± standard deviation, SD) of at least 4 
independent experiments, each one carried out with triplicate determinations. *P < 0.05, **P < 0.01, 
or ***P < 0.001 were obtained for control versus treated samples in the case of SVT2 cells treated 
with VLL-28 peptide for 48 and 72 h.     
Figure 2. Internalization of VLL-28 peptide in SVT2 (a) and BALBc 3T3 (b) cells. Cells were 
cultured on coverslips, incubated for 12 h with 20 µM VLL-28 peptide (green) and stained with 
WGA (5 µg/ml, Alexa Fluor®594 Conjugate). Cells were analyzed by confocal microscopy. 
Figure 3. Far UV VLL-28 CD spectra (●) recorded in the presence of a) BALBc 3T3 cells and b) 
SVT2 cells at 0 (■), 10 (▲), 30 (♦), 60 (*) min and 24 h (○) of incubation. 
Figure 4. (a) Chemical shift deviation from random coil values of Hα backbone atoms (∆Ηα) 
plotted as a function of residue number. Two segments with helical conformation encompassing 
residues V37-R58, V50-S59, as suggested from the ∆Ηαs, are indicated above the plot. (b) and (c) 
Expansions of the HN-HN correlation region of the 2D [
1H, 1H] NOESY spectra of VLL-28 in 
phosphate buffer pH 7.0 at 298K in the absence and presence of TFE 25%, respectively. HNi-HNi+1 
cross-peaks, observed only in (C), are labeled. 
Figure 5. Reference 1H (a) and (STD)-NMR spectra of VLL-28 in the absence (b) and in the 
presence of SVT2 (C) and BALBc 3T3 (D) cell membranes. 
 
Figure 6. (a) Bar graphs of STD signal intensities (ISTD) for the VLL-28 H
N/aromatic and aliphatic 
protons receiving saturation transfer in the presence of BALBc 3T3 (red bars) and SVT2 (blue bars) 
cell membranes. In the x-axis label, HNbb=not assigned backbone amide protons, R =  
R44/R48/R53/R61/R64; K = K54/K64; Y = Y52/Y63; L =  L38/L39/L45; T = T41/T43. (b) The 
VLL-28 sequence is reported. VLL-28 residues showing STD effect in the presence of the both cell 
membranes are highlighted in magenta, whereas those affected only in the presence of BALBc 3T3 
in red. Asterisk indicates that, due to overlapped proton resonances, one or both the threonine are 
possibly involved in the interaction with BALBc 3T3 and SVT2 cell membranes. Residues that are 
not involved in the binding or that could not be identified unambiguously are indicated in black. 
Figure 7. a) VLL-28 effect on the Z-potential of SVT2 cells. b) VLL-28 effect on the Z-potential of 
BALBc 3T3  cells. At 4x105cells/mL cells were incubated and stabilized for 5 min with different 
peptide concentrations and the potential was measured at 37°C. Data represent the mean (± standard 
deviation, SD) of 2 independent experiments. 
Figure 8. Analysis of cell death pathway activated by the treatment with 20 µM VLL-28 peptide of 
SVT2 (a) and BALBc 3T3 (c) cells. Lane 1, cell lysate of untreated cells; lane 2, lysate of cells 
treated with rapamycin; lane 3, lysate of cells treated with puromycin; lane 4, lysate of cells treated 
with the peptide for 6 h; lane 5, lysate of cells treated with the peptide for 12 h; lane 6, lysate of 
cells treated with the peptide for 24 h. Western blots were performed by using antibodies directed 
towards procaspase-3, p62, and endogenous β-actin used as an internal standard (a, c). 
Densitometric analyses of protein bands specifically recognized by anti-procaspase-3 and anti-p62 
antibodies are reported in b and d, respectively, where data represent the mean (± standard 
deviation, SD) of 3 independent experiments. *P < 0.05, **P < 0.01, or ***P < 0.001 were obtained 
for control versus treated samples.     
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